1	Myocardial	O
2	perfusion	O
3	was	O
4	evaluated	O
5	using	O
6	the	O
7	enhanced	O
8	gray	O
9	level	O
10	after	O
11	contrast	O
12	injection	O
13	,	O
14	and	O
15	the	O
16	level	O
17	was	O
18	compared	O
19	with	O
20	the	O
21	morphology	O
22	and	O
23	degree	O
24	of	O
25	collateral	O
26	development	O
27	.	O

1	VP	O
2	-	O
3	16	O
4	,	O
5	ifosfamide	O
6	and	O
7	cisplatin	O
8	(	O
9	VIP	O
10	)	O
11	for	O
12	extensive	O
13	small	O
14	cell	O
15	lung	O
16	cancer	O
17	.	O

1	We	O
2	have	O
3	cloned	O
4	and	O
5	sequenced	O
6	COX12	O
7	,	O
8	the	O
9	nuclear	O
10	gene	O
11	for	O
12	subunit	O
13	VIb	O
14	of	O
15	Saccharomyces	B
16	cerevisiae	I
17	cytochrome	I
18	c	I
19	oxidase	I
20	.	O

1	Erythrocyte	O
2	delta	O
3	-	O
4	aminolevulinic	O
5	acid	O
6	dehydratase	O
7	(	O
8	ALAD	B
9	)	O
10	activity	O
11	,	O
12	erythrocyte	O
13	zinc	O
14	protoporphyrin	O
15	(	O
16	ZPP	O
17	)/	O
18	heme	O
19	ratio	O
20	,	O
21	and	O
22	urinary	O
23	coproporphyrin	O
24	(	O
25	UC	O
26	)	O
27	concentration	O
28	have	O
29	been	O
30	employed	O
31	as	O
32	biological	O
33	indicators	O
34	of	O
35	moderate	O
36	-	O
37	to	O
38	high	O
39	-	O
40	level	O
41	lead	O
42	exposure	O
43	,	O
44	corresponding	O
45	to	O
46	blood	O
47	levels	O
48	in	O
49	excess	O
50	of	O
51	50	O
52	micrograms	O
53	/	O
54	dl	O
55	,	O
56	in	O
57	human	O
58	subjects	O
59	.	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	EKLF	O
6	provides	O
7	a	O
8	crucial	O
9	transactivation	O
10	function	O
11	for	O
12	globin	B
13	expression	O
14	and	O
15	further	O
16	reinforce	O
17	the	O
18	idea	O
19	that	O
20	EKLF	O
21	is	O
22	an	O
23	important	O
24	regulator	O
25	of	O
26	CACCC	O
27	element	O
28	-	O
29	directed	O
30	transcription	O
31	in	O
32	erythroid	O
33	cells	O
34	.	O

1	Factor	B
2	XI	I
3	deficiency	O
4	is	O
5	a	O
6	rare	O
7	hereditary	O
8	bleeding	O
9	disorder	O
10	affecting	O
11	the	O
12	intrinsic	O
13	pathway	O
14	.	O

1	Transient	O
2	,	O
3	high	O
4	-	O
5	level	O
6	Ras	B
7	-	O
8	expression	O
9	induces	O
10	transcriptional	O
11	activation	O
12	of	O
13	p21	B
14	mediated	O
15	by	O
16	a	O
17	GC	O
18	-	O
19	rich	O
20	region	O
21	in	O
22	p21	B
23	promoter	I
24	-	I
25	83	I
26	-	I
27	54	O
28	bp	O
29	relative	O
30	to	O
31	the	O
32	transcription	O
33	initiation	O
34	site	O
35	containing	O
36	binding	O
37	sites	O
38	for	O
39	Sp1	B
40	-	I
41	family	I
42	transcription	I
43	factors	I
44	.	O

1	In	O
2	order	O
3	to	O
4	provide	O
5	adequate	O
6	local	O
7	control	O
8	without	O
9	compromising	O
10	cosmetic	O
11	outcome	O
12	,	O
13	the	O
14	amount	O
15	of	O
16	breast	O
17	tissue	O
18	that	O
19	must	O
20	be	O
21	excised	O
22	in	O
23	BCT	O
24	needs	O
25	to	O
26	be	O
27	individualized	O
28	.	O

1	In	O
2	the	O
3	same	O
4	period	O
5	we	O
6	pointed	O
7	out	O
8	an	O
9	increase	O
10	of	O
11	hematocrit	O
12	(	O
13	from	O
14	29	O
15	%	O
16	to	O
17	35	O
18	%)	O
19	and	O
20	of	O
21	the	O
22	Hb	B
23	(	O
24	from	O
25	9	O
26	.	O
27	3	O
28	to	O
29	11	O
30	.	O
31	2	O
32	g	O
33	/	O
34	dl	O
35	).	O

1	Mean	O
2	rCBF	O
3	increased	O
4	in	O
5	some	O
6	patients	O
7	4	O
8	-	O
9	8	O
10	weeks	O
11	after	O
12	surgery	O
13	on	O
14	the	O
15	ipsilateral	O
16	side	O
17	.	O

1	Activation	O
2	of	O
3	the	O
4	mitogen	B
5	activated	I
6	protein	I
7	(	I
8	MAP	I
9	)	I
10	kinase	I
11	is	O
12	a	O
13	primary	O
14	consequence	O
15	of	O
16	Ras	B
17	activation	O
18	and	O
19	plays	O
20	a	O
21	key	O
22	role	O
23	in	O
24	mediating	O
25	Ras	B
26	signal	O
27	transduction	O
28	.	O

1	Posttranslational	O
2	regulation	O
3	of	O
4	Ty1	B
5	retrotransposition	O
6	by	O
7	mitogen	B
8	-	I
9	activated	I
10	protein	I
11	kinase	I
12	Fus3	I
13	.	O

1	Moreover	O
2	,	O
3	it	O
4	is	O
5	the	O
6	assumptions	O
7	behind	O
8	steady	O
9	-	O
10	state	O
11	O2	O
12	uptake	O
13	that	O
14	do	O
15	not	O
16	permit	O
17	proper	O
18	interpretation	O
19	of	O
20	energy	O
21	expenditure	O
22	during	O
23	EPOC	O
24	;	O
25	1	O
26	l	O
27	O2	O
28	not	O
29	=	O
30	20	O
31	.	O
32	9	O
33	kJ	O
34	.	O

1	Decreased	O
2	levels	O
3	of	O
4	alpha2	B
5	-	O
6	antiplasmin	I
7	were	O
8	also	O
9	observed	O
10	in	O
11	the	O
12	mediastinum	O
13	(	O
14	0	O
15	.	O
16	50	O
17	versus	O
18	0	O
19	.	O
20	61	O
21	U	O
22	/	O
23	mL	O
24	;	O
25	p	O
26	<	O
27	0	O
28	.	O
29	05	O
30	).	O

1	While	O
2	fusion	O
3	to	O
4	the	O
5	N	O
6	-	O
7	terminus	O
8	required	O
9	a	O
10	linker	O
11	to	O
12	become	O
13	surface	O
14	accessible	O
15	,	O
16	both	O
17	fusion	O
18	to	O
19	the	O
20	N	O
21	-	O
22	terminus	O
23	and	O
24	to	O
25	the	O
26	C	O
27	-	O
28	terminus	O
29	was	O
30	compatible	O
31	with	O
32	particle	O
33	assembly	O
34	and	O
35	preserved	O
36	the	O
37	native	O
38	antigenicity	O
39	and	O
40	immunogenicity	O
41	of	O
42	HBcAg	O
43	.	O

1	However	O
2	,	O
3	limited	O
4	comparisons	O
5	reveal	O
6	domains	O
7	in	O
8	the	O
9	NH2	O
10	and	O
11	COOH	O
12	termini	O
13	that	O
14	have	O
15	a	O
16	high	O
17	degree	O
18	of	O
19	similarity	O
20	suggesting	O
21	functional	O
22	conservation	O
23	.	O

1	The	O
2	p130	B
3	and	O
4	p62	B
5	tyrosine	I
6	-	O
7	phosphorylated	O
8	proteins	O
9	that	O
10	complexed	B
11	v	B
12	-	I
13	Src	I
14	SH2	I
15	in	O
16	vitro	O
17	also	O
18	associated	O
19	with	O
20	v	B
21	-	I
22	Src	I
23	in	O
24	v	B
25	-	I
26	src	I
27	-	O
28	transformed	O
29	Rat	O
30	-	O
31	2	O
32	cells	O
33	;	O
34	this	O
35	in	O
36	vivo	O
37	binding	O
38	was	O
39	dependent	O
40	on	O
41	the	O
42	v	B
43	-	I
44	Src	I
45	SH2	I
46	domain	O
47	.	O

1	The	O
2	absence	O
3	of	O
4	H4PteGlun	O
5	bound	O
6	to	O
7	the	O
8	T	B
9	protein	I
10	in	O
11	our	O
12	experimental	O
13	conditions	O
14	demonstrates	O
15	that	O
16	H4PteGlun	O
17	is	O
18	not	O
19	covalently	O
20	linked	O
21	to	O
22	the	O
23	T	B
24	protein	I
25	.	O

1	There	O
2	was	O
3	significant	O
4	correlation	O
5	of	O
6	LVM	O
7	/	O
8	M2	O
9	and	O
10	PWVn	O
11	for	O
12	pre	O
13	-	O
14	AVR	O
15	and	O
16	post	O
17	AVR	O
18	studies	O
19	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	sMtCK	B
6	genomic	O
7	upstream	O
8	sequences	O
9	reveals	O
10	a	O
11	typical	O
12	TATAA	O
13	box	O
14	within	O
15	the	O
16	80	O
17	base	O
18	pairs	O
19	(	O
20	bp	O
21	)	O
22	that	O
23	,	O
24	by	O
25	transfection	O
26	experiments	O
27	,	O
28	are	O
29	sufficient	O
30	to	O
31	promote	O
32	expression	O
33	of	O
34	chimeric	O
35	plasmids	O
36	with	O
37	the	O
38	chloramphenicol	B
39	acetyltransferase	I
40	reporter	O
41	.	O

1	The	O
2	repetitive	O
3	ETn	O
4	(	O
5	early	O
6	transposon	O
7	)	O
8	family	O
9	of	O
10	sequences	O
11	represents	O
12	an	O
13	active	O
14	"	O
15	mobile	O
16	mutagen	O
17	"	O
18	in	O
19	the	O
20	mouse	O
21	genome	O
22	.	O

1	Estimation	O
2	of	O
3	renin	B
4	secretion	O
5	rate	O
6	and	O
7	renal	O
8	plasma	O
9	flow	O
10	from	O
11	peripheral	O
12	and	O
13	renal	O
14	vein	O
15	renin	B
16	levels	O
17	.	O

1	Therefore	O
2	,	O
3	we	O
4	have	O
5	identified	O
6	a	O
7	cis	O
8	-	O
9	acting	O
10	element	O
11	,	O
12	the	O
13	E1	B
14	E	I
15	-	I
16	box	I
17	,	O
18	located	O
19	in	O
20	the	O
21	GAP	B
22	-	I
23	43	I
24	promoter	I
25	region	O
26	that	O
27	modulates	O
28	either	O
29	positively	O
30	or	O
31	negatively	O
32	the	O
33	expression	O
34	of	O
35	the	O
36	GAP	B
37	-	I
38	43	I
39	gene	I
40	depending	O
41	on	O
42	which	O
43	E	O
44	-	O
45	box	I
46	-	I
47	binding	I
48	proteins	I
49	occupy	O
50	this	O
51	site	O
52	.	O

1	Deletion	O
2	analysis	O
3	indicates	O
4	that	O
5	TBP	B
6	and	O
7	hTAFII18	O
8	bind	O
9	to	O
10	distinct	O
11	domains	O
12	of	O
13	hTAFII28	O
14	.	O
15	hTAFII18	O
16	also	O
17	interacts	O
18	with	O
19	TBP	B
20	,	O
21	but	O
22	it	O
23	interacts	O
24	more	O
25	strongly	O
26	with	O
27	hTAFII28	O
28	and	O
29	hTAFII30	O
30	.	O

1	After	O
2	a	O
3	year	O
4	of	O
5	planning	O
6	in	O
7	the	O
8	Laboratory	O
9	Assistants	O
10	'	O
11	School	O
12	in	O
13	Stockholm	O
14	:	O
15	new	O
16	education	O
17	for	O
18	laboratory	O
19	assistants	O
20	is	O
21	now	O
22	arranged	O

1	Increasing	O
2	mean	O
3	arterial	O
4	pressure	O
5	by	O
6	phenylephrine	O
7	infusion	O
8	to	O
9	levels	O
10	much	O
11	greater	O
12	than	O
13	produced	O
14	by	O
15	NMA	O
16	and	O
17	NNA	O
18	caused	O
19	only	O
20	small	O
21	reductions	O
22	in	O
23	cardiac	O
24	output	O
25	.	O

1	Blood	O
2	levels	O
3	of	O
4	melatonin	O
5	,	O
6	serotonin	O
7	,	O
8	cortisol	O
9	,	O
10	and	O
11	prolactin	B
12	in	O
13	relation	O
14	to	O
15	the	O
16	circadian	O
17	rhythm	O
18	of	O
19	platelet	O
20	serotonin	I
21	uptake	O
22	.	O

1	Among	O
2	mammalian	B
3	HSFs	O
4	,	O
5	HSF1	B
6	has	O
7	been	O
8	shown	O
9	to	O
10	be	O
11	important	O
12	for	O
13	regulation	O
14	of	O
15	the	O
16	heat	O
17	-	O
18	induced	O
19	stress	B
20	gene	O
21	expression	O
22	,	O
23	whereas	O
24	the	O
25	function	O
26	of	O
27	HSF2	B
28	in	O
29	stress	O
30	response	O
31	is	O
32	unclear	O
33	.	O

1	In	O
2	patients	O
3	in	O
4	group	O
5	A	O
6	("	O
7	normal	O
8	"	O
9	CI	O
10	),	O
11	the	O
12	CI	O
13	,	O
14	heart	O
15	rate	O
16	and	O
17	the	O
18	mean	O
19	circumferential	O
20	fiber	O
21	shortening	O
22	velocity	O
23	(	O
24	mVCF	O
25	)	O
26	were	O
27	normal	O
28	,	O
29	but	O
30	the	O
31	TPR	O
32	was	O
33	increased	O
34	significantly	O
35	.	O

1	We	O
2	have	O
3	isolated	O
4	and	O
5	characterised	O
6	a	O
7	differentially	O
8	-	O
9	regulated	O
10	gene	O
11	family	O
12	in	O
13	the	O
14	protozoan	O
15	parasite	O
16	Leishmania	O
17	major	O
18	.	O

1	The	O
2	intracoronary	O
3	administration	O
4	of	O
5	both	O
6	drugs	O
7	markedly	O
8	reduced	O
9	the	O
10	incidence	O
11	of	O
12	VF	O
13	induced	O
14	by	O
15	the	O
16	release	O
17	of	O
18	a	O
19	40	O
20	-	O
21	min	O
22	coronary	O
23	artery	O
24	occlusion	O
25	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	overall	O
6	chance	O
7	that	O
8	a	O
9	patient	O
10	would	O
11	undergo	O
12	ET	O
13	was	O
14	greater	O
15	in	O
16	a	O
17	cycle	O
18	in	O
19	which	O
20	more	O
21	than	O
22	one	O
23	follicle	O
24	20	O
25	mm	O
26	or	O
27	larger	O
28	was	O
29	developing	O
30	than	O
31	in	O
32	a	O
33	cycle	O
34	in	O
35	which	O
36	a	O
37	single	O
38	large	O
39	follicle	O
40	was	O
41	developing	O
42	.	O

1	RNase	B
2	protection	O
3	analysis	O
4	of	O
5	two	O
6	rRNA	O
7	fragments	O
8	whose	O
9	genes	O
10	are	O
11	adjacent	O
12	provided	O
13	evidence	O
14	for	O
15	a	O
16	polycistronic	O
17	transcript	O
18	containing	O
19	sequences	O
20	from	O
21	both	O
22	,	O
23	as	O
24	well	O
25	as	O
26	separate	O
27	small	O
28	RNAs	O
29	.	O

1	This	O
2	spindle	O
3	defect	O
4	of	O
5	pds1	O
6	mutants	O
7	results	O
8	from	O
9	a	O
10	temperature	O
11	-	O
12	sensitive	O
13	step	O
14	that	O
15	occurs	O
16	around	O
17	the	O
18	G1	O
19	/	O
20	S	O
21	boundary	O
22	about	O
23	the	O
24	time	O
25	of	O
26	spindle	O
27	assembly	O
28	.	O

1	The	O
2	Pro	O
3	-	O
4	258	O
5	-->	O
6	Leu	O
7	(	O
8	P258L	O
9	)	O
10	mutation	O
11	caused	O
12	constitutive	O
13	receptor	O
14	signaling	O
15	that	O
16	was	O
17	equivalent	O
18	to	O
19	about	O
20	45	O
21	%	O
22	of	O
23	the	O
24	maximum	O
25	level	O
26	observed	O
27	in	O
28	wild	O
29	-	O
30	type	O
31	cells	O
32	stimulated	O
33	with	O
34	alpha	B
35	-	I
36	factor	I
37	.	O

1	Bisoprolol	O
2	was	O
3	found	O
4	to	O
5	be	O
6	an	O
7	effective	O
8	beta	B
9	-	O
10	adrenoceptor	I
11	antagonist	O
12	,	O
13	the	O
14	pA2	O
15	values	O
16	determined	O
17	against	O
18	isoprenaline	O
19	in	O
20	guinea	O
21	pig	O
22	atria	O
23	and	O
24	tracheal	O
25	muscle	O
26	being	O
27	7	O
28	.	O
29	45	O
30	and	O
31	6	O
32	.	O
33	41	O
34	,	O
35	respectively	O
36	.	O

1	The	O
2	growth	B
3	factor	I
4	receptor	I
5	-	I
6	bound	O
7	protein	I
8	2	I
9	(	O
10	Grb2	B
11	)	O
12	adaptor	O
13	when	O
14	complexed	O
15	with	O
16	Sos	B
17	(	O
18	Son	O
19	of	O
20	sevenless	O
21	),	O
22	the	O
23	exchange	O
24	factor	I
25	of	O
26	Ras	B
27	,	O
28	conveys	O
29	the	O
30	signal	O
31	induced	O
32	by	O
33	tyrosine	B
34	kinase	I
35	-	I
36	activated	I
37	receptor	I
38	to	O
39	Ras	B
40	by	O
41	recruiting	B
42	Sos	B
43	to	O
44	the	O
45	membrane	O
46	,	O
47	allowing	O
48	activation	O
49	of	O
50	Ras	B
51	.	O

1	An	O
2	industry	O
3	-	O
4	wide	O
5	retrospective	O
6	cohort	O
7	mortality	O
8	study	O
9	was	O
10	conducted	O
11	on	O
12	6	O
13	,	O
14	152	O
15	chemical	O
16	workers	O
17	(	O
18	2	O
19	,	O
20	460	O
21	exposed	O
22	and	O
23	3	O
24	,	O
25	692	O
26	nonexposed	O
27	)	O
28	engaged	O
29	in	O
30	chloromethyl	O
31	ether	O
32	manufacture	O
33	at	O
34	7	O
35	major	O
36	U	O
37	.	O
38	S	O
39	.	O
40	companies	O
41	between	O
42	1948	O
43	and	O
44	1980	O
45	.	O

1	In	O
2	30	O
3	dogs	O
4	the	O
5	left	O
6	limb	O
7	(	O
8	tail	O
9	)	O
10	of	O
11	the	O
12	pancreas	O
13	was	O
14	removed	O
15	but	O
16	left	O
17	in	O
18	the	O
19	abdominal	O
20	cavity	O
21	after	O
22	cessation	O
23	of	O
24	blood	O
25	flow	O
26	to	O
27	produce	O
28	warm	O
29	ischemia	O
30	for	O
31	30	O
32	,	O
33	60	O
34	,	O
35	and	O
36	120	O
37	min	O
38	(	O
39	10	O
40	dogs	O
41	at	O
42	each	O
43	time	O
44	point	O
45	),	O
46	and	O
47	then	O
48	was	O
49	flushed	O
50	with	O
51	cold	O
52	Ringers	O
53	'	O
54	lactate	O
55	and	O
56	transplanted	O
57	to	O
58	the	O
59	iliac	O
60	vessels	O
61	.	O

1	Rapid	O
2	detection	O
3	of	O
4	this	O
5	mutation	O
6	is	O
7	achieved	O
8	by	O
9	restriction	O
10	digestion	O
11	of	O
12	PCR	O
13	-	O
14	amplified	O
15	genomic	O
16	DNA	O
17	;	O
18	a	O
19	mismatch	O
20	primer	O
21	combined	O
22	with	O
23	the	O
24	point	O
25	mutation	O
26	creates	O
27	a	O
28	Tru9I	O
29	restriction	O
30	site	O
31	.	O

1	One	O
2	group	O
3	(	O
4	n	O
5	=	O
6	9	O
7	)	O
8	was	O
9	premedicated	O
10	with	O
11	midazolam	O
12	,	O
13	0	O
14	.	O
15	1	O
16	mg	O
17	kg	O
18	-	O
19	1	O
20	,	O
21	and	O
22	atropine	O
23	0	O
24	.	O
25	2	O
26	-	O
27	0	O
28	.	O
29	4	O
30	mg	O
31	i	O
32	.	O
33	m	O
34	.	O

1	A	O
2	method	O
3	for	O
4	the	O
5	simultaneous	O
6	determination	O
7	of	O
8	de	O
9	(	O
10	N	O
11	-	O
12	methyl	O
13	)-	O
14	N	O
15	-	O
16	ethyl	O
17	-	O
18	8	O
19	,	O
20	9	O
21	-	O
22	anhydroerythromycin	O
23	A	O
24	6	O
25	,	O
26	9	O
27	-	O
28	hemiacetal	O
29	(	O
30	EM523	O
31	,	O
32	I	O
33	)	O
34	and	O
35	its	O
36	three	O
37	metabolites	O
38	in	O
39	human	O
40	plasma	O
41	and	O
42	urine	O
43	has	O
44	been	O
45	developed	O
46	using	O
47	high	O
48	-	O
49	performance	O
50	liquid	O
51	chromatography	O
52	(	O
53	HPLC	O
54	)	O
55	with	O
56	chemiluminescence	O
57	(	O
58	CL	O
59	)	O
60	detection	O
61	.	O

1	This	O
2	approximately	O
3	125	O
4	-	O
5	nt	O
6	RNA	O
7	proved	O
8	to	O
9	arise	O
10	via	O
11	RNase	B
12	E	O
13	cleavage	O
14	from	O
15	the	O
16	3	O
17	'-	O
18	terminal	O
19	region	O
20	of	O
21	the	O
22	mRNAs	O
23	bearing	O
24	the	O
25	terminator	O
26	.	O

1	Point	O
2	mutations	O
3	of	O
4	the	O
5	site	O
6	that	O
7	suppressed	O
8	Pit	B
9	-	I
10	1	I
11	binding	O
12	in	O
13	vitro	O
14	restored	O
15	full	O
16	tiGH	O
17	promoter	O
18	activity	O
19	.	O

1	Reperfusion	O
2	with	O
3	normal	O
4	blood	O
5	in	O
6	the	O
7	beating	O
8	,	O
9	working	O
10	hearts	O
11	caused	O
12	extensive	O
13	structural	O
14	damage	O
15	,	O
16	reduced	O
17	reflow	O
18	,	O
19	and	O
20	failed	O
21	to	O
22	restore	O
23	contractility	O
24	in	O
25	any	O
26	instance	O
27	(-	O
28	27	O
29	%	O
30	systolic	O
31	shortening	O
32	,	O
33	p	O
34	less	O
35	than	O
36	0	O
37	.	O
38	05	O
39	).	O

1	The	O
2	observation	O
3	that	O
4	beta	B
5	2m	I
6	with	O
7	covalently	O
8	attached	O
9	peptide	O
10	can	O
11	effectively	O
12	create	O
13	CTL	O
14	target	O
15	structures	O
16	in	O
17	vitro	O
18	offers	O
19	new	O
20	possibilities	O
21	for	O
22	the	O
23	in	O
24	vivo	O
25	induction	O
26	of	O
27	epitope	O
28	-	O
29	specific	O
30	CTL	O
31	responses	O
32	by	O
33	either	O
34	DNA	O
35	immunization	O
36	or	O
37	injection	O
38	of	O
39	the	O
40	purified	O
41	epitope	O
42	-	O
43	linked	O
44	beta	O
45	2m	I
46	.	O

1	Plasma	O
2	leptin	B
3	concentrations	O
4	were	O
5	higher	O
6	in	O
7	women	O
8	than	O
9	men	O
10	,	O
11	even	O
12	after	O
13	the	O
14	adjustment	O
15	for	O
16	differences	O
17	in	O
18	fat	O
19	mass	O
20	(	O
21	28	O
22	+/-	O
23	3	O
24	ng	O
25	/	O
26	ml	O
27	for	O
28	women	O
29	vs	O
30	.	O

1	The	O
2	XS2	O
3	gene	O
4	down	O
5	-	O
6	regulates	O
7	but	O
8	does	O
9	not	O
10	abolish	O
11	expression	O
12	of	O
13	LU	O
14	genes	O
15	and	O
16	does	O
17	not	O
18	affect	O
19	expression	O
20	of	O
21	CD44	B
22	.	O

1	Studies	O
2	on	O
3	the	O
4	method	O
5	of	O
6	size	O
7	reduction	O
8	of	O
9	medicinal	O
10	compounds	O
11	.	O

1	The	O
2	emerging	O
3	complexity	O
4	of	O
5	the	O
6	5	O
7	'	O
8	regulatory	O
9	region	O
10	of	O
11	the	O
12	GH	B
13	receptor	I
14	gene	I
15	was	O
16	emphasised	O
17	by	O
18	the	O
19	observation	O
20	that	O
21	probes	O
22	derived	O
23	from	O
24	exon	O
25	1B	O
26	and	O
27	the	O
28	distal	O
29	3	O
30	'	O
31	intron	O
32	boundary	O
33	do	O
34	not	O
35	hybridise	O
36	with	O
37	previously	O
38	cloned	O
39	genomic	O
40	sequences	O
41	that	O
42	span	O
43	the	O
44	liver	O
45	-	O
46	specific	O
47	P1	O
48	promoter	O
49	and	O
50	exon	O
51	2	O
52	.	O

1	However	O
2	,	O
3	in	O
4	a	O
5	new	O
6	experiment	O
7	in	O
8	which	O
9	the	O
10	deletion	O
11	task	O
12	was	O
13	presented	O
14	as	O
15	a	O
16	puppet	O
17	game	O
18	,	O
19	and	O
20	with	O
21	pretraining	O
22	and	O
23	selection	O
24	on	O
25	vowel	O
26	deletion	O
27	,	O
28	a	O
29	significantly	O
30	higher	O
31	level	O
32	of	O
33	success	O
34	was	O
35	achieved	O
36	by	O
37	the	O
38	children	O
39	working	O
40	with	O
41	the	O
42	CVCC	O
43	material	O
44	.	O

1	Pulmonary	O
2	vascular	O
3	resistance	O
4	was	O
5	not	O
6	altered	O
7	,	O
8	ejection	O
9	fraction	O
10	remained	O
11	unchanged	O
12	and	O
13	isovolumic	O
14	relaxation	O
15	period	O
16	was	O
17	lengthened	O
18	(	O
19	119	O
20	+/-	O
21	20	O
22	.	O
23	1	O
24	to	O
25	147	O
26	.	O
27	39	O
28	+/-	O
29	21	O
30	.	O
31	15	O
32	,	O
33	P	O
34	less	O
35	than	O
36	0	O
37	.	O
38	05	O
39	).	O

1	Mycoplasma	O
2	hominis	O
3	infections	O
4	are	O
5	easily	O
6	missed	O
7	because	O
8	conventional	O
9	methods	O
10	for	O
11	bacterial	O
12	detection	O
13	may	O
14	fail	O
15	.	O

1	Her	O
2	serum	O
3	FT3	O
4	concentration	O
5	was	O
6	,	O
7	however	O
8	,	O
9	much	O
10	higher	O
11	than	O
12	the	O
13	ranges	O
14	in	O
15	normal	O
16	pregnancy	O
17	or	O
18	in	O
19	GTD	O
20	patients	O
21	without	O
22	clinical	O
23	hyperthyroidism	O
24	.	O

1	Collectively	O
2	,	O
3	our	O
4	findings	O
5	demonstrate	O
6	that	O
7	SF	B
8	-	I
9	1	I
10	plays	O
11	a	O
12	key	O
13	role	O
14	in	O
15	controlling	O
16	the	O
17	basal	O
18	and	O
19	cAMP	O
20	-	O
21	stimulated	O
22	expression	O
23	of	O
24	the	O
25	StAR	B
26	gene	I
27	.	O

1	This	O
2	study	O
3	was	O
4	aimed	O
5	at	O
6	assessing	O
7	whether	O
8	c	O
9	-	O
10	DDP	O
11	administration	O
12	immediately	O
13	before	O
14	radiotherapy	O
15	could	O
16	increase	O
17	frequency	O
18	and	O
19	duration	O
20	of	O
21	objective	O
22	responses	O
23	,	O
24	as	O
25	well	O
26	as	O
27	survival	O
28	,	O
29	in	O
30	patients	O
31	affected	O
32	with	O
33	locally	O
34	advanced	O
35	stages	O
36	of	O
37	squamous	O
38	carcinomas	O
39	of	O
40	the	O
41	head	O
42	and	O
43	neck	O
44	.	O

1	cDNA	O
2	cloning	O
3	,	O
4	expression	O
5	analysis	O
6	,	O
7	and	O
8	chromosomal	O
9	localization	O
10	of	O
11	a	O
12	gene	O
13	with	O
14	high	O
15	homology	O
16	to	O
17	wheat	B
18	eIF	I
19	-(	O
20	iso	I
21	)	O
22	4F	O
23	and	O
24	mammalian	B
25	eIF	I
26	-	I
27	4G	I
28	.	O

1	Expression	O
2	and	O
3	regulation	O
4	by	O
5	interferon	B
6	of	O
7	a	O
8	double	O
9	-	O
10	stranded	O
11	-	O
12	RNA	I
13	-	I
14	specific	O
15	adenosine	I
16	deaminase	I
17	from	O
18	human	O
19	cells	O
20	:	O
21	evidence	O
22	for	O
23	two	O
24	forms	O
25	of	O
26	the	O
27	deaminase	B
28	.	O

1	With	O
2	this	O
3	GH	B
4	and	O
5	estrogen	O
6	treatment	O
7	regimen	O
8	,	O
9	most	O
10	girls	O
11	with	O
12	TS	O
13	can	O
14	grow	O
15	and	O
16	develop	O
17	much	O
18	more	O
19	in	O
20	conformity	O
21	with	O
22	their	O
23	healthy	O
24	peers	O
25	.	O

1	When	O
2	nifA	B
3	mRNA	I
4	5	O
5	'	O
6	start	O
7	points	O
8	were	O
9	mapped	O
10	by	O
11	primer	O
12	extension	O
13	,	O
14	both	O
15	a	O
16	minor	O
17	upstream	O
18	transcript	O
19	(	O
20	s	O
21	)	O
22	starting	O
23	45	O
24	bp	O
25	distal	O
26	to	O
27	the	O
28	anaerobox	O
29	and	O
30	a	O
31	major	O
32	downstream	O
33	transcript	O
34	starting	O
35	10	O
36	bp	O
37	distal	O
38	to	O
39	the	O
40	sigma	B
41	54	I
42	box	I
43	were	O
44	observed	O
45	.	O

1	Static	O
2	magnetic	O
3	fields	O
4	affect	O
5	the	O
6	diffusion	O
7	of	O
8	biological	O
9	particles	O
10	in	O
11	solutions	O
12	through	O
13	the	O
14	Lorentz	O
15	force	O
16	and	O
17	Maxwell	O
18	stress	O
19	.	O

1	Specifically	O
2	,	O
3	the	O
4	deduced	O
5	FR	B
6	-	O
7	19	O
8	amino	O
9	acid	O
10	sequence	O
11	has	O
12	approximately89	O
13	,	O
14	77	O
15	,	O
16	and	O
17	68	O
18	%	O
19	overall	O
20	identity	O
21	to	O
22	chicken	B
23	TEF	I
24	-	I
25	1A	I
26	,	O
27	mouse	O
28	TEF	B
29	-	I
30	1	I
31	,	O
32	and	O
33	mouse	O
34	embryonic	O
35	TEA	O
36	domain	O
37	-	O
38	containing	O
39	factor	O
40	,	O
41	respectively	O
42	.	O

1	It	O
2	contained	O
3	seven	O
4	extra	O
5	amino	O
6	acids	O
7	of	O
8	FVVLNLQ	O
9	;	O
10	this	O
11	short	O
12	stretch	O
13	of	O
14	extra	O
15	sequence	O
16	was	O
17	found	O
18	between	O
19	Gln	O
20	(	O
21	421	O
22	)	O
23	and	O
24	Phe	O
25	(	O
26	422	O
27	)	O
28	within	O
29	the	O
30	SET	O
31	(	O
32	Suvar3	O
33	-	O
34	9	O
35	,	O
36	Enhancer	O
37	-	O
38	of	O
39	-	O
40	zeste	O
41	,	O
42	Trithorax	O
43	)	O
44	interacting	O
45	domain	O
46	(	O
47	SID	O
48	)	O
49	of	O
50	rMTM	O
51	.	O

1	FASEB	O
2	Federal	O
3	Funding	O
4	Consensus	O
5	Conference	O
6	FY	O
7	2000	O
8	.	O

1	An	O
2	essential	O
3	role	O
4	of	O
5	c	B
6	-	I
7	Jun	I
8	and	O
9	c	B
10	-	I
11	Fos	I
12	in	O
13	basal	O
14	and	O
15	PMA	O
16	-	O
17	stimulated	O
18	transcription	O
19	of	O
20	the	O
21	PAI	B
22	-	I
23	1	I
24	gene	I
25	is	O
26	demonstrated	O
27	by	O
28	our	O
29	finding	O
30	that	O
31	antisense	O
32	c	B
33	-	I
34	jun	I
35	and	O
36	c	B
37	-	I
38	fos	I
39	oligodeoxynucleotides	O
40	both	O
41	strongly	O
42	reduced	O
43	basal	O
44	and	O
45	PMA	O
46	-	O
47	stimulated	O
48	PAI	B
49	-	I
50	1	I
51	synthesis	O
52	.	O

1	Identification	O
2	and	O
3	characterization	O
4	of	O
5	specific	O
6	DNA	O
7	-	O
8	binding	O
9	complexes	O
10	containing	O
11	members	O
12	of	O
13	the	O
14	Myc	B
15	/	I
16	Max	B
17	/	O
18	Mad	B
19	network	O
20	of	O
21	transcriptional	O
22	regulators	O
23	.	O

1	The	O
2	second	O
3	complex	O
4	,	O
5	when	O
6	purified	O
7	,	O
8	contained	O
9	four	O
10	protein	O
11	components	O
12	including	O
13	the	O
14	36	O
15	-	O
16	kDa	O
17	protein	O
18	.	O

1	The	O
2	IE13	O
3	.	O
4	1	O
5	cell	O
6	line	O
7	was	O
8	able	O
9	to	O
10	complement	O
11	a	O
12	recombinant	O
13	virus	O
14	in	O
15	which	O
16	both	O
17	copies	O
18	of	O
19	the	O
20	IE	B
21	gene	I
22	were	O
23	replaced	O
24	by	O
25	insertion	O
26	of	O
27	the	O
28	Escherichia	B
29	coli	I
30	lacZ	B
31	gene	I
32	.	O

1	Within	O
2	each	O
3	lobe	O
4	,	O
5	the	O
6	PA	O
7	dispersion	O
8	was	O
9	up	O
10	to	O
11	10	O
12	cmH2O	O
13	at	O
14	CFV	O
15	of	O
16	90	O
17	l	O
18	/	O
19	min	O
20	;	O
21	when	O
22	flow	O
23	decreased	O
24	,	O
25	PA	O
26	at	O
27	all	O
28	sites	O
29	decreased	O
30	,	O
31	as	O
32	did	O
33	the	O
34	intralobar	O
35	dispersion	O
36	.	O

1	The	O
2	negative	O
3	predictive	O
4	value	O
5	is	O
6	92	O
7	%,	O
8	vs	O
9	80	O
10	%	O
11	for	O
12	the	O
13	NCEP	O
14	I	O
15	.	O

1	METHODS	O
2	:	O
3	Forty	O
4	-	O
5	nine	O
6	cases	O
7	with	O
8	intrahepatic	O
9	multiple	O
10	nodules	O
11	of	O
12	HCC	O
13	,	O
14	by	O
15	gross	O
16	examination	O
17	,	O
18	among	O
19	184	O
20	consecutive	O
21	resected	O
22	HCCs	O
23	were	O
24	examined	O
25	clinicopathologically	O
26	.	O

1	Spatial	O
2	accuracy	O
3	of	O
4	primary	O
5	and	O
6	secondary	O
7	memory	O
8	-	O
9	guided	O
10	saccades	O
11	in	O
12	schizophrenic	O
13	patients	O
14	.	O

1	Partial	O
2	engorgement	O
3	was	O
4	higher	O
5	in	O
6	the	O
7	treatments	O
8	.	O

1	Cerebrospinal	O
2	fluid	O
3	transferrin	B
4	II	O
5	studies	O
6	in	O
7	ischemic	O
8	disorders	O
9	of	O
10	the	O
11	central	O
12	nervous	O
13	system	O
14	.	O

1	Identification	O
2	of	O
3	an	O
4	AfsA	O
5	homologue	O
6	(	O
7	BarX	O
8	)	O
9	from	O
10	Streptomyces	O
11	virginiae	O
12	as	O
13	a	O
14	pleiotropic	O
15	regulator	O
16	controlling	O
17	autoregulator	O
18	biosynthesis	O
19	,	O
20	virginiamycin	O
21	biosynthesis	O
22	and	O
23	virginiamycin	O
24	M1	O
25	resistance	O
26	.	O

1	Consistently	O
2	,	O
3	activation	O
4	of	O
5	c	B
6	-	I
7	Jun	I
8	N	I
9	-	I
10	terminal	I
11	kinase	I
12	downstream	O
13	of	O
14	Rho	B
15	family	I
16	GTP	I
17	-	I
18	binding	I
19	proteins	I
20	was	O
21	also	O
22	enhanced	O
23	when	O
24	Dbl	B
25	was	O
26	tyrosine	O
27	-	O
28	phosphorylated	O
29	.	O

1	The	O
2	PDE4A	B
3	-	I
4	subfamily	I
5	-	O
6	specific	O
7	linker	O
8	region	O
9	LR1	O
10	,	O
11	which	O
12	joins	O
13	UCR1	O
14	and	O
15	UCR2	O
16	,	O
17	is	O
18	encoded	O
19	by	O
20	two	O
21	exons	O
22	,	O
23	whereas	O
24	LR2	O
25	,	O
26	which	O
27	joins	O
28	UCR2	O
29	to	O
30	the	O
31	catalytic	O
32	unit	O
33	,	O
34	is	O
35	encoded	O
36	by	O
37	a	O
38	single	O
39	exon	O
40	.	O

1	Increases	O
2	in	O
3	the	O
4	perfusate	O
5	PCO2	O
6	but	O
7	not	O
8	in	O
9	the	O
10	perfusate	O
11	H	O
12	+	O
13	were	O
14	highly	O
15	correlated	O
16	with	O
17	decreases	O
18	in	O
19	both	O
20	myocardial	O
21	contractility	O
22	and	O
23	oxygen	O
24	consumption	O
25	(	O
26	r2	O
27	=	O
28	.	O
29	88	O
30	).	O

1	The	O
2	enzymic	O
3	hydrolysis	O
4	of	O
5	urea	O
6	produces	O
7	ammonia	O
8	which	O
9	causes	O
10	a	O
11	vivid	O
12	yellow	O
13	to	O
14	purple	O
15	colour	O
16	change	O
17	in	O
18	the	O
19	pH	O
20	indicator	O
21	.	O

1	The	O
2	concentrations	O
3	of	O
4	vitamin	O
5	A	O
6	precursors	O
7	and	O
8	vitamin	O
9	E	O
10	in	O
11	the	O
12	hay	O
13	were	O
14	below	O
15	currently	O
16	recommended	O
17	dietary	O
18	levels	O
19	for	O
20	llamas	O
21	,	O
22	and	O
23	alfalfa	O
24	hay	O
25	appears	O
26	to	O
27	provide	O
28	an	O
29	unreliable	O
30	source	O
31	of	O
32	vitamins	O
33	A	O
34	and	O
35	E	O
36	in	O
37	this	O
38	species	O
39	.	O

1	In	O
2	all	O
3	instances	O
4	the	O
5	apparent	O
6	alcohol	O
7	responses	O
8	were	O
9	very	O
10	small	O
11	and	O
12	never	O
13	exceeded	O
14	a	O
15	reading	O
16	of	O
17	1	O
18	microgram	O
19	/	O
20	100ml	O
21	for	O
22	breath	O
23	samples	O
24	more	O
25	than	O
26	10min	O
27	post	O
28	-	O
29	exposure	O
30	.	O

1	Binding	O
2	of	O
3	U2	B
4	small	I
5	nuclear	I
6	ribonucleoprotein	I
7	(	O
8	snRNP	O
9	)	O
10	to	O
11	the	O
12	pre	O
13	-	O
14	mRNA	O
15	is	O
16	an	O
17	early	O
18	and	O
19	important	O
20	step	O
21	in	O
22	spliceosome	O
23	assembly	O
24	.	O

1	Experiments	O
2	showed	O
3	that	O
4	temporary	O
5	arrest	O
6	of	O
7	pulmonary	O
8	circulation	O
9	under	O
10	conditions	O
11	of	O
12	extracorporeal	O
13	circulation	O
14	is	O
15	attended	O
16	by	O
17	the	O
18	development	O
19	of	O
20	ischemia	O
21	of	O
22	the	O
23	respiratory	O
24	pulmonary	O
25	tissue	O
26	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	the	O
6	F	O
7	-	O
8	wave	O
9	may	O
10	be	O
11	elicited	O
12	in	O
13	motoneuron	O
14	of	O
15	different	O
16	depolarization	O
17	threshold	O
18	but	O
19	primarily	O
20	in	O
21	larger	O
22	and	O
23	faster	O
24	nerve	O
25	fibers	O
26	,	O
27	with	O
28	a	O
29	lower	O
30	threshold	O
31	of	O
32	depolarization	O
33	.	O

1	Replacement	O
2	of	O
3	the	O
4	wild	O
5	-	O
6	type	O
7	5	O
8	'-	O
9	regulatory	O
10	region	O
11	with	O
12	either	O
13	of	O
14	the	O
15	mutants	O
16	'	O
17	cis	O
18	-	O
19	acting	O
20	regulatory	O
21	element	O
22	resulted	O
23	in	O
24	the	O
25	anaerobic	O
26	expression	O
27	of	O
28	active	O
29	Mn	O
30	-	O
31	superoxide	B
32	dismutase	I
33	.	O

1	Our	O
2	findings	O
3	provide	O
4	the	O
5	first	O
6	evidence	O
7	that	O
8	the	O
9	function	O
10	of	O
11	WT1	B
12	can	O
13	be	O
14	modulated	O
15	by	O
16	its	O
17	phosphorylation	O
18	in	O
19	vivo	O
20	.	O

1	Quantitative	O
2	computed	O
3	tomography	O
4	for	O
5	measuring	O
6	vertebral	O
7	bone	O
8	mineral	O
9	content	O
10	offers	O
11	high	O
12	sensitivity	O
13	and	O
14	reproducibility	O
15	.	O

1	Clinical	O
2	and	O
3	haematological	O
4	signs	O
5	are	O
6	not	O
7	specific	O
8	in	O
9	this	O
10	setting	O
11	,	O
12	and	O
13	the	O
14	diagnosis	O
15	relies	O
16	on	O
17	histological	O
18	features	O
19	,	O
20	mainly	O
21	bone	O
22	marrow	O
23	examination	O
24	.	O

1	The	O
2	human	B
3	papillomavirus	O
4	type	I
5	16	I
6	E7	B
7	protein	I
8	complements	I
9	adenovirus	I
10	type	I
11	5	I
12	E1A	I
13	amino	O
14	-	O
15	terminus	O
16	-	O
17	dependent	O
18	transactivation	O
19	of	O
20	adenovirus	O
21	type	I
22	5	I
23	early	I
24	genes	O
25	and	O
26	increases	O
27	ATF	B
28	and	O
29	Oct	B
30	-	I
31	1	I
32	DNA	O
33	binding	O
34	activity	O
35	.	O

1	Lymphatics	O
2	in	O
3	the	O
4	aorta	O
5	of	O
6	rats	O
7	treated	O
8	with	O
9	a	O
10	soy	O
11	-	O
12	bean	O
13	oil	O
14	extract	O
15	(	O
16	lipofundin	O
17	).	O

1	Immunohistochemical	O
2	analysis	O
3	of	O
4	several	O
5	rat	O
6	organs	O
7	also	O
8	showed	O
9	staining	O
10	in	O
11	epithelial	O
12	cells	O
13	.	O

1	On	O
2	cessation	O
3	of	O
4	steroid	O
5	therapy	O
6	the	O
7	patient	O
8	was	O
9	noted	O
10	to	O
11	have	O
12	radiologic	O
13	manifestations	O
14	of	O
15	hypertrophic	O
16	osteoarthropathy	O
17	(	O
18	HOA	O
19	)	O
20	as	O
21	well	O
22	as	O
23	clinical	O
24	and	O
25	laboratory	O
26	features	O
27	of	O
28	rheumatoid	O
29	arthritis	O
30	(	O
31	RA	O
32	).	O

1	Although	O
2	antisperm	B
3	antibodies	O
4	are	O
5	associated	O
6	with	O
7	infertility	O
8	,	O
9	many	O
10	hospital	O
11	laboratories	O
12	do	O
13	not	O
14	test	O
15	for	O
16	these	O
17	antibodies	O
18	.	O

1	Selection	O
2	of	O
3	the	O
4	22	O
5	items	O
6	of	O
7	the	O
8	Clinical	O
9	Institute	O
10	Withdrawal	O
11	Assessment	O
12	-	O
13	Benzodiazepines	O
14	(	O
15	CIWA	O
16	-	O
17	B	O
18	)	O
19	was	O
20	based	O
21	on	O
22	statistically	O
23	significant	O
24	differences	O
25	between	O
26	baseline	O
27	and	O
28	critical	O
29	withdrawal	O
30	periods	O
31	in	O
32	high	O
33	-	O
34	dose	O
35	subjects	O
36	and	O
37	between	O
38	symptoms	O
39	associated	O
40	with	O
41	placebo	O
42	and	O
43	diazepam	O
44	in	O
45	low	O
46	-	O
47	dose	O
48	subjects	O
49	,	O
50	using	O
51	contingency	O
52	tables	O
53	and	O
54	logistic	O
55	regression	O
56	analysis	O
57	.	O

1	An	O
2	experiment	O
3	on	O
4	the	O
5	return	O
6	-	O
7	of	O
8	-	O
9	fear	O
10	(	O
11	ROF	O
12	)	O
13	was	O
14	carried	O
15	out	O
16	on	O
17	40	O
18	snake	O
19	-	O
20	or	O
21	spider	O
22	-	O
23	phobic	O
24	subjects	O
25	in	O
26	order	O
27	to	O
28	determine	O
29	whether	O
30	an	O
31	arousing	O
32	event	O
33	that	O
34	occurs	O
35	shortly	O
36	before	O
37	retest	O
38	influences	O
39	the	O
40	magnitude	O
41	of	O
42	the	O
43	ROF	O
44	.	O

1	We	O
2	describe	O
3	a	O
4	genetic	O
5	system	O
6	for	O
7	further	O
8	characterizing	O
9	the	O
10	role	O
11	of	O
12	the	O
13	extreme	O
14	C	O
15	-	O
16	terminus	O
17	of	O
18	the	O
19	beta	O
20	subunit	O
21	of	O
22	E	B
23	.	O
24	coli	I
25	RNA	I
26	polymerase	I
27	.	O

1	The	O
2	corticosterone	O
3	synthesis	O
4	inhibitor	O
5	metyrapone	O
6	(	O
7	75	O
8	mg	O
9	/	O
10	kg	O
11	i	O
12	.	O
13	p	O
14	.)	O
15	was	O
16	given	O
17	to	O
18	attenuate	O
19	the	O
20	rise	O
21	of	O
22	corticosterone	O
23	to	O
24	a	O
25	level	O
26	typical	O
27	of	O
28	stressed	O
29	males	O
30	.	O

1	Mean	O
2	increase	O
3	of	O
4	milk	O
5	protein	O
6	yield	O
7	was	O
8	46	O
9	g	O
10	/	O
11	d	O
12	with	O
13	Met	O
14	plus	O
15	Lys	O
16	,	O
17	and	O
18	mean	O
19	increase	O
20	of	O
21	true	O
22	protein	O
23	content	O
24	was	O
25	1	O
26	.	O
27	1	O
28	g	O
29	/	O
30	kg	O
31	of	O
32	milk	O
33	.	O

1	Phosphorylation	O
2	and	O
3	spindle	O
4	pole	O
5	body	O
6	localization	O
7	of	O
8	the	O
9	Cdc15p	O
10	mitotic	O
11	regulatory	B
12	protein	I
13	kinase	I
14	in	O
15	budding	O
16	yeast	O
17	.	O

1	Interestingly	O
2	,	O
3	addition	O
4	of	O
5	purified	O
6	CBP	B
7	to	O
8	the	O
9	nuclear	O
10	extracts	O
11	of	O
12	T47D	O
13	cells	O
14	markedly	O
15	stimulated	O
16	progesterone	O
17	-	O
18	and	O
19	PR	B
20	-	O
21	dependent	O
22	transcription	O
23	from	O
24	a	O
25	nucleosome	O
26	-	O
27	free	O
28	,	O
29	progesterone	O
30	response	O
31	element	O
32	(	O
33	PRE	O
34	)-	O
35	linked	O
36	reporter	O
37	DNA	O
38	template	O
39	.	O

1	Dosage	O
2	in	O
3	both	O
4	cases	O
5	was	O
6	0	O
7	.	O
8	2	O
9	g	O
10	/	O
11	m2	O
12	.	O

1	Immunochemotherapy	O
2	with	O
3	schizophyllan	O
4	(	O
5	SPG	O
6	)	O
7	combined	O
8	with	O
9	chemotherapeutic	O
10	agents	O
11	was	O
12	evaluated	O
13	in	O
14	two	O
15	syngeneic	O
16	tumor	O
17	-	O
18	C3H	O
19	/	O
20	He	O
21	mouse	O
22	systems	O
23	.	O

1	2	O
2	.	O

1	The	O
2	genome	O
3	of	O
4	Thogoto	O
5	virus	O
6	comprises	O
7	six	O
8	segments	O
9	of	O
10	single	O
11	-	O
12	stranded	O
13	,	O
14	negative	O
15	sense	O
16	RNA	O
17	.	O

1	Because	O
2	the	O
3	mutant	O
4	defective	O
5	in	O
6	DNA	O
7	binding	O
8	also	O
9	fails	O
10	to	O
11	stimulate	O
12	Abf1	B
13	ARS1	O
14	DNA	I
15	-	I
16	binding	O
17	activity	O
18	,	O
19	our	O
20	results	O
21	suggest	O
22	that	O
23	Cdc6	B
24	DNA	I
25	-	O
26	binding	O
27	activity	O
28	may	O
29	play	O
30	a	O
31	pivotal	O
32	role	O
33	in	O
34	the	O
35	initiation	O
36	of	O
37	DNA	O
38	replication	O
39	.	O

1	Consistent	O
2	with	O
3	previous	O
4	reports	O
5	,	O
6	addition	O
7	of	O
8	a	O
9	myristoylation	O
10	signal	O
11	to	O
12	mSos1	O
13	(	O
14	MyrSos1	O
15	)	O
16	rendered	O
17	it	O
18	transforming	O
19	for	O
20	NIH	O
21	3T3	O
22	cells	O
23	and	O
24	deletion	O
25	of	O
26	the	O
27	mSos	O
28	C	I
29	terminus	O
30	(	O
31	MyrSos1	O
32	-	O
33	deltaC	O
34	)	O
35	did	O
36	not	O
37	interfere	O
38	with	O
39	this	O
40	activity	O
41	.	O

1	Revascularization	O
2	after	O
3	anterior	O
4	maxillary	O
5	and	O
6	mandibular	O
7	osteotomy	O

1	During	O
2	the	O
3	program	O
4	'	O
5	s	O
6	use	O
7	at	O
8	the	O
9	RSNA	O
10	meeting	O
11	,	O
12	the	O
13	program	O
14	selected	O
15	the	O
16	correct	O
17	diagnosis	O
18	in	O
19	the	O
20	top	O
21	five	O
22	22	O
23	%	O
24	of	O
25	the	O
26	time	O
27	.	O

1	Baseline	O
2	measurements	O
3	of	O
4	forced	O
5	expiratory	O
6	volume	O
7	in	O
8	1	O
9	s	O
10	(	O
11	FEV1	O
12	),	O
13	specific	O
14	airway	O
15	conductance	O
16	(	O
17	SGaw	O
18	)	O
19	and	O
20	the	O
21	provocative	O
22	dose	O
23	of	O
24	carbachol	O
25	causing	O
26	a	O
27	35	O
28	%	O
29	reduction	O
30	in	O
31	SGaw	O
32	(	O
33	PD35	O
34	),	O
35	and	O
36	a	O
37	20	O
38	%	O
39	reduction	O
40	in	O
41	FEV1	O
42	(	O
43	PD20	O
44	)	O
45	were	O
46	established	O
47	on	O
48	entry	O
49	while	O
50	each	O
51	subject	O
52	was	O
53	still	O
54	smoking	O
55	.	O

1	Factors	O
2	involved	O
3	in	O
4	specific	O
5	transcription	O
6	by	O
7	mammalian	B
8	RNA	I
9	polymerase	I
10	II	I
11	:	O
12	purification	O
13	,	O
14	genetic	O
15	specificity	O
16	,	O
17	and	O
18	TATA	O
19	box	O
20	-	O
21	promoter	O
22	interactions	O
23	of	O
24	TFIID	B
25	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	T	O
6	.	O
7	C	O
8	.,	O
9	LDL	B
10	-	O
11	C	O
12	.,	O
13	HDL	B
14	-	O
15	C	O
16	.,	O
17	HDL2	B
18	-	O
19	C	O
20	.,	O
21	apo	B
22	B	O
23	,	O
24	apo	B
25	A	I
26	-	I
27	I	I
28	/	O
29	B	O
30	ratio	O
31	and	O
32	apo	B
33	A	I
34	-	I
35	II	I
36	/	O
37	B	O
38	ratio	O
39	are	O
40	predictive	O
41	risk	O
42	factors	O
43	of	O
44	the	O
45	coronary	O
46	heart	O
47	disease	O
48	.	O

1	Blocked	O
2	shift	O
3	/	O
4	supershift	O
5	analysis	O
6	indicates	O
7	that	O
8	Fos	B
9	family	I
10	member	I
11	proteins	I
12	especially	O
13	Fra	B
14	-	I
15	1	I
16	and	O
17	Fra	B
18	-	I
19	2	I
20	are	O
21	related	O
22	to	O
23	progression	O
24	and	O
25	no	O
26	changes	O
27	found	O
28	in	O
29	the	O
30	Jun	B
31	family	I
32	member	O
33	proteins	O
34	although	O
35	they	O
36	are	O
37	present	O
38	in	O
39	the	O
40	AP	B
41	-	I
42	1	I
43	/	O
44	DNA	O
45	binding	O
46	complex	O
47	.	O

1	The	O
2	major	O
3	myosin	B
4	-	I
5	binding	I
6	domain	I
7	of	O
8	skeletal	B
9	muscle	I
10	MyBP	I
11	-	I
12	C	I
13	(	O
14	C	B
15	protein	I
16	)	O
17	resides	O
18	in	O
19	the	O
20	COOH	O
21	-	O
22	terminal	O
23	,	O
24	immunoglobulin	B
25	C2	I
26	motif	I
27	.	O

1	However	O
2	,	O
3	whether	O
4	or	O
5	not	O
6	nonsense	O
7	codon	O
8	recognition	O
9	within	O
10	TPI	O
11	transcripts	O
12	takes	O
13	place	O
14	prior	O
15	to	O
16	or	O
17	after	O
18	splicing	O
19	remained	O
20	unresolved	O
21	.	O

1	Specimens	O
2	were	O
3	assayed	O
4	for	O
5	alpha	O
6	-	O
7	fetoprotein	I
8	,	O
9	unconjugated	O
10	estriol	O
11	,	O
12	free	O
13	alpha	O
14	hCG	B
15	,	O
16	and	O
17	total	O
18	hCG	B
19	.	O

1	Mutational	O
2	analysis	O
3	shows	O
4	that	O
5	both	O
6	an	O
7	AP	B
8	-	I
9	1	I
10	like	I
11	sequence	I
12	(-	O
13	294	O
14	/-	O
15	285	O
16	,	O
17	TGAATCATCA	O
18	)	O
19	and	O
20	an	O
21	A	O
22	/	O
23	T	B
24	-	I
25	rich	I
26	myocyte	B
27	enhancer	I
28	factor	I
29	(	O
30	MEF	B
31	)-	I
32	2	I
33	like	I
34	sequence	I
35	(-	O
36	310	O
37	/-	O
38	298	O
39	,	O
40	TTAAAAATAAAAA	O
41	)	O
42	in	O
43	the	O
44	33	O
45	-	O
46	bp	O
47	region	O
48	are	O
49	necessary	O
50	for	O
51	the	O
52	OP	B
53	-	O
54	1	O
55	effect	O
56	.	O

1	This	O
2	technique	O
3	has	O
4	a	O
5	sensitivity	O
6	and	O
7	a	O
8	specificity	O
9	of	O
10	almost	O
11	100	O
12	%,	O
13	and	O
14	is	O
15	currently	O
16	the	O
17	best	O
18	way	O
19	to	O
20	diagnose	O
21	nodal	O
22	involvement	O
23	,	O
24	apart	O
25	from	O
26	laparotomy	O
27	.	O

1	A	O
2	striking	O
3	feature	O
4	of	O
5	the	O
6	recombinant	B
7	H19	I
8	allele	I
9	is	O
10	the	O
11	occurrence	O
12	of	O
13	a	O
14	parental	O
15	imprint	O
16	set	O
17	on	O
18	the	O
19	neo	B
20	replacement	O
21	cassette	O
22	.	O

1	The	O
2	toxicological	O
3	evaluation	O
4	of	O
5	chlorofluorocarbon	O
6	22	O
7	(	O
8	CFC	O
9	22	O
10	).	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	the	O
6	M	O
7	.	O
8	jannaschii	O
9	as	O
10	well	O
11	as	O
12	related	O
13	archaeal	B
14	20S	I
15	proteasomes	O
16	require	O
17	a	O
18	nucleotidase	B
19	complex	O
20	such	O
21	as	O
22	PAN	O
23	to	O
24	mediate	O
25	the	O
26	energy	O
27	-	O
28	dependent	O
29	hydrolysis	O
30	of	O
31	folded	O
32	-	O
33	substrate	O
34	proteins	O
35	and	O
36	that	O
37	the	O
38	N	O
39	-	O
40	terminal	O
41	73	O
42	amino	O
43	acid	O
44	residues	O
45	of	O
46	PAN	O
47	are	O
48	not	O
49	absolutely	O
50	required	O
51	for	O
52	this	O
53	reaction	O
54	.	O

1	We	O
2	report	O
3	herein	O
4	the	O
5	case	O
6	of	O
7	a	O
8	30	O
9	-	O
10	year	O
11	-	O
12	old	O
13	man	O
14	in	O
15	whom	O
16	ectopic	O
17	mediastinal	O
18	parathyroid	O
19	adenoma	O
20	was	O
21	detected	O
22	by	O
23	99mTc	O
24	-	O
25	methoxyisobutylisonitrile	O
26	scintigraphy	O
27	(	O
28	99mTc	O
29	-	O
30	MIBI	O
31	).	O

1	Thus	O
2	,	O
3	although	O
4	multiple	O
5	senescence	O
6	pathways	O
7	are	O
8	activated	O
9	in	O
10	response	O
11	to	O
12	a	O
13	ras	B
14	oncogene	I
15	,	O
16	inactivation	O
17	of	O
18	TGFbeta1	O
19	secretion	O
20	or	O
21	response	O
22	is	O
23	sufficient	O
24	to	O
25	block	O
26	the	O
27	senescence	O
28	program	O
29	.	O

1	Some	O
2	users	O
3	will	O
4	willingly	O
5	comply	O
6	with	O
7	management	O
8	measures	O
9	,	O
10	other	O
11	users	O
12	will	O
13	comply	O
14	in	O
15	response	O
16	to	O
17	education	O
18	,	O
19	but	O
20	there	O
21	will	O
22	be	O
23	another	O
24	group	O
25	who	O
26	will	O
27	only	O
28	respond	O
29	to	O
30	enforcement	O
31	activities	O
32	.	O

1	Sequence	O
2	comparisons	O
3	strongly	O
4	suggest	O
5	that	O
6	the	O
7	S27a	O
8	and	O
9	the	O
10	ubiquitin	B
11	coding	I
12	sequences	O
13	found	O
14	in	O
15	the	O
16	genome	O
17	of	O
18	CP	O
19	Rit	O
20	were	O
21	both	O
22	derived	O
23	from	O
24	a	O
25	bovine	O
26	mRNA	O
27	encoding	O
28	a	O
29	hybrid	O
30	protein	O
31	with	O
32	the	O
33	structure	O
34	NH2	O
35	-	O
36	ubiquitin	I
37	-	I
38	S27a	I
39	-	O
40	COOH	O
41	.	O

1	However	O
2	,	O
3	in	O
4	the	O
5	subgroup	O
6	with	O
7	normal	O
8	Ht	O
9	(<	O
10	0	O
11	.	O
12	45	O
13	l	O
14	/	O
15	l	O
16	;	O
17	n	O
18	=	O
19	201	O
20	)	O
21	there	O
22	was	O
23	a	O
24	significant	O
25	reduction	O
26	(	O
27	p	O
28	<	O
29	0	O
30	.	O
31	05	O
32	)	O
33	of	O
34	the	O
35	mortality	O
36	after	O
37	3	O
38	months	O
39	(	O
40	27	O
41	%	O
42	and	O
43	16	O
44	%,	O
45	respectively	O
46	)	O
47	and	O
48	an	O
49	increase	O
50	of	O
51	independence	O
52	at	O
53	home	O
54	(	O
55	35	O
56	%	O
57	and	O
58	48	O
59	%,	O
60	respectively	O
61	)	O
62	due	O
63	to	O
64	a	O
65	reduction	O
66	of	O
67	the	O
68	viscosity	O
69	by	O
70	means	O
71	of	O
72	haemodilution	O
73	with	O
74	albumin	B
75	(	O
76	a	O
77	specific	O
78	viscosity	O
79	effect	O
80	in	O
81	the	O
82	normovolaemic	O
83	group	O
84	).	O

1	Immobilization	O
2	of	O
3	the	O
4	fracture	O
5	in	O
6	a	O
7	collar	O
8	and	O
9	cuff	O
10	sling	O
11	was	O
12	as	O
13	effective	O
14	as	O
15	more	O
16	elaborate	O
17	methods	O
18	.	O

1	Changes	O
2	in	O
3	tissue	O
4	PCO2	O
5	were	O
6	less	O
7	dramatic	O
8	and	O
9	did	O
10	not	O
11	vary	O
12	significantly	O
13	from	O
14	those	O
15	recorded	O
16	in	O
17	venous	O
18	blood	O
19	.	O

1	Hemodynamic	O
2	assessment	O
3	was	O
4	obtained	O
5	before	O
6	and	O
7	following	O
8	administration	O
9	of	O
10	digoxin	O
11	10	O
12	micrograms	O
13	/	O
14	kg	O
15	IV	O
16	or	O
17	dopamine	O
18	,	O
19	5	O
20	to	O
21	12	O
22	micrograms	O
23	/	O
24	kg	O
25	/	O
26	min	O
27	IV	O
28	.	O

1	To	O
2	study	O
3	the	O
4	sensitivity	O
5	of	O
6	some	O
7	central	O
8	brain	O
9	structures	O
10	to	O
11	the	O
12	action	O
13	of	O
14	an	O
15	electromagnetic	O
16	field	O
17	of	O
18	decimeter	O
19	waves	O
20	(	O
21	EMF	O
22	of	O
23	DW	O
24	)	O
25	a	O
26	dynamic	O
27	investigation	O
28	of	O
29	single	O
30	unit	O
31	activity	O
32	was	O
33	undertaken	O
34	.	O

1	Third	O
2	-	O
3	and	O
4	later	O
5	-	O
6	parity	O
7	cows	O
8	were	O
9	randomly	O
10	assigned	O
11	after	O
12	each	O
13	parturition	O
14	to	O
15	Charolais	O
16	and	O
17	Red	O
18	Poll	O
19	bulls	O
20	in	O
21	multiple	O
22	-	O
23	sire	O
24	pastures	O
25	.	O

1	We	O
2	conclude	O
3	that	O
4	TA	O
5	caused	O
6	a	O
7	specific	O
8	decrease	O
9	in	O
10	AGD	O
11	on	O
12	GD	O
13	20	O
14	that	O
15	was	O
16	largely	O
17	reversed	O
18	by	O
19	PCD	O
20	23	O
21	.	O

1	The	O
2	nifJ	O
3	and	O
4	nifH	B
5	promoters	O
6	of	O
7	Klebsiella	O
8	pneumoniae	O
9	are	O
10	divergently	O
11	transcribed	O
12	sigma	B
13	54	I
14	-	I
15	dependent	O
16	promoters	O
17	that	O
18	are	O
19	positively	O
20	activated	O
21	by	O
22	the	O
23	NifA	B
24	protein	I
25	.	O

1	However	O
2	,	O
3	it	O
4	remains	O
5	an	O
6	open	O
7	question	O
8	whether	O
9	vertebrate	O
10	Hox	B
11	genes	I
12	expressed	O
13	under	O
14	the	O
15	control	O
16	of	O
17	Drosophila	O
18	regulatory	I
19	sequences	I
20	can	O
21	substitute	O
22	the	O
23	function	O
24	of	O
25	Drosophila	B
26	Hox	I
27	genes	I
28	.	O

1	Analysis	O
2	of	O
3	the	O
4	sequences	O
5	with	O
6	the	O
7	BLAST	O
8	and	O
9	GRAIL	O
10	programs	O
11	provided	O
12	additional	O
13	independent	O
14	evidence	O
15	that	O
16	15	O
17	of	O
18	these	O
19	17	O
20	clones	O
21	contain	O
22	coding	O
23	sequences	O
24	and	O
25	that	O
26	nine	O
27	other	O
28	clones	O
29	are	O
30	likely	O
31	to	O
32	contain	O
33	sequences	O
34	coding	O
35	for	O
36	portions	O
37	of	O
38	new	O
39	genes	O
40	.	O

1	The	O
2	mean	O
3	blood	O
4	flow	O
5	in	O
6	the	O
7	penile	O
8	foreskin	O
9	was	O
10	estimated	O
11	to	O
12	be	O
13	15	O
14	ml	O
15	/	O
16	min	O
17	/	O
18	100	O
19	g	O
20	and	O
21	it	O
22	increased	O
23	to	O
24	150	O
25	-	O
26	200	O
27	%	O
28	after	O
29	the	O
30	induction	O
31	of	O
32	anesthesia	O
33	,	O
34	and	O
35	then	O
36	decreased	O
37	to	O
38	72	O
39	%	O
40	at	O
41	the	O
42	tip	O
43	of	O
44	the	O
45	created	O
46	parameatal	O
47	foreskin	O
48	flap	O
49	.	O

1	The	O
2	early	O
3	dg	O
4	.	O
5	of	O
6	rejection	O
7	and	O
8	especially	O
9	acute	O
10	rejection	O
11	,	O
12	it	O
13	'	O
14	s	O
15	adequate	O
16	management	O
17	,	O
18	decreased	O
19	risk	O
20	for	O
21	the	O
22	future	O
23	chronic	O
24	rejection	O
25	nephropathy	O
26	.	O

1	The	O
2	TEA1	O
3	(	O
4	Ty	B
5	enhancer	I
6	activator	I
7	)	I
8	gene	I
9	sequence	O
10	predicts	O
11	a	O
12	protein	O
13	of	O
14	86	O
15	.	O
16	9	O
17	kDa	O
18	whose	O
19	N	O
20	terminus	O
21	contains	O
22	a	O
23	zinc	O
24	cluster	O
25	and	O
26	dimerization	O
27	motif	O
28	typical	O
29	of	O
30	the	O
31	Gal4	B
32	-	O
33	type	O
34	family	O
35	of	O
36	DNA	O
37	-	O
38	binding	O
39	proteins	O
40	.	O

1	Nonlocal	O
2	approach	O
3	to	O
4	scattering	O
5	in	O
6	a	O
7	one	O
8	-	O
9	dimensional	O
10	problem	O
11	.	O

1	The	O
2	expression	O
3	of	O
4	the	O
5	pilin	B
6	gene	I
7	,	O
8	tcpA	O
9	,	O
10	is	O
11	dependent	O
12	upon	O
13	ToxR	B
14	and	O
15	upon	O
16	ToxT	O
17	.	O

1	Five	O
2	cell	O
3	strains	O
4	of	O
5	human	O
6	dermal	O
7	fibroblasts	O
8	were	O
9	each	O
10	treated	O
11	with	O
12	three	O
13	samples	O
14	of	O
15	burn	O
16	blister	O
17	fluid	O
18	and	O
19	the	O
20	effect	O
21	compared	O
22	with	O
23	the	O
24	rate	O
25	of	O
26	contraction	O
27	of	O
28	free	O
29	floating	O
30	fibroblast	O
31	populated	I
32	collagen	I
33	lattices	I
34	(	O
35	FPCL	O
36	).	O

1	Scotchbond	O
2	2	O
3	showed	O
4	the	O
5	least	O
6	dye	O
7	penetration	O
8	but	O
9	not	O
10	statistically	O
11	less	O
12	than	O
13	the	O
14	XR	O
15	bond	O
16	/	O
17	Silus	O
18	Plus	O
19	combination	O
20	.	O

1	This	O
2	study	O
3	was	O
4	designed	O
5	to	O
6	compare	O
7	the	O
8	efficacy	O
9	of	O
10	efegatran	O
11	plus	O
12	streptokinase	O
13	versus	O
14	heparin	O
15	plus	O
16	accelerated	O
17	tissue	O
18	plasminogen	B
19	activator	O
20	(	O
21	TPA	O
22	)	O
23	in	O
24	coronary	O
25	reperfusion	O
26	in	O
27	acute	O
28	MI	O
29	.	O

1	Prenatal	O
2	diagnosis	O
3	of	O
4	galactosaemia	O
5	.	O

1	This	O
2	paper	O
3	describes	O
4	the	O
5	advantages	O
6	and	O
7	limitations	O
8	of	O
9	the	O
10	main	O
11	study	O
12	approaches	O
13	used	O
14	.	O

1	Small	O
2	Maf	B
3	proteins	I
4	heterodimerize	O
5	with	O
6	Fos	B
7	and	O
8	may	O
9	act	O
10	as	O
11	competitive	O
12	repressors	O
13	of	O
14	the	O
15	NF	B
16	-	I
17	E2	I
18	transcription	I
19	factor	I
20	.	O

1	4	O
2	.	O

1	BCL6	B
2	encodes	O
3	a	O
4	POZ	O
5	/	O
6	Zn	B
7	finger	O
8	protein	O
9	,	O
10	a	O
11	structure	O
12	similar	O
13	to	O
14	that	O
15	of	O
16	many	O
17	Drosophila	O
18	developmental	O
19	regulators	O
20	and	O
21	to	O
22	another	O
23	protein	O
24	involved	O
25	in	O
26	a	O
27	human	O
28	hematopoietic	O
29	malignancy	O
30	,	O
31	PLZF	B
32	.	O

1	Aedes	O
2	aegypti	O
3	(	O
4	L	O
5	.)	O
6	and	O
7	Aedes	O
8	albopictus	O
9	(	O
10	Skuse	O
11	)	O
12	in	O
13	Singapore	O
14	City	O
15	.	O

1	A	O
2	36	O
3	year	O
4	-	O
5	old	O
6	woman	O
7	was	O
8	given	O
9	Ergotamine	O
10	Tartrate	O
11	4	O
12	.	O
13	5	O
14	mg	O
15	p	O
16	.	O
17	d	O
18	.	O
19	during	O
20	seven	O
21	days	O
22	,	O
23	after	O
24	an	O
25	abortion	O
26	(	O
27	a	O
28	still	O
29	birth	O
30	).	O

1	Deadenylation	O
2	and	O
3	decay	O
4	of	O
5	beta	B
6	-	I
7	globin	I
8	mRNA	I
9	in	O
10	K562	O
11	cells	O
12	is	O
13	extraordinarily	O
14	slow	O
15	compared	O
16	with	O
17	NIH	O
18	3T3	O
19	cells	O
20	,	O
21	suggesting	O
22	that	O
23	the	O
24	increased	O
25	stability	O
26	gained	O
27	by	O
28	beta	B
29	-	I
30	globin	I
31	mRNA	O
32	in	O
33	K562	O
34	cells	O
35	is	O
36	mainly	O
37	controlled	O
38	at	O
39	the	O
40	deadenylation	O
41	step	O
42	.	O

1	Oseltamivir	O
2	(	O
3	GS4104	O
4	),	O
5	which	O
6	can	O
7	be	O
8	administered	O
9	orally	O
10	,	O
11	is	O
12	the	O
13	prodrug	O
14	of	O
15	GS4071	O
16	,	O
17	a	O
18	potent	O
19	and	O
20	selective	O
21	inhibitor	O
22	of	O
23	influenzavirus	O
24	neuraminidases	O
25	.	O

1	The	O
2	first	O
3	146	O
4	consecutive	O
5	patients	O
6	treated	O
7	with	O
8	EVL	O
9	during	O
10	the	O
11	period	O
12	from	O
13	August	O
14	,	O
15	1986	O
16	to	O
17	July	O
18	,	O
19	1989	O
20	are	O
21	reported	O
22	.	O

1	Thus	O
2	,	O
3	despite	O
4	the	O
5	potential	O
6	for	O
7	common	O
8	regulatory	O
9	mechanisms	O
10	,	O
11	the	O
12	available	O
13	evidence	O
14	indicates	O
15	that	O
16	the	O
17	Mtx	B
18	minimal	O
19	promoter	I
20	does	O
21	not	O
22	significantly	O
23	affect	O
24	Thbs3	O
25	gene	O
26	expression	O
27	.	O

1	These	O
2	data	O
3	show	O
4	that	O
5	the	O
6	spv	O
7	virulence	O
8	genes	O
9	belong	O
10	simultaneously	O
11	to	O
12	several	O
13	regulons	O
14	in	O
15	the	O
16	cell	O
17	,	O
18	raising	O
19	the	O
20	possibility	O
21	that	O
22	spv	O
23	expression	O
24	can	O
25	be	O
26	fine	O
27	-	O
28	tuned	O
29	in	O
30	response	O
31	to	O
32	multiple	O
33	environmental	O
34	inputs	O
35	.	O

1	Using	O
2	a	O
3	v	O
4	-	O
5	erbA	I
6	probe	O
7	,	O
8	we	O
9	obtained	O
10	a	O
11	cDNA	O
12	which	O
13	encodes	O
14	a	O
15	novel	O
16	445	O
17	-	O
18	amino	O
19	-	I
20	acid	I
21	protein	I
22	,	O
23	RLD	B
24	-	I
25	1	I
26	,	O
27	that	O
28	contains	O
29	the	O
30	characteristic	O
31	domains	O
32	of	O
33	nuclear	O
34	receptors	I
35	.	O

1	Eight	O
2	of	O
3	14	O
4	infectious	O
5	or	O
6	inflammatory	O
7	lesions	O
8	could	O
9	be	O
10	detected	O
11	in	O
12	the	O
13	early	O
14	scan	O
15	(	O
16	4	O
17	-	O
18	6	O
19	h	O
20	p	O
21	.	O
22	i	O
23	.).	O

1	Treatment	O
2	of	O
3	2	O
4	patients	O
5	with	O
6	pseudohypoparathyroidism	O
7	type	O
8	I	O
9	with	O
10	vitamin	B
11	-	O
12	D	I
13	-	I
14	3	I
15	and	O
16	1	O
17	alpha	I
18	-	I
19	Hydroxycholecalciferol	O
20	consecutively	O
21	resulted	O
22	in	O
23	a	O
24	nonuniform	O
25	response	O
26	with	O
27	regard	O
28	to	O
29	the	O
30	normalisation	O
31	of	O
32	serum	O
33	-	O
34	calcium	O
35	.	O

1	Parodoxical	O
2	rise	O
3	in	O
4	urinary	O
5	albumin	B
6	levels	O
7	after	O
8	treatment	O
9	of	O
10	essential	O
11	hypertension	O
12	.	O

1	Histogenetic	O
2	aspects	O
3	of	O
4	mesoblastic	O
5	nephroma	O
6	.	O

1	Analyses	O
2	of	O
3	additional	O
4	tumors	O
5	induced	O
6	in	O
7	mice	O
8	from	O
9	two	O
10	reciprocal	O
11	crosses	O
12	,	O
13	A	O
14	/	O
15	J	O
16	x	O
17	C3H	O
18	/	O
19	HeJ	O
20	F1	O
21	(	O
22	hereafter	O
23	called	O
24	AC3F1	O
25	)	O
26	and	O
27	C3H	O
28	/	O
29	HeJ	O
30	x	O
31	A	O
32	/	O
33	J	O
34	F1	O
35	(	O
36	hereafter	O
37	called	O
38	C3AF1	O
39	),	O
40	provided	O
41	evidence	O
42	for	O
43	the	O
44	inactivation	O
45	of	O
46	one	O
47	allele	O
48	of	O
49	the	O
50	putative	O
51	chromosome	O
52	4	O
53	tumor	O
54	suppressor	I
55	gene	O
56	by	O
57	parental	O
58	imprinting	O
59	.	O

1	Causes	O
2	of	O
3	death	O
4	found	O
5	in	O
6	an	O
7	epidemiological	O
8	study	O
9	of	O
10	native	O
11	chickens	O
12	in	O
13	Thai	O
14	villages	O
15	.	O

1	SUMMARY	O
2	OF	O
3	REVIEW	O
4	:	O
5	We	O
6	discuss	O
7	the	O
8	criteria	O
9	that	O
10	make	O
11	such	O
12	studies	O
13	comparable	O
14	,	O
15	drawing	O
16	on	O
17	the	O
18	experiences	O
19	of	O
20	recent	O
21	studies	O
22	performed	O
23	around	O
24	the	O
25	world	O
26	.	O

1	Epidermal	B
2	growth	I
3	factor	I
4	receptor	I
5	transcriptionally	O
6	up	O
7	-	O
8	regulates	O
9	vascular	B
10	endothelial	I
11	growth	I
12	factor	I
13	expression	O
14	in	O
15	human	O
16	glioblastoma	O
17	cells	O
18	via	O
19	a	O
20	pathway	O
21	involving	O
22	phosphatidylinositol	B
23	3	O
24	'-	O
25	kinase	O
26	and	O
27	distinct	O
28	from	O
29	that	O
30	induced	O
31	by	O
32	hypoxia	O
33	.	O

1	By	O
2	screening	O
3	a	O
4	cDNA	O
5	library	O
6	with	O
7	a	O
8	probe	O
9	derived	O
10	from	O
11	sequences	O
12	downstream	O
13	of	O
14	the	O
15	p53p2	O
16	start	O
17	site	O
18	,	O
19	we	O
20	have	O
21	cloned	O
22	and	O
23	characterized	O
24	a	O
25	cDNA	O
26	that	O
27	represents	O
28	a	O
29	mRNA	O
30	that	O
31	appears	O
32	to	O
33	have	O
34	been	O
35	initiated	O
36	from	O
37	the	O
38	p53p2	O
39	promoter	O
40	.	O

1	It	O
2	is	O
3	,	O
4	however	O
5	,	O
6	extremely	O
7	homologous	O
8	to	O
9	a	O
10	third	O
11	'	O
12	non	O
13	-	O
14	classical	O
15	'	O
16	gene	I
17	,	O
18	HLA	B
19	-	I
20	5	I
21	.	O
22	4	I
23	,	O
24	and	O
25	to	O
26	the	O
27	chimpanzee	O
28	gene	O
29	,	O
30	Ch28	O
31	.	O

1	However	O
2	,	O
3	by	O
4	immobilized	O
5	metal	O
6	affinity	O
7	chromatography	O
8	assay	O
9	,	O
10	self	O
11	-	O
12	association	O
13	of	O
14	PR	B
15	-	I
16	A	I
17	was	O
18	3	O
19	.	O
20	5	O
21	-	O
22	fold	O
23	more	O
24	efficient	O
25	than	O
26	that	O
27	of	O
28	either	O
29	the	O
30	DhLBD	O
31	or	O
32	hLBD	O
33	constructs	O
34	.	O

1	Partial	O
2	characterization	O
3	of	O
4	the	O
5	active	O
6	site	O
7	human	I
8	platelet	I
9	cAMP	I
10	phosphodiesterase	I
11	,	O
12	PDE3A	O
13	,	O
14	by	O
15	site	O
16	-	O
17	directed	O
18	mutagenesis	O
19	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	a	O
6	range	O
7	of	O
8	microenvironmental	O
9	conditions	O
10	exist	O
11	within	O
12	purified	O
13	water	O
14	systems	O
15	,	O
16	leading	O
17	to	O
18	variable	O
19	populations	O
20	of	O
21	bacteria	O
22	.	O

1	State	O
2	of	O
3	the	O
4	body	O
5	in	O
6	disorders	O
7	of	O
8	diurnal	O
9	physiological	O
10	rhythms	O
11	and	O
12	long	O
13	-	O
14	term	O
15	hypokinesia	O

1	W	O
2	.	O

1	Mapping	O
2	features	O
3	of	O
4	HIV	O
5	-	O
6	1	I
7	integrase	I
8	near	O
9	selected	O
10	sites	O
11	on	O
12	viral	O
13	and	O
14	target	O
15	DNA	O
16	molecules	O
17	in	O
18	an	O
19	active	O
20	enzyme	O
21	-	O
22	DNA	O
23	complex	O
24	by	O
25	photo	O
26	-	O
27	cross	O
28	-	O
29	linking	O
30	.	O

1	We	O
2	have	O
3	previously	O
4	mapped	O
5	the	O
6	defect	O
7	in	O
8	RIIIS	O
9	/	O
10	J	O
11	to	O
12	distal	O
13	mouse	O
14	Chr	O
15	11	O
16	,	O
17	distinct	O
18	from	O
19	the	O
20	Vwf	O
21	locus	O
22	on	O
23	Chr	O
24	6	O
25	.	O

1	During	O
2	exercise	O
3	K	O
4	+	O
5	is	O
6	released	O
7	from	O
8	contracting	O
9	muscle	O
10	and	O
11	plasma	O
12	K	I
13	+	I
14	concentration	O
15	rises	O
16	.	O

1	TaV	O
2	particles	O
3	have	O
4	a	O
5	buoyant	O
6	density	O
7	of	O
8	1	O
9	.	O
10	296	O
11	g	O
12	/	O
13	cm3	O
14	in	O
15	CsCl	O
16	and	O
17	consist	O
18	of	O
19	two	O
20	capsid	O
21	proteins	O
22	of	O
23	56	O
24	and	O
25	6	O
26	kDa	O
27	.	O

1	The	O
2	R2	O
3	region	O
4	within	O
5	the	O
6	class	O
7	I	I
8	enhancer	I
9	acts	O
10	as	O
11	a	O
12	negative	O
13	element	O
14	in	O
15	Ad12	O
16	-	O
17	transformed	O
18	cells	O
19	and	O
20	exhibits	O
21	a	O
22	stronger	O
23	binding	O
24	activity	O
25	than	O
26	is	O
27	observed	O
28	in	O
29	nontumorigenic	O
30	Ad5	O
31	-	O
32	transformed	O
33	cells	O
34	,	O
35	which	O
36	are	O
37	not	O
38	reduced	O
39	in	O
40	class	O
41	I	O
42	expression	O
43	.	O

1	These	O
2	sequences	O
3	were	O
4	then	O
5	used	O
6	to	O
7	clone	O
8	the	O
9	full	O
10	-	O
11	length	O
12	genes	O
13	from	O
14	a	O
15	yeast	O
16	genomic	O
17	library	O
18	.	O

1	Antipyretic	O
2	therapy	O
3	:	O
4	physiologic	O
5	rationale	O
6	,	O
7	diagnostic	O
8	implications	O
9	,	O
10	and	O
11	clinical	O
12	consequences	O
13	.	O

1	Automatic	O
2	view	O
3	box	O
4	.	O

1	Homozygous	O
2	null	O
3	embryos	O
4	also	O
5	displayed	O
6	abnormalities	O
7	in	O
8	heart	O
9	development	O
10	,	O
11	consistent	O
12	with	O
13	the	O
14	conclusion	O
15	that	O
16	Tek	O
17	is	O
18	necessary	O
19	for	O
20	endocardial	O
21	/	O
22	myocardial	O
23	interactions	O
24	during	O
25	development	O
26	.	O

1	We	O
2	introduced	O
3	the	O
4	gel	O
5	technique	O
6	as	O
7	a	O
8	routine	O
9	assay	O
10	for	O
11	antibody	O
12	detection	O
13	and	O
14	identification	O
15	in	O
16	1993	O
17	.	O

1	A	O
2	second	O
3	study	O
4	group	O
5	,	O
6	with	O
7	intact	O
8	cardiac	O
9	innervation	O
10	,	O
11	consisted	O
12	of	O
13	19	O
14	patients	O
15	with	O
16	stable	O
17	angina	O
18	pectoris	O
19	class	O
20	I	O
21	to	O
22	III	O
23	.	O

1	Amino	O
2	acid	O
3	sequence	O
4	of	O
5	one	O
6	human	O
7	liver	O
8	clone	O
9	(	O
10	HL	B
11	-	I
12	14	I
13	)	O
14	was	O
15	identical	O
16	to	O
17	the	O
18	rabbit	B
19	skeletal	I
20	muscle	I
21	phosphatase	I
22	2A	I
23	cDNA	I
24	(	O
25	with	O
26	97	O
27	%	O
28	nucleotide	O
29	identity	O
30	).	O

1	In	O
2	viral	O
3	infections	O
4	,	O
5	G	B
6	-	O
7	CSF	I
8	was	O
9	correlated	O
10	with	O
11	mononuclear	O
12	cells	O
13	(	O
14	rs	O
15	=	O
16	0	O
17	.	O
18	41	O
19	,	O
20	P	O
21	<	O
22	0	O
23	.	O
24	05	O
25	),	O
26	white	O
27	blood	O
28	cell	O
29	counts	O
30	(	O
31	rs	O
32	=	O
33	0	O
34	.	O
35	56	O
36	,	O
37	P	O
38	<	O
39	0	O
40	.	O
41	01	O
42	),	O
43	neutrophils	O
44	(	O
45	rs	O
46	=	O
47	0	O
48	.	O
49	41	O
50	,	O
51	P	O
52	<	O
53	0	O
54	.	O
55	05	O
56	)	O
57	and	O
58	CRP	B
59	(	O
60	rs	O
61	=	O
62	0	O
63	.	O
64	47	O
65	,	O
66	P	O
67	<	O
68	0	O
69	.	O
70	05	O
71	).	O

1	A	O
2	prospective	O
3	observational	O
4	study	O
5	was	O
6	conducted	O
7	to	O
8	identify	O
9	early	O
10	indicators	O
11	of	O
12	acute	O
13	dengue	O
14	virus	O
15	infection	O
16	.	O

1	Variations	O
2	in	O
3	the	O
4	5	O
5	'	O
6	half	O
7	of	O
8	U3	O
9	were	O
10	primarily	O
11	due	O
12	to	O
13	insertions	O
14	and	O
15	deletions	O
16	.	O

1	Protein	B
2	tyrosine	I
3	phosphatases	I
4	(	O
5	PTPs	O
6	),	O
7	together	O
8	with	O
9	protein	B
10	tyrosine	I
11	kinases	I
12	(	O
13	PTKs	B
14	),	O
15	are	O
16	involved	O
17	in	O
18	the	O
19	regulation	O
20	of	O
21	cell	O
22	activation	O
23	,	O
24	growth	O
25	,	O
26	and	O
27	differentiation	O
28	.	O

1	PRL	I
2	receptor	I
3	also	O
4	activates	O
5	SHP	B
6	-	I
7	2	I
8	,	O
9	a	O
10	cytosolic	O
11	tyrosine	B
12	phosphatase	I
13	.	O

1	The	O
2	most	O
3	common	O
4	grade	O
5	3	O
6	toxicity	O
7	was	O
8	neutropenia	O
9	,	O
10	thrombocytopenia	O
11	,	O
12	and	O
13	parasthesias	O
14	(	O
15	observed	O
16	in	O
17	<	O
18	10	O
19	%	O
20	of	O
21	cycles	O
22	).	O

1	Behaviorally	O
2	,	O
3	a	O
4	pain	O
5	-	O
6	tolerant	O
7	group	O
8	(	O
9	PT	O
10	=	O
11	29	O
12	Ss	O
13	)	O
14	tolerated	O
15	the	O
16	entire	O
17	3	O
18	-	O
19	min	O
20	test	O
21	(	O
22	means	O
23	=	O
24	180	O
25	+/-	O
26	0	O
27	sec	O
28	),	O
29	while	O
30	a	O
31	pain	O
32	-	O
33	sensitive	O
34	group	O
35	(	O
36	PS	O
37	=	O
38	13	O
39	Ss	O
40	)	O
41	averaged	O
42	only	O
43	50	O
44	.	O
45	31	O
46	+/-	O
47	20	O
48	.	O
49	81	O
50	sec	O
51	of	O
52	the	O
53	cold	O
54	-	O
55	pressor	O
56	test	O
57	(	O
58	t	O
59	=	O
60	16	O
61	.	O
62	75	O
63	,	O
64	P	O
65	less	O
66	than	O
67	0	O
68	.	O
69	0001	O
70	),	O
71	replicating	O
72	our	O
73	earlier	O
74	studies	O
75	.	O

1	Taken	O
2	together	O
3	,	O
4	our	O
5	data	O
6	indicate	O
7	that	O
8	multiple	O
9	survival	O
10	pathways	O
11	are	O
12	triggered	O
13	via	O
14	this	O
15	receptor	O
16	,	O
17	whereas	O
18	NF	B
19	-	I
20	kappaB	I
21	/	O
22	Rel	B
23	and	O
24	PI	O
25	-	O
26	3K	O
27	are	O
28	crucial	O
29	for	O
30	CD40	O
31	-	O
32	induced	O
33	proliferation	O
34	.	O

1	We	O
2	measured	O
3	serum	B
4	hepatocyte	B
5	growth	I
6	factor	I
7	(	O
8	HGF	B
9	)	O
10	in	O
11	patients	O
12	with	O
13	acute	O
14	myocardial	O
15	infarction	O
16	,	O
17	angina	O
18	pectoris	O
19	,	O
20	and	O
21	other	O
22	heart	O
23	diseases	O
24	.	O

1	Deletion	O
2	of	O
3	the	O
4	proximal	O
5	octanucleotide	O
6	motif	O
7	from	O
8	the	O
9	plasmid	O
10	containing	O
11	the	O
12	-	O
13	461	O
14	fragment	O
15	of	O
16	the	O
17	LPL	B
18	promoter	I
19	,	O
20	resulted	O
21	in	O
22	a	O
23	79	O
24	and	O
25	76	O
26	%	O
27	decrease	O
28	in	O
29	the	O
30	level	O
31	of	O
32	expression	O
33	in	O
34	transfected	O
35	3T3	O
36	-	O
37	L1	O
38	adipocytes	O
39	and	O
40	HepG2	O
41	hepatocytes	O
42	,	O
43	respectively	O
44	.	O

1	ENV	O
2	also	O
3	was	O
4	secreted	O
5	from	O
6	P	O
7	.	O
8	pastoris	O
9	using	O
10	the	O
11	S	O
12	.	O
13	cerevisiae	I
14	alpha	I
15	-	I
16	factor	I
17	prepro	I
18	secretion	O
19	leader	O
20	and	O
21	the	O
22	S	O
23	.	O
24	cerevisiae	O
25	invertase	B
26	signal	I
27	sequence	O
28	.	O

1	We	O
2	identify	O
3	considerable	O
4	spatio	O
5	-	O
6	temporal	O
7	similarities	O
8	between	O
9	reported	O
10	expression	O
11	patterns	O
12	of	O
13	Ypr10	O
14	genes	O
15	and	O
16	ribonuclease	O
17	genes	O
18	,	O
19	which	O
20	,	O
21	together	O
22	with	O
23	the	O
24	significant	O
25	sequence	O
26	similarity	O
27	to	O
28	the	O
29	ginseng	O
30	ribonuclease	O
31	,	O
32	support	O
33	the	O
34	hypothesis	O
35	of	O
36	a	O
37	ribonuclease	O
38	function	O
39	for	O
40	PR	B
41	-	I
42	10	I
43	proteins	I
44	and	O
45	allow	O
46	the	O
47	prediction	O
48	of	O
49	possible	O
50	biological	O
51	roles	O
52	.	O

1	Both	O
2	inserts	O
3	are	O
4	larger	O
5	than	O
6	their	O
7	homologues	O
8	in	O
9	eIF	B
10	-	I
11	2alpha	I
12	kinases	I
13	.	O

1	On	O
2	the	O
3	other	O
4	hand	O
5	,	O
6	neither	O
7	phosphate	O
8	buffered	O
9	saline	O
10	injection	O
11	into	O
12	the	O
13	ES	O
14	nor	O
15	primary	O
16	KLH	O
17	challenges	O
18	of	O
19	the	O
20	ES	O
21	were	O
22	capable	O
23	of	O
24	elevating	O
25	the	O
26	threshold	O
27	level	O
28	and	O
29	changing	O
30	the	O
31	latency	O
32	.	O

1	The	O
2	experiments	O
3	show	O
4	that	O
5	it	O
6	is	O
7	the	O
8	micromilieu	O
9	of	O
10	the	O
11	alveoli	O
12	and	O
13	the	O
14	condition	O
15	of	O
16	the	O
17	AM	O
18	(	O
19	certain	O
20	physiological	O
21	activation	O
22	states	O
23	,	O
24	such	O
25	as	O
26	phagocytic	O
27	activity	O
28	)	O
29	that	O
30	essentially	O
31	determine	O
32	the	O
33	degree	O
34	of	O
35	recovery	O
36	.	O

1	To	O
2	identify	O
3	structural	O
4	features	O
5	of	O
6	residues	O
7	flanking	O
8	the	O
9	c	B
10	-	I
11	region	O
12	that	O
13	influence	O
14	the	O
15	fidelity	O
16	and	O
17	efficiency	O
18	of	O
19	signal	O
20	peptidase	O
21	cleavage	O
22	as	O
23	well	O
24	as	O
25	co	O
26	-	O
27	translational	O
28	translocation	O
29	,	O
30	we	O
31	introduced	O
32	six	O
33	amino	O
34	acid	O
35	substitutions	O
36	into	O
37	the	O
38	COOH	O
39	terminus	O
40	of	O
41	the	O
42	hydrophobic	O
43	core	O
44	and	O
45	seven	O
46	substitutions	O
47	at	O
48	the	O
49	NH2	O
50	terminus	O
51	of	O
52	the	O
53	mature	O
54	region	O
55	(	O
56	the	O
57	+	O
58	1	O
59	position	O
60	)	O
61	of	O
62	a	O
63	model	O
64	eukaryotic	O
65	preprotein	O
66	-	O
67	human	O
68	pre	O
69	(	O
70	delta	O
71	pro	O
72	)	O
73	apoA	O
74	-	O
75	II	O
76	.	O

1	The	O
2	role	O
3	of	O
4	HIV	O
5	tat	B
6	,	O
7	which	O
8	is	O
9	the	O
10	main	O
11	enhancing	O
12	factor	O
13	for	O
14	viral	O
15	LTR	O
16	,	O
17	in	O
18	the	O
19	regulation	O
20	of	O
21	IL	B
22	-	I
23	2	I
24	gene	I
25	transcription	O
26	has	O
27	been	O
28	studied	O
29	following	O
30	transient	O
31	expression	O
32	of	O
33	the	O
34	tat	B
35	gene	O
36	in	O
37	phorbol	O
38	ester	O
39	and	O
40	calcium	O
41	ionophore	O
42	-	O
43	activated	O
44	Jurkat	O
45	cells	O
46	transfected	O
47	with	O
48	IL	B
49	-	I
50	2	I
51	promoter	I
52	-	I
53	chloramphenicol	I
54	acetyltransferase	I
55	reporter	O
56	constructs	O
57	.	O

1	In	O
2	transformed	O
3	E	O
4	.	O
5	coli	O
6	,	O
7	constitutive	O
8	CAT	B
9	expression	O
10	is	O
11	maintained	O
12	when	O
13	as	O
14	little	O
15	as	O
16	0	O
17	.	O
18	3	O
19	kilobase	O
20	of	O
21	DNA	O
22	from	O
23	the	O
24	3	O
25	'	O
26	end	O
27	of	O
28	the	O
29	1	O
30	.	O
31	6	O
32	-	O
33	kilobase	O
34	segment	O
35	is	O
36	inserted	O
37	in	O
38	the	O
39	correct	O
40	orientation	O
41	in	O
42	front	O
43	of	O
44	the	O
45	CAT	B
46	gene	I
47	.	O

1	This	O
2	multiple	O
3	-	O
4	electrode	O
5	array	O
6	for	O
7	round	O
8	window	O
9	cochlear	O
10	implantation	O
11	is	O
12	a	O
13	robust	O
14	,	O
15	reliable	O
16	system	O
17	for	O
18	inserting	O
19	20	O
20	mm	O
21	along	O
22	the	O
23	scala	O
24	tympani	O
25	with	O
26	a	O
27	minimum	O
28	of	O
29	trauma	O
30	and	O
31	can	O
32	provide	O
33	for	O
34	bipolar	O
35	stimulation	O
36	.	O

1	Serum	B
2	prostatic	B
3	acid	I
4	phosphatase	I
5	levels	O
6	showed	O
7	a	O
8	significantly	O
9	weaker	O
10	correlation	O
11	with	O
12	cancer	O
13	volume	O
14	(	O
15	r	O
16	equals	O
17	0	O
18	.	O
19	51	O
20	)	O
21	and	O
22	every	O
23	other	O
24	pathological	O
25	parameter	O
26	.	O

1	Mothers	O
2	with	O
3	severe	O
4	anatomical	O
5	abnormalities	O
6	,	O
7	who	O
8	are	O
9	HIV	O
10	positive	O
11	,	O
12	have	O
13	active	O
14	TB	O
15	or	O
16	whose	O
17	children	O
18	have	O
19	inherited	O
20	mono	O
21	-	O
22	or	O
23	disaccharide	O
24	intolerances	O
25	should	O
26	not	O
27	breastfeed	O
28	.	O

1	The	O
2	expression	O
3	of	O
4	the	O
5	first	O
6	two	O
7	genes	O
8	located	O
9	in	O
10	this	O
11	unit	O
12	(	O
13	c	B
14	-	I
15	gvpD	I
16	and	O
17	c	B
18	-	I
19	gvpE	I
20	)	O
21	was	O
22	also	O
23	monitored	O
24	by	O
25	Western	O
26	blot	O
27	(	O
28	immunoblot	O
29	)	O
30	analyses	O
31	using	O
32	antisera	O
33	raised	O
34	against	O
35	these	O
36	proteins	O
37	synthesized	O
38	in	O
39	Escherichia	O
40	coli	O
41	.	O

1	The	O
2	architecture	O
3	of	O
4	microvasculature	O
5	in	O
6	these	O
7	two	O
8	regions	O
9	was	O
10	also	O
11	examined	O
12	by	O
13	scanning	O
14	electron	O
15	microscopy	O
16	,	O
17	using	O
18	the	O
19	resin	O
20	casting	O
21	method	O
22	.	O

1	A	O
2	cluster	O
3	of	O
4	basic	O
5	amino	O
6	acids	O
7	,	O
8	KKKR	O
9	,	O
10	generated	O
11	by	O
12	joining	O
13	of	O
14	the	O
15	sequences	O
16	encoded	O
17	by	O
18	the	O
19	constitutive	O
20	exon	O
21	13	O
22	and	O
23	the	O
24	alternative	O
25	exon	O
26	16	O
27	,	O
28	is	O
29	necessary	O
30	for	O
31	the	O
32	nuclear	O
33	targeting	O
34	of	O
35	4	O
36	.	O
37	1H	O
38	,	O
39	as	O
40	demonstrated	O
41	by	O
42	site	O
43	-	O
44	directed	O
45	mutagenesis	O
46	analysis	O
47	.	O

1	The	O
2	experimental	O
3	design	O
4	incorporated	O
5	a	O
6	multiple	O
7	regression	O
8	model	O
9	,	O
10	sequential	O
11	treatments	O
12	and	O
13	a	O
14	proportional	O
15	end	O
16	point	O
17	(	O
18	95	O
19	%)	O
20	for	O
21	protection	O
22	time	O
23	.	O

1	Dry	O
2	matter	O
3	intake	O
4	,	O
5	apparent	O
6	nutrient	O
7	digestibilities	O
8	,	O
9	serum	O
10	chemistry	O
11	profiles	O
12	,	O
13	sphingolipid	O
14	concentrations	O
15	,	O
16	and	O
17	persistency	O
18	of	O
19	FB1	O
20	in	O
21	tissues	O
22	were	O
23	evaluated	O
24	.	O

1	As	O
2	shown	O
3	previously	O
4	,	O
5	EBNA2	B
6	transactivates	O
7	the	O
8	promoters	O
9	of	O
10	the	O
11	viral	B
12	latent	I
13	membrane	I
14	proteins	I
15	.	O

1	Handling	O
2	on	O
3	PND	O
4	9	O
5	did	O
6	not	O
7	result	O
8	in	O
9	elevated	O
10	CORT	O
11	levels	O
12	in	O
13	any	O
14	of	O
15	the	O
16	groups	O
17	.	O

1	Whole	O
2	-	O
3	mount	O
4	in	O
5	situ	O
6	hybridization	O
7	to	O
8	early	O
9	mouse	O
10	embryos	O
11	of	O
12	9	O
13	.	O
14	5	O
15	-	O
16	10	O
17	.	O
18	5	O
19	days	O
20	indicated	O
21	a	O
22	complex	O
23	pattern	O
24	of	O
25	Arp1	O
26	expression	O
27	spatially	O
28	overlapping	O
29	with	O
30	the	O
31	expression	O
32	of	O
33	All1	O
34	.	O

1	All	O
2	problems	O
3	were	O
4	associated	O
5	with	O
6	fractured	O
7	or	O
8	lost	O
9	screws	O
10	.	O

1	G	O
2	.	O

1	Reactivities	O
2	to	O
3	horse	B
4	anti	I
5	-	I
6	lymphocyte	I
7	globulin	I
8	.	O

1	This	O
2	suggests	O
3	that	O
4	cardiovascular	O
5	magnetic	O
6	resonance	O
7	is	O
8	the	O
9	preferred	O
10	technique	O
11	for	O
12	volume	O
13	and	O
14	ejection	O
15	fraction	O
16	estimation	O
17	in	O
18	heart	O
19	failure	O
20	patients	O
21	,	O
22	because	O
23	of	O
24	its	O
25	3D	O
26	approach	O
27	for	O
28	non	O
29	-	O
30	symmetric	O
31	ventricles	O
32	and	O
33	superior	O
34	image	O
35	quality	O
36	.	O

1	Beyond	O
2	the	O
3	Tower	O
4	of	O
5	Babel	O
6	:	O
7	a	O
8	nomenclature	O
9	for	O
10	suicidology	O
11	.	O

1	RESULTS	O
2	:	O
3	The	O
4	cardiac	O
5	index	O
6	significantly	O
7	changed	O
8	with	O
9	varying	O
10	PaCO2	O
11	levels	O
12	(	O
13	hypocapnia	O
14	,	O
15	-	O
16	9	O
17	%;	O
18	hypercapnia	O
19	,	O
20	13	O
21	%).	O

1	The	O
2	gene	O
3	was	O
4	expressed	O
5	as	O
6	an	O
7	approximately	O
8	1	O
9	.	O
10	5	O
11	-	O
12	kb	O
13	mRNA	O
14	in	O
15	most	O
16	nonlymphoid	O
17	human	O
18	cells	O
19	/	O
20	tissues	O
21	including	O
22	prostate	O
23	,	O
24	lung	O
25	,	O
26	liver	O
27	,	O
28	and	O
29	colon	O
30	.	O

1	Altogether	O
2	,	O
3	the	O
4	results	O
5	demonstrate	O
6	that	O
7	the	O
8	two	O
9	isoforms	O
10	elicit	O
11	similar	O
12	responses	O
13	in	O
14	vivo	O
15	despite	O
16	differences	O
17	in	O
18	their	O
19	regulation	O
20	.	O

1	The	O
2	Dox	B
3	-	I
4	A2	I
5	locus	I
6	is	O
7	within	O
8	3	O
9	.	O
10	4	O
11	to	O
12	4	O
13	.	O
14	4	O
15	kb	O
16	of	O
17	the	O
18	Df	O
19	(	O
20	2L	O
21	)	O
22	OD15	O
23	breakpoint	O
24	,	O
25	placing	O
26	four	O
27	of	O
28	the	O
29	vital	O
30	loci	O
31	within	O
32	a	O
33	maximum	O
34	of	O
35	15	O
36	.	O
37	5	O
38	kb	O
39	.	O

1	We	O
2	report	O
3	the	O
4	identification	O
5	and	O
6	characterization	O
7	of	O
8	myr	B
9	4	I
10	(	O
11	myosin	B
12	from	O
13	rat	O
14	),	O
15	the	O
16	first	O
17	mammalian	B
18	myosin	I
19	I	I
20	that	O
21	is	O
22	not	O
23	closely	O
24	related	O
25	to	O
26	brush	O
27	border	O
28	myosin	B
29	I	I
30	.	O

1	We	O
2	have	O
3	determined	O
4	the	O
5	structure	O
6	of	O
7	the	O
8	WNT	B
9	-	I
10	2B	I
11	gene	I
12	.	O

1	To	O
2	determine	O
3	whether	O
4	interaction	O
5	of	O
6	arsenite	O
7	with	O
8	the	O
9	hormone	O
10	-	O
11	binding	O
12	domain	O
13	results	O
14	in	O
15	receptor	O
16	activation	O
17	,	O
18	COS	O
19	-	O
20	1	O
21	cells	O
22	were	O
23	transiently	O
24	cotransfected	O
25	with	O
26	the	O
27	chimeric	B
28	receptors	I
29	GAL	B
30	-	I
31	ER	I
32	,	O
33	which	O
34	contains	O
35	the	O
36	hormone	O
37	-	O
38	binding	O
39	domain	O
40	of	O
41	ERalpha	B
42	and	O
43	the	O
44	DNA	O
45	-	O
46	binding	O
47	domain	O
48	of	O
49	the	O
50	transcription	O
51	factor	I
52	GAL4	B
53	,	O
54	and	O
55	a	O
56	GAL4	B
57	-	O
58	responsive	O
59	CAT	B
60	reporter	O
61	gene	O
62	.	O

1	Oligonucleotide	O
2	mutagenesis	O
3	of	O
4	these	O
5	binding	O
6	domains	O
7	indicated	O
8	their	O
9	importance	O
10	in	O
11	the	O
12	transcriptional	O
13	regulation	O
14	of	O
15	the	O
16	E3	B
17	promoter	I
18	in	O
19	yeast	O
20	cells	O
21	.	O

1	There	O
2	was	O
3	a	O
4	close	O
5	correlation	O
6	between	O
7	plasma	O
8	clearance	O
9	of	O
10	NT	O
11	by	O
12	10	O
13	-	O
14	hydroxylation	O
15	and	O
16	the	O
17	D	O
18	metabolic	O
19	ratio	O
20	(	O
21	D	O
22	/	O
23	4	O
24	-	O
25	OH	O
26	-	O
27	D	O
28	in	O
29	urine	O
30	)	O
31	in	O
32	the	O
33	Ghanaians	O
34	(	O
35	rs	O
36	=	O
37	-	O
38	0	O
39	.	O
40	95	O
41	;	O
42	P	O
43	less	O
44	than	O
45	0	O
46	.	O
47	01	O
48	)	O
49	and	O
50	Swedes	O
51	(	O
52	rs	O
53	=	O
54	-	O
55	0	O
56	.	O
57	84	O
58	;	O
59	P	O
60	less	O
61	than	O
62	0	O
63	.	O
64	01	O
65	).	O

1	These	O
2	data	O
3	strongly	O
4	implicate	O
5	the	O
6	normal	O
7	product	O
8	of	O
9	the	O
10	int	B
11	-	I
12	2	I
13	gene	I
14	,	O
15	which	O
16	is	O
17	related	O
18	to	O
19	the	O
20	fibroblast	B
21	growth	I
22	factor	I
23	family	I
24	,	O
25	as	O
26	a	O
27	contributory	O
28	factor	O
29	in	O
30	virally	O
31	induced	O
32	mammary	O
33	tumors	O
34	.	O

1	That	O
2	of	O
3	the	O
4	T2	B
5	gene	O
6	contains	O
7	numerous	O
8	potential	O
9	sites	O
10	for	O
11	binding	O
12	the	O
13	mammalian	B
14	transcription	I
15	factor	I
16	SP1	B
17	,	O
18	but	O
19	no	O
20	TATA	O
21	or	O
22	CCAAT	O
23	sequences	O
24	are	O
25	evident	O
26	near	O
27	to	O
28	its	O
29	5	O
30	'	O
31	end	O
32	,	O
33	although	O
34	these	O
35	latter	O
36	features	O
37	are	O
38	associated	O
39	with	O
40	the	O
41	human	O
42	T1	O
43	gene	O
44	.	O

1	The	O
2	MMPI	O
3	-	O
4	A	O
5	(	O
6	Butcher	O
7	et	O
8	al	O
9	.,	O
10	1992	O
11	),	O
12	like	O
13	the	O
14	older	O
15	MMPI	O
16	(	O
17	Hathaway	O
18	&	O
19	McKinley	O
20	,	O
21	1983	O
22	),	O
23	distinguishes	O
24	between	O
25	anorexia	O
26	and	O
27	bulimia	O
28	.	O

1	Interleukin	B
2	-	I
3	8	I
4	(	O
5	IL	B
6	-	I
7	8	I
8	)	O
9	is	O
10	a	O
11	potent	O
12	inflammatory	O
13	mediator	O
14	that	O
15	belongs	O
16	to	O
17	the	O
18	family	O
19	of	O
20	C	O
21	-	O
22	X	O
23	-	O
24	C	O
25	chemokines	O
26	.	O

1	CONCLUSION	O
2	:	O
3	These	O
4	findings	O
5	imply	O
6	that	O
7	eotaxin	B
8	either	O
9	is	O
10	mechanistically	O
11	involved	O
12	in	O
13	acute	O
14	asthma	O
15	or	O
16	serves	O
17	as	O
18	a	O
19	biomarker	O
20	for	O
21	activity	O
22	of	O
23	the	O
24	CCR3	B
25	receptor	I
26	ligand	O
27	system	O
28	,	O
29	which	O
30	is	O
31	functionally	O
32	linked	O
33	to	O
34	asthma	O
35	.	O

1	In	O
2	summary	O
3	,	O
4	Ca	O
5	(	O
6	2	O
7	+)-	O
8	dependent	O
9	activation	O
10	of	O
11	NO	O
12	production	O
13	mediates	O
14	apoptosis	O
15	after	O
16	TG	O
17	exposure	O
18	in	O
19	JT	O
20	/	O
21	Neo	O
22	cells	O
23	.	O

1	We	O
2	have	O
3	identified	O
4	two	O
5	functional	O
6	elements	O
7	,	O
8	both	O
9	located	O
10	downstream	O
11	from	O
12	the	O
13	TATA	O
14	motif	O
15	,	O
16	that	O
17	control	O
18	Id4	B
19	promoter	I
20	activity	O
21	.	O

1	In	O
2	vivo	O
3	,	O
4	CARbeta	O
5	/	O
6	RXRalpha	B
7	activated	O
8	transcription	O
9	from	O
10	an	O
11	HD	B
12	-	O
13	PPRE	O
14	luciferase	B
15	reporter	I
16	construct	I
17	.	O

1	There	O
2	was	O
3	no	O
4	apparent	O
5	effect	O
6	of	O
7	growth	O
8	temperature	O
9	on	O
10	the	O
11	steady	O
12	-	O
13	state	O
14	levels	O
15	of	O
16	fad7	O
17	mRNA	O
18	in	O
19	wild	O
20	type	O
21	plants	O
22	.	O

1	Analysis	O
2	of	O
3	nucleotide	O
4	sequence	O
5	of	O
6	the	O
7	rightmost	O
8	43	O
9	kbp	O
10	of	O
11	herpesvirus	O
12	saimiri	O
13	(	O
14	HVS	O
15	)	O
16	L	O
17	-	O
18	DNA	O
19	:	O
20	general	O
21	conservation	O
22	of	O
23	genetic	O
24	organization	O
25	between	O
26	HVS	O
27	and	O
28	Epstein	O
29	-	O
30	Barr	O
31	virus	O
32	.	O

1	Five	O
2	of	O
3	the	O
4	Aeromonas	O
5	strains	O
6	and	O
7	one	O
8	of	O
9	V	O
10	cholerae	I
11	non	I
12	-	I
13	O1	I
14	were	O
15	positive	O
16	for	O
17	enterotoxin	O
18	activity	O
19	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	the	O
5	47	O
6	-	O
7	kilodalton	O
8	major	O
9	integral	O
10	membrane	O
11	immunogen	O
12	of	O
13	Treponema	O
14	pallidum	O
15	.	O

1	The	O
2	levels	O
3	of	O
4	galactosyltransferase	B
5	activity	O
6	in	O
7	sera	O
8	from	O
9	normal	O
10	children	O
11	and	O
12	patients	O
13	with	O
14	cystic	O
15	fibrosis	O
16	.	O

1	Adaptation	O
2	of	O
3	taurocholate	O
4	transport	O
5	maximum	O
6	to	O
7	increased	O
8	secretory	O
9	load	O
10	in	O
11	the	O
12	rat	O
13	.	O

1	Extramedullary	O
2	relapse	O
3	in	O
4	childhood	O
5	leukemia	O
6	.	O

1	If	O
2	,	O
3	however	O
4	,	O
5	the	O
6	mean	O
7	temperature	O
8	rise	O
9	was	O
10	higher	O
11	(	O
12	0	O
13	.	O
14	57	O
15	degrees	O
16	C	O
17	or	O
18	0	O
19	.	O
20	69	O
21	degrees	O
22	C	O
23	),	O
24	such	O
25	a	O
26	selection	O
27	practically	O
28	resulted	O
29	in	O
30	the	O
31	disappearance	O
32	of	O
33	'	O
34	passable	O
35	'	O
36	qualifications	O
37	in	O
38	the	O
39	triplet	O
40	groups	O
41	and	O
42	a	O
43	great	O
44	predominance	O
45	of	O
46	'	O
47	to	O
48	be	O
49	rejected	O
50	'	O
51	qualifications	O
52	in	O
53	the	O
54	large	O
55	groups	O
56	.	O

1	In	O
2	this	O
3	report	O
4	we	O
5	describe	O
6	for	O
7	the	O
8	first	O
9	time	O
10	the	O
11	complete	O
12	primary	O
13	structure	O
14	of	O
15	type	B
16	X	I
17	collagen	I
18	,	O
19	based	O
20	on	O
21	cloning	O
22	and	O
23	sequencing	O
24	of	O
25	cDNA	O
26	and	O
27	genomic	O
28	DNA	O
29	.	O

1	These	O
2	results	O
3	demonstrate	O
4	that	O
5	a	O
6	class	O
7	of	O
8	proline	O
9	-	O
10	rich	O
11	activator	I
12	proteins	I
13	and	O
14	RNA	B
15	polymerase	I
16	II	I
17	possess	O
18	a	O
19	common	O
20	structural	O
21	and	O
22	functional	O
23	component	O
24	which	O
25	can	O
26	interact	O
27	with	O
28	the	O
29	same	O
30	target	O
31	in	O
32	the	O
33	general	O
34	transcription	O
35	machinery	O
36	.	O

1	Using	O
2	mouse	O
3	-	O
4	human	O
5	somatic	O
6	hybrids	O
7	and	O
8	FISH	O
9	analysis	O
10	,	O
11	the	O
12	PE	B
13	-	I
14	2	I
15	gene	I
16	is	O
17	localized	O
18	to	O
19	human	O
20	chromosome	O
21	19q13	O
22	.	O
23	2	O
24	,	O
25	a	O
26	region	O
27	involved	O
28	in	O
29	translocations	O
30	and	O
31	deletions	O
32	in	O
33	leukemias	O
34	and	O
35	several	O
36	solid	O
37	tumors	O
38	,	O
39	suggesting	O
40	that	O
41	this	O
42	novel	O
43	ETS	B
44	factor	I
45	may	O
46	play	O
47	a	O
48	role	O
49	in	O
50	carcinogenesis	O
51	.	O

1	Thus	O
2	,	O
3	an	O
4	increase	O
5	in	O
6	plasma	O
7	TBG	B
8	and	O
9	a	O
10	shift	O
11	from	O
12	adrenal	O
13	androgen	O
14	and	O
15	mineralocorticoid	O
16	steroid	O
17	secretion	O
18	towards	O
19	cortisol	O
20	secretion	O
21	may	O
22	be	O
23	endocrine	O
24	markers	O
25	for	O
26	progression	O
27	of	O
28	the	O
29	disease	O
30	in	O
31	patients	O
32	with	O
33	HIV	O
34	-	O
35	infection	O
36	.	O

1	Technetium	O
2	-	O
3	99m	O
4	stannous	O
5	pyrophosphate	O
6	myocardial	O
7	scintigrams	O
8	were	O
9	obtained	O
10	in	O
11	138	O
12	clinically	O
13	stable	O
14	patients	O
15	32	O
16	.	O
17	7	O
18	+/-	O
19	47	O
20	.	O
21	3	O
22	weeks	O
23	(	O
24	range	O
25	6	O
26	to	O
27	260	O
28	)	O
29	after	O
30	acute	O
31	myocardial	O
32	infarction	O
33	.	O

1	However	O
2	,	O
3	mandibular	O
4	position	O
5	(	O
6	S	O
7	-	O
8	N	O
9	-	O
10	B	O
11	and	O
12	S	O
13	-	I
14	N	I
15	-	I
16	Pog	I
17	)	O
18	was	O
19	found	O
20	to	O
21	be	O
22	significantly	O
23	more	O
24	retrusive	O
25	in	O
26	Class	O
27	II	O
28	when	O
29	compared	O
30	with	O
31	Class	O
32	I	O
33	subjects	O
34	.	O

1	Overproduction	O
2	of	O
3	HrcA	O
4	protein	O
5	from	O
6	a	O
7	second	O
8	copy	O
9	of	O
10	hrcA	O
11	derived	O
12	from	O
13	a	O
14	plasmid	O
15	(	O
16	phrcA	O
17	+)	O
18	in	O
19	B	O
20	.	O
21	subtilis	O
22	wild	O
23	-	O
24	type	O
25	and	O
26	delta	O
27	hrcA	O
28	strains	O
29	prevented	O
30	heat	O
31	shock	O
32	induction	O
33	of	O
34	the	O
35	dnaK	O
36	and	O
37	groE	O
38	operons	O
39	at	O
40	the	O
41	level	O
42	of	O
43	transcription	O
44	almost	O
45	completely	O
46	and	O
47	strongly	O
48	reduced	O
49	the	O
50	amounts	O
51	of	O
52	mRNA	O
53	at	O
54	a	O
55	low	O
56	temperature	O
57	as	O
58	well	O
59	.	O

1	In	O
2	contrast	O
3	,	O
4	the	O
5	CRE	O
6	of	O
7	the	O
8	human	B
9	c	I
10	-	I
11	fos	I
12	promoter	I
13	located	O
14	at	O
15	-	O
16	60	O
17	was	O
18	weakly	O
19	induced	O
20	by	O
21	cAMP	O
22	and	O
23	E1a	O
24	in	O
25	both	O
26	HeLa	O
27	and	O
28	PC12	O
29	cells	O
30	.	O

1	Maize	O
2	rbcS	O
3	promoter	O
4	activity	O
5	depends	O
6	on	O
7	sequence	O
8	elements	O
9	not	O
10	found	O
11	in	O
12	dicot	B
13	rbcS	O
14	promoters	O
15	.	O

1	A	O
2	5	O
3	.	O
4	0	O
5	-	O
6	kb	O
7	transcript	O
8	detected	O
9	by	O
10	the	O
11	differential	O
12	display	O
13	amplicon	O
14	3G1	O
15	was	O
16	found	O
17	to	O
18	correlate	O
19	strongly	O
20	with	O
21	RAG1	O
22	mRNA	O
23	expression	O
24	in	O
25	various	O
26	human	O
27	cell	O
28	lines	O
29	.	O

1	Detailed	O
2	analysis	O
3	of	O
4	alpha1	O
5	,	O
6	3GT	O
7	transcripts	O
8	revealed	O
9	two	O
10	major	O
11	alternative	O
12	splicing	O
13	patterns	O
14	in	O
15	the	O
16	5	O
17	'-	O
18	untranslated	O
19	region	O
20	(	O
21	5	O
22	'-	O
23	UTR	O
24	)	O
25	and	O
26	evidence	O
27	for	O
28	minor	O
29	splicing	O
30	activity	O
31	that	O
32	occurs	O
33	in	O
34	a	O
35	tissue	O
36	-	O
37	specific	O
38	manner	O
39	.	O

1	The	O
2	RNA	O
3	genome	O
4	of	O
5	rabbit	O
6	hemorrhagic	O
7	disease	O
8	virus	O
9	(	O
10	RHDV	O
11	)	O
12	was	O
13	molecularly	O
14	cloned	O
15	.	O

1	Cortical	O
2	afferents	O
3	to	O
4	the	O
5	entorhinal	O
6	cortex	O
7	of	O
8	the	O
9	Rhesus	O
10	monkey	O
11	.	O

1	The	O
2	effect	O
3	of	O
4	low	O
5	dosage	O
6	radiation	O
7	on	O
8	metabolism	O
9	and	O
10	function	O
11	of	O
12	the	O
13	rat	O
14	kidney	O
15	damaged	O
16	by	O
17	ischemia	O

1	Both	O
2	verapamil	O
3	and	O
4	propranolol	O
5	can	O
6	exhibit	O
7	additive	O
8	effects	O
9	with	O
10	adenosine	O
11	in	O
12	prolonging	O
13	AV	O
14	nodal	O
15	conduction	O
16	time	O
17	;	O
18	however	O
19	,	O
20	only	O
21	verapamil	O
22	can	O
23	reduce	O
24	the	O
25	dose	O
26	of	O
27	adenosine	O
28	required	O
29	to	O
30	produce	O
31	AV	O
32	nodal	O
33	block	O
34	.	O

1	These	O
2	temperature	O
3	-	O
4	and	O
5	cold	O
6	-	O
7	sensitive	O
8	strains	O
9	were	O
10	used	O
11	to	O
12	prepare	O
13	extracts	O
14	deficient	O
15	in	O
16	BRF1	O
17	activity	O
18	and	O
19	were	O
20	tested	O
21	for	O
22	transcriptional	O
23	activity	O
24	by	O
25	RNA	B
26	polymerases	I
27	I	I
28	,	O
29	II	O
30	,	O
31	and	O
32	III	O
33	in	O
34	vitro	O
35	.	O

1	Tec	B
2	kinase	I
3	signaling	O
4	in	O
5	T	O
6	cells	O
7	is	O
8	regulated	O
9	by	O
10	phosphatidylinositol	B
11	3	I
12	-	I
13	kinase	I
14	and	O
15	the	O
16	Tec	B
17	pleckstrin	I
18	homology	I
19	domain	I
20	.	O

1	Addition	O
2	of	O
3	soluble	O
4	recombinant	O
5	human	O
6	SLF	O
7	to	O
8	SI4	O
9	-	O
10	h220	O
11	cultures	O
12	enhanced	O
13	reduction	O
14	of	O
15	cell	O
16	-	O
17	surface	O
18	c	B
19	-	I
20	kit	I
21	expression	O
22	and	O
23	its	O
24	protein	O
25	degradation	O
26	.	O

1	This	O
2	experiment	O
3	was	O
4	conducted	O
5	to	O
6	determine	O
7	if	O
8	the	O
9	sex	O
10	or	O
11	actual	O
12	egg	O
13	production	O
14	was	O
15	the	O
16	important	O
17	factor	O
18	.(	O
19	ABSTRACT	O
20	TRUNCATED	O
21	AT	O
22	250	O
23	WORDS	O
24	)	O

1	Isolation	O
2	and	O
3	identification	O
4	of	O
5	genes	O
6	activating	O
7	UAS2	O
8	-	O
9	dependent	O
10	ADH2	B
11	expression	O
12	in	O
13	Saccharomyces	O
14	cerevisiae	O
15	.	O

1	Unexpectedly	O
2	,	O
3	ALK7	O
4	signaling	O
5	produced	O
6	a	O
7	remarkable	O
8	change	O
9	in	O
10	cell	O
11	morphology	O
12	characterized	O
13	by	O
14	cell	O
15	flattening	O
16	and	O
17	elaboration	O
18	of	O
19	blunt	O
20	,	O
21	short	O
22	cell	O
23	processes	O
24	.	O

1	The	O
2	infected	O
3	cell	O
4	protein	O
5	no	O
6	.	O
7	0	O
8	(	O
9	ICP0	B
10	)	O
11	of	O
12	herpes	O
13	simplex	O
14	virus	O
15	1	O
16	is	O
17	a	O
18	promiscuous	O
19	transactivator	O
20	shown	O
21	to	O
22	enhance	O
23	the	O
24	expression	O
25	of	O
26	genes	O
27	introducted	O
28	into	O
29	cells	O
30	by	O
31	infection	O
32	or	O
33	transfection	O
34	.	O

1	Baseline	O
2	data	O
3	were	O
4	obtained	O
5	from	O
6	10	O
7	adults	O
8	.	O

1	Levels	O
2	of	O
3	TSG	O
4	-	O
5	14	O
6	protein	O
7	(	O
8	also	O
9	termed	O
10	PTX	O
11	-	O
12	3	O
13	)	O
14	become	O
15	elevated	O
16	in	O
17	the	O
18	serum	O
19	of	O
20	mice	O
21	and	O
22	humans	O
23	after	O
24	injection	O
25	with	O
26	bacterial	O
27	lipopolysaccharide	O
28	,	O
29	but	O
30	in	O
31	contrast	O
32	to	O
33	conventional	O
34	acute	O
35	phase	O
36	proteins	O
37	,	O
38	the	O
39	bulk	O
40	of	O
41	TSG	O
42	-	O
43	14	O
44	synthesis	O
45	in	O
46	the	O
47	intact	O
48	organism	O
49	occurs	O
50	outside	O
51	the	O
52	liver	O
53	.	O

1	Zn	O
2	(	O
3	II	O
4	)	O
5	coordination	O
6	domain	O
7	mutants	O
8	of	O
9	T4	B
10	gene	I
11	32	I
12	protein	I
13	.	O

1	Here	O
2	,	O
3	it	O
4	is	O
5	shown	O
6	that	O
7	TAFII250	O
8	,	O
9	the	O
10	largest	O
11	subunit	O
12	of	O
13	TFIID	B
14	,	O
15	contains	O
16	two	O
17	tandem	O
18	bromodomain	O
19	modules	O
20	that	O
21	bind	O
22	selectively	O
23	to	O
24	multiply	O
25	acetylated	B
26	histone	B
27	H4	I
28	peptides	O
29	.	O

1	Isolation	O
2	of	O
3	Proteus	O
4	vulgaris	O
5	MC	O
6	-	O
7	63	O
8	from	O
9	carcinoma	O
10	63	O
11	and	O
12	its	O
13	antitumor	O
14	effect	O
15	on	O
16	Crocker	O
17	sarcoma	O
18	180	O
19	and	O
20	Ehrlich	O
21	carcinoma	O
22	.	O

1	The	O
2	major	O
3	RNase	B
4	E	I
5	cleavage	I
6	product	I
7	(	O
8	denoted	O
9	pSok	B
10	-	O
11	6	I
12	)	O
13	is	O
14	rapidly	O
15	degraded	O
16	by	O
17	polynucleotide	O
18	phosphorylase	O
19	(	O
20	PNPase	O
21	).	O

1	Remarkably	O
2	,	O
3	a	O
4	construct	O
5	corresponding	O
6	to	O
7	residues	O
8	631	O
9	to	O
10	970	O
11	,	O
12	which	O
13	contains	O
14	only	O
15	the	O
16	LXXLL	O
17	motifs	O
18	and	O
19	the	O
20	AD1	O
21	region	O
22	of	O
23	SRC1	B
24	,	O
25	retained	O
26	strong	O
27	coactivator	O
28	activity	O
29	in	O
30	our	O
31	assays	O
32	.	O

1	The	O
2	coordinated	O
3	expression	O
4	of	O
5	CD4	B
6	and	O
7	CD8	B
8	during	O
9	T	O
10	-	O
11	cell	O
12	development	O
13	is	O
14	tightly	O
15	coupled	O
16	with	O
17	the	O
18	maturation	O
19	state	O
20	of	O
21	the	O
22	T	O
23	cell	O
24	.	O

1	SECONDARY	O
2	OUTCOME	O
3	MEASURE	O
4	--	O
5	Double	O
6	-	O
7	blind	O
8	caffeine	O
9	-	O
10	withdrawal	O
11	evaluation	O
12	.	O

1	In	O
2	contrast	O
3	to	O
4	this	O
5	mRNA	O
6	,	O
7	90	O
8	%	O
9	of	O
10	alpha	B
11	and	O
12	beta	B
13	actin	I
14	mRNAs	I
15	were	O
16	translated	O
17	in	O
18	both	O
19	myoblasts	O
20	and	O
21	myotubes	O
22	.	O

1	Although	O
2	upstream	O
3	regulators	O
4	of	O
5	Tec	B
6	family	I
7	kinases	I
8	are	O
9	relatively	O
10	well	O
11	characterized	O
12	,	O
13	little	O
14	is	O
15	known	O
16	of	O
17	the	O
18	downstream	O
19	effectors	O
20	of	O
21	these	O
22	enzymes	O
23	.	O

1	The	O
2	3ASubE	O
3	cells	O
4	expressing	O
5	CXCR2	O
6	with	O
7	mutation	O
8	of	O
9	Ser	O
10	-	O
11	346	O
12	,	O
13	-	O
14	347	O
15	,	O
16	and	O
17	-	O
18	348	O
19	to	O
20	alanine	O
21	,	O
22	or	O
23	with	O
24	mutation	O
25	of	O
26	only	O
27	one	O
28	serine	O
29	in	O
30	this	O
31	domain	O
32	,	O
33	continue	O
34	to	O
35	be	O
36	phosphorylated	O
37	in	O
38	response	O
39	to	O
40	ligand	O
41	and	O
42	are	O
43	60	O
44	-	O
45	70	O
46	%	O
47	desensitized	O
48	following	O
49	the	O
50	initial	O
51	ligand	O
52	challenge	O
53	.	O

1	5	O
2	.	O

1	An	O
2	ASIC	O
3	-	O
4	chip	O
5	for	O
6	stereoscopic	O
7	depth	O
8	analysis	O
9	in	O
10	video	O
11	-	O
12	real	O
13	-	O
14	time	O
15	based	O
16	on	O
17	visual	O
18	cortical	O
19	cell	O
20	behavior	O
21	.	O

1	Their	O
2	afterglows	O
3	are	O
4	brighter	O
5	than	O
6	supernovae	O
7	and	O
8	therefore	O
9	are	O
10	called	O
11	hypernovae	O
12	.	O

1	The	O
2	UV	O
3	absorption	O
4	spectrum	O
5	revealed	O
6	a	O
7	shoulder	O
8	at	O
9	250	O
10	nm	O
11	,	O
12	characteristic	O
13	of	O
14	CysS	O
15	-	O
16	Cd	O
17	(	O
18	II	O
19	)	O
20	ligand	O
21	-	O
22	to	O
23	-	O
24	metal	O
25	charge	O
26	-	O
27	transfer	O
28	transitions	O
29	,	O
30	and	O
31	the	O
32	difference	O
33	absorption	O
34	coefficient	O
35	after	O
36	acidification	O
37	(	O
38	delta	O
39	epsilon	O
40	248	O
41	,	O
42	24	O
43	mM	O
44	-	O
45	1	O
46	cm	O
47	-	O
48	1	O
49	)	O
50	indicated	O
51	the	O
52	presence	O
53	of	O
54	a	O
55	Cd	O
56	(	O
57	Cys	O
58	-	O
59	S	O
60	)	O
61	4	O
62	center	O
63	.	O

1	Conversely	O
2	,	O
3	activation	O
4	of	O
5	Oct	B
6	-	I
7	3	I
8	/	I
9	4	I
10	promoter	I
11	by	O
12	RAR	B
13	:	O
14	RXR	B
15	heterodimers	O
16	was	O
17	completely	O
18	abolished	O
19	by	O
20	EAR	O
21	-	O
22	3	O
23	/	O
24	COUP	B
25	-	I
26	TFI	I
27	and	O
28	by	O
29	ARP	B
30	-	I
31	1	I
32	/	O
33	COUP	B
34	-	I
35	TFII	I
36	.	O

1	Treatment	O
2	is	O
3	instituted	O
4	with	O
5	prednisone	O
6	and	O
7	cyclophosphamide	O
8	.	O

1	Chronic	O
2	hepatitis	O
3	B	O
4	in	O
5	adopted	O
6	Romanian	O
7	children	O
8	.	O

1	Distal	O
2	lower	O
3	motor	O
4	neuron	O
5	syndrome	O
6	with	O
7	high	O
8	-	O
9	titer	O
10	serum	O
11	IgM	I
12	anti	I
13	-	I
14	GM1	I
15	antibodies	I
16	:	O
17	improvement	O
18	following	O
19	immunotherapy	O
20	with	O
21	monthly	O
22	plasma	O
23	exchange	O
24	and	O
25	intravenous	O
26	cyclophosphamide	O
27	.	O

1	Delayed	O
2	gallbladder	O
3	visualization	O
4	and	O
5	reduction	O
6	in	O
7	ejection	O
8	fraction	O
9	were	O
10	sensitive	O
11	but	O
12	nonspecific	O
13	indicators	O
14	of	O
15	biliary	O
16	disease	O
17	.	O

1	Vesicles	O
2	could	O
3	be	O
4	induced	O
5	only	O
6	with	O
7	multiple	O
8	exposures	O
9	to	O
10	UVA	O
11	.	O

1	In	O
2	the	O
3	absence	O
4	of	O
5	MHC	B
6	class	I
7	II	I
8	,	O
9	purified	O
10	soluble	O
11	D10	I
12	TCR	I
13	bound	O
14	to	O
15	Staphylococcus	B
16	aureus	B
17	enterotoxin	I
18	C2	O
19	with	O
20	an	O
21	association	O
22	rate	O
23	of	O
24	1	O
25	.	O
26	69	O
27	+/-	O
28	0	O
29	.	O
30	12	O
31	x	O
32	10	O
33	(	O
34	4	O
35	)	O
36	M	O
37	(-	O
38	1	O
39	)	O
40	sec	O
41	(-	O
42	1	O
43	)	O
44	and	O
45	a	O
46	dissociation	O
47	rate	O
48	of	O
49	1	O
50	.	O
51	9	O
52	+/-	O
53	0	O
54	.	O
55	47	O
56	x	O
57	10	O
58	(-	O
59	2	O
60	)	O
61	sec	O
62	(-	O
63	1	O
64	),	O
65	giving	O
66	a	O
67	dissociation	O
68	constant	O
69	of	O
70	1	O
71	.	O
72	1	O
73	microM	O
74	.	O

1	The	O
2	RNA	O
3	transcripts	O
4	structurally	O
5	equivalent	O
6	to	O
7	I	O
8	(	O
9	2	O
10	)	O
11	sgRNAs	O
12	of	O
13	TMV	O
14	U1	O
15	and	O
16	crTMV	O
17	,	O
18	but	O
19	containing	O
20	a	O
21	hairpin	O
22	structure	O
23	(	O
24	H	O
25	)	O
26	immediately	O
27	upstream	O
28	of	O
29	IRES	O
30	(	O
31	MP	O
32	,	O
33	75	O
34	)	O
35	(	O
36	HIRES	O
37	(	O
38	MP	O
39	),	O
40	(	O
41	75	O
42	)(	O
43	CR	O
44	)-	O
45	MP	O
46	-	O
47	CP	O
48	-	O
49	3	O
50	'	O
51	UTR	O
52	;	O
53	HIRES	O
54	(	O
55	MP	O
56	,	O
57	75	O
58	)(	O
59	U1	B
60	)-	O
61	MP	O
62	-	O
63	CP	I
64	-	I
65	3	I
66	'	O
67	UTR	O
68	),	O
69	were	O
70	able	O
71	to	O
72	express	O
73	the	O
74	MP	O
75	gene	O
76	in	O
77	vitro	O
78	.	O

1	This	O
2	study	O
3	tested	O
4	the	O
5	hypothesis	O
6	that	O
7	sodium	O
8	channel	O
9	blocking	O
10	drugs	O
11	selectively	O
12	prolong	O
13	the	O
14	late	O
15	potential	O
16	,	O
17	or	O
18	terminal	O
19	low	O
20	amplitude	O
21	signal	O
22	,	O
23	portion	O
24	of	O
25	the	O
26	signal	O
27	-	O
28	averaged	O
29	QRS	O
30	complex	O
31	and	O
32	that	O
33	prolongation	O
34	of	O
35	the	O
36	late	O
37	potential	O
38	would	O
39	correlate	O
40	with	O
41	slowing	O
42	of	O
43	ventricular	O
44	tachycardia	O
45	.	O

1	We	O
2	recently	O
3	reported	O
4	a	O
5	placenta	O
6	-	O
7	specific	O
8	enhancer	O
9	in	O
10	the	O
11	human	B
12	leukemia	I
13	inhibitory	I
14	factor	I
15	receptor	I
16	(	O
17	LIFR	B
18	)	O
19	gene	O
20	and	O
21	now	O
22	show	O
23	detailed	O
24	characterization	O
25	of	O
26	the	O
27	226	O
28	-	O
29	base	O
30	pair	O
31	enhancer	O
32	(-	O
33	4625	O
34	/-	O
35	4400	O
36	nucleotides	O
37	).	O

1	These	O
2	combined	O
3	observations	O
4	define	O
5	a	O
6	promoter	O
7	and	O
8	an	O
9	enhancer	O
10	for	O
11	the	O
12	chicken	B
13	L	I
14	-	I
15	CAM	I
16	gene	I
17	.	O

1	Greek	O
2	classicism	O
3	in	O
4	living	O
5	structure	O
6	?	O
7	Some	O
8	deductive	O
9	pathways	O
10	in	O
11	animal	O
12	morphology	O
13	.	O

1	We	O
2	established	O
3	that	O
4	the	O
5	2	O
6	.	O
7	6	I
8	kb	I
9	mRNA	I
10	V	I
11	-	I
12	1	I
13	and	O
14	the	O
15	2	O
16	.	O
17	3	O
18	kb	O
19	GGT	I
20	mRNA	I
21	V	I
22	-	I
23	2	I
24	derive	O
25	,	O
26	by	O
27	alternate	O
28	splicing	O
29	,	O
30	from	O
31	a	O
32	primary	O
33	transcript	O
34	initiated	O
35	on	O
36	a	O
37	distal	O
38	promoter	O
39	on	O
40	the	O
41	rat	O
42	GGT	O
43	gene	O
44	.	O

1	The	O
2	homeobox	B
3	gene	I
4	ATK1	O
5	of	O
6	Arabidopsis	O
7	thaliana	O
8	is	O
9	expressed	O
10	in	O
11	the	O
12	shoot	O
13	apex	O
14	of	O
15	the	O
16	seedling	O
17	and	O
18	in	O
19	flowers	O
20	and	O
21	inflorescence	O
22	stems	O
23	of	O
24	mature	O
25	plants	O
26	.	O

1	Esophageal	O
2	brush	O
3	cytological	O
4	screening	O
5	was	O
6	undertaken	O
7	and	O
8	blood	O
9	concentrations	O
10	of	O
11	micronutrients	O
12	(	O
13	vitamin	O
14	A	O
15	,	O
16	E	O
17	,	O
18	B12	O
19	,	O
20	folic	O
21	acid	O
22	and	O
23	methionine	O
24	)	O
25	determined	O
26	from	O
27	adults	O
28	at	O
29	risk	O
30	for	O
31	esophageal	O
32	carcinoma	O
33	(	O
34	EC	O
35	)	O
36	in	O
37	Transkei	O
38	and	O
39	Ciskei	O
40	,	O
41	Southern	O
42	Africa	O
43	.	O

1	RUSH	B
2	-	I
3	1	I
4	beta	I
5	is	O
6	a	O
7	95	O
8	-	O
9	kDa	O
10	truncated	O
11	version	O
12	of	O
13	RUSH	B
14	-	I
15	1	I
16	alpha	I
17	that	O
18	results	O
19	from	O
20	alternative	O
21	splicing	O
22	of	O
23	a	O
24	57	O
25	-	O
26	bp	O
27	exon	O
28	as	O
29	confirmed	O
30	by	O
31	genomic	O
32	cloning	O
33	.	O

1	Renal	O
2	cell	O
3	carcinoma	O
4	in	O
5	children	O
6	:	O
7	a	O
8	single	O
9	institution	O
10	'	O
11	s	O
12	experience	O
13	.	O

1	Utilizing	O
2	transient	O
3	transfection	O
4	studies	O
5	in	O
6	HepG2	O
7	cells	O
8	,	O
9	we	O
10	have	O
11	shown	O
12	that	O
13	deletion	O
14	of	O
15	the	O
16	factor	B
17	VIII	I
18	promoter	I
19	sequences	I
20	distal	O
21	to	O
22	nucleotide	O
23	-	O
24	44	O
25	results	O
26	in	O
27	a	O
28	significant	O
29	but	O
30	small	O
31	increase	O
32	in	O
33	promoter	O
34	activity	O
35	.	O

1	Copper	O
2	and	O
3	ceruloplasmin	O
4	content	O
5	in	O
6	pregnant	O
7	women	O
8	and	O
9	in	O
10	women	O
11	with	O
12	certain	O
13	gynecological	O
14	diseases	O

1	Several	O
2	highly	O
3	conserved	O
4	regions	O
5	were	O
6	identified	O
7	at	O
8	the	O
9	near	O
10	N	O
11	terminus	O
12	,	O
13	middle	O
14	and	O
15	C	O
16	terminus	O
17	.	O

1	The	O
2	phi	O
3	AP3	B
4	factor	O
5	is	O
6	a	O
7	nuclear	O
8	phosphoprotein	O
9	;	O
10	the	O
11	extent	O
12	of	O
13	its	O
14	phosphorylation	O
15	is	O
16	regulated	O
17	during	O
18	the	O
19	cell	O
20	cycle	O
21	.	O

1	Computer	O
2	analysis	O
3	included	O
4	digital	O
5	averaging	O
6	,	O
7	followed	O
8	by	O
9	digital	O
10	filtering	O
11	in	O
12	different	O
13	frequency	O
14	bands	O
15	in	O
16	order	O
17	to	O
18	determine	O
19	the	O
20	frequency	O
21	range	O
22	corresponding	O
23	to	O
24	notches	O
25	and	O
26	slurs	O
27	.	O

1	The	O
2	mRNAs	O
3	of	O
4	these	O
5	genes	O
6	contain	O
7	respectively	O
8	one	O
9	(	O
10	YAP1	O
11	uORF	O
12	)	O
13	and	O
14	two	O
15	(	O
16	YAP2	O
17	uORF1	O
18	and	O
19	uORF2	O
20	)	O
21	upstream	O
22	open	O
23	reading	O
24	frames	O
25	.	O
26	uORF	O
27	-	O
28	mediated	O
29	modulation	O
30	of	O
31	post	O
32	-	O
33	termination	O
34	events	O
35	on	O
36	the	O
37	5	O
38	'-	O
39	untranslated	O
40	region	O
41	(	O
42	5	O
43	'-	O
44	UTR	O
45	)	O
46	directs	O
47	differential	O
48	control	O
49	not	O
50	only	O
51	of	O
52	translation	O
53	but	O
54	also	O
55	of	O
56	mRNA	O
57	decay	O
58	.	O

1	After	O
2	nitric	O
3	oxide	O
4	inhalation	O
5	,	O
6	the	O
7	results	O
8	showed	O
9	moderate	O
10	increases	O
11	in	O
12	PaO2	O
13	and	O
14	SaO2	O
15	(	O
16	P	O
17	>	O
18	0	O
19	.	O
20	05	O
21	)	O
22	and	O
23	a	O
24	significant	O
25	decrease	O
26	in	O
27	Qs	O
28	/	O
29	Q	O
30	tau	O
31	ratio	O
32	(	O
33	P	O
34	<	O
35	0	O
36	.	O
37	01	O
38	).	O

1	Binding	O
2	of	O
3	SSP	O
4	to	O
5	the	O
6	stage	O
7	selector	O
8	element	O
9	(	O
10	SSE	O
11	)	O
12	in	O
13	the	O
14	proximal	B
15	gamma	I
16	-	I
17	globin	I
18	promoter	I
19	is	O
20	integral	O
21	to	O
22	the	O
23	competitive	O
24	silencing	O
25	of	O
26	a	O
27	linked	O
28	beta	B
29	-	I
30	promoter	I
31	in	O
32	embryonic	O
33	/	O
34	fetal	O
35	stage	O
36	erythroleukemia	O
37	(	O
38	K562	O
39	)	O
40	cells	O
41	.	O

1	Transcriptional	O
2	analysis	O
3	of	O
4	a	O
5	series	O
6	of	O
7	deletion	O
8	mutants	O
9	of	O
10	the	O
11	gene	O
12	in	O
13	the	O
14	nuclear	O
15	extracts	O
16	prepared	O
17	from	O
18	the	O
19	middle	O
20	silk	O
21	gland	O
22	of	O
23	2	O
24	-	O
25	day	O
26	-	O
27	old	O
28	fifth	O
29	instar	O
30	larvae	O
31	revealed	O
32	the	O
33	presence	O
34	of	O
35	multiple	O
36	cis	O
37	-	O
38	regulatory	O
39	elements	O
40	located	O
41	both	O
42	upstream	O
43	and	O
44	downstream	O
45	of	O
46	the	O
47	initiation	O
48	site	O
49	.	O

1	We	O
2	examined	O
3	Akt	B
4	activation	O
5	in	O
6	Lyn	B
7	-,	O
8	Syk	B
9	-	O
10	and	O
11	Btk	B
12	-	O
13	deficient	O
14	DT40	O
15	cells	O
16	and	O
17	B	O
18	cells	O
19	from	O
20	Lyn	B
21	(-/-)	I
22	mice	O
23	.	O

1	The	O
2	average	O
3	annual	O
4	cost	O
5	per	O
6	head	O
7	of	O
8	population	O
9	was	O
10	US	O
11	+	O
12	0	O
13	X	O
14	46	O
15	.	O

1	Protein	B
2	kinases	I
3	play	O
4	pivotal	O
5	roles	O
6	in	O
7	the	O
8	control	O
9	of	O
10	many	O
11	cellular	O
12	processes	O
13	.	O

1	The	O
2	ratio	O
3	of	O
4	the	O
5	activity	O
6	of	O
7	arogenate	O
8	dehydrogenase	I
9	to	O
10	that	O
11	of	O
12	prephenate	B
13	dehydrogenase	I
14	(	O
15	approximately	O
16	3	O
17	:	O
18	1	O
19	)	O
20	remained	O
21	constant	O
22	throughout	O
23	purification	O
24	,	O
25	and	O
26	the	O
27	two	O
28	activities	O
29	were	O
30	therefore	O
31	inseparable	O
32	.	O

1	In	O
2	budding	O
3	yeast	O
4	,	O
5	the	O
6	protein	O
7	Skp1p	O
8	,	O
9	the	O
10	cullin	B
11	-	I
12	family	I
13	member	O
14	Cdc53p	O
15	,	O
16	and	O
17	the	O
18	F	B
19	-	I
20	box	I
21	/	I
22	WD	I
23	-	I
24	repeat	I
25	protein	I
26	Cdc4p	I
27	form	O
28	the	O
29	SCFCdc4p	B
30	ubiquitin	B
31	ligase	I
32	complex	O
33	,	O
34	which	O
35	targets	O
36	the	O
37	cyclin	B
38	-	I
39	dependent	I
40	kinase	I
41	(	O
42	Cdk	B
43	)	O
44	inhibitor	O
45	Sic1p	O
46	for	O
47	proteolysis	O
48	[	O
49	3	O
50	]	O
51	[	O
52	4	O
53	]	O
54	[	O
55	5	O
56	]	O
57	[	O
58	6	O
59	]	O
60	[	O
61	7	O
62	]	O
63	[	O
64	8	O
65	].	O

1	Fourth	O
2	,	O
3	the	O
4	3	O
5	'-	O
6	region	O
7	splice	O
8	junctions	O
9	of	O
10	the	O
11	MSRs	O
12	during	O
13	latent	O
14	and	O
15	productive	O
16	infection	O
17	were	O
18	determined	O
19	by	O
20	sequencing	O
21	RNA	O
22	-	O
23	PCR	O
24	products	O
25	generated	O
26	with	O
27	primers	O
28	that	O
29	flank	O
30	the	O
31	3	O
32	'	O
33	splice	O
34	region	O
35	.	O

1	Hydrocortisone	O
2	caused	O
3	lymphopenia	O
4	and	O
5	inhibited	O
6	the	O
7	blastogenic	O
8	response	O
9	of	O
10	peripheral	O
11	blood	O
12	lymphocytes	O
13	to	O
14	phytohemagglutinin	B
15	and	O
16	concanavalin	O
17	A	O
18	mitogens	O
19	.	O

1	On	O
2	admission	O
3	to	O
4	the	O
5	ICU	O
6	,	O
7	117	O
8	patients	O
9	(	O
10	61	O
11	percent	O
12	)	O
13	had	O
14	hypomagnesemia	O
15	(	O
16	serum	O
17	Mg	O
18	less	O
19	than	O
20	1	O
21	.	O
22	5	O
23	mEq	O
24	/	O
25	dl	O
26	),	O
27	66	O
28	patients	O
29	(	O
30	34	O
31	percent	O
32	)	O
33	had	O
34	normomagnesemia	O
35	(	O
36	1	O
37	.	O
38	5	O
39	to	O
40	2	O
41	.	O
42	0	O
43	mEq	O
44	/	O
45	dl	O
46	),	O
47	and	O
48	ten	O
49	patients	O
50	(	O
51	5	O
52	percent	O
53	)	O
54	had	O
55	hypermagnesemia	O
56	(	O
57	greater	O
58	than	O
59	2	O
60	.	O
61	0	O
62	mEq	O
63	/	O
64	dl	O
65	).	O

1	We	O
2	show	O
3	here	O
4	that	O
5	the	O
6	binding	O
7	of	O
8	C1F	O
9	in	O
10	vitro	O
11	is	O
12	sensitive	O
13	to	O
14	the	O
15	concentration	O
16	of	O
17	calcium	O
18	ions	O
19	.	O

1	As	O
2	high	O
3	-	O
4	speed	O
5	,	O
6	volumetric	O
7	imaging	O
8	,	O
9	computed	O
10	tomographic	O
11	scan	O
12	machines	O
13	such	O
14	as	O
15	the	O
16	Dynamic	O
17	Spatial	O
18	Reconstructor	O
19	become	O
20	available	O
21	with	O
22	higher	O
23	density	O
24	resolution	O
25	,	O
26	perhaps	O
27	a	O
28	single	O
29	injection	O
30	of	O
31	contrast	O
32	agent	O
33	into	O
34	the	O
35	right	O
36	atrium	O
37	or	O
38	even	O
39	a	O
40	peripheral	O
41	vein	O
42	may	O
43	be	O
44	adequate	O
45	to	O
46	obtain	O
47	all	O
48	these	O
49	measurements	O
50	.	O

1	Rabbits	O
2	developed	O
3	profound	O
4	hypocalcemia	O
5	,	O
6	with	O
7	levels	O
8	falling	O
9	from	O
10	15	O
11	.	O
12	5	O
13	+/-	O
14	0	O
15	.	O
16	2	O
17	to	O
18	7	O
19	.	O
20	6	O
21	+/-	O
22	0	O
23	.	O
24	4	O
25	mg	O
26	/	O
27	dl	O
28	under	O
29	the	O
30	influence	O
31	of	O
32	TSST	B
33	-	O
34	1	O
35	.	O

1	The	O
2	basal	O
3	promoter	O
4	elements	O
5	of	O
6	murine	B
7	cytochrome	I
8	c	I
9	oxidase	I
10	subunit	I
11	IV	I
12	gene	I
13	consist	O
14	of	O
15	tandemly	O
16	duplicated	O
17	ets	B
18	motifs	O
19	that	O
20	bind	O
21	to	O
22	GABP	B
23	-	O
24	related	I
25	transcription	O
26	factors	O
27	.	O

1	The	O
2	"	O
3	28	O
4	percent	O
5	"	O
6	Venturi	O
7	mask	O
8	in	O
9	obstructive	O
10	airway	O
11	disease	O
12	.	O

1	Drug	O
2	and	O
3	personnel	O
4	costs	O
5	were	O
6	reduced	O
7	when	O
8	batch	O
9	manufacturing	O
10	with	O
11	40	O
12	-	O
13	mL	O
14	multidose	O
15	vials	O
16	was	O
17	compared	O
18	with	O
19	extemporaneous	O
20	compounding	O
21	with	O
22	unit	O
23	-	O
24	dose	O
25	vials	O
26	.	O

1	This	O
2	region	O
3	binds	O
4	two	O
5	ubiquitous	O
6	nuclear	O
7	factors	O
8	,	O
9	USF	B
10	/	O
11	MLTF	I
12	and	O
13	the	O
14	CAAT	B
15	-	I
16	binding	I
17	transcription	I
18	factor	I
19	/	I
20	nuclear	I
21	factor	I
22	1	I
23	(	O
24	CTF	B
25	/	O
26	NF1	B
27	).	O

1	Patients	O
2	who	O
3	have	O
4	undergone	O
5	thyroidectomy	O
6	for	O
7	thyroid	O
8	carcinoma	O
9	are	O
10	frequently	O
11	subjected	O
12	to	O
13	periods	O
14	of	O
15	induced	O
16	severe	O
17	hypothyroidism	O
18	in	O
19	preparation	O
20	for	O
21	131I	O
22	whole	O
23	body	O
24	scanning	O
25	and	O
26	measurement	O
27	of	O
28	serum	O
29	TG	O
30	.	O

1	Area	O
2	under	O
3	the	O
4	drug	O
5	concentration	O
6	-	O
7	time	O
8	curves	O
9	(	O
10	AUC0	O
11	-	O
12	24	O
13	hr	O
14	)	O
15	for	O
16	MTX	O
17	were	O
18	2379	O
19	and	O
20	3534	O
21	ng	O
22	*	O
23	hr	O
24	/	O
25	ml	O
26	from	O
27	PG	O
28	-	O
29	2	O
30	.	O
31	5	O
32	%	O
33	Azone	O
34	and	O
35	PG	O
36	-	O
37	7	O
38	.	O
39	5	O
40	%	O
41	Azone	O
42	systems	O
43	respectively	O
44	.	O

1	We	O
2	now	O
3	show	O
4	that	O
5	regulation	O
6	of	O
7	flaN	O
8	transcription	O
9	in	O
10	vivo	O
11	depends	O
12	on	O
13	a	O
14	sigma	B
15	54	I
16	promoter	I
17	and	O
18	two	O
19	ftr	O
20	elements	O
21	located	O
22	downstream	O
23	of	O
24	the	O
25	transcription	O
26	start	O
27	site	O
28	at	O
29	+	O
30	86	O
31	(	O
32	ftr2	O
33	)	O
34	and	O
35	+	O
36	120	O
37	(	O
38	ftr3	O
39	).	O

1	Tumor	B
2	stages	O
3	were	O
4	IIB	O
5	(	O
6	T3	O
7	N0	O
8	)	O
9	in	O
10	52	O
11	%,	O
12	IIIA	O
13	in	O
14	15	O
15	%,	O
16	and	O
17	IIIB	O
18	in	O
19	27	O
20	%	O
21	of	O
22	patients	O
23	.	O

1	In	O
2	the	O
3	evening	O
4	,	O
5	the	O
6	amplitude	O
7	of	O
8	the	O
9	responses	O
10	to	O
11	both	O
12	O2	O
13	and	O
14	CO2	O
15	increased	O
16	but	O
17	the	O
18	increase	O
19	in	O
20	CO2	O
21	sensitivity	O
22	was	O
23	proportionally	O
24	more	O
25	important	O
26	.	O

1	Furthermore	O
2	,	O
3	in	O
4	vitro	O
5	decay	O
6	reaction	O
7	mixtures	O
8	supplemented	O
9	with	O
10	the	O
11	20	O
12	-	O
13	nt	O
14	sense	O
15	RNA	O
16	transcript	O
17	resulted	O
18	in	O
19	stabilization	O
20	of	O
21	R2	O
22	message	O
23	.	O

1	They	O
2	were	O
3	almost	O
4	regularly	O
5	excited	O
6	by	O
7	pressure	O
8	to	O
9	the	O
10	ipsilateral	O
11	cornea	O
12	or	O
13	to	O
14	both	O
15	corneas	O
16	at	O
17	a	O
18	strength	O
19	well	O
20	above	O
21	the	O
22	human	O
23	corneal	O
24	pain	O
25	threshold	O
26	.	O

1	Forty	O
2	-	O
3	one	O
4	ASA	O
5	physical	O
6	status	O
7	I	O
8	or	O
9	II	O
10	adult	O
11	patients	O
12	undergoing	O
13	a	O
14	variety	O
15	of	O
16	1	O
17	-	O
18	1	O
19	.	O
20	5	O
21	h	O
22	surgical	O
23	procedures	O
24	were	O
25	randomly	O
26	allocated	O
27	to	O
28	receive	O
29	CCA	O
30	with	O
31	desflurane	O
32	or	O
33	isoflurane	O
34	with	O
35	ventilation	O
36	being	O
37	either	O
38	spontaneous	O
39	or	O
40	controlled	O
41	.	O

1	No	O
2	difference	O
3	in	O
4	percentage	O
5	of	O
6	males	O
7	in	O
8	semen	O
9	production	O
10	was	O
11	noted	O
12	between	O
13	strains	O
14	,	O
15	CP	O
16	levels	O
17	,	O
18	or	O
19	feeding	O
20	regimens	O
21	.	O

1	Acute	O
2	experiments	O
3	on	O
4	nembutal	O
5	-	O
6	anesthetized	O
7	cats	O
8	(	O
9	50	O
10	mg	O
11	/	O
12	kg	O
13	)	O
14	were	O
15	employed	O
16	to	O
17	investigate	O
18	the	O
19	effect	O
20	of	O
21	1	O
22	T	O
23	pulsating	O
24	magnetic	O
25	field	O
26	(	O
27	PMF	O
28	)	O
29	on	O
30	neuromuscular	O
31	system	O
32	of	O
33	the	O
34	leg	O
35	.	O

1	The	O
2	exonic	O
3	sequence	O
4	encodes	O
5	a	O
6	protein	O
7	of	O
8	495	O
9	amino	O
10	acids	O
11	that	O
12	is	O
13	nearly	O
14	identical	O
15	to	O
16	the	O
17	previously	O
18	reported	O
19	protein	O
20	sequence	I
21	of	O
22	human	B
23	GPT	I
24	-	I
25	1	I
26	.	O

1	Evidence	O
2	for	O
3	the	O
4	involvement	O
5	of	O
6	the	O
7	Glc7	B
8	-	O
9	Reg1	I
10	phosphatase	I
11	and	O
12	the	O
13	Snf1	B
14	-	I
15	Snf4	I
16	kinase	I
17	in	O
18	the	O
19	regulation	O
20	of	O
21	INO1	O
22	transcription	O
23	in	O
24	Saccharomyces	O
25	cerevisiae	O
26	.	O

1	Two	O
2	classes	O
3	of	O
4	inactive	O
5	receptors	O
6	were	O
7	identified	O
8	:	O
9	one	O
10	in	O
11	which	O
12	both	O
13	transcriptional	O
14	activation	O
15	and	O
16	dimerization	O
17	were	O
18	compromised	O
19	and	O
20	a	O
21	second	O
22	in	O
23	which	O
24	only	O
25	transcriptional	O
26	activation	O
27	was	O
28	abolished	O
29	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	,	O
6	in	O
7	this	O
8	experimental	O
9	model	O
10	,	O
11	ACE	B
12	inhibitors	O
13	limit	O
14	the	O
15	arrhythmias	O
16	following	O
17	ischemia	O
18	-	O
19	reperfusion	O
20	and	O
21	free	O
22	radical	O
23	scavenging	O
24	action	O
25	of	O
26	these	O
27	drugs	O
28	does	O
29	not	O
30	have	O
31	a	O
32	major	O
33	contributory	O
34	role	O
35	in	O
36	their	O
37	protective	O
38	effect	O
39	.	O

1	These	O
2	techniques	O
3	have	O
4	been	O
5	used	O
6	by	O
7	many	O
8	people	O
9	for	O
10	many	O
11	years	O
12	and	O
13	no	O
14	claim	O
15	is	O
16	being	O
17	made	O
18	for	O
19	any	O
20	innovation	O
21	in	O
22	this	O
23	regard	O
24	.	O

1	Monospecific	O
2	antibodies	O
3	raised	O
4	against	O
5	rat	B
6	cytochrome	I
7	P	I
8	-	I
9	450	I
10	1A1	I
11	recognized	O
12	a	O
13	protein	O
14	in	O
15	the	O
16	hepatic	O
17	microsomes	O
18	of	O
19	the	O
20	double	O
21	-	O
22	crested	O
23	cormorant	O
24	,	O
25	and	O
26	also	O
27	in	O
28	those	O
29	of	O
30	the	O
31	great	O
32	blue	O
33	heron	O
34	(	O
35	Ardea	O
36	herodias	O
37	),	O
38	using	O
39	immunoblotting	O
40	.	O

1	On	O
2	parents	O

1	Previous	O
2	experimental	O
3	evidence	O
4	had	O
5	indicated	O
6	that	O
7	Reg1	O
8	might	O
9	target	O
10	Glc7	O
11	to	O
12	nuclear	O
13	substrates	O
14	such	O
15	as	O
16	the	O
17	Snf1	B
18	kinase	I
19	complex	O
20	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	the	O
6	G	B
7	-	I
8	protein	I
9	gene	I
10	family	I
11	may	O
12	be	O
13	distributed	O
14	over	O
15	at	O
16	least	O
17	two	O
18	human	O
19	chromosomes	O
20	.	O

1	In	O
2	this	O
3	way	O
4	it	O
5	is	O
6	possible	O
7	to	O
8	simulate	O
9	the	O
10	growth	O
11	function	O
12	of	O
13	the	O
14	embryofetal	O
15	curve	O
16	of	O
17	the	O
18	length	O
19	'	O
20	increase	O
21	of	O
22	man	O
23	and	O
24	the	O
25	curve	O
26	of	O
27	the	O
28	mass	O
29	'	O
30	increase	O
31	of	O
32	rat	O
33	.	O

1	Six	O
2	(	O
3	four	O
4	FAP	O
5	;	O
6	two	O
7	primary	O
8	amyloidosis	O
9	)	O
10	also	O
11	had	O
12	diffusely	O
13	positive	O
14	myocardial	O
15	uptakes	O
16	,	O
17	but	O
18	the	O
19	intensity	O
20	was	O
21	less	O
22	than	O
23	that	O
24	of	O
25	the	O
26	sternum	O
27	.	O

1	The	O
2	smaller	O
3	uptake	O
4	rate	O
5	and	O
6	faster	O
7	clearance	O
8	rate	O
9	resulted	O
10	in	O
11	the	O
12	lower	O
13	BCF	O
14	for	O
15	SWA	O
16	killifish	O
17	.	O

1	This	O
2	negative	O
3	regulatory	O
4	pathway	O
5	may	O
6	be	O
7	important	O
8	for	O
9	determining	O
10	cell	O
11	fate	O
12	or	O
13	maintaining	O
14	an	O
15	inducible	O
16	state	O
17	in	O
18	the	O
19	ventroposterior	O
20	region	O
21	of	O
22	the	O
23	embryo	O
24	.	O

1	This	O
2	report	O
3	substantiates	O
4	that	O
5	at	O
6	least	O
7	two	O
8	of	O
9	the	O
10	18	O
11	kDa	O
12	hsps	O
13	in	O
14	maize	O
15	are	O
16	products	O
17	of	O
18	different	O
19	but	O
20	related	O
21	genes	O
22	.	O

1	Several	O
2	demographic	O
3	indices	O
4	of	O
5	isolated	O
6	populations	O
7	in	O
8	Uzbekistan	O

1	Northern	O
2	blot	O
3	analysis	O
4	revealed	O
5	the	O
6	expression	O
7	of	O
8	LIMK	B
9	-	I
10	1	I
11	mRNA	O
12	predominantly	O
13	in	O
14	the	O
15	brain	O
16	and	O
17	the	O
18	expression	O
19	of	O
20	LIMK	B
21	-	I
22	2	I
23	mRNA	O
24	in	O
25	various	O
26	tissues	O
27	in	O
28	the	O
29	rat	O
30	.	O

1	Roux	O
2	-	O
3	en	I
4	-	I
5	Y	I
6	gastroenterostomy	O
7	severely	O
8	disturbs	O
9	emptying	O
10	of	O
11	the	O
12	gallbladder	O
13	.	O

1	The	O
2	hsp70	B
3	gene	I
4	family	I
5	of	O
6	Neurospora	I
7	crassa	I
8	:	O
9	cloning	O
10	,	O
11	sequence	O
12	analysis	O
13	,	O
14	expression	O
15	,	O
16	and	O
17	genetic	O
18	mapping	O
19	of	O
20	the	O
21	major	O
22	stress	O
23	-	O
24	inducible	O
25	member	O
26	.	O

1	We	O
2	conclude	O
3	that	O
4	Hansel	O
5	'	O
6	s	O
7	stain	O
8	substantially	O
9	improves	O
10	the	O
11	recognition	O
12	of	O
13	eosinophiluria	O
14	as	O
15	compared	O
16	with	O
17	Wright	O
18	'	O
19	s	O
20	stain	O
21	.	O

1	The	O
2	nucleotide	O
3	sequence	O
4	of	O
5	the	O
6	chloroplast	O
7	(	O
8	cp	O
9	)	O
10	DNA	O
11	from	O
12	maize	B
13	(	O
14	Zea	B
15	mays	I
16	)	O
17	has	O
18	been	O
19	completed	O
20	.	O

1	A	O
2	pathway	O
3	for	O
4	regulation	O
5	of	O
6	B	B
7	lymphocyte	I
8	antigen	I
9	receptor	I
10	-	O
11	induced	O
12	calcium	O
13	flux	O
14	.	O

1	The	O
2	maximal	O
3	effect	O
4	was	O
5	seen	O
6	at	O
7	100	O
8	ng	O
9	/	O
10	ml	O
11	EGF	B
12	,	O
13	with	O
14	a	O
15	time	O
16	lag	O
17	of	O
18	about	O
19	5	O
20	h	O
21	.	O

1	The	O
2	determination	O
3	of	O
4	immunoglobulin	B
5	E	I
6	(	I
7	IgE	B
8	)	I
9	antibodies	I
10	by	O
11	one	O
12	of	O
13	several	O
14	laboratory	O
15	tests	O
16	,	O
17	by	O
18	skin	O
19	-	O
20	prick	O
21	tests	O
22	or	O
23	by	O
24	appropriate	O
25	challenge	O
26	procedures	O
27	is	O
28	useful	O
29	either	O
30	to	O
31	identify	O
32	atopic	O
33	individuals	O
34	or	O
35	as	O
36	outcome	O
37	predictors	O
38	in	O
39	wheezy	O
40	children	O
41	.	O

1	As	O
2	expected	O
3	,	O
4	the	O
5	heparin	O
6	did	O
7	produce	O
8	increased	O
9	recalcification	O
10	times	O
11	and	O
12	the	O
13	development	O
14	of	O
15	occasional	O
16	subcutaneous	O
17	hematomas	O
18	.	O

1	In	O
2	invertebrates	O
3	,	O
4	Fhit	O
5	is	O
6	encoded	O
7	as	O
8	a	O
9	fusion	O
10	protein	O
11	with	O
12	Nit	O
13	,	O
14	a	O
15	member	O
16	of	O
17	the	O
18	nitrilase	B
19	superfamily	I
20	.	O

1	In	O
2	the	O
3	mouse	O
4	,	O
5	CtBP1	O
6	is	O
7	expressed	O
8	from	O
9	embryo	O
10	to	O
11	adult	O
12	,	O
13	but	O
14	CtBP2	O
15	is	O
16	mainly	O
17	expressed	O
18	during	O
19	embryogenesis	O
20	.	O

1	Use	O
2	of	O
3	serum	O
4	thyroglobulin	B
5	determination	O
6	in	O
7	the	O
8	follow	O
9	-	O
10	up	O
11	of	O
12	differentiated	O
13	carcinomas	O
14	of	O
15	the	O
16	thyroid	O

1	The	O
2	rad9	O
3	.	O
4	192	O
5	DNA	O
6	repair	O
7	mutant	O
8	from	O
9	the	O
10	fission	O
11	yeast	O
12	,	O
13	Schizosaccharomyces	O
14	pombe	O
15	,	O
16	is	O
17	sensitive	O
18	to	O
19	both	O
20	UV	O
21	and	O
22	ionising	O
23	radiation	O
24	.	O

1	Sequencing	O
2	of	O
3	a	O
4	40	O
5	-	O
6	kb	O
7	DNA	O
8	segment	O
9	of	O
10	the	O
11	FK506	O
12	gene	O
13	cluster	O
14	from	O
15	Streptomyces	O
16	sp	O
17	.	O

1	They	O
2	also	O
3	negatively	O
4	modulate	O
5	the	O
6	PI	B
7	3	I
8	-	I
9	kinase	I
10	catalytic	O
11	activity	O
12	but	O
13	to	O
14	different	O
15	extents	O
16	,	O
17	dependent	O
18	on	O
19	the	O
20	unique	O
21	N	O
22	-	O
23	terminal	O
24	structure	O
25	of	O
26	each	O
27	isoform	O
28	.	O

1	The	O
2	Wnt	B
3	signaling	O
4	pathway	O
5	functions	O
6	reiteratively	O
7	during	O
8	animal	O
9	development	O
10	to	O
11	control	O
12	cell	O
13	fate	O
14	decisions	O
15	.	O

1	By	O
2	adapting	O
3	a	O
4	method	O
5	for	O
6	DNA	O
7	-	O
8	footprinting	O
9	using	O
10	impure	O
11	extracts	O
12	of	O
13	ner	O
14	overproducing	O
15	cells	O
16	,	O
17	we	O
18	were	O
19	able	O
20	to	O
21	determine	O
22	that	O
23	the	O
24	ner	O
25	-	O
26	binding	O
27	sites	O
28	are	O
29	located	O
30	between	O
31	nucleotides	O
32	1026	O
33	and	O
34	1058	O
35	from	O
36	the	O
37	Mu	O
38	left	O
39	end	O
40	.	O

1	Abnormal	O
2	urinary	O
3	coproporphyrin	O
4	levels	O
5	in	O
6	patients	O
7	infected	O
8	by	O
9	hepatitis	O
10	C	O
11	virus	O
12	with	O
13	or	O
14	without	O
15	human	O
16	immunodeficiency	O
17	virus	O
18	.	O

1	The	O
2	pJR	O
3	vectors	O
4	differ	O
5	among	O
6	them	O
7	in	O
8	:	O
9	(	O
10	a	O
11	)	O
12	the	O
13	selectable	O
14	marker	O
15	(	O
16	Saccharomyces	O
17	cerevisiae	O
18	LEU	B
19	2	I
20	gene	I
21	,	O
22	which	O
23	complements	O
24	S	I
25	.	O
26	pombe	O
27	leu1	I
28	-	I
29	gene	I
30	and	O
31	S	O
32	.	O
33	pombe	O
34	ura4	O
35	+	O
36	and	O
37	his3	B
38	+	I
39	genes	O
40	);	O
41	(	O
42	b	O
43	)	O
44	the	O
45	thiamine	O
46	-	O
47	repressible	O
48	nmt1	B
49	promoter	I
50	(	O
51	3X	O
52	,	O
53	41X	O
54	and	O
55	81X	O
56	with	O
57	extremely	O
58	high	O
59	,	O
60	moderate	O
61	or	O
62	low	O
63	transcription	O
64	efficiency	O
65	,	O
66	respectively	O
67	);	O
68	and	O
69	(	O
70	c	B
71	)	O
72	the	O
73	multiple	O
74	cloning	O
75	site	O
76	(	O
77	two	O
78	multiple	O
79	cloning	O
80	sites	O
81	,	O
82	with	O
83	12	O
84	restriction	O
85	sites	O
86	each	O
87	).	O

1	If	O
2	facilities	O
3	for	O
4	measurements	O
5	of	O
6	O2	O
7	consumption	O
8	and	O
9	hence	O
10	metabolic	O
11	rate	O
12	are	O
13	available	O
14	,	O
15	these	O
16	should	O
17	be	O
18	utilized	O
19	.	O

1	A	O
2	variety	O
3	of	O
4	professional	O
5	and	O
6	self	O
7	-	O
8	applied	O
9	fluoride	O
10	products	O
11	are	O
12	available	O
13	and	O
14	new	O
15	fluoride	O
16	delivery	O
17	systems	O
18	have	O
19	recently	O
20	entered	O
21	the	O
22	market	O
23	.	O

1	Moreover	O
2	,	O
3	unlike	O
4	control	O
5	rats	O
6	operated	O
7	animals	O
8	did	O
9	not	O
10	show	O
11	aversion	O
12	to	O
13	the	O
14	highest	O
15	concentrations	O
16	of	O
17	saccharin	O
18	solutions	O
19	.	O

1	KFC	O
2	,	O
3	a	O
4	Ste20	O
5	-	O
6	like	O
7	kinase	O
8	with	O
9	mitogenic	O
10	potential	O
11	and	O
12	capability	O
13	to	O
14	activate	O
15	the	O
16	SAPK	B
17	/	O
18	JNK	B
19	pathway	O
20	.	O

1	Hepatitis	O
2	B	O
3	vaccination	O
4	strategy	O
5	for	O
6	health	O
7	-	O
8	care	O
9	workers	O
10	in	O
11	a	O
12	country	O
13	of	O
14	intermediate	O
15	hepatitis	O
16	B	O
17	endemicity	O
18	.	O

1	SCFFWD1	O
2	may	O
3	be	O
4	critical	O
5	for	O
6	tumor	O
7	development	O
8	and	O
9	suppression	O
10	through	O
11	regulation	O
12	of	O
13	beta	B
14	-	I
15	catenin	I
16	protein	I
17	stability	O
18	.	O

1	Gene	O
2	constructs	O
3	possessing	O
4	the	O
5	complete	O
6	tat	B
7	,	O
8	rev	B
9	(	O
10	tat	B
11	+	I
12	rev	I
13	+)	O
14	and	O
15	env	B
16	genes	O
17	were	O
18	transiently	O
19	expressed	O
20	in	O
21	COS	O
22	-	O
23	1	O
24	cells	O
25	as	O
26	precursor	O
27	SU	I
28	-	I
29	TM	I
30	(	O
31	gp160	B
32	),	O
33	SU	B
34	.	O
35	TM	B
36	(	O
37	gp120	B
38	x	O
39	41	O
40	),	O
41	and	O
42	nucleolar	B
43	rev	B
44	protein	I
45	.	O

1	Functional	O
2	analysis	O
3	of	O
4	promoter	O
5	activity	O
6	of	O
7	the	O
8	5	O
9	'-	O
10	flanking	O
11	region	O
12	of	O
13	cyclin	B
14	D2	I
15	suggested	O
16	that	O
17	the	O
18	region	O
19	-	O
20	1	O
21	,	O
22	100	O
23	to	O
24	-	O
25	805	O
26	including	O
27	C	B
28	/	O
29	EBP	I
30	,	O
31	PEA3	B
32	,	O
33	AP2	B
34	,	O
35	NF	B
36	-	I
37	Y	I
38	,	O
39	c	B
40	-	I
41	Myc	I
42	,	O
43	and	O
44	Sp1	B
45	may	O
46	have	O
47	a	O
48	major	O
49	positive	O
50	regulatory	O
51	activity	O
52	for	O
53	expression	O
54	of	O
55	cyclin	B
56	D2	I
57	.	O

1	BACKGROUND	O
2	:	O
3	Hepatic	O
4	encephalopathy	O
5	is	O
6	a	O
7	neuropsychiatric	O
8	syndrome	O
9	associated	O
10	with	O
11	acute	O
12	liver	O
13	failure	O
14	,	O
15	chronic	O
16	parenchymal	O
17	liver	O
18	disease	O
19	or	O
20	portal	O
21	systemic	O
22	anastomosis	O
23	.	O

1	Because	O
2	of	O
3	the	O
4	functional	O
5	conservation	O
6	of	O
7	cell	O
8	cycle	O
9	control	O
10	elements	O
11	,	O
12	the	O
13	expression	O
14	of	O
15	a	O
16	vertebrate	O
17	wee1	O
18	or	O
19	mik1	O
20	homolog	O
21	would	O
22	be	O
23	expected	O
24	to	O
25	rescue	O
26	such	O
27	lethal	O
28	mutations	O
29	in	O
30	yeast	O
31	.	O

1	Petrous	O
2	meningioma	O
3	en	O
4	plaque	O
5	presenting	O
6	as	O
7	a	O
8	right	O
9	middle	O
10	ear	O
11	tumor	O
12	.	O

1	Studies	O
2	on	O
3	powdered	O
4	preparations	O
5	.	O

1	It	O
2	is	O
3	now	O
4	recognized	O
5	that	O
6	essentially	O
7	all	O
8	eukaryotic	O
9	and	O
10	prokaryotic	O
11	genes	O
12	whose	O
13	5	O
14	'-	O
15	flanking	O
16	regions	O
17	are	O
18	known	O
19	and	O
20	that	O
21	encode	O
22	barbiturate	O
23	-	O
24	inducible	O
25	proteins	O
26	contain	O
27	the	O
28	Barbie	B
29	box	I
30	element	I
31	.	O

1	Muscle	O
2	GSH	B
3	-	O
4	Px	I
5	activity	O
6	after	O
7	prolonged	O
8	exercise	O
9	,	O
10	training	O
11	,	O
12	and	O
13	selenium	O
14	supplementation	O
15	.	O

1	These	O
2	CTD	B
3	kinases	O
4	,	O
5	designated	O
6	CTDK1	O
7	and	O
8	CTDK2	O
9	,	O
10	are	O
11	fractionated	O
12	by	O
13	chromatography	O
14	on	O
15	Mono	O
16	Q	O
17	.	O

1	No	O
2	homology	O
3	was	O
4	found	O
5	between	O
6	the	O
7	36K	O
8	protein	O
9	and	O
10	known	O
11	structures	O
12	of	O
13	proteins	O
14	.	O

1	Saccharomyces	O
2	cerevisiae	O
3	has	O
4	been	O
5	used	O
6	widely	O
7	both	O
8	as	O
9	a	O
10	model	O
11	system	O
12	for	O
13	unraveling	O
14	the	O
15	biochemical	O
16	,	O
17	genetic	O
18	,	O
19	and	O
20	molecular	O
21	details	O
22	of	O
23	gene	O
24	expression	O
25	and	O
26	the	O
27	secretion	O
28	process	O
29	,	O
30	and	O
31	as	O
32	a	O
33	host	O
34	for	O
35	the	O
36	production	O
37	of	O
38	heterologous	O
39	proteins	O
40	of	O
41	biotechnological	O
42	interest	O
43	.	O

1	To	O
2	identify	O
3	some	O
4	of	O
5	the	O
6	genes	O
7	expressed	O
8	in	O
9	LPS	O
10	-	O
11	activated	O
12	coelomocytes	O
13	,	O
14	we	O
15	sequenced	O
16	randomly	O
17	chosen	O
18	clones	O
19	from	O
20	a	O
21	directionally	O
22	constructed	O
23	cDNA	O
24	library	O
25	to	O
26	produce	O
27	a	O
28	set	O
29	of	O
30	expressed	O
31	sequence	O
32	tags	O
33	(	O
34	ESTs	O
35	).	O

1	The	O
2	hormonal	O
3	response	O
4	to	O
5	a	O
6	standardized	O
7	bicycle	O
8	exercise	O
9	test	O
10	was	O
11	studied	O
12	in	O
13	11	O
14	male	O
15	cadets	O
16	exposed	O
17	to	O
18	a	O
19	course	O
20	of	O
21	107	O
22	h	O
23	of	O
24	continuous	O
25	activity	O
26	with	O
27	less	O
28	than	O
29	2	O
30	h	O
31	sleep	O
32	.	O

1	NF	B
2	-	I
3	kappaB	I
4	is	O
5	a	O
6	redox	O
7	-	O
8	sensitive	O
9	transcription	O
10	factor	O
11	known	O
12	to	O
13	be	O
14	activated	O
15	by	O
16	oxidative	O
17	stress	O
18	as	O
19	well	O
20	as	O
21	chemical	O
22	and	O
23	biological	O
24	reductants	O
25	.	O

1	We	O
2	further	O
3	found	O
4	that	O
5	KmMig1p	O
6	is	O
7	fully	O
8	functional	O
9	when	O
10	expressed	O
11	in	O
12	S	O
13	.	O
14	cerevisiae	O
15	.	O

1	The	O
2	micturition	O
3	pressure	O
4	was	O
5	significantly	O
6	decreased	O
7	only	O
8	after	O
9	injection	O
10	with	O
11	BUP	O
12	-	O
13	4	O
14	in	O
15	both	O
16	normal	O
17	and	O
18	obstructed	O
19	rats	O
20	.	O

1	UK	O
2	'	O
3	s	O
4	biotechnology	O
5	lacking	O
6	specialists	O
7	.	O

1	Drug	O
2	use	O
3	in	O
4	trauma	O
5	victims	O
6	.	O

1	Colorectal	O
2	polyps	O
3	should	O
4	be	O
5	removed	O
6	endoscopically	O
7	whenever	O
8	possible	O
9	.	O

1	Recombinant	O
2	Leishmania	O
3	surface	O
4	glycoprotein	O
5	GP63	O
6	is	O
7	secreted	O
8	in	O
9	the	O
10	baculovirus	O
11	expression	O
12	system	O
13	as	O
14	a	O
15	latent	O
16	metalloproteinase	I
17	.	O

1	Thus	O
2	,	O
3	diamide	O
4	treatment	O
5	of	O
6	nuclear	O
7	extracts	O
8	strongly	O
9	reduces	O
10	the	O
11	binding	O
12	of	O
13	NFI	O
14	proteins	O
15	,	O
16	and	O
17	the	O
18	addition	O
19	of	O
20	higher	O
21	concentrations	O
22	of	O
23	dithiothreitol	O
24	to	O
25	nuclear	O
26	extracts	O
27	from	O
28	TG	O
29	-	O
30	treated	O
31	cells	O
32	restores	O
33	NFI	O
34	-	O
35	DNA	O
36	binding	O
37	to	O
38	levels	O
39	in	O
40	extracts	O
41	from	O
42	untreated	O
43	cells	O
44	.	O

1	Ultrasonography	O
2	provides	O
3	excellent	O
4	intraoperative	O
5	evaluation	O
6	of	O
7	spinal	O
8	cord	O
9	injury	O
10	.	O

1	However	O
2	,	O
3	the	O
4	presence	O
5	of	O
6	effacement	O
7	seems	O
8	to	O
9	be	O
10	a	O
11	more	O
12	reliable	O
13	and	O
14	practical	O
15	parameter	O
16	that	O
17	will	O
18	be	O
19	preferred	O
20	in	O
21	that	O
22	prediction	O
23	.	O

1	Furthermore	O
2	,	O
3	we	O
4	demonstrated	O
5	that	O
6	Galpha11	B
7	Q209L	I
8	stimulated	O
9	Src	B
10	family	I
11	kinase	I
12	activity	O
13	and	O
14	induced	O
15	tyrosine	O
16	phosphorylation	O
17	of	O
18	several	O
19	proteins	O
20	in	O
21	HEK	O
22	-	O
23	293	O
24	cells	O
25	.	O

1	Single	O
2	-	O
3	photon	O
4	emission	O
5	computed	O
6	tomography	O
7	(	O
8	SPECT	O
9	)	O
10	with	O
11	99mTc	O
12	-	O
13	hexamethylpropyleneamine	O
14	oxime	O
15	(	O
16	HMPAO	O
17	)	O
18	was	O
19	used	O
20	to	O
21	investigate	O
22	changes	O
23	in	O
24	cerebral	O
25	blood	O
26	flow	O
27	in	O
28	seven	O
29	patients	O
30	with	O
31	cortical	O
32	visual	O
33	impairment	O
34	.	O

1	Sequence	O
2	analysis	O
3	suggests	O
4	that	O
5	TtrA	O
6	contains	O
7	a	O
8	molybdopterin	O
9	guanine	O
10	dinucleotide	O
11	cofactor	O
12	and	O
13	a	O
14	[	O
15	4Fe	O
16	-	O
17	4S	O
18	]	O
19	cluster	O
20	,	O
21	that	O
22	TtrB	O
23	binds	O
24	four	O
25	[	O
26	4Fe	O
27	-	O
28	4S	O
29	]	O
30	clusters	O
31	,	O
32	and	O
33	that	O
34	TtrC	O
35	is	O
36	an	O
37	integral	O
38	membrane	O
39	protein	O
40	containing	O
41	a	O
42	quinol	O
43	oxidation	O
44	site	O
45	.	O

1	CONCLUSION	O
2	:	O
3	Chronic	O
4	administration	O
5	of	O
6	misoprostol	O
7	may	O
8	have	O
9	caused	O
10	a	O
11	negative	O
12	natriuretic	O
13	effect	O
14	in	O
15	cirrhotic	O
16	patients	O
17	with	O
18	ascites	O
19	.	O

1	Cytohesin	B
2	-	O
3	1	O
4	,	O
5	a	O
6	protein	O
7	abundant	O
8	in	O
9	cells	O
10	of	O
11	the	O
12	immune	O
13	system	O
14	,	O
15	has	O
16	been	O
17	proposed	O
18	to	O
19	be	O
20	a	O
21	human	O
22	homolog	O
23	of	O
24	the	O
25	Saccharomyces	B
26	cerevisiae	I
27	Sec7	I
28	gene	I
29	product	I
30	,	O
31	which	O
32	is	O
33	crucial	O
34	in	O
35	protein	O
36	transport	O
37	.	O

1	In	O
2	connective	O
3	tissue	O
4	,	O
5	cell	O
6	structure	O
7	contributes	O
8	to	O
9	type	B
10	I	I
11	collagen	I
12	expression	O
13	.	O

1	Therapeutic	O
2	effects	O
3	of	O
4	cefpirome	O
5	(	O
6	HR	O
7	810	O
8	)	O
9	on	O
10	experimental	O
11	mixed	O
12	infections	O
13	with	O
14	Enterococcus	O
15	faecalis	O
16	and	O
17	Escherichia	O
18	coli	O
19	in	O
20	mice	O
21	.	O

1	We	O
2	conclude	O
3	that	O
4	androgenic	O
5	hormones	O
6	reduce	O
7	HDL	B
8	-	I
9	cholesterol	I
10	concentrations	O
11	and	O
12	the	O
13	HDL2	B
14	-	I
15	cholesterol	I
16	subfraction	O
17	,	O
18	possibly	O
19	by	O
20	enhancing	O
21	hepatic	O
22	triglyceride	O
23	lipase	B
24	activity	O
25	.	O

1	Protein	B
2	phosphatases	I
3	play	O
4	a	O
5	critical	O
6	role	O
7	in	O
8	the	O
9	regulation	O
10	of	O
11	the	O
12	eukaryotic	O
13	cell	O
14	cycle	O
15	and	O
16	signal	O
17	transduction	O
18	.	O

1	A	O
2	new	O
3	bioencapsulation	O
4	technology	O
5	for	O
6	microbial	O
7	inoculants	O
8	.	O

1	When	O
2	the	O
3	downstream	O
4	operator	O
5	was	O
6	altered	O
7	,	O
8	there	O
9	was	O
10	a	O
11	fourfold	O
12	reduction	O
13	in	O
14	reporter	O
15	enzyme	O
16	levels	O
17	.	O

1	To	O
2	explore	O
3	the	O
4	functional	O
5	relationship	O
6	between	O
7	c	B
8	-	I
9	fos	I
10	and	O
11	Rb	B
12	,	O
13	a	O
14	eukaryotic	O
15	expression	O
16	plasmid	O
17	was	O
18	constructed	O
19	containing	O
20	the	O
21	c	B
22	-	I
23	fos	I
24	gene	I
25	under	O
26	control	O
27	of	O
28	the	O
29	SV40	B
30	promoter	I
31	complex	O
32	.	O

1	A	O
2	significant	O
3	relationship	O
4	existed	O
5	during	O
6	the	O
7	evolution	O
8	of	O
9	the	O
10	disease	O
11	between	O
12	CRS	B
13	/	O
14	BW	O
15	and	O
16	gas	O
17	exchange	O
18	parameters	O
19	(	O
20	FIO2	O
21	and	O
22	a	O
23	/	O
24	AO2	O
25	ratio	O
26	)	O
27	(	O
28	P	O
29	less	O
30	than	O
31	0	O
32	.	O
33	01	O
34	),	O
35	but	O
36	gas	O
37	exchange	O
38	improved	O
39	earlier	O
40	than	O
41	lung	O
42	mechanics	O
43	.	O

1	Hematology	O
2	problem	O
3	of	O
4	the	O
5	month	O
6	:	O
7	band	O
8	or	O
9	seg	O
10	?	O

1	This	O
2	approach	O
3	enables	O
4	the	O
5	sources	O
6	of	O
7	error	O
8	in	O
9	the	O
10	calculation	O
11	of	O
12	nutrient	O
13	utilization	O
14	to	O
15	be	O
16	readily	O
17	identified	O
18	,	O
19	and	O
20	their	O
21	effect	O
22	on	O
23	precision	O
24	to	O
25	be	O
26	assessed	O
27	in	O
28	different	O
29	nutritional	O
30	and	O
31	metabolic	O
32	states	O
33	.	O

1	Arm	O
2	function	O
3	tests	O
4	.	O

1	Mycobacterium	O
2	avium	O
3	-	O
4	intracellulare	O
5	complex	O
6	infections	O
7	in	O
8	the	O
9	acquired	O
10	immunodeficiency	O
11	syndrome	O
12	.	O

1	Liquid	O
2	chromatographic	O
3	separation	O
4	was	O
5	achieved	O
6	on	O
7	a	O
8	Zorbax	O
9	RX	O
10	C8	O
11	analytical	O
12	column	O
13	using	O
14	gradient	O
15	elution	O
16	.	O

1	(	O
2	2	O
3	)	O
4	The	O
5	inappropriateness	O
6	of	O
7	adaptive	O
8	segmentation	O
9	for	O
10	the	O
11	isolation	O
12	of	O
13	spikes	O
14	and	O
15	sharp	O
16	waves	O
17	,	O
18	which	O
19	had	O
20	been	O
21	anticipated	O
22	in	O
23	view	O
24	of	O
25	the	O
26	short	O
27	duration	O
28	of	O
29	such	O
30	transients	O
31	in	O
32	relation	O
33	to	O
34	the	O
35	length	O
36	of	O
37	the	O
38	window	O
39	(	O
40	1	O
41	.	O
42	2	O
43	sec	O
44	)	O
45	used	O
46	for	O
47	the	O
48	autocorrelation	O
49	functions	O
50	employed	O
51	in	O
52	the	O
53	segmentation	O
54	algorithm	O
55	,	O
56	was	O
57	confirmed	O
58	.	O

1	In	O
2	the	O
3	infected	O
4	neonates	O
5	serum	B
6	alpha	I
7	-	I
8	amylase	I
9	value	O
10	,	O
11	as	O
12	determined	O
13	by	O
14	the	O
15	blue	O
16	starch	O
17	method	O
18	,	O
19	was	O
20	only	O
21	40	O
22	%	O
23	that	O
24	of	O
25	healthy	O
26	controls	O
27	;	O
28	the	O
29	mean	O
30	value	O
31	of	O
32	175	O
33	.	O
34	1	O
35	+/-	O
36	64	O
37	.	O
38	9	O
39	IU	O
40	/	O
41	l	O
42	for	O
43	healthy	O
44	neonates	O
45	was	O
46	significantly	O
47	higher	O
48	(	O
49	p	O
50	less	O
51	than	O
52	0	O
53	.	O
54	0010	O
55	)	O
56	than	O
57	the	O
58	value	O
59	of	O
60	82	O
61	.	O
62	8	O
63	+/-	O
64	44	O
65	.	O
66	4	O
67	IU	O
68	/	O
69	l	O
70	for	O
71	the	O
72	infected	O
73	neonates	O
74	.	O

1	Dopamine	B
2	caused	O
3	a	O
4	prominent	O
5	potassium	O
6	efflux	O
7	measured	O
8	as	O
9	86Rb	O
10	+	O
11	efflux	O
12	from	O
13	control	O
14	glands	O
15	,	O
16	but	O
17	was	O
18	without	O
19	effect	O
20	in	O
21	denervated	O
22	glands	O
23	.	O

1	The	O
2	interaction	O
3	between	O
4	piroxicam	O
5	and	O
6	poloxamer	O
7	was	O
8	studied	O
9	by	O
10	x	O
11	-	O
12	ray	O
13	diffractometry	O
14	(	O
15	XRD	O
16	),	O
17	infrared	O
18	(	O
19	IR	O
20	)	O
21	spectroscopy	O
22	and	O
23	differential	O
24	thermal	O
25	analysis	O
26	(	O
27	DTA	O
28	)	O
29	with	O
30	a	O
31	solid	O
32	dispersion	O
33	,	O
34	coprecipitate	O
35	,	O
36	or	O
37	physical	O
38	mixture	O
39	.	O

1	A	O
2	new	O
3	method	O
4	for	O
5	the	O
6	in	O
7	vitro	O
8	transfer	O
9	of	O
10	delayed	O
11	hypersensitivity	O
12	by	O
13	dialysed	O
14	transfer	O
15	factor	O
16	.	O

1	PCNA	B
2	mRNA	O
3	has	O
4	a	O
5	3	O
6	'	O
7	UTR	O
8	antisense	O
9	to	O
10	yellow	O
11	crescent	O
12	RNA	O
13	and	O
14	is	O
15	localized	O
16	in	O
17	ascidian	O
18	eggs	O
19	and	O
20	embryos	O
21	.	O

1	METHODS	O
2	:	O
3	Total	O
4	muscle	O
5	paralysis	O
6	was	O
7	induced	O
8	under	O
9	general	O
10	anesthesia	O
11	in	O
12	a	O
13	group	O
14	of	O
15	obese	O
16	persons	O
17	(	O
18	n	O
19	=	O
20	9	O
21	;	O
22	body	O
23	mass	O
24	index	O
25	,	O
26	32	O
27	+/-	O
28	3	O
29	kg	O
30	[-	O
31	2	O
32	])	O
33	and	O
34	in	O
35	a	O
36	group	O
37	of	O
38	nonobese	O
39	persons	O
40	(	O
41	n	O
42	=	O
43	9	O
44	;	O
45	body	O
46	mas	O
47	index	O
48	,	O
49	21	O
50	+/-	O
51	2	O
52	kg	O
53	[-	O
54	2	O
55	]).	O

1	D3S1261	O
2	is	O
3	physically	O
4	located	O
5	at	O
6	or	O
7	near	O
8	the	O
9	MITF	O
10	locus	O
11	,	O
12	while	O
13	D3S2465	O
14	and	O
15	D3S1766	O
16	are	O
17	flanking	O
18	the	O
19	locus	O
20	at	O
21	about	O
22	17	O
23	.	O
24	5	O
25	cM	O
26	genetic	O
27	distance	O
28	each	O
29	side	O
30	.	O

1	Titration	O
2	of	O
3	the	O
4	human	O
5	and	O
6	porcine	O
7	proteins	O
8	with	O
9	2	O
10	-	O
11	nitro	O
12	-	O
13	5	I
14	-	O
15	thiosulfabenzoate	O
16	indicates	O
17	that	O
18	membrane	O
19	dipeptidase	O
20	additionally	O
21	possesses	O
22	two	O
23	intrachain	O
24	disulfide	O
25	bonds	O
26	.	O

1	The	O
2	alternative	O
3	splice	O
4	sites	O
5	for	O
6	the	O
7	smallest	B
8	adducin	I
9	isoform	I
10	,	O
11	beta	B
12	-	I
13	3	I
14	,	O
15	are	O
16	alternative	O
17	donor	O
18	and	O
19	acceptor	O
20	sites	O
21	within	O
22	exons	O
23	7	O
24	and	O
25	12	O
26	.	O

1	Relationship	O
2	of	O
3	mast	O
4	cells	O
5	to	O
6	sarcoidosis	O
7	granuloma	O
8	of	O
9	the	O
10	skin	O

1	CASE	O
2	REPORT	O
3	:	O
4	Referred	O
5	because	O
6	of	O
7	a	O
8	right	O
9	corneal	O
10	perforation	O
11	with	O
12	cellular	O
13	reaction	O
14	in	O
15	anterior	O
16	chamber	O
17	,	O
18	a	O
19	patient	O
20	was	O
21	sutured	O
22	and	O
23	treated	O
24	with	O
25	a	O
26	single	O
27	intravitreal	O
28	injection	O
29	of	O
30	0	O
31	.	O
32	2	O
33	ml	O
34	(	O
35	1	O
36	mg	O
37	)	O
38	Amikacin	O
39	and	O
40	0	O
41	.	O
42	2	O
43	ml	O
44	(	O
45	1	O
46	mg	O
47	)	O
48	Vancomycin	O
49	.	O

1	Remarkably	O
2	,	O
3	both	O
4	TTD	O
5	-	O
6	A	O
7	and	O
8	XP	O
9	-	O
10	D	O
11	defects	O
12	are	O
13	associated	O
14	with	O
15	subunits	O
16	of	O
17	TFIIH	O
18	,	O
19	a	O
20	basal	O
21	transcription	O
22	factor	O
23	with	O
24	a	O
25	second	O
26	function	O
27	in	O
28	DNA	O
29	repair	O
30	.	O

1	Today	O
2	there	O
3	is	O
4	no	O
5	doubt	O
6	that	O
7	elevated	O
8	plasma	O
9	cholesterol	O
10	levels	O
11	should	O
12	be	O
13	lowered	O
14	first	O
15	by	O
16	dietary	O
17	modification	O
18	even	O
19	in	O
20	early	O
21	childhood	O
22	,	O
23	beginning	O
24	at	O
25	the	O
26	age	O
27	of	O
28	two	O
29	years	O
30	.	O

1	Krox	B
2	-	I
3	24	O
4	is	O
5	therefore	O
6	a	O
7	sequence	O
8	-	O
9	specific	O
10	transcriptional	O
11	activator	O
12	.	O

1	Deletion	O
2	analysis	O
3	of	O
4	rOC	B
5	promoter	I
6	-	I
7	chloramphenicol	I
8	acetyltransferase	I
9	constructs	O
10	demonstrates	O
11	that	O
12	an	O
13	AML	B
14	-	I
15	1	I
16	-	I
17	binding	O
18	sequence	O
19	within	O
20	the	O
21	proximal	O
22	promoter	O
23	(-	O
24	138	O
25	to	O
26	-	O
27	130	O
28	nt	O
29	)	O
30	contributes	O
31	to	O
32	75	O
33	%	O
34	of	O
35	the	O
36	level	O
37	of	O
38	osteocalcin	B
39	gene	I
40	expression	O
41	.	O

1	The	O
2	investigation	O
3	was	O
4	thereafter	O
5	continued	O
6	in	O
7	an	O
8	open	O
9	fashion	O
10	by	O
11	administering	O
12	a	O
13	single	O
14	10	O
15	mg	O
16	dose	O
17	of	O
18	the	O
19	MAO	B
20	-	I
21	B	I
22	inhibitor	O
23	deprenyl	O
24	to	O
25	the	O
26	same	O
27	subjects	O
28	.	O

1	The	O
2	human	O
3	purH	O
4	cDNA	O
5	is	O
6	1776	O
7	base	O
8	pairs	O
9	in	O
10	length	O
11	encoding	O
12	for	O
13	a	O
14	591	O
15	-	O
16	amino	O
17	acid	O
18	polypeptic	O
19	(	O
20	Mr	O
21	=	O
22	64	O
23	,	O
24	425	O
25	).	O

1	Here	O
2	we	O
3	investigate	O
4	the	O
5	role	O
6	of	O
7	c	B
8	-	I
9	Cbl	I
10	in	O
11	development	O
12	and	O
13	homeostasis	O
14	in	O
15	mice	O
16	by	O
17	targeted	O
18	disruption	O
19	of	O
20	the	O
21	c	B
22	-	I
23	Cbl	I
24	locus	I
25	.	O
26	c	B
27	-	I
28	Cbl	I
29	-	O
30	deficient	O
31	mice	O
32	were	O
33	viable	O
34	,	O
35	fertile	O
36	,	O
37	and	O
38	outwardly	O
39	normal	O
40	in	O
41	appearance	O
42	.	O

1	Protein	B
2	phosphatase	I
3	2A	I
4	is	O
5	a	O
6	critical	O
7	regulator	O
8	of	O
9	protein	B
10	kinase	I
11	C	I
12	zeta	I
13	signaling	O
14	targeted	O
15	by	O
16	SV40	B
17	small	I
18	t	O
19	to	O
20	promote	O
21	cell	O
22	growth	O
23	and	O
24	NF	B
25	-	I
26	kappaB	I
27	activation	O
28	.	O

1	However	O
2	,	O
3	its	O
4	participation	O
5	in	O
6	gagging	O
7	induced	O
8	by	O
9	oropharyngeal	O
10	irritation	O
11	is	O
12	unclear	O
13	.	O

1	Streptococcal	O
2	preparation	O
3	(	O
4	OK	O
5	-	O
6	432	O
7	),	O
8	a	O
9	new	O
10	type	O
11	of	O
12	anti	O
13	-	O
14	cancer	O
15	agent	O
16	,	O
17	was	O
18	given	O
19	to	O
20	the	O
21	patients	O
22	with	O
23	advanced	O
24	cancer	O
25	in	O
26	combination	O
27	with	O
28	Mitomycin	O
29	-	O
30	C	O
31	,	O
32	5	O
33	-	O
34	FU	O
35	and	O
36	Cytosine	O
37	arabinoside	O
38	.	O

1	These	O
2	women	O
3	should	O
4	not	O
5	be	O
6	given	O
7	the	O
8	current	O
9	estrogen	O
10	PPI	O
11	,	O
12	which	O
13	was	O
14	designed	O
15	to	O
16	warn	O
17	women	O
18	of	O
19	the	O
20	risks	O
21	of	O
22	long	O
23	-	O
24	term	O
25	estrogen	O
26	use	O
27	;	O
28	a	O
29	PPI	O
30	should	O
31	be	O
32	written	O
33	specifically	O
34	for	O
35	patients	O
36	receiving	O
37	short	O
38	courses	O
39	.	O

1	Identification	O
2	of	O
3	dynein	B
4	heavy	I
5	chain	I
6	genes	I
7	expressed	O
8	in	O
9	human	O
10	and	O
11	mouse	O
12	testis	O
13	:	O
14	chromosomal	O
15	localization	O
16	of	O
17	an	O
18	axonemal	B
19	dynein	I
20	gene	I
21	.	O

1	MAIN	O
2	OUTCOME	O
3	MEASURES	O
4	:	O
5	Associations	O
6	of	O
7	factor	O
8	analysis	O
9	-	O
10	derived	O
11	syndromes	O
12	with	O
13	risk	O
14	factors	O
15	for	O
16	chemical	O
17	interactions	O
18	that	O
19	inhibit	O
20	butyrylcholinesterase	B
21	and	O
22	neuropathy	B
23	target	O
24	esterase	I
25	.	O

1	The	O
2	combination	O
3	of	O
4	Pitx2	O
5	and	O
6	another	O
7	homeodomain	B
8	protein	I
9	,	O
10	Pit	B
11	-	I
12	1	I
13	,	O
14	yielded	O
15	a	O
16	synergistic	O
17	55	O
18	-	O
19	fold	O
20	activation	O
21	of	O
22	the	O
23	prolactin	B
24	promoter	I
25	in	O
26	transfection	O
27	assays	O
28	.	O

1	Along	O
2	with	O
3	previously	O
4	mapped	O
5	genes	O
6	including	O
7	Ly	B
8	-	I
9	1	I
10	and	O
11	CD20	B
12	,	O
13	OSBP	B
14	defines	O
15	a	O
16	new	O
17	conserved	O
18	syntenic	O
19	group	O
20	on	O
21	the	O
22	long	O
23	arm	O
24	of	O
25	chromosome	O
26	11	O
27	in	O
28	the	O
29	human	O
30	and	O
31	the	O
32	proximal	O
33	end	O
34	of	O
35	chromosome	O
36	19	O
37	in	O
38	the	O
39	mouse	O
40	.	O

1	Consistent	O
2	with	O
3	this	O
4	interpretation	O
5	,	O
6	recombinant	B
7	CREB	B
8	and	O
9	activating	B
10	transcription	I
11	factor	I
12	proteins	I
13	bound	O
14	the	O
15	junB	B
16	CRE	O
17	-	O
18	like	O
19	site	O
20	,	O
21	but	O
22	did	O
23	not	O
24	interact	O
25	with	O
26	a	O
27	mutant	O
28	CRE	O
29	-	O
30	like	O
31	site	O
32	.	O

1	Studies	O
2	suggest	O
3	that	O
4	the	O
5	DGOR	O
6	without	O
7	acid	O
8	reflux	O
9	may	O
10	result	O
11	in	O
12	symptoms	O
13	but	O
14	unless	O
15	acid	O
16	reflux	O
17	is	O
18	present	O
19	simultaneously	O
20	,	O
21	it	O
22	does	O
23	not	O
24	cause	O
25	oesophagitis	O
26	.	O

1	The	O
2	position	O
3	,	O
4	transcription	O
5	orientation	O
6	,	O
7	and	O
8	imprinted	O
9	status	O
10	of	O
11	the	O
12	genes	O
13	immediately	O
14	flanking	O
15	Igf2r	O
16	have	O
17	been	O
18	assessed	O
19	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	Thr115	O
6	may	O
7	play	O
8	an	O
9	important	O
10	role	O
11	in	O
12	the	O
13	regulation	O
14	of	O
15	MyoD	B
16	function	O
17	under	O
18	conditions	O
19	of	O
20	high	O
21	mitogenesis	O
22	.	O

1	Instead	O
2	,	O
3	mRNA	O
4	of	O
5	2	O
6	.	O
7	0	O
8	and	O
9	2	O
10	.	O
11	8	O
12	kb	O
13	are	O
14	detected	O
15	in	O
16	varying	O
17	abundance	O
18	.	O

1	In	O
2	concert	O
3	with	O
4	the	O
5	coactivator	B
6	CREB	B
7	binding	I
8	protein	I
9	/	O
10	p300	B
11	,	O
12	which	O
13	interacts	O
14	with	O
15	GABPalpha	B
16	,	O
17	the	O
18	binding	O
19	of	O
20	GABPalpha	B
21	and	O
22	-	O
23	beta	I
24	to	O
25	the	O
26	dyad	O
27	symmetry	O
28	element	O
29	controls	O
30	the	O
31	induction	O
32	of	O
33	IL	B
34	-	I
35	16	I
36	promoter	I
37	in	O
38	T	O
39	cells	O
40	.	O

1	RESULTS	O
2	:	O
3	CK	B
4	-	O
5	MB	O
6	elevation	O
7	was	O
8	detected	O
9	in	O
10	313	O
11	patients	O
12	(	O
13	18	O
14	.	O
15	7	O
16	%),	O
17	with	O
18	1	O
19	-	O
20	3x	O
21	in	O
22	12	O
23	.	O
24	8	O
25	%,	O
26	3	O
27	-	O
28	5x	O
29	in	O
30	3	O
31	.	O
32	5	O
33	%	O
34	and	O
35	>	O
36	5x	O
37	normal	O
38	in	O
39	2	O
40	.	O
41	4	O
42	%	O
43	of	O
44	patients	O
45	.	O

1	The	O
2	absolute	O
3	configuration	O
4	at	O
5	C	O
6	-	O
7	2	O
8	in	O
9	monocrotalic	O
10	acid	O
11	.	O

1	In	O
2	some	O
3	instances	O
4	,	O
5	this	O
6	is	O
7	partly	O
8	mediated	O
9	by	O
10	the	O
11	expression	O
12	of	O
13	virally	O
14	encoded	O
15	proteases	O
16	which	O
17	lead	O
18	to	O
19	the	O
20	cleavage	O
21	of	O
22	initiation	O
23	factor	O
24	eIF4G	O
25	.	O

1	The	O
2	partial	O
3	farm	O
4	budget	O
5	highlighted	O
6	the	O
7	importance	O
8	of	O
9	reducing	O
10	sub	O
11	-	O
12	clinical	O
13	lesions	O
14	in	O
15	a	O
16	feedlot	O
17	.	O

1	The	O
2	rhaB	O
3	transcription	O
4	start	O
5	site	O
6	was	O
7	mapped	O
8	to	O
9	-	O
10	24	O
11	relative	O
12	to	O
13	the	O
14	start	O
15	of	O
16	translation	O
17	.	O

1	PM	O
2	12	O
3	or	O
4	18	O
5	mg	O
6	/	O
7	kg	O
8	daily	O
9	plus	O
10	a	O
11	standard	O
12	dose	O
13	of	O
14	SB	O
15	for	O
16	21	O
17	days	O
18	was	O
19	statistically	O
20	more	O
21	effective	O
22	than	O
23	SB	O
24	in	O
25	producing	O
26	a	O
27	final	O
28	cure	O
29	for	O
30	patients	O
31	with	O
32	VL	B
33	in	O
34	Bihar	O
35	,	O
36	India	O
37	.	O

1	The	O
2	Prolactin	O
3	levels	O
4	were	O
5	within	O
6	the	O
7	physiological	O
8	norms	O
9	;	O
10	the	O
11	responses	O
12	to	O
13	TRH	B
14	were	O
15	normal	O
16	,	O
17	and	O
18	elevated	O
19	only	O
20	in	O
21	a	O
22	few	O
23	cases	O
24	.	O

1	Epithelial	O
2	and	O
3	corneal	O
4	thickness	O
5	measurements	O
6	by	O
7	in	O
8	vivo	O
9	confocal	O
10	microscopy	O
11	through	O
12	focusing	O
13	(	O
14	CMTF	O
15	).	O

1	From	O
2	our	O
3	ultrastructural	O
4	and	O
5	biochemical	O
6	studies	O
7	,	O
8	it	O
9	is	O
10	evident	O
11	that	O
12	Type	O
13	II	O
14	pneumocytes	O
15	are	O
16	an	O
17	early	O
18	target	O
19	of	O
20	radiation	O
21	and	O
22	the	O
23	release	O
24	of	O
25	surfactant	O
26	into	O
27	the	O
28	alveolus	O
29	shortly	O
30	after	O
31	exposure	O
32	persists	O
33	for	O
34	days	O
35	and	O
36	weeks	O
37	.	O

1	The	O
2	PDGFR	B
3	mutants	O
4	that	O
5	failed	O
6	to	O
7	associate	O
8	with	O
9	PLC	B
10	gamma	I
11	were	O
12	not	O
13	able	O
14	to	O
15	mediate	O
16	the	O
17	PDGF	B
18	-	O
19	dependent	O
20	production	O
21	of	O
22	inositol	O
23	phosphates	O
24	.	O

1	Pulmonary	O
2	hypertension	O
3	,	O
4	with	O
5	or	O
6	without	O
7	coronary	O
8	arterial	O
9	narrowing	O
10	,	O
11	is	O
12	the	O
13	major	O
14	condition	O
15	leading	O
16	to	O
17	isolated	O
18	atrial	O
19	infarction	O
20	.	O

1	These	O
2	two	O
3	mRNA	O
4	species	O
5	are	O
6	produced	O
7	by	O
8	differential	O
9	polyadenylation	O
10	site	O
11	usage	O
12	.	O

1	When	O
2	expressed	O
3	in	O
4	COS	O
5	-	O
6	7	O
7	cells	O
8	,	O
9	MKP	B
10	-	I
11	4	I
12	blocks	O
13	activation	O
14	of	O
15	MAP	B
16	kinases	I
17	with	O
18	the	O
19	selectivity	O
20	ERK	B
21	>	O
22	p38	B
23	=	O
24	JNK	B
25	/	O
26	SAPK	B
27	.	O

1	The	O
2	MAP	B
3	kinase	I
4	cascade	O
5	is	O
6	highly	O
7	conserved	O
8	in	O
9	all	O
10	eukaryotes	O
11	and	O
12	involved	O
13	in	O
14	numerous	O
15	cellular	O
16	responses	O
17	.	O

1	One	O
2	missense	O
3	allele	O
4	(	O
5	P236S	O
6	)	O
7	with	O
8	complete	O
9	loss	O
10	of	O
11	function	O
12	at	O
13	30	O
14	degreesC	O
15	and	O
16	four	O
17	missense	O
18	alleles	O
19	(	O
20	L173F	O
21	,	O
22	E225K	O
23	,	O
24	S269L	O
25	and	O
26	E274K	O
27	)	O
28	that	O
29	conferred	O
30	a	O
31	temperature	O
32	sensitive	O
33	phenotype	O
34	were	O
35	identified	O
36	.	O

1	Nuclear	B
2	factor	I
3	III	I
4	(	O
5	NFIII	O
6	)	O
7	is	O
8	a	O
9	protein	O
10	from	O
11	HeLa	O
12	cells	O
13	that	O
14	stimulates	O
15	the	O
16	initiation	O
17	of	O
18	adenovirus	O
19	type	O
20	2	I
21	(	O
22	Ad2	O
23	)	O
24	DNA	O
25	replication	O
26	by	O
27	binding	O
28	to	O
29	a	O
30	specific	O
31	nucleotide	O
32	sequence	O
33	in	O
34	the	O
35	origin	O
36	,	O
37	adjacent	O
38	to	O
39	the	O
40	nuclear	B
41	factor	I
42	I	I
43	recognition	I
44	site	I
45	.	O

1	Notably	O
2	,	O
3	SRF	B
4	has	O
5	been	O
6	found	O
7	to	O
8	be	O
9	a	O
10	key	O
11	regulator	O
12	of	O
13	members	O
14	of	O
15	a	O
16	class	O
17	of	O
18	cellular	O
19	response	O
20	genes	O
21	termed	O
22	immediate	B
23	-	I
24	early	I
25	genes	O
26	(	O
27	IEGs	O
28	),	O
29	many	O
30	of	O
31	which	O
32	are	O
33	believed	O
34	to	O
35	be	O
36	involved	O
37	in	O
38	regulating	O
39	cell	O
40	growth	O
41	and	O
42	differentiation	O
43	.	O

1	METHODS	O
2	:	O
3	A	O
4	total	O
5	of	O
6	15	O
7	pigs	O
8	were	O
9	randomised	O
10	to	O
11	ligation	O
12	of	O
13	left	O
14	marginal	O
15	arteries	O
16	(	O
17	infarction	O
18	group	O
19	,	O
20	n	O
21	=	O
22	5	O
23	),	O
24	to	O
25	TMLR	O
26	of	O
27	the	O
28	left	O
29	lateral	O
30	wall	O
31	using	O
32	a	O
33	holmium	O
34	:	O
35	yttrium	O
36	-	O
37	aluminium	O
38	garnet	O
39	(	O
40	Ho	O
41	:	O
42	YAG	O
43	)	O
44	laser	O
45	(	O
46	laser	O
47	group	O
48	,	O
49	n	O
50	=	O
51	5	O
52	),	O
53	and	O
54	to	O
55	both	O
56	(	O
57	laser	O
58	-	O
59	infarction	O
60	group	O
61	,	O
62	n	O
63	=	O
64	5	O
65	).	O

1	These	O
2	regions	O
3	overlap	O
4	with	O
5	the	O
6	HIT	O
7	protein	O
8	similarity	O
9	regions	O
10	.	O

1	Intensive	O
2	synthesis	O
3	of	O
4	PNA	O
5	in	O
6	the	O
7	cells	O
8	of	O
9	microvascular	O
10	wall	O
11	evidenced	O
12	of	O
13	their	O
14	high	O
15	functional	O
16	activity	O
17	,	O
18	and	O
19	the	O
20	synthesis	O
21	of	O
22	DNA	O
23	in	O
24	them	O
25	showed	O
26	their	O
27	ability	O
28	for	O
29	proliferation	O
30	,	O
31	i	O
32	.	O
33	g	O
34	.--	O
35	for	O
36	growth	O
37	.	O

1	The	O
2	intracellular	O
3	basic	O
4	region	O
5	/	O
6	helix	O
7	-	O
8	loop	O
9	-	O
10	helix	I
11	(	O
12	bHLH	B
13	)	O
14	dioxin	B
15	receptor	I
16	mediates	O
17	signal	O
18	transduction	O
19	by	O
20	dioxin	O
21	(	O
22	2	O
23	,	O
24	3	O
25	,	O
26	7	O
27	,	O
28	8	O
29	-	O
30	tetrachlorodibenzo	O
31	-	O
32	p	O
33	-	O
34	dioxin	O
35	)	O
36	and	O
37	functions	O
38	as	O
39	a	O
40	ligand	O
41	-	O
42	activated	O
43	DNA	O
44	binding	O
45	protein	O
46	directly	O
47	interacting	O
48	with	O
49	target	O
50	genes	O
51	by	O
52	binding	O
53	to	O
54	dioxin	O
55	response	O
56	elements	O
57	.	O

1	FN	B
2	-	O
3	stimulated	O
4	c	B
5	-	I
6	Src	I
7	PTK	I
8	activity	O
9	was	O
10	enhanced	O
11	by	O
12	wild	O
13	type	O
14	FAK	B
15	expression	O
16	,	O
17	whereas	O
18	FN	B
19	-	O
20	stimulated	O
21	activation	O
22	of	O
23	ERK2	B
24	was	O
25	blocked	O
26	by	O
27	expression	O
28	of	O
29	the	O
30	c	B
31	-	I
32	Src	I
33	binding	I
34	site	I
35	Phe	I
36	-	I
37	397	I
38	mutant	I
39	of	O
40	FAK	B
41	.	O

1	Previously	O
2	,	O
3	we	O
4	showed	O
5	that	O
6	SNF2	B
7	,	O
8	SNF5	B
9	,	O
10	and	O
11	SNF6	B
12	function	O
13	interdependently	O
14	in	O
15	transcriptional	O
16	activation	O
17	,	O
18	possibly	O
19	forming	O
20	a	O
21	heteromeric	O
22	complex	O
23	.	O

1	An	O
2	RNA	B
3	-	I
4	binding	I
5	protein	I
6	gene	I
7	(	O
8	rbp1	O
9	)	O
10	from	O
11	Drosophila	O
12	melanogaster	O
13	,	O
14	encoding	O
15	an	O
16	RNA	O
17	recognition	O
18	motif	O
19	and	O
20	an	O
21	Arg	O
22	-	O
23	Ser	O
24	rich	O
25	(	O
26	RS	O
27	)	O
28	domain	O
29	,	O
30	has	O
31	been	O
32	characterized	O
33	.	O

1	These	O
2	results	O
3	were	O
4	compared	O
5	with	O
6	those	O
7	obtained	O
8	in	O
9	-	O
10	D	O
11	mothers	O
12	and	O
13	pups	O
14	,	O
15	after	O
16	giving	O
17	the	O
18	mothers	O
19	an	O
20	oral	O
21	supplement	O
22	(	O
23	10	O
24	i	O
25	.	O
26	u	O
27	.	O
28	vitamin	O
29	D3	O
30	/	O
31	day	O
32	)	O
33	during	O
34	the	O
35	period	O
36	of	O
37	lactation	O
38	(	O
39	20	O
40	days	O
41	).	O

1	Application	O
2	of	O
3	different	O
4	criteria	O
5	of	O
6	cure	O
7	revealed	O
8	that	O
9	19	O
10	patients	O
11	(	O
12	66	O
13	%)	O
14	had	O
15	basal	O
16	GH	B
17	levels	O
18	below	O
19	5	O
20	ng	O
21	/	O
22	ml	O
23	,	O
24	17	O
25	patients	O
26	(	O
27	59	O
28	%)	O
29	had	O
30	normal	O
31	somatomedin	B
32	-	O
33	C	O
34	values	O
35	,	O
36	16	O
37	patients	O
38	(	O
39	55	O
40	%)	O
41	had	O
42	complete	O
43	GH	B
44	suppression	O
45	(	O
46	less	O
47	than	O
48	1	O
49	ng	O
50	/	O
51	ml	O
52	)	O
53	during	O
54	OGTT	O
55	,	O
56	and	O
57	13	O
58	patients	O
59	(	O
60	45	O
61	%)	O
62	met	O
63	the	O
64	above	O
65	-	O
66	mentioned	O
67	criteria	O
68	with	O
69	disappearance	O
70	of	O
71	the	O
72	paradoxical	O
73	GH	B
74	response	O
75	to	O
76	TRH	B
77	/	O
78	GnRH	I
79	test	O
80	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	investigated	O
7	the	O
8	signal	O
9	transduction	O
10	pathways	O
11	that	O
12	are	O
13	involved	O
14	in	O
15	OM	O
16	-	O
17	induced	O
18	LDLR	O
19	transcription	O
20	.	O

1	Comparisons	O
2	of	O
3	the	O
4	four	O
5	operon	O
6	control	O
7	regions	O
8	studied	O
9	indicate	O
10	that	O
11	the	O
12	NarL	O
13	heptamers	O
14	are	O
15	arranged	O
16	with	O
17	diverse	O
18	orientations	O
19	and	O
20	spacing	O
21	.	O

1	Testing	O
2	blood	O
3	donors	O
4	for	O
5	non	O
6	-	O
7	A	O
8	,	O
9	non	O
10	-	O
11	B	I
12	hepatitis	O
13	:	O
14	irrational	O
15	,	O
16	perhaps	O
17	,	O
18	but	O
19	inescapable	O
20	.	O

1	Role	O
2	of	O
3	the	O
4	infectious	O
5	-	O
6	disease	O
7	specialist	O
8	of	O
9	a	O
10	polyclinic	O
11	in	O
12	reducing	O
13	the	O
14	incidence	O
15	of	O
16	communicable	O
17	diseases	O

1	Regulatory	O
2	regions	O
3	in	O
4	the	O
5	promoter	O
6	and	O
7	third	O
8	intron	O
9	of	O
10	the	O
11	growth	B
12	hormone	I
13	gene	I
14	in	O
15	rainbow	O
16	trout	O
17	,	O
18	Oncorhynchus	O
19	mykiss	O
20	walbaum	O
21	.	O

1	We	O
2	conclude	O
3	that	O
4	sequences	O
5	outside	O
6	of	O
7	the	O
8	hLEF	O
9	HMG	B
10	box	O
11	mediate	O
12	cell	O
13	-	O
14	and	O
15	context	O
16	-	O
17	specific	O
18	activation	O
19	of	O
20	the	O
21	TCR	B
22	alpha	I
23	enhancer	I
24	and	O
25	may	O
26	facilitate	O
27	interactions	O
28	between	O
29	hLEF	O
30	and	O
31	other	O
32	T	O
33	-	O
34	cell	O
35	-	O
36	specific	O
37	factors	O
38	recruited	O
39	to	O
40	the	O
41	enhancer	O
42	.	O

1	At	O
2	the	O
3	same	O
4	time	O
5	,	O
6	the	O
7	results	O
8	indicate	O
9	that	O
10	p53	B
11	plays	O
12	a	O
13	defensive	O
14	role	O
15	against	O
16	HBV	O
17	by	O
18	transcriptionally	O
19	repressing	O
20	the	O
21	HBV	O
22	core	O
23	promoter	O
24	through	O
25	liver	O
26	-	O
27	specific	O
28	enhancer	I
29	II	I
30	and	O
31	HBx	B
32	is	O
33	required	O
34	to	O
35	counteract	O
36	this	O
37	inhibitory	O
38	function	O
39	of	O
40	p53	B
41	.	O

1	A	O
2	2	I
3	kb	O
4	transcript	O
5	was	O
6	isolated	O
7	from	O
8	brain	O
9	that	O
10	encodes	O
11	a	O
12	approximately	O
13	57	O
14	kDa	O
15	protein	O
16	;	O
17	the	O
18	predicted	O
19	protein	O
20	contains	O
21	the	O
22	known	O
23	N	O
24	-	O
25	terminal	O
26	Ets	B
27	domain	I
28	of	O
29	PE1	B
30	and	O
31	a	O
32	novel	O
33	C	O
34	-	O
35	terminal	O
36	domain	O
37	with	O
38	signficant	O
39	homology	O
40	to	O
41	murine	O
42	ERF	I
43	.	O

1	RNA	O
2	polymerase	I
3	bound	O
4	to	O
5	the	O
6	+	O
7	10A	I
8	promoter	I
9	partially	O
10	protects	O
11	a	O
12	20	O
13	base	O
14	-	O
15	pair	O
16	sequence	O
17	from	O
18	DNase	B
19	I	I
20	digestion	O
21	upstream	O
22	of	O
23	the	O
24	start	O
25	site	O
26	.	O

1	The	O
2	bile	O
3	acid	O
4	sequestrants	O
5	(	O
6	cholestyramine	O
7	and	O
8	colestipol	O
9	),	O
10	nicotinic	B
11	acid	O
12	,	O
13	fenofibrate	O
14	and	O
15	inhibitors	O
16	of	O
17	hydroxymethylglutaryl	B
18	coenzyme	I
19	A	I
20	(	I
21	HMG	B
22	CoA	I
23	)	I
24	reductase	I
25	(	O
26	e	O
27	.	O
28	g	O
29	.	O
30	lovastatin	O
31	or	O
32	simvastatin	O
33	)	O
34	are	O
35	the	O
36	most	O
37	effective	O
38	drugs	O
39	for	O
40	use	O
41	in	O
42	patients	O
43	with	O
44	primary	O
45	hypercholesterolaemia	O
46	;	O
47	these	O
48	agents	O
49	reduce	O
50	plasma	O
51	concentrations	O
52	of	O
53	total	O
54	and	O
55	LDL	B
56	-	O
57	cholesterol	O
58	by	O
59	15	O
60	to	O
61	45	O
62	%.	O

1	Research	O
2	was	O
3	carried	O
4	out	O
5	on	O
6	the	O
7	rheumatoid	B
8	factors	I
9	in	O
10	the	O
11	serum	O
12	of	O
13	917	O
14	patients	O
15	by	O
16	means	O
17	of	O
18	two	O
19	tests	O
20	(	O
21	one	O
22	using	O
23	polystyrene	O
24	and	O
25	one	O
26	with	O
27	erythrocytes	O
28	)	O
29	and	O
30	the	O
31	results	O
32	obtained	O
33	were	O
34	compared	O
35	using	O
36	a	O
37	method	O
38	of	O
39	reference	O
40	.	O

1	Thus	O
2	RV	O
3	O2	O
4	demand	O
5	fell	O
6	when	O
7	RC	O
8	O2	O
9	supply	O
10	was	O
11	reduced	O
12	,	O
13	although	O
14	a	O
15	flow	O
16	reserve	O
17	was	O
18	available	O
19	.	O

1	SRF	B
2	-	O
3	deficient	O
4	embryos	O
5	(	O
6	Srf	O
7	-/-)	O
8	have	O
9	a	O
10	severe	O
11	gastrulation	O
12	defect	O
13	and	O
14	do	O
15	not	O
16	develop	O
17	to	O
18	term	O
19	.	O

1	The	O
2	patient	O
3	was	O
4	a	O
5	78	O
6	-	O
7	year	O
8	-	O
9	old	O
10	male	O
11	in	O
12	whom	O
13	skin	O
14	lesions	O
15	preceded	O
16	the	O
17	diagnosis	O
18	of	O
19	myelofibrosis	O
20	.	O

1	Montelukast	O
2	reduces	O
3	airway	O
4	eosinophilic	O
5	inflammation	O
6	in	O
7	asthma	O
8	:	O
9	a	O
10	randomized	O
11	,	O
12	controlled	O
13	trial	O
14	.	O

1	Functional	O
2	analysis	O
3	of	O
4	the	O
5	mutant	O
6	desmin	I
7	in	O
8	SW13	O
9	(	O
10	vim	O
11	-)	O
12	cells	O
13	showed	O
14	aggregation	O
15	of	O
16	abnormal	O
17	coarse	O
18	clumps	O
19	of	O
20	desmin	O
21	positive	O
22	material	O
23	dispersed	O
24	throughout	O
25	the	O
26	cytoplasm	O
27	.	O

1	Both	O
2	the	O
3	intact	O
4	A1	B
5	protein	O
6	and	O
7	its	O
8	proteolytic	O
9	fragment	O
10	,	O
11	the	O
12	UP1	O
13	protein	O
14	,	O
15	can	O
16	be	O
17	cleaved	O
18	by	O
19	Staphylococcus	O
20	aureus	O
21	V	O
22	-	O
23	8	O
24	protease	O
25	to	O
26	produce	O
27	two	O
28	polypeptides	O
29	of	O
30	92	O
31	amino	O
32	acids	O
33	.	O

1	The	O
2	spontaneous	O
3	mutation	O
4	blocking	O
5	pca	B
6	gene	O
7	expression	O
8	was	O
9	located	O
10	in	O
11	the	O
12	promoter	O
13	for	O
14	the	O
15	pca	B
16	operon	I
17	.	O

1	The	O
2	combination	O
3	of	O
4	MISO	O
5	and	O
6	WR	O
7	-	O
8	2721	O
9	gave	O
10	an	O
11	intermediate	O
12	response	O
13	compared	O
14	with	O
15	either	O
16	drug	O
17	used	O
18	alone	O
19	,	O
20	resulting	O
21	in	O
22	some	O
23	sensitization	O
24	with	O
25	single	O
26	doses	O
27	and	O
28	an	O
29	overall	O
30	protection	O
31	with	O
32	repeated	O
33	small	O
34	doses	O
35	.	O

1	It	O
2	is	O
3	likely	O
4	that	O
5	other	O
6	pathways	O
7	involve	O
8	alternate	O
9	signal	O
10	transduction	O
11	events	O
12	(	O
13	e	O
14	.	O
15	g	O
16	.,	O
17	calcium	O
18	mobilization	O
19	)	O
20	and	O
21	promoter	O
22	response	O
23	elements	O
24	(	O
25	e	O
26	.	O
27	g	O
28	.,	O
29	SRE	O
30	).	O

1	The	O
2	Psc2	O
3	cDNA	O
4	contained	O
5	an	O
6	open	O
7	reading	O
8	frame	O
9	homologous	O
10	to	O
11	CP2	B
12	family	I
13	proteins	I
14	.	O

1	When	O
2	tethered	O
3	to	O
4	a	O
5	heterologous	O
6	DNA	O
7	-	O
8	binding	O
9	domain	O
10	,	O
11	PSU1	O
12	can	O
13	activate	O
14	transcription	O
15	on	O
16	its	O
17	own	O
18	.	O

1	CDC31	O
2	is	O
3	required	O
4	for	O
5	SPB	O
6	duplication	O
7	and	O
8	encodes	O
9	a	O
10	calmodulin	B
11	-	I
12	like	I
13	protein	O
14	that	O
15	is	O
16	most	O
17	closely	O
18	related	O
19	to	O
20	caltractin	O
21	/	O
22	centrin	O
23	,	O
24	a	O
25	protein	O
26	associated	O
27	with	O
28	the	O
29	Chlamydomonas	O
30	basal	O
31	body	O
32	.	O

1	J	O
2	.	O

1	In	O
2	contrast	O
3	to	O
4	hemodynamic	O
5	and	O
6	histopathological	O
7	predictors	O
8	of	O
9	survival	O
10	,	O
11	vWF	B
12	:	O
13	Ag	B
14	does	O
15	not	O
16	require	O
17	invasive	O
18	techniques	O
19	to	O
20	be	O
21	determined	O
22	.	O

1	We	O
2	show	O
3	that	O
4	these	O
5	three	O
6	gain	O
7	-	O
8	of	O
9	-	O
10	function	O
11	mutants	O
12	differ	O
13	considerably	O
14	in	O
15	their	O
16	ability	O
17	to	O
18	bypass	O
19	the	O
20	sex	O
21	determination	O
22	signal	O
23	,	O
24	with	O
25	SxlM4	O
26	being	O
27	the	O
28	strongest	O
29	and	O
30	SxlM1	O
31	the	O
32	weakest	O
33	.	O

1	At	O
2	the	O
3	carboxyl	O
4	terminus	O
5	,	O
6	deletion	O
7	as	O
8	far	O
9	as	O
10	residue	O
11	388	O
12	did	O
13	not	O
14	affect	O
15	in	O
16	vitro	O
17	TRF	O
18	.	O
19	C	O
20	assembly	O
21	,	O
22	although	O
23	trans	O
24	-	O
25	activating	O
26	activity	O
27	was	O
28	abolished	O
29	.	O

1	When	O
2	desipramine	O
3	was	O
4	injected	O
5	16	O
6	hrs	O
7	after	O
8	fluoxetine	O
9	injection	O
10	,	O
11	brain	O
12	levels	O
13	of	O
14	desipramine	O
15	were	O
16	no	O
17	longer	O
18	elevated	O
19	.	O

1	Moreover	O
2	,	O
3	a	O
4	high	O
5	proportion	O
6	of	O
7	blood	O
8	samples	O
9	from	O
10	a	O
11	random	O
12	sample	O
13	of	O
14	the	O
15	rest	O
16	of	O
17	the	O
18	suspects	O
19	tested	O
20	positive	O
21	for	O
22	trypanosome	O
23	-	O
24	specific	O
25	DNA	O
26	by	O
27	PCR	O
28	(	O
29	79	O
30	.	O
31	9	O
32	%	O
33	for	O
34	T	O
35	.	O
36	b	O
37	.	O
38	gambiense	O
39	and	O
40	13	O
41	.	O
42	9	O
43	%	O
44	for	O
45	T	O
46	.	O
47	b	O
48	.	O
49	rhodesiense	O
50	).	O

1	Ongoing	O
2	and	O
3	future	O
4	investigations	O
5	may	O
6	better	O
7	define	O
8	the	O
9	optimal	O
10	approach	O
11	for	O
12	local	O
13	control	O
14	,	O
15	the	O
16	optimal	O
17	duration	O
18	of	O
19	maintenance	O
20	chemotherapy	O
21	,	O
22	and	O
23	the	O
24	possible	O
25	role	O
26	of	O
27	biologic	O
28	response	O
29	modifiers	I
30	and	O
31	growth	O
32	factors	O
33	in	O
34	further	O
35	improving	O
36	the	O
37	outcome	O
38	for	O
39	patients	O
40	with	O
41	this	O
42	disease	O
43	.	O

1	O	O
2	.	O
3	novo	O
4	-	O
5	ulmi	O
6	RNA	O
7	-	O
8	7	O
9	,	O
10	previously	O
11	believed	O
12	to	O
13	be	O
14	a	O
15	satellite	O
16	-	O
17	like	O
18	RNA	O
19	,	O
20	is	O
21	shown	O
22	to	O
23	be	O
24	a	O
25	defective	O
26	RNA	O
27	,	O
28	derived	O
29	from	O
30	OnuMV4	O
31	-	O
32	Ld	O
33	RNA	O
34	by	O
35	multiple	O
36	internal	O
37	deletions	O
38	.	O

1	Signaling	O
2	from	O
3	the	O
4	small	B
5	GTP	I
6	-	I
7	binding	I
8	proteins	I
9	Rac1	I
10	and	O
11	Cdc42	B
12	to	O
13	the	O
14	c	B
15	-	I
16	Jun	I
17	N	I
18	-	I
19	terminal	I
20	kinase	I
21	/	O
22	stress	B
23	-	I
24	activated	I
25	protein	I
26	kinase	I
27	pathway	O
28	.	O

1	State	O
2	-	O
3	approved	O
4	schools	O
5	of	O
6	nursing	O
7	R	O
8	.	O
9	N	O
10	.	O

1	Clinical	O
2	use	O
3	of	O
4	absorbable	O
5	polyglycolic	O
6	acid	O
7	suture	O
8	in	O
9	Blalock	O
10	-	O
11	Taussig	O
12	'	O
13	s	O
14	operation	O

1	Raf	B
2	is	O
3	a	O
4	key	O
5	serine	B
6	-	O
7	threonine	I
8	protein	I
9	kinase	I
10	which	O
11	participates	O
12	in	O
13	the	O
14	transmission	O
15	of	O
16	growth	O
17	,	O
18	anti	O
19	-	O
20	apoptotic	O
21	and	O
22	differentiation	O
23	messages	O
24	.	O

1	Methods	O
2	used	O
3	include	O
4	Cobb	O
5	angle	O
6	and	O
7	a	O
8	segmental	O
9	evaluation	O
10	(	O
11	T7	O
12	-	O
13	T12	O
14	)	O
15	of	O
16	each	O
17	of	O
18	convex	O
19	and	O
20	concave	O
21	rib	O
22	-	O
23	vertebra	O
24	angles	O
25	(	O
26	RVAs	O
27	),	O
28	rib	B
29	-	O
30	vertebra	O
31	angle	O
32	differences	O
33	(	O
34	RVADs	O
35	),	O
36	vertebral	O
37	rotation	O
38	,	O
39	tilt	O
40	and	O
41	displacement	O
42	.	O

1	All	O
2	anti	B
3	-	O
4	I	I
5	and	O
6	anti	B
7	-	I
8	i	I
9	CA	I
10	were	O
11	shown	O
12	to	O
13	express	O
14	VH4	B
15	heavy	I
16	chains	I
17	,	O
18	and	O
19	14	O
20	of	O
21	17	O
22	CA	O
23	expressed	O
24	a	O
25	previously	O
26	described	O
27	VH4	O
28	second	O
29	hypervariable	O
30	region	O
31	determinant	O
32	,	O
33	termed	O
34	VH4	O
35	-	O
36	HV2a	O
37	.	O

1	Further	O
2	experiments	O
3	will	O
4	be	O
5	required	O
6	to	O
7	highlight	O
8	the	O
9	in	O
10	vivo	O
11	role	O
12	of	O
13	ELE1	B
14	in	O
15	nuclear	O
16	receptor	O
17	functioning	O
18	.	O

1	Asymptomatic	O
2	bacteriospermia	O
3	and	O
4	fertility	O

1	The	O
2	genes	O
3	encoding	O
4	(	O
5	2Fe	O
6	-	O
7	2S	O
8	)	O
9	plant	O
10	-	O
11	like	O
12	ferredoxins	O
13	were	O
14	studied	O
15	in	O
16	the	O
17	widely	O
18	used	O
19	cyanobacterium	O
20	Synechocystis	O
21	PCC6803	O
22	.	O

1	Interactions	O
2	between	O
3	adrenergics	O
4	,	O
5	adrenolytics	O
6	and	O
7	monoamine	B
8	oxidase	I
9	inhibitors	O

1	DATA	O
2	SOURCES	O
3	:	O
4	Epidemiologic	O
5	studies	O
6	,	O
7	research	O
8	studies	O
9	,	O
10	review	O
11	articles	O
12	,	O
13	and	O
14	government	O
15	reports	O
16	pertaining	O
17	to	O
18	epidemiology	O
19	of	O
20	lung	O
21	cancer	O
22	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	there	O
6	may	O
7	be	O
8	a	O
9	relationship	O
10	between	O
11	the	O
12	pathogenesis	O
13	of	O
14	MAL	B
15	,	O
16	narcolepsy	O
17	,	O
18	and	O
19	OSA	O
20	.	O

1	Cyclin	B
2	D1	I
3	-	I
4	associated	I
5	kinase	I
6	activity	O
7	and	O
8	protein	O
9	levels	O
10	were	O
11	increased	O
12	in	O
13	mammary	O
14	tumors	O
15	from	O
16	murine	O
17	mammary	O
18	tumor	O
19	virus	O
20	-	O
21	pp60	O
22	(	O
23	c	B
24	-	I
25	src527F	I
26	)	O
27	transgenic	O
28	mice	O
29	.	O

1	The	O
2	proteasome	O
3	is	O
4	a	O
5	large	O
6	complex	O
7	consisting	O
8	of	O
9	two	O
10	multisubunit	O
11	structures	O
12	,	O
13	the	O
14	20S	B
15	and	O
16	19S	O
17	(	O
18	PA700	O
19	)	O
20	or	O
21	P28	O
22	complexes	O
23	,	O
24	that	O
25	combine	O
26	to	O
27	form	O
28	the	O
29	26S	B
30	particles	O
31	.	O

1	However	O
2	,	O
3	if	O
4	EMPD	O
5	involves	O
6	the	O
7	glans	O
8	penis	O
9	or	O
10	perianal	O
11	area	O
12	,	O
13	a	O
14	search	O
15	for	O
16	internal	O
17	malignancy	O
18	is	O
19	still	O
20	warranted	O
21	.	O

1	This	O
2	survey	O
3	included	O
4	3000	O
5	randomly	O
6	selected	O
7	Norwegians	O
8	above	O
9	18	O
10	years	O
11	of	O
12	age	O
13	who	O
14	received	O
15	the	O
16	European	O
17	Organization	O
18	for	O
19	Research	O
20	and	O
21	Treatment	O
22	of	O
23	Cancer	O
24	Core	O
25	Quality	O
26	of	O
27	Life	O
28	Questionnaire	O
29	(	O
30	EORTC	O
31	QLQ	O
32	-	O
33	C30	O
34	(+	O
35	3	O
36	)	O
37	by	O
38	mail	O
39	.	O

1	The	O
2	12	O
3	,	O
4	000	O
5	MW	O
6	(	O
7	12K	B
8	)	O
9	IE	B
10	polypeptide	O
11	encoded	O
12	by	O
13	IEmRNA	O
14	-	O
15	5	O
16	is	O
17	translated	O
18	from	O
19	an	O
20	88	O
21	codon	O
22	open	O
23	reading	O
24	frame	O
25	,	O
26	leaving	O
27	a	O
28	1200	O
29	base	O
30	3	O
31	'	O
32	non	O
33	-	O
34	translated	O
35	region	O
36	.	O

1	PowerBLAST	O
2	analysis	O
3	identified	O
4	six	O
5	clusters	O
6	of	O
7	expressed	O
8	sequence	O
9	tags	O
10	(	O
11	ESTs	O
12	),	O
13	two	O
14	known	O
15	genes	O
16	(	O
17	BIR	B
18	,	O
19	SUR1	B
20	)	O
21	mapped	O
22	previously	O
23	to	O
24	this	O
25	region	O
26	,	O
27	and	O
28	a	O
29	previously	O
30	characterized	O
31	but	O
32	unmapped	B
33	gene	O
34	NEFA	O
35	(	O
36	DNA	O
37	binding	O
38	/	O
39	EF	O
40	hand	O
41	/	O
42	acidic	O
43	amino	O
44	-	O
45	acid	O
46	-	O
47	rich	O
48	).	O

1	Northern	O
2	(	O
3	RNA	O
4	)	O
5	blot	O
6	analyses	O
7	indicated	O
8	that	O
9	the	O
10	cdh	O
11	genes	O
12	encoding	O
13	the	O
14	five	O
15	subunits	O
16	and	O
17	an	O
18	open	O
19	reading	O
20	frame	O
21	(	O
22	ORF1	O
23	)	O
24	with	O
25	unknown	O
26	function	O
27	are	O
28	cotranscribed	O
29	during	O
30	growth	O
31	on	O
32	acetate	O
33	.	O

1	The	O
2	transcriptional	O
3	activities	O
4	of	O
5	the	O
6	full	O
7	-	O
8	length	O
9	promoter	O
10	(-	O
11	295	O
12	to	O
13	+	O
14	85	O
15	)	O
16	and	O
17	of	O
18	three	O
19	deletion	O
20	constructs	O
21	(-	O
22	197	O
23	,	O
24	-	O
25	154	O
26	and	O
27	-	O
28	74	O
29	to	O
30	+	O
31	85	I
32	)	O
33	were	O
34	significantly	O
35	down	O
36	-	O
37	regulated	O
38	in	O
39	resistant	O
40	cells	O
41	.	O

1	Two	O
2	other	O
3	peptides	O
4	,	O
5	either	O
6	partially	O
7	or	O
8	totally	O
9	lacking	O
10	the	O
11	basic	O
12	region	O
13	,	O
14	but	O
15	containing	O
16	the	O
17	intact	O
18	leucine	O
19	zipper	O
20	domain	O
21	,	O
22	readily	O
23	form	O
24	dimers	O
25	but	O
26	do	O
27	not	O
28	bind	O
29	to	O
30	the	O
31	CRE	O
32	.	O

1	The	O
2	hydropathy	O
3	plot	O
4	revealed	O
5	a	O
6	rather	O
7	hydrophilic	O
8	N	O
9	-	O
10	terminal	O
11	region	O
12	and	O
13	the	O
14	absence	O
15	of	O
16	a	O
17	hydrophobic	O
18	signal	O
19	peptide	O
20	.	O

1	amino	O
2	acid	O
3	residues	O
4	,	O
5	K69	O
6	,	O
7	D88	O
8	,	O
9	E94	O
10	,	O
11	D134	O
12	,	O
13	R154	O
14	,	O
15	K169	O
16	,	O
17	H197	O
18	,	O
19	D233	O
20	,	O
21	G235	O
22	,	O
23	G236	O
24	,	O
25	G237	O
26	,	O
27	F238	O
28	,	O
29	E274	O
30	,	O
31	G276	O
32	,	O
33	R277	O
34	,	O
35	Y278	O
36	,	O
37	K294	O
38	,	O
39	Y323	O
40	,	O
41	Y331	O
42	,	O
43	D332	O
44	,	O
45	C360	O
46	,	O
47	D361	O
48	,	O
49	D364	O
50	,	O
51	G387	O
52	,	O
53	Y389	O
54	,	O
55	and	O
56	F397	O
57	(	O
58	mouse	B
59	ODC	I
60	numbering	O
61	),	O
62	all	O
63	of	O
64	which	O
65	are	O
66	implicated	O
67	in	O
68	the	O
69	formation	O
70	of	O
71	the	O
72	pyridoxal	O
73	phosphate	O
74	-	O
75	binding	O
76	domain	O
77	and	O
78	the	O
79	substrate	O
80	-	O
81	binding	O
82	domain	O
83	and	O
84	in	O
85	dimer	O
86	stabilization	O
87	with	O
88	the	O
89	eukaryotic	O
90	ODCs	O
91	,	O
92	were	O
93	also	O
94	conserved	O
95	in	O
96	S	O
97	.	O
98	ruminantium	O
99	LDC	I
100	.	O
1	To	O
2	examine	O
3	the	O
4	basis	O
5	for	O
6	the	O
7	apparent	O
8	differences	O
9	in	O
10	postsegregational	O
11	killing	O
12	between	O
13	the	O
14	two	O
15	E	O
16	.	O
17	coli	O
18	strains	O
19	,	O
20	transformation	O
21	assays	O
22	were	O
23	carried	O
24	out	O
25	to	O
26	determine	O
27	the	O
28	relative	O
29	sensitivities	O
30	of	O
31	the	O
32	strains	O
33	to	O
34	the	O
35	ParE	B
36	toxin	I
37	protein	I
38	.	O

1	The	O
2	carboxyl	O
3	-	O
4	terminal	O
5	CCCC	O
6	module	B
7	is	O
8	structurally	O
9	related	O
10	to	O
11	the	O
12	DNA	O
13	-	O
14	binding	O
15	domain	O
16	of	O
17	the	O
18	erythroid	B
19	transcription	I
20	factor	I
21	GATA	I
22	-	I
23	1	I
24	.	O

1	Pharmacological	O
2	and	O
3	pharmacokinetic	O
4	characteristics	O
5	of	O
6	the	O
7	non	O
8	-	O
9	ionic	O
10	monomeric	O
11	X	O
12	-	O
13	ray	O
14	contrast	O
15	agent	O
16	iopromide	O
17	(	O
18	Ultravist	O
19	,	O
20	CAS	O
21	73334	O
22	-	O
23	07	O
24	-	O
25	3	O
26	)	O
27	were	O
28	evaluated	O
29	in	O
30	preclinical	O
31	studies	O
32	.	O

1	Our	O
2	results	O
3	demonstrate	O
4	that	O
5	distinct	O
6	cytoplasmic	O
7	domains	O
8	of	O
9	these	O
10	cytokine	O
11	receptors	O
12	elicit	O
13	convergent	O
14	signaling	O
15	pathways	O
16	and	O
17	provide	O
18	evidence	O
19	that	O
20	beta	B
21	c	I
22	and	I
23	IL	B
24	-	I
25	2R	I
26	beta	I
27	function	O
28	as	O
29	a	O
30	complete	O
31	signal	O
32	transducer	O
33	.	O

1	Enhancement	O
2	of	O
3	the	O
4	immune	O
5	response	O
6	by	O
7	aspecific	O
8	action	O
9	of	O
10	vaccine	O
11	additives	O
12	in	O
13	the	O
14	aerogenic	O
15	immunization	O
16	of	O
17	swine	O
18	against	O
19	swine	O
20	plague	O

1	The	O
2	activation	O
3	of	O
4	the	O
5	HIV	O
6	promoter	O
7	required	O
8	the	O
9	nuclear	O
10	localization	O
11	of	O
12	c	B
13	-	I
14	Abl	I
15	and	O
16	could	O
17	be	O
18	correlated	O
19	with	O
20	increased	O
21	tyrosine	O
22	phosphorylation	O
23	of	O
24	RNA	B
25	polymerase	I
26	II	I
27	.	O

1	We	O
2	conclude	O
3	from	O
4	this	O
5	study	O
6	that	O
7	Arix	B
8	and	O
9	NBPhox	B
10	exhibit	O
11	indistinguishable	O
12	and	O
13	independent	O
14	transcriptional	O
15	regulatory	O
16	properties	O
17	on	O
18	the	O
19	DBH	B
20	promoter	I
21	.	O

1	Age	O
2	and	O
3	sex	O
4	structure	O
5	of	O
6	the	O
7	natural	O
8	population	O
9	of	O
10	Ornithodoros	O
11	tatarovski	O
12	Ol	O
13	.	O

1	Mechanistically	O
2	,	O
3	the	O
4	presence	O
5	of	O
6	the	O
7	GRR	O
8	appears	O
9	to	O
10	stop	O
11	further	O
12	degradation	O
13	of	O
14	p50	B
15	and	O
16	to	O
17	stabilize	O
18	the	O
19	molecule	O
20	.	O

1	T	B
2	antigen	I
3	contains	O
4	four	O
5	H	O
6	-	O
7	2Db	O
8	-	O
9	restricted	O
10	cytotoxic	O
11	T	O
12	lymphocyte	O
13	(	O
14	CTL	O
15	)	O
16	recognition	O
17	epitopes	O
18	that	O
19	are	O
20	targets	O
21	for	O
22	CTL	O
23	clones	O
24	Y	I
25	-	I
26	1	I
27	,	O
28	Y	B
29	-	I
30	2	I
31	,	O
32	Y	O
33	-	I
34	3	I
35	,	O
36	and	O
37	Y	O
38	-	O
39	5	O
40	.	O

1	After	O
2	profound	O
3	normovolemic	O
4	hemodilution	O
5	(	O
6	Hct	O
7	9	O
8	%)	O
9	superiority	O
10	of	O
11	LV	O
12	MC	O
13	and	O
14	LV	O
15	diastolic	O
16	properties	O
17	was	O
18	found	O
19	,	O
20	when	O
21	myocardial	O
22	oxygenation	O
23	was	O
24	supported	O
25	by	O
26	i	O
27	.	O
28	v	O
29	.	O
30	perflubron	O
31	emulsion	O
32	,	O
33	a	O
34	temporary	O
35	O2	O
36	carrier	O
37	.	O

1	A	O
2	comparison	O
3	of	O
4	the	O
5	Flavobacterium	O
6	glycosylasparaginase	O
7	with	O
8	a	O
9	mammalian	O
10	glycosylasparaginase	O
11	revealed	O
12	30	O
13	%	O
14	structural	O
15	identity	O
16	and	O
17	60	O
18	%	O
19	overall	O
20	similarity	O
21	between	O
22	the	O
23	prokaryotic	O
24	and	O
25	eukaryotic	O
26	forms	O
27	of	O
28	the	O
29	enzyme	O
30	.	O

1	These	O
2	findings	O
3	indicate	O
4	that	O
5	hypergastrinemia	O
6	induced	O
7	by	O
8	surgical	O
9	removal	O
10	of	O
11	acid	O
12	-	O
13	producing	O
14	mucosa	O
15	in	O
16	the	O
17	rat	O
18	has	O
19	the	O
20	same	O
21	effects	O
22	on	O
23	oxyntical	O
24	mucosal	O
25	HDC	O
26	activity	O
27	,	O
28	histamine	O
29	concentration	O
30	and	O
31	ECL	O
32	cell	O
33	density	O
34	as	O
35	hypergastrinemia	O
36	induced	O
37	by	O
38	continuous	O
39	gastrin	B
40	infusion	O
41	or	O
42	by	O
43	long	O
44	-	O
45	term	O
46	treatment	O
47	with	O
48	effective	O
49	antisecretagogues	O
50	.	O

1	Two	O
2	variant	O
3	PRP	O
4	-	O
5	precursor	O
6	alleles	O
7	occur	O
8	which	O
9	slightly	O
10	differ	O
11	in	O
12	the	O
13	number	O
14	of	O
15	repeats	O
16	in	O
17	domain	O
18	C	O
19	.	O

1	A	O
2	rate	O
3	-	O
4	decreasing	O
5	dose	O
6	of	O
7	physostigmine	O
8	,	O
9	an	O
10	acetylcholinesterase	B
11	inhibitor	O
12	,	O
13	was	O
14	studied	O
15	in	O
16	combination	O
17	with	O
18	the	O
19	range	O
20	of	O
21	atropine	O
22	doses	O
23	.	O

1	Letter	O
2	:	O
3	Aryl	B
4	hydrocarbon	I
5	hydroxylase	I
6	and	O
7	smoking	O
8	.	O

1	In	O
2	the	O
3	cell	O
4	-	O
5	free	O
6	import	O
7	assay	O
8	,	O
9	beta	B
10	-	O
11	catenin	I
12	rapidly	O
13	migrates	O
14	into	O
15	the	O
16	nucleus	O
17	without	O
18	the	O
19	exogenous	O
20	addition	O
21	of	O
22	cytosol	O
23	,	O
24	Ran	B
25	,	O
26	or	O
27	ATP	O
28	/	O
29	GTP	O
30	.	O

1	SRY	O
2	-	O
3	related	O
4	cDNA	O
5	encoding	O
6	a	O
7	protein	O
8	with	O
9	a	O
10	high	B
11	-	I
12	mobility	I
13	-	I
14	group	I
15	(	O
16	HMG	B
17	)	O
18	box	O
19	and	O
20	a	O
21	leucine	O
22	zipper	O
23	motif	O
24	,	O
25	which	O
26	was	O
27	designated	O
28	SOX	B
29	-	I
30	LZ	I
31	,	O
32	was	O
33	isolated	O
34	from	O
35	a	O
36	rainbow	O
37	trout	O
38	testis	O
39	cDNA	O
40	library	O
41	.	O

1	BiP670	O
2	retains	O
3	basal	O
4	and	O
5	Ca2	O
6	+	O
7	ionophore	O
8	A23187	O
9	-	O
10	inducible	O
11	activities	O
12	.	O

1	Plasma	B
2	renin	I
3	activity	O
4	rose	O
5	and	O
6	the	O
7	plasma	O
8	aldosterone	O
9	level	O
10	fell	O
11	after	O
12	taking	O
13	lisinopril	O
14	.	O

1	To	O
2	address	O
3	the	O
4	biological	O
5	effect	O
6	of	O
7	specific	O
8	isoform	O
9	expression	O
10	,	O
11	NIH3T3	O
12	cells	O
13	were	O
14	transfected	O
15	with	O
16	a	O
17	eukaryotic	O
18	expression	O
19	vector	O
20	containing	O
21	cDNA	O
22	for	O
23	FGF8a	O
24	,	O
25	FGF8b	O
26	,	O
27	or	O
28	FGF8e	O
29	.	O

1	19	O
2	-	O
3	32	O
4	.	O

1	The	O
2	UAS	O
3	of	O
4	the	O
5	AAC2	O
6	gene	O
7	contains	O
8	at	O
9	least	O
10	two	O
11	distinct	O
12	motifs	O
13	for	O
14	DNA	O
15	-	O
16	binding	O
17	transcriptional	O
18	activators	O
19	,	O
20	including	O
21	one	O
22	which	O
23	is	O
24	identical	O
25	with	O
26	the	O
27	core	B
28	HAP2	I
29	/	I
30	3	I
31	/	O
32	4	I
33	binding	O
34	motif	O
35	,	O
36	and	O
37	a	O
38	second	O
39	one	O
40	with	O
41	the	O
42	ABF1	O
43	consensus	O
44	binding	O
45	sequence	O
46	.	O

1	Trichloroethylene	O
2	,	O
3	in	O
4	turn	O
5	,	O
6	increased	O
7	the	O
8	AUC	O
9	5	O
10	.	O
11	0	O
12	(	O
13	1	O
14	.	O
15	9	O
16	-	O
17	13	O
18	.	O
19	4	O
20	),	O
21	25	O
22	.	O
23	8	O
24	(	O
25	8	O
26	.	O
27	2	O
28	-	O
29	80	O
30	.	O
31	8	O
32	)	O
33	and	O
34	2	O
35	.	O
36	9	O
37	(	O
38	1	O
39	.	O
40	6	O
41	-	O
42	5	O
43	.	O
44	4	O
45	),	O
46	respectively	O
47	,	O
48	whereas	O
49	the	O
50	corresponding	O
51	values	O
52	for	O
53	n	O
54	-	O
55	hexane	O
56	were	O
57	1	O
58	.	O
59	9	O
60	(	O
61	0	O
62	.	O
63	7	O
64	-	O
65	5	O
66	.	O
67	1	O
68	),	O
69	1	O
70	.	O
71	5	O
72	(	O
73	0	O
74	.	O
75	5	O
76	-	O
77	4	O
78	.	O
79	6	O
80	),	O
81	and	O
82	3	O
83	.	O
84	2	O
85	(	O
86	1	O
87	.	O
88	8	O
89	-	O
90	5	O
91	.	O
92	9	O
93	).	O

1	The	O
2	concentrations	O
3	of	O
4	plasma	O
5	ACTH	B
6	and	O
7	cortisol	O
8	increased	O
9	by	O
10	40	O
11	%	O
12	and	O
13	60	O
14	%	O
15	after	O
16	MPTP	O
17	treatment	O
18	,	O
19	respectively	O
20	.	O

1	Clinical	O
2	applications	O
3	of	O
4	inhibition	O
5	of	O
6	beta	B
7	-	O
8	adrenergic	I
9	receptors	O
10	with	O
11	propranolol	O
12	.	O

1	The	O
2	inhibitory	O
3	response	O
4	to	O
5	taps	O
6	is	O
7	essentially	O
8	a	O
9	protective	O
10	reflex	O
11	which	O
12	probably	O
13	serves	O
14	to	O
15	reduce	O
16	the	O
17	activity	O
18	of	O
19	the	O
20	jaw	O
21	-	O
22	closing	O
23	muscles	O
24	when	O
25	one	O
26	bites	O
27	unexpectedly	O
28	on	O
29	hard	O
30	objects	O
31	.	O

1	Citrate	B
2	synthase	I
3	activity	O
4	was	O
5	increased	O
6	in	O
7	the	O
8	medial	O
9	head	O
10	(	O
11	81	O
12	%,	O
13	P	O
14	<	O
15	0	O
16	.	O
17	001	O
18	)	O
19	and	O
20	the	O
21	red	O
22	long	O
23	head	O
24	(	O
25	88	O
26	%,	O
27	P	O
28	<	O
29	0	O
30	.	O
31	001	O
32	)	O
33	of	O
34	the	O
35	triceps	O
36	brachii	O
37	muscle	O
38	in	O
39	R	O
40	rats	O
41	but	O
42	not	O
43	in	O
44	the	O
45	white	O
46	long	O
47	head	O
48	(	O
49	25	O
50	%,	O
51	P	O
52	=	O
53	0	O
54	.	O
55	06	O
56	).	O

1	This	O
2	technique	O
3	was	O
4	employed	O
5	in	O
6	12	O
7	patients	O
8	with	O
9	a	O
10	unicameral	O
11	bone	O
12	cyst	O
13	.	O

1	Reproducing	O
2	populations	O
3	of	O
4	this	O
5	aphid	O
6	were	O
7	first	O
8	detected	O
9	in	O
10	Puerto	O
11	Rico	O
12	in	O
13	April	O
14	1992	O
15	.	O

1	In	O
2	cells	O
3	limited	O
4	for	O
5	His	O
6	,	O
7	increased	O
8	expression	O
9	of	O
10	arg	O
11	-	O
12	2	I
13	and	O
14	cpc	O
15	-	O
16	1	O
17	,	O
18	and	O
19	decreased	O
20	expression	O
21	of	O
22	cox	O
23	-	O
24	5	O
25	,	O
26	also	O
27	had	O
28	translational	O
29	and	O
30	transcriptional	O
31	components	O
32	.	O

1	271	O
2	:	O
3	31290	O
4	-	O
5	31295	O
6	,	O
7	1996	O
8	).	O

1	As	O
2	control	O
3	,	O
4	the	O
5	cells	O
6	were	O
7	transfected	O
8	with	O
9	DNA	O
10	mixtures	O
11	containing	O
12	vector	O
13	mU6	O
14	-	O
15	C1	O
16	or	O
17	mU6	O
18	-	O
19	C2	O
20	.	O

1	Hybridization	O
2	of	O
3	a	O
4	probe	O
5	from	O
6	this	O
7	region	O
8	to	O
9	electrophoretic	O
10	blots	O
11	of	O
12	RNAs	O
13	from	O
14	different	O
15	human	O
16	tissues	O
17	showed	O
18	a	O
19	predominant	O
20	2	O
21	.	O
22	8	O
23	-	O
24	kilobase	O
25	(	O
26	kb	O
27	)	O
28	message	O
29	accompanied	O
30	by	O
31	weaker	O
32	bands	B
33	4	I
34	.	I
35	1	I
36	and	O
37	2	I
38	.	O
39	1	O
40	kb	O
41	in	O
42	size	O
43	.	O

1	Ischemic	O
2	heart	O
3	disease	O
4	,	O
5	age	O
6	of	O
7	more	O
8	than	O
9	75	O
10	years	O
11	,	O
12	and	O
13	the	O
14	fact	O
15	that	O
16	the	O
17	patient	O
18	was	O
19	a	O
20	woman	O
21	were	O
22	independent	O
23	predictors	O
24	of	O
25	poor	O
26	cardiac	O
27	function	O
28	.	O

1	The	O
2	sequencing	O
3	of	O
4	the	O
5	conditional	O
6	lethal	O
7	mutation	O
8	ts	I
9	-	O
10	A13	O
11	,	O
12	localized	O
13	in	O
14	the	O
15	nrdE	O
16	cistron	O
17	,	O
18	and	O
19	the	O
20	lethality	O
21	of	O
22	insertional	B
23	mutations	I
24	targeted	O
25	in	O
26	the	O
27	internal	O
28	region	O
29	of	O
30	nrdE	O
31	and	O
32	nrdF	O
33	,	O
34	demonstrated	O
35	the	O
36	essential	O
37	role	O
38	of	O
39	this	O
40	locus	O
41	.	O

1	Eastern	O
2	Cooperative	O
3	Oncology	O
4	Group	O
5	trial	O
6	E3186	O
7	was	O
8	initiated	O
9	to	O
10	explore	O
11	this	O
12	question	O
13	.	O

1	A	O
2	beta2	I
3	RARE	O
4	reporter	O
5	construct	O
6	in	O
7	which	O
8	the	O
9	methylation	O
10	-	O
11	susceptible	O
12	cytosines	O
13	in	O
14	the	O
15	sense	O
16	strand	O
17	were	O
18	replaced	O
19	by	O
20	thymine	O
21	displayed	O
22	marked	O
23	loss	O
24	of	O
25	activity	O
26	in	O
27	a	O
28	replicated	O
29	chromatin	O
30	-	O
31	dependent	O
32	manner	O
33	.	O

1	(	O
2	1998	O
3	)	O
4	FASEB	O
5	J	O
6	.	O

1	Isolation	O
2	and	O
3	characterization	O
4	of	O
5	a	O
6	vinculin	B
7	cDNA	O
8	from	O
9	chick	O
10	-	O
11	embryo	O
12	fibroblasts	O
13	.	O

1	In	O
2	this	O
3	study	O
4	,	O
5	we	O
6	used	O
7	footprinting	O
8	and	O
9	gel	O
10	mobility	O
11	retardation	O
12	assays	O
13	to	O
14	reveal	O
15	that	O
16	bacterially	O
17	synthesized	O
18	Zta	B
19	fusion	O
20	proteins	O
21	bound	O
22	directly	O
23	to	O
24	six	O
25	TGTGCAA	O
26	-	O
27	like	O
28	motifs	O
29	within	O
30	DSL	O
31	.	O

1	Cumulated	O
2	maximum	O
3	lod	O
4	scores	O
5	between	O
6	FRDA	O
7	and	O
8	D9S5	O
9	and	O
10	between	O
11	FRDA	O
12	and	O
13	D9S15	O
14	are	O
15	above	O
16	36	O
17	and	O
18	61	O
19	,	O
20	respectively	O
21	,	O
22	at	O
23	a	O
24	recombination	O
25	fraction	O
26	of	O
27	0	O
28	,	O
29	indicating	O
30	that	O
31	recombination	O
32	events	O
33	needed	O
34	to	O
35	orient	O
36	the	O
37	search	O
38	of	O
39	the	O
40	gene	O
41	are	O
42	very	O
43	difficult	O
44	to	O
45	identify	O
46	and	O
47	ascertain	O
48	.	O

1	The	O
2	kallistatin	B
3	gene	O
4	was	O
5	localized	O
6	by	O
7	in	O
8	situ	O
9	hybridization	O
10	to	O
11	human	O
12	chromosome	O
13	14q31	O
14	-	O
15	q32	O
16	.	O
17	1	O
18	,	O
19	close	O
20	to	O
21	the	O
22	serpin	B
23	genes	I
24	encoding	O
25	alpha	I
26	1	I
27	-	I
28	antichymotrypsin	I
29	,	O
30	protein	B
31	C	I
32	inhibitor	I
33	,	O
34	alpha	B
35	1	I
36	-	I
37	antitrypsin	I
38	,	O
39	and	O
40	corticosteroid	O
41	-	O
42	binding	I
43	globulin	I
44	.	O

1	Thus	O
2	,	O
3	in	O
4	the	O
5	presence	O
6	of	O
7	active	O
8	S	O
9	-	I
10	CDKs	I
11	and	O
12	Dbf4	O
13	/	O
14	Cdc7	O
15	,	O
16	Mcms	O
17	may	O
18	open	O
19	origins	O
20	and	O
21	thereby	O
22	facilitate	O
23	the	O
24	loading	O
25	of	O
26	RPA	B
27	.	O

1	D	O
2	.	O

1	Measurement	O
2	of	O
3	open	O
4	-	O
5	loop	O
6	responses	O
7	to	O
8	electrical	O
9	stimulation	O
10	in	O
11	olfactory	O
12	bulb	O
13	of	O
14	cat	O
15	.	O

1	A	O
2	protein	O
3	lacking	O
4	the	O
5	SH2	B
6	and	O
7	RING	O
8	finger	O
9	domains	O
10	has	O
11	no	O
12	activity	O
13	,	O
14	but	O
15	a	O
16	chimeric	O
17	protein	O
18	with	O
19	the	O
20	SH2	B
21	and	O
22	RING	O
23	finger	O
24	domains	O
25	of	O
26	SLI	B
27	-	I
28	1	I
29	replaced	O
30	by	O
31	the	O
32	equivalent	O
33	domains	O
34	of	O
35	c	B
36	-	I
37	Cbl	I
38	has	O
39	activity	O
40	.	O

1	A	O
2	pre	O
3	-	O
4	boutonniere	O
5	deformity	O
6	was	O
7	simulated	O
8	by	O
9	dividing	O
10	the	O
11	central	O
12	slip	O
13	.	O

1	ATP	O
2	-	O
3	dependent	O
4	assembly	O
5	of	O
6	a	O
7	ternary	O
8	complex	O
9	consisting	O
10	of	O
11	a	O
12	DNA	O
13	mismatch	O
14	and	O
15	the	O
16	yeast	O
17	MSH2	O
18	-	O
19	MSH6	O
20	and	O
21	MLH1	B
22	-	O
23	PMS1	I
24	protein	I
25	complexes	O
26	.	O

1	Isopenicillin	B
2	N	B
3	isomerase	I
4	(	O
5	epimerase	O
6	)	O
7	has	O
8	been	O
9	purified	O
10	from	O
11	Streptomyces	O
12	clavuligerus	O
13	,	O
14	and	O
15	the	O
16	amino	O
17	acid	O
18	sequence	O
19	of	O
20	the	O
21	N	O
22	-	O
23	terminus	O
24	has	O
25	been	O
26	determined	O
27	.	O

1	The	O
2	variability	O
3	is	O
4	most	O
5	likely	O
6	a	O
7	result	O
8	of	O
9	alternative	O
10	splicing	O
11	of	O
12	exons	O
13	from	O
14	the	O
15	primary	O
16	elastin	B
17	transcripts	I
18	.	O

1	Angiography	O
2	was	O
3	performed	O
4	following	O
5	the	O
6	rCBF	O
7	study	O
8	and	O
9	the	O
10	degree	O
11	of	O
12	vasospasm	O
13	was	O
14	measured	O
15	on	O
16	the	O
17	angiograms	O
18	.	O

1	Here	O
2	,	O
3	we	O
4	report	O
5	that	O
6	swa5	B
7	-	O
8	1	O
9	is	O
10	a	O
11	new	O
12	temperature	O
13	-	O
14	sensitive	O
15	allele	O
16	of	O
17	the	O
18	clathrin	B
19	heavy	I
20	chain	I
21	gene	I
22	(	O
23	chc1	O
24	-	O
25	5	O
26	),	O
27	which	O
28	carries	O
29	a	O
30	frameshift	O
31	mutation	O
32	near	O
33	the	O
34	3	O
35	'	O
36	end	O
37	of	O
38	the	O
39	CHC1	O
40	open	O
41	reading	O
42	frame	O
43	.	O

1	Commercially	O
2	available	O
3	formulations	O
4	of	O
5	2	O
6	.	O
7	5	O
8	%	O
9	and	O
10	5	O
11	%	O
12	lambdacyhalothrin	O
13	can	O
14	be	O
15	diluted	O
16	either	O
17	with	O
18	water	O
19	for	O
20	ULV	O
21	cold	O
22	aerosol	O
23	space	O
24	-	O
25	spraying	O
26	or	O
27	with	O
28	diesel	O
29	/	O
30	kerosene	O
31	for	O
32	thermal	O
33	fogging	O
34	at	O
35	recommended	O
36	application	O
37	rates	O
38	of	O
39	0	O
40	.	O
41	5	O
42	-	O
43	1	O
44	g	O
45	ai	O
46	/	O
47	ha	O
48	for	O
49	mosquito	O
50	control	O
51	and	O
52	2	O
53	g	O
54	ai	O
55	/	O
56	ha	O
57	for	O
58	housefly	O
59	control	O
60	.	O

1	Role	O
2	of	O
3	histoclinical	O
4	studies	O
5	in	O
6	the	O
7	prophylaxis	O
8	of	O
9	spontaneous	O
10	abortions	O

1	Mean	O
2	total	O
3	lung	O
4	capacity	O
5	,	O
6	functional	O
7	residual	O
8	capacity	O
9	,	O
10	and	O
11	residual	O
12	volume	O
13	increased	O
14	significantly	O
15	,	O
16	and	O
17	the	O
18	mean	O
19	closing	O
20	volume	O
21	,	O
22	the	O
23	lung	O
24	volume	O
25	above	O
26	residual	O
27	volume	O
28	at	O
29	which	O
30	phase	O
31	IV	O
32	begins	O
33	,	O
34	decreased	O
35	significantly	O
36	with	O
37	11	O
38	cm	O
39	H20	O
40	continuous	O
41	positive	O
42	airway	O
43	pressure	O
44	;	O
45	differences	O
46	at	O
47	5	O
48	cm	O
49	H20	O
50	were	O
51	not	O
52	significant	O
53	.	O

1	In	O
2	angiodysplasia	O
3	,	O
4	ectatic	O
5	vessels	O
6	in	O
7	the	O
8	mucosa	O
9	appeared	O
10	to	O
11	contain	O
12	less	O
13	collagen	B
14	type	I
15	IV	I
16	than	O
17	similarly	O
18	sized	O
19	vessels	O
20	in	O
21	the	O
22	submucosa	O
23	,	O
24	and	O
25	perforating	O
26	vessels	O
27	appeared	O
28	in	O
29	many	O
30	cases	O
31	to	O
32	lose	O
33	staining	O
34	at	O
35	the	O
36	level	O
37	of	O
38	the	O
39	muscularis	O
40	mucosae	O
41	.	O

1	ESS	O
2	type	O
3	1	O
4	,	O
5	with	O
6	FT3	O
7	low	O
8	and	O
9	FT4	O
10	and	O
11	TSH	B
12	normal	O
13	,	O
14	is	O
15	the	O
16	most	O
17	frequent	O
18	form	O
19	.	O

1	Expression	O
2	of	O
3	the	O
4	phenylalanine	B
5	hydroxylase	I
6	gene	I
7	in	O
8	livers	O
9	and	O
10	kidneys	O
11	of	O
12	rodents	O
13	is	O
14	activated	O
15	at	O
16	birth	O
17	and	O
18	is	O
19	induced	O
20	by	O
21	glucocorticoids	O
22	and	O
23	cyclic	O
24	AMP	O
25	in	O
26	the	O
27	liver	O
28	.	O

1	Characterization	O
2	of	O
3	LRP	O
4	,	O
5	a	O
6	leucine	O
7	-	O
8	rich	O
9	repeat	O
10	(	O
11	LRR	B
12	)	I
13	protein	I
14	from	O
15	tomato	O
16	plants	O
17	that	O
18	is	O
19	processed	O
20	during	O
21	pathogenesis	O
22	.	O

1	Expression	O
2	of	O
3	activated	O
4	Cdc42	B
5	results	O
6	in	O
7	the	O
8	translocation	O
9	of	O
10	PKClambda	O
11	from	O
12	the	O
13	nucleus	O
14	into	O
15	the	O
16	cytosol	O
17	,	O
18	and	O
19	Cdc42	B
20	and	O
21	PKClambda	O
22	colocalize	O
23	at	O
24	the	O
25	plasma	O
26	membrane	O
27	and	O
28	in	O
29	the	O
30	cytoplasm	O
31	.	O

1	Comparison	O
2	of	O
3	propofol	O
4	and	O
5	thiopentone	O
6	as	O
7	anaesthetic	O
8	agents	O
9	for	O
10	electroconvulsive	O
11	therapy	O
12	.	O

1	All	O
2	other	O
3	normal	O
4	and	O
5	transformed	O
6	lymphoid	O
7	and	O
8	nonlymphoid	O
9	cell	O
10	lines	O
11	and	O
12	normal	O
13	tissues	O
14	were	O
15	negative	O
16	for	O
17	PANG	O
18	expression	O
19	except	O
20	for	O
21	the	O
22	brain	O
23	,	O
24	wherein	O
25	unique	O
26	4	O
27	.	O
28	0	O
29	-	O
30	and	O
31	6	O
32	.	O
33	1	O
34	-	O
35	kb	O
36	transcripts	O
37	were	O
38	detected	O
39	.	O

1	Truncated	B
2	mammalian	I
3	Notch1	I
4	activates	O
5	CBF1	B
6	/	O
7	RBPJk	O
8	-	O
9	repressed	O
10	genes	O
11	by	O
12	a	O
13	mechanism	O
14	resembling	O
15	that	O
16	of	O
17	Epstein	O
18	-	O
19	Barr	I
20	virus	I
21	EBNA2	I
22	.	O

1	A	O
2	.	O

1	Members	O
2	of	O
3	the	O
4	C	B
5	/	I
6	EBP	I
7	family	I
8	of	O
9	basic	O
10	-	I
11	leucine	I
12	zipper	O
13	(	O
14	bZip	O
15	)	O
16	transcription	O
17	factors	O
18	form	O
19	heterodimers	O
20	and	O
21	bind	O
22	to	O
23	the	O
24	CAAT	O
25	box	O
26	and	O
27	other	O
28	sequence	O
29	-	I
30	related	I
31	enhancer	I
32	motifs	I
33	.	O

1	The	O
2	calcitonin	B
3	-	O
4	induced	O
5	tyrosine	O
6	phosphorylation	O
7	of	O
8	HEF1	B
9	increased	O
10	in	O
11	a	O
12	time	O
13	-	O
14	and	O
15	dose	O
16	-	O
17	dependent	O
18	manner	O
19	.	O

1	51	O
2	.	O
3	9	O
4	%	O
5	(	O
6	P	O
7	=	O
8	0	O
9	.	O
10	0006	O
11	)	O
12	in	O
13	the	O
14	MMF	O
15	versus	O
16	the	O
17	AZA	O
18	groups	O
19	,	O
20	respectively	O
21	.	O

1	Feline	O
2	leukemia	O
3	viruses	O
4	(	O
5	FeLVs	O
6	),	O
7	which	O
8	are	O
9	replication	O
10	-	O
11	competent	O
12	oncoretroviruses	O
13	of	O
14	the	O
15	domestic	O
16	cat	O
17	species	O
18	,	O
19	are	O
20	contagiously	O
21	transmitted	O
22	in	O
23	natural	O
24	environments	O
25	.	O

1	Ovaries	O
2	of	O
3	10	O
4	animals	O
5	per	O
6	group	O
7	from	O
8	16	O
9	studies	O
10	in	O
11	CD	O
12	-	O
13	1	O
14	mice	O
15	and	O
16	1	O
17	study	O
18	each	O
19	in	O
20	C3H	O
21	and	O
22	C57BL	O
23	/	O
24	6	O
25	mice	O
26	were	O
27	sectioned	O
28	serially	O
29	at	O
30	6	O
31	microm	O
32	.	O

1	Qualitatively	O
2	,	O
3	the	O
4	results	O
5	are	O
6	similar	O
7	for	O
8	the	O
9	two	O
10	species	O
11	:	O
12	Both	O
13	rhesus	O
14	monkey	O
15	and	O
16	man	O
17	have	O
18	photopic	O
19	and	O
20	scotopic	O
21	branches	O
22	,	O
23	which	O
24	cross	O
25	at	O
26	approximately	O
27	the	O
28	same	O
29	time	O
30	in	O
31	the	O
32	dark	O
33	and	O
34	at	O
35	approximately	O
36	the	O
37	same	O
38	background	O
39	luminance	O
40	.	O

1	Statistically	O
2	significant	O
3	effects	O
4	were	O
5	noted	O
6	at	O
7	doses	O
8	which	O
9	did	O
10	not	O
11	appear	O
12	to	O
13	be	O
14	maternally	O
15	toxic	O
16	.	O

1	Letter	O
2	:	O
3	Perspectives	O
4	in	O
5	bone	O
6	marrow	O
7	transplantation	O
8	.	O

1	High	O
2	-	O
3	pressure	O
4	effects	O
5	on	O
6	ultrafast	O
7	-	O
8	relaxation	O
9	kinetics	O
10	of	O
11	excitons	O
12	in	O
13	polydiacetylene	O
14	4BCMU	O
15	.	O

1	We	O
2	investigated	O
3	the	O
4	diagnostic	O
5	value	O
6	of	O
7	a	O
8	new	O
9	in	O
10	vitro	O
11	test	O
12	,	O
13	Pharmacia	O
14	CAP	O
15	System	O
16	(	O
17	Pharmacia	O
18	Diagnostics	O
19	AB	O
20	,	O
21	Uppsala	O
22	,	O
23	Sweden	O
24	),	O
25	for	O
26	the	O
27	quantitative	O
28	measurement	O
29	of	O
30	allergen	B
31	-	O
32	specific	O
33	IgE	B
34	antibodies	I
35	by	O
36	comparison	O
37	with	O
38	RAST	O
39	in	O
40	2	O
41	groups	O
42	of	O
43	patients	O
44	,	O
45	71	O
46	atopic	O
47	and	O
48	48	O
49	non	O
50	-	O
51	atopic	O
52	.	O

1	Genomic	O
2	DNA	O
3	sequencing	O
4	in	O
5	the	O
6	vicinity	O
7	of	O
8	methylmalonyl	B
9	-	I
10	CoA	I
11	mutase	I
12	gene	I
13	(	O
14	mutAB	O
15	)	O
16	from	O
17	a	O
18	rifamycin	O
19	SV	O
20	-	O
21	producing	O
22	Amycolatopsis	O
23	mediterranei	O
24	U32	O
25	allowed	O
26	us	O
27	to	O
28	clone	O
29	,	O
30	sequence	O
31	,	O
32	and	O
33	identify	O
34	a	O
35	gene	O
36	encoding	O
37	a	O
38	novel	O
39	serine	B
40	/	I
41	threonine	I
42	protein	I
43	kinase	I
44	(	O
45	amk	O
46	).	O

1	It	O
2	is	O
3	the	O
4	oxidation	O
5	peak	O
6	of	O
7	this	O
8	product	O
9	,	O
10	arising	O
11	in	O
12	acidic	O
13	media	O
14	at	O
15	0	O
16	.	O
17	42	O
18	V	O
19	,	O
20	which	O
21	was	O
22	analysed	O
23	using	O
24	DPV	O
25	,	O
26	again	O
27	following	O
28	the	O
29	accumulation	O
30	of	O
31	clenbuterol	O
32	at	O
33	the	O
34	Nafion	O
35	-	O
36	modified	O
37	CPE	O
38	.	O

1	By	O
2	site	O
3	-	O
4	specific	O
5	mutagenesis	O
6	,	O
7	we	O
8	also	O
9	show	O
10	that	O
11	individual	O
12	ICP27	B
13	C	I
14	-	I
15	terminal	O
16	amino	O
17	acid	O
18	residues	O
19	that	O
20	are	O
21	positionally	O
22	conserved	O
23	in	O
24	ICP27	B
25	homologs	I
26	in	O
27	other	O
28	herpesviruses	O
29	(	O
30	D	O
31	-	O
32	357	O
33	,	O
34	E	O
35	-	O
36	358	O
37	,	O
38	H	O
39	-	O
40	479	O
41	,	O
42	C	O
43	-	O
44	400	O
45	,	O
46	C	O
47	-	O
48	483	O
49	,	O
50	and	O
51	C	O
52	-	O
53	488	O
54	)	O
55	are	O
56	critical	O
57	for	O
58	trans	O
59	-	O
60	regulatory	O
61	activity	O
62	.	O

1	We	O
2	report	O
3	an	O
4	example	O
5	of	O
6	an	O
7	MDV	O
8	-	O
9	transformed	O
10	T	O
11	-	O
12	lymphoblastoid	O
13	cell	O
14	line	O
15	(	O
16	T9	O
17	)	O
18	expressing	O
19	high	O
20	levels	O
21	of	O
22	a	O
23	truncated	O
24	C	I
25	-	I
26	MYB	O
27	protein	O
28	as	O
29	a	O
30	result	O
31	of	O
32	RAV	O
33	integration	O
34	within	O
35	one	O
36	c	B
37	-	I
38	myb	I
39	allele	I
40	.	O

1	Ent	B
2	-	O
3	kaurene	I
4	synthase	I
5	from	O
6	the	O
7	fungus	O
8	Phaeosphaeria	O
9	sp	O
10	.	O

1	Deletion	O
2	mutagenesis	O
3	demonstrated	O
4	that	O
5	these	O
6	two	O
7	elements	O
8	are	O
9	involved	O
10	in	O
11	the	O
12	positive	O
13	regulation	O
14	of	O
15	MLC	B
16	-	I
17	2	I
18	gene	I
19	transcription	O
20	.	O

1	Twenty	O
2	eligible	O
3	patients	O
4	with	O
5	cirrhosis	O
6	were	O
7	randomized	O
8	into	O
9	two	O
10	groups	O
11	:	O
12	10	O
13	patients	O
14	treated	O
15	with	O
16	6	O
17	million	O
18	units	O
19	of	O
20	natural	O
21	IFN	B
22	-	I
23	beta	I
24	twice	O
25	a	O
26	week	O
27	for	O
28	36	O
29	months	O
30	and	O
31	10	O
32	patients	O
33	without	O
34	IFN	B
35	therapy	O
36	.	O

1	Among	O
2	three	O
3	isoforms	O
4	,	O
5	the	O
6	beta	O
7	isoform	O
8	has	O
9	the	O
10	greatest	O
11	Vmax	O
12	value	O
13	for	O
14	the	O
15	PtdIns	B
16	(	O
17	4	I
18	)	I
19	P	I
20	kinase	I
21	activity	O
22	and	O
23	the	O
24	gamma	B
25	isoform	I
26	is	O
27	most	O
28	markedly	O
29	stimulated	O
30	by	O
31	phosphatidic	O
32	acid	O
33	.	O

1	The	O
2	following	O
3	data	O
4	were	O
5	recorded	O
6	at	O
7	arrival	O
8	in	O
9	the	O
10	intensive	O
11	care	O
12	unit	O
13	6	O
14	,	O
15	12	O
16	,	O
17	24	O
18	,	O
19	and	O
20	48	O
21	hours	O
22	after	O
23	termination	O
24	of	O
25	CPB	O
26	:	O
27	heart	O
28	rate	O
29	,	O
30	blood	O
31	pressure	O
32	,	O
33	left	O
34	atrial	O
35	pressure	O
36	,	O
37	central	O
38	-	O
39	peripheral	O
40	temperature	O
41	difference	O
42	,	O
43	arterial	O
44	-	O
45	central	O
46	venous	O
47	oxygen	O
48	saturation	O
49	difference	O
50	,	O
51	urine	O
52	output	O
53	,	O
54	serum	O
55	creatinine	O
56	,	O
57	lactate	O
58	and	O
59	neutrophil	B
60	elastase	I
61	levels	O
62	,	O
63	the	O
64	Doppler	O
65	echocardiographic	O
66	factors	O
67	shortening	O
68	fraction	O
69	and	O
70	preejection	O
71	period	O
72	/	O
73	left	O
74	-	O
75	ventricular	O
76	ejection	O
77	time	O
78	,	O
79	and	O
80	cumulative	O
81	doses	O
82	of	O
83	catecholamines	O
84	(	O
85	epinephrine	O
86	),	O
87	enoximone	O
88	,	O
89	and	O
90	furosemide	O
91	.	O

1	Here	O
2	we	O
3	report	O
4	the	O
5	cloning	O
6	of	O
7	the	O
8	protein	O
9	that	O
10	binds	O
11	to	O
12	enhancer	I
13	site	I
14	III	I
15	.	O

1	The	O
2	origins	O
3	of	O
4	reflected	O
5	light	O
6	changes	O
7	associated	O
8	with	O
9	neuronal	O
10	activity	O
11	(	O
12	optical	O
13	signals	O
14	)	O
15	were	O
16	investigated	O
17	in	O
18	rat	O
19	somatosensory	O
20	cortex	O
21	with	O
22	optical	O
23	imaging	O
24	,	O
25	microspectrophotometry	O
26	,	O
27	and	O
28	laser	O
29	-	O
30	Doppler	O
31	flowmetry	O
32	,	O
33	and	O
34	dynamic	O
35	changes	O
36	in	O
37	local	O
38	hemoglobin	B
39	concentration	O
40	and	O
41	oxygenation	O
42	were	O
43	focused	O
44	on	O
45	.	O

1	Animals	O
2	received	O
3	a	O
4	dose	O
5	of	O
6	dexamethasone	O
7	(	O
8	10	O
9	mg	O
10	/	O
11	kg	O
12	i	O
13	.	O
14	p	O
15	.)	O
16	prior	O
17	to	O
18	the	O
19	protein	O
20	-	O
21	free	O
22	surfactant	O
23	preparation	O
24	Exosurf	O
25	(	O
26	pure	O
27	phospholipids	O
28	containing	O
29	surfactant	O
30	,	O
31	Wellcome	O
32	GmbH	O
33	,	O
34	Burgwedel	O
35	,	O
36	Germany	O
37	)	O
38	and	O
39	a	O
40	rSP	O
41	-	O
42	C	O
43	based	O
44	surfactant	O
45	,	O
46	respectively	O
47	.	O

1	Is	O
2	radical	O
3	trachelectomy	O
4	a	O
5	safe	O
6	alternative	O
7	to	O
8	radical	O
9	hysterectomy	O
10	for	O
11	patients	O
12	with	O
13	stage	O
14	IA	O
15	-	O
16	B	O
17	carcinoma	O
18	of	O
19	the	O
20	cervix	O
21	?	O
22	BACKGROUND	O
23	:	O
24	The	O
25	prognosis	O
26	associated	O
27	with	O
28	lymph	O
29	node	O
30	negative	O
31	,	O
32	early	O
33	stage	O
34	carcinoma	O
35	of	O
36	the	O
37	cervix	O
38	is	O
39	excellent	O
40	,	O
41	with	O
42	5	O
43	-	O
44	year	O
45	survival	O
46	rates	O
47	greater	O
48	than	O
49	90	O
50	%.	O

1	The	O
2	human	O
3	2	O
4	',	O
5	5	O
6	'-	O
7	oligoadenylate	O
8	(	O
9	2	O
10	-	I
11	5A	I
12	)	O
13	synthetases	I
14	are	O
15	members	O
16	of	O
17	a	O
18	family	B
19	interferon	I
20	(	O
21	IFN	B
22	)-	I
23	inducible	O
24	anti	B
25	-	I
26	viral	I
27	proteins	I
28	.	O

1	Germ	O
2	-	O
3	free	O
4	rabbits	O
5	given	O
6	mouse	O
7	CRF	B
8	-	O
9	flora	O
10	showed	O
11	values	O
12	quite	O
13	different	O
14	from	O
15	control	O
16	animals	O
17	for	O
18	most	O
19	parameters	O
20	,	O
21	indicating	O
22	unsuitability	O
23	of	O
24	mouse	O
25	CRF	I
26	flora	O
27	to	O
28	'	O
29	normalize	O
30	'	O
31	rabbits	O
32	.	O

1	Focused	O
2	beams	O
3	of	O
4	classical	O
5	light	O
6	ablate	O
7	elements	O
8	of	O
9	the	O
10	cell	O
11	division	O
12	machinery	O
13	and	O
14	switch	O
15	the	O
16	beating	O
17	of	O
18	hearts	O
19	on	O
20	a	O
21	cellular	O
22	basis	O
23	.	O

1	Electrocardiograms	O
2	of	O
3	the	O
4	month	O
5	.	O

1	Oral	O
2	candidiasis	O

1	In	O
2	the	O
3	brain	O
4	,	O
5	muscarinic	B
6	receptors	I
7	mediate	O
8	motor	O
9	and	O
10	memory	O
11	function	O
12	by	O
13	interaction	O
14	with	O
15	their	O
16	ligand	O
17	acetylcholine	O
18	.	O

1	Isolation	O
2	and	O
3	characterization	O
4	of	O
5	SRF	B
6	accessory	O
7	proteins	O
8	.	O

1	Substrates	O
2	for	O
3	p210	B
4	(	O
5	bcr	B
6	-	I
7	abl	I
8	)	O
9	are	O
10	likely	O
11	to	O
12	be	O
13	involved	O
14	in	O
15	the	O
16	pathogenesis	O
17	of	O
18	CML	O
19	.	O

1	The	O
2	lacS	O
3	gene	O
4	was	O
5	cloned	O
6	in	O
7	an	O
8	E	O
9	.	O
10	coli	O
11	-	O
12	Streptococcus	O
13	shuttle	O
14	vector	O
15	and	O
16	was	O
17	expressed	O
18	both	O
19	in	O
20	a	O
21	lacS	O
22	deletion	O
23	derivative	O
24	of	O
25	S	O
26	.	O
27	thermophilus	O
28	and	O
29	in	O
30	a	O
31	pNZ63	O
32	-	O
33	cured	O
34	strain	O
35	,	O
36	L	O
37	.	O
38	lactis	O
39	NZ6091	O
40	.	O

1	SPECT	O
2	is	O
3	an	O
4	important	O
5	aid	O
6	in	O
7	the	O
8	diagnosis	O
9	of	O
10	AIDS	O
11	dementia	O
12	complex	O
13	and	O
14	contributes	O
15	to	O
16	the	O
17	understanding	O
18	of	O
19	the	O
20	pathophysiological	O
21	mechanisms	O
22	of	O
23	this	O
24	disorder	O
25	.	O

1	Structural	O
2	organization	O
3	and	O
4	developmental	O
5	expression	O
6	pattern	O
7	of	O
8	the	O
9	mouse	B
10	WD	I
11	-	I
12	repeat	I
13	gene	I
14	DMR	O
15	-	O
16	N9	O
17	immediately	O
18	upstream	O
19	of	O
20	the	O
21	myotonic	O
22	dystrophy	O
23	locus	O
24	.	O

1	Ischemia	O
2	-	O
3	induced	O
4	biphasic	O
5	arrhythmias	O
6	were	O
7	suppressed	O
8	in	O
9	both	O
10	zatebradine	O
11	and	O
12	propranolol	O
13	groups	O
14	.	O

1	A	O
2	single	O
3	N	O
4	-	O
5	glycosylation	O
6	site	O
7	present	O
8	in	O
9	chicken	O
10	gp42	O
11	is	O
12	conserved	O
13	among	O
14	all	O
15	five	O
16	of	O
17	these	O
18	proteins	O
19	:	O
20	carbohydrate	O
21	analysis	O
22	of	O
23	gp42	O
24	revealed	O
25	the	O
26	presence	O
27	of	O
28	a	O
29	complex	O
30	type	O
31	glycan	O
32	chain	O
33	at	O
34	this	O
35	site	O
36	.	O

1	Complete	O
2	nucleotide	O
3	sequence	O
4	of	O
5	the	O
6	bacteriophage	O
7	K1F	O
8	tail	O
9	gene	O
10	encoding	O
11	endo	O
12	-	O
13	N	I
14	-	O
15	acylneuraminidase	O
16	(	O
17	endo	O
18	-	O
19	N	O
20	)	O
21	and	O
22	comparison	O
23	to	O
24	an	O
25	endo	O
26	-	O
27	N	O
28	homolog	O
29	in	O
30	bacteriophage	O
31	PK1E	O
32	.	O

1	Interleukin	B
2	-	I
3	6	I
4	(	O
5	IL	B
6	-	I
7	6	I
8	)	O
9	is	O
10	a	O
11	pleiotropic	O
12	cytokine	O
13	,	O
14	which	O
15	is	O
16	involved	O
17	in	O
18	inflammatory	O
19	and	O
20	immune	O
21	responses	O
22	,	O
23	acute	O
24	phase	O
25	reactions	O
26	,	O
27	and	O
28	hematopoiesis	O
29	.	O

1	Sensitization	O
2	to	O
3	hyperlactatemia	O
4	induced	O
5	by	O
6	phenformin	O
7	after	O
8	subtotal	O
9	ablation	O
10	of	O
11	the	O
12	pancreas	O
13	.	O

1	The	O
2	effect	O
3	of	O
4	independent	O
5	predictors	O
6	on	O
7	survival	O
8	was	O
9	examined	O
10	in	O
11	a	O
12	Cox	O
13	regression	O
14	model	O
15	with	O
16	adjustment	O
17	for	O
18	existing	O
19	illnesses	O
20	.	O

1	His	O
2	carnitine	O
3	palmitoyltransferase	B
4	(	O
5	CPT	I
6	)	O
7	I	O
8	and	O
9	II	O
10	activities	O
11	were	O
12	0	O
13	.	O
14	06	O
15	and	O
16	0	O
17	.	O
18	12	O
19	nmol	O
20	/	O
21	min	O
22	/	O
23	mg	O
24	protein	O
25	,	O
26	as	O
27	compared	O
28	with	O
29	a	O
30	mean	O
31	value	O
32	of	O
33	0	O
34	.	O
35	22	O
36	+/-	O
37	0	O
38	.	O
39	14	O
40	and	O
41	0	O
42	.	O
43	27	O
44	+/-	O
45	0	O
46	.	O
47	07	O
48	nmol	O
49	/	O
50	min	O
51	/	O
52	mg	O
53	protein	O
54	,	O
55	respectively	O
56	,	O
57	in	O
58	control	O
59	subjects	O
60	.	O

1	A	O
2	role	O
3	for	O
4	glycogen	B
5	synthase	I
6	kinase	I
7	-	I
8	3	I
9	in	O
10	the	O
11	control	O
12	of	O
13	gene	O
14	expression	O
15	.	O

1	The	O
2	patient	O
3	initially	O
4	attained	O
5	complete	O
6	remission	O
7	(	O
8	CR1	B
9	)	O
10	with	O
11	conventional	O
12	chemotherapy	O
13	and	O
14	then	O
15	relapsed	O
16	14	O
17	months	O
18	later	O
19	.	O

1	Lars	O
2	has	O
3	AIDS	O
4	--	O
5	a	O
6	more	O
7	dignified	O
8	life	O
9	with	O
10	care	O
11	at	O
12	home	O
13	.	O

1	This	O
2	report	O
3	presents	O
4	an	O
5	analysis	O
6	of	O
7	the	O
8	vocal	O
9	repertoire	O
10	of	O
11	howler	O
12	monkeys	O
13	(	O
14	Alouatta	O
15	palliata	O
16	)	O
17	observed	O
18	during	O
19	a	O
20	field	O
21	study	O
22	in	O
23	southwestern	O
24	Panama	O
25	.	O

1	The	O
2	SCH9	B
3	protein	I
4	kinase	I
5	mRNA	O
6	contains	O
7	a	O
8	long	O
9	5	O
10	'	O
11	leader	O
12	with	O
13	a	O
14	small	O
15	open	O
16	reading	O
17	frame	O
18	.	O

1	BACKGROUND	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	this	O
7	study	O
8	was	O
9	to	O
10	determine	O
11	and	O
12	compare	B
13	interleukin	B
14	-	I
15	6	I
16	(	O
17	IL	B
18	-	I
19	6	I
20	)	O
21	levels	O
22	in	O
23	gingival	O
24	crevicular	O
25	fluid	O
26	(	O
27	GCF	O
28	)	O
29	and	O
30	clinical	O
31	periodontal	O
32	findings	O
33	in	O
34	patients	O
35	with	O
36	rheumatoid	O
37	arthritis	O
38	(	O
39	RA	O
40	)	O
41	and	O
42	adult	O
43	periodontitis	O
44	(	O
45	AP	B
46	).	O

1	In	O
2	canrenoate	O
3	-	O
4	treated	O
5	rats	O
6	,	O
7	ANP	B
8	infusion	O
9	caused	O
10	greater	O
11	increases	O
12	in	O
13	sodium	O
14	excretion	O
15	(	O
16	FENA	O
17	from	O
18	3	O
19	.	O
20	05	O
21	+/-	O
22	0	O
23	.	O
24	71	O
25	to	O
26	7	O
27	.	O
28	21	O
29	+/-	O
30	0	O
31	.	O
32	45	O
33	%;	O
34	P	O
35	<	O
36	0	O
37	.	O
38	05	O
39	;	O
40	n	O
41	=	O
42	8	O
43	)	O
44	than	O
45	saline	O
46	infusion	O
47	(	O
48	FENA	O
49	from	O
50	4	O
51	.	O
52	16	O
53	+/-	O
54	1	O
55	.	O
56	11	O
57	to	O
58	5	O
59	.	O
60	47	O
61	+/-	O
62	0	O
63	.	O
64	66	O
65	%;	O
66	n	O
67	=	O
68	6	O
69	),	O
70	despite	O
71	the	O
72	hypocapnia	O
73	.	O

1	The	O
2	C	O
3	-	O
4	terminal	O
5	mutants	O
6	were	O
7	strongly	O
8	dominant	O
9	over	O
10	TraR	B
11	,	O
12	suggesting	O
13	that	O
14	they	O
15	can	O
16	form	O
17	heteromultimers	O
18	with	O
19	the	O
20	wild	O
21	-	O
22	type	I
23	activator	I
24	.	O

1	Furthermore	O
2	,	O
3	unlike	O
4	the	O
5	case	O
6	for	O
7	HIS3	B
8	where	O
9	only	O
10	a	O
11	limited	O
12	subset	O
13	of	O
14	TATA	O
15	-	O
16	like	O
17	sequences	O
18	can	O
19	activate	O
20	transcription	O
21	in	O
22	conjunction	O
23	with	O
24	GCN4p	O
25	,	O
26	many	O
27	divergent	O
28	TATA	O
29	-	O
30	like	O
31	sequences	O
32	allowed	O
33	GCN4p	O
34	activation	O
35	of	O
36	TRP3	O
37	.	O

1	The	O
2	coding	O
3	sequence	O
4	for	O
5	a	O
6	260	O
7	-	O
8	amino	O
9	-	O
10	acid	O
11	residue	O
12	polypeptide	O
13	was	O
14	interrupted	O
15	by	O
16	a	O
17	single	O
18	short	O
19	intron	O
20	of	O
21	60	O
22	base	O
23	pairs	O
24	(	O
25	bp	O
26	),	O
27	and	O
28	about	O
29	70	O
30	%	O
31	of	O
32	the	O
33	deduced	O
34	amino	O
35	acid	O
36	sequence	O
37	of	O
38	the	O
39	Drosophila	B
40	PCNA	B
41	was	O
42	identical	O
43	to	O
44	the	O
45	rat	O
46	and	O
47	human	B
48	PCNA	B
49	polypeptides	I
50	,	O
51	with	O
52	conserved	O
53	unique	O
54	repeats	O
55	of	O
56	leucine	O
57	in	O
58	the	O
59	C	O
60	-	O
61	terminal	O
62	region	O
63	.	O

1	In	O
2	three	O
3	of	O
4	the	O
5	seven	O
6	,	O
7	inhalation	O
8	of	O
9	2	O
10	ml	O
11	normal	O
12	saline	O
13	produced	O
14	FEV1	O
15	falls	O
16	of	O
17	25	O
18	%	O
19	to	O
20	30	O
21	%,	O
22	but	O
23	these	O
24	falls	O
25	were	O
26	not	O
27	as	O
28	great	O
29	as	O
30	each	O
31	subject	O
32	'	O
33	s	O
34	reactions	O
35	to	O
36	the	O
37	test	O
38	solutions	O
39	.	O

1	These	O
2	cells	O
3	fail	O
4	to	O
5	generate	O
6	the	O
7	signals	O
8	to	O
9	phosphorylate	O
10	CREB	B
11	and	O
12	produce	O
13	significantly	O
14	less	O
15	of	O
16	the	O
17	cytokine	O
18	Interleukin	B
19	-	I
20	2	I
21	(	O
22	IL	B
23	-	I
24	2	I
25	)	O
26	in	O
27	response	O
28	to	O
29	agents	O
30	that	O
31	either	O
32	increase	O
33	intracellular	O
34	Ca2	O
35	+	O
36	and	O
37	/	O
38	or	O
39	activate	O
40	protein	B
41	kinase	I
42	C	I
43	.	O

1	RNase	B
2	protection	O
3	assays	O
4	revealed	O
5	a	O
6	correlation	O
7	between	O
8	the	O
9	levels	O
10	of	O
11	dorsal	O
12	and	O
13	ventral	O
14	skin	O
15	expression	O
16	with	O
17	pigmentation	O
18	/	O
19	phaeomelanin	O
20	phenotypes	O
21	.	O

1	Looming	O
2	detectors	O
3	in	O
4	the	O
5	human	O
6	visual	O
7	pathway	O
8	.	O

1	With	O
2	exon	O
3	trapping	O
4	,	O
5	we	O
6	could	O
7	isolate	O
8	five	O
9	potential	O
10	exons	O
11	from	O
12	the	O
13	YAC	O
14	946E12	O
15	that	O
16	spans	O
17	the	O
18	region	O
19	,	O
20	four	O
21	of	O
22	which	O
23	could	O
24	be	O
25	placed	O
26	in	O
27	the	O
28	contig	O
29	in	O
30	the	O
31	vicinity	O
32	of	O
33	the	O
34	breakpoints	O
35	.	O

1	Serum	O
2	relaxin	O
3	levels	O
4	in	O
5	prostaglandin	O
6	E2	O
7	induced	O
8	abortions	O
9	.	O

1	2	O
2	-	O
3	Chemical	O
4	occlusion	O
5	of	O
6	vas	O
7	is	O
8	quite	O
9	effective	O
10	in	O
11	producing	O
12	a	O
13	block	O
14	in	O
15	the	O
16	vas	O
17	deferens	O
18	of	O
19	dogs	O
20	.	O

1	It	O
2	contains	O
3	a	O
4	5	O
5	'-	O
6	noncoding	O
7	region	O
8	(	O
9	NCR	O
10	)	O
11	of	O
12	73	O
13	nucleotides	O
14	,	O
15	five	O
16	open	O
17	reading	O
18	frames	O
19	(	O
20	ORFs	O
21	1	O
22	to	O
23	5	O
24	)	O
25	which	O
26	encode	O
27	proteins	O
28	with	O
29	M	O
30	(	O
31	r	B
32	)	O
33	160	O
34	kDa	O
35	RNA	I
36	-	I
37	dependent	I
38	RNA	I
39	polymerase	I
40	(	O
41	ORF1	O
42	),	O
43	26	O
44	kDa	O
45	movement	O
46	protein	O
47	1	O
48	(	O
49	ORF2	O
50	),	O
51	13	O
52	kDa	O
53	movement	O
54	protein	O
55	2	O
56	(	O
57	ORF3	O
58	),	O
59	10	O
60	kDa	O
61	movement	O
62	protein	O
63	3	O
64	(	O
65	ORF4	O
66	),	O
67	24	O
68	kDa	O
69	coat	I
70	protein	I
71	(	O
72	OFR5	O
73	),	O
74	and	O
75	a	O
76	3	O
77	'	O
78	NCR	O
79	of	O
80	76	O
81	nucleotides	O
82	.	O

1	PATIENTS	O
2	AND	O
3	METHODS	O
4	:	O
5	In	O
6	807	O
7	consecutive	O
8	patients	O
9	from	O
10	the	O
11	Chilean	O
12	National	O
13	Registry	O
14	of	O
15	Acute	O
16	Myocardial	O
17	Infarction	O
18	we	O
19	analyzed	O
20	the	O
21	resolution	O
22	of	O
23	chest	O
24	pain	O
25	and	O
26	ST	O
27	segment	O
28	elevation	O
29	over	O
30	50	O
31	%	O
32	within	O
33	the	O
34	first	O
35	90	O
36	min	O
37	,	O
38	abrupt	O
39	CK	O
40	rise	O
41	within	O
42	8	O
43	h	O
44	and	O
45	T	O
46	wave	O
47	inversion	O
48	in	O
49	infarct	O
50	related	O
51	EKG	O
52	leads	O
53	within	O
54	the	O
55	first	O
56	24	O
57	h	O
58	after	O
59	thrombolysis	O
60	.	O

1	Cross	O
2	-	O
3	reaction	O
4	between	O
5	a	O
6	monoclonal	O
7	antibody	O
8	and	O
9	two	O
10	alpha	B
11	beta	I
12	T	I
13	cell	I
14	receptors	I
15	.	O

1	In	O
2	several	O
3	cases	O
4	of	O
5	definite	O
6	SjS	O
7	,	O
8	labial	O
9	salivary	O
10	gland	O
11	examinations	O
12	after	O
13	more	O
14	than	O
15	a	O
16	one	O
17	year	O
18	interval	O
19	were	O
20	performed	O
21	on	O
22	two	O
23	occasions	O
24	,	O
25	and	O
26	the	O
27	clinical	O
28	and	O
29	histopathological	O
30	changes	O
31	were	O
32	investigated	O
33	.	O

1	We	O
2	have	O
3	cloned	O
4	cDNA	O
5	and	O
6	genomic	O
7	DNA	O
8	for	O
9	a	O
10	mouse	O
11	gene	O
12	encoding	O
13	a	O
14	protein	O
15	with	O
16	significant	O
17	sequence	O
18	similarity	O
19	to	O
20	conserved	O
21	domains	O
22	found	O
23	in	O
24	proteins	O
25	of	O
26	the	O
27	Spo11p	B
28	family	I
29	.	O

1	No	O
2	recombination	O
3	signal	O
4	sequences	O
5	have	O
6	been	O
7	found	O
8	contiguous	O
9	to	O
10	the	O
11	recombination	O
12	point	O
13	.	O

1	F	I
2	(	O
3	1	O
4	,	O
5	14	O
6	)	O
7	=	O
8	7	O
9	.	O
10	5	O
11	,	O
12	p	O
13	<	O
14	0	O
15	.	O
16	05	O
17	)	O
18	and	O
19	from	O
20	55	O
21	.	O
22	0	O
23	+/-	O
24	5	O
25	.	O
26	5	O
27	to	O
28	88	O
29	.	O
30	3	O
31	+/-	O
32	2	O
33	.	O
34	5	O
35	in	O
36	24	O
37	h	O
38	memory	O
39	retention	O
40	(	O
41	F	O
42	(	O
43	1	O
44	,	O
45	12	O
46	)	O
47	27	O
48	.	O
49	5	O
50	,	O
51	p	O
52	<	O
53	0	O
54	.	O
55	01	O
56	)	O
57	as	O
58	well	O
59	as	O
60	from	O
61	60	O
62	.	O
63	0	O
64	+/-	O
65	6	O
66	.	O
67	8	O
68	to	O
69	85	O
70	.	O
71	6	O
72	+/-	O
73	6	O
74	.	O
75	9	O
76	in	O
77	48	O
78	h	O
79	memory	O
80	retrieval	O
81	(	O
82	F	O
83	(	O
84	1	O
85	,	O
86	12	O
87	)	O
88	=	O
89	5	O
90	.	O
91	2	O
92	,	O
93	p	O
94	<	O
95	0	O
96	.	O
97	05	O
98	),	O
99	respectively	O
100	.	O
1	Several	O
2	different	O
3	oncogenes	O
4	and	O
5	growth	O
6	factors	O
7	promote	O
8	G1	O
9	phase	O
10	progression	O
11	.	O

1	When	O
2	examined	O
3	as	O
4	adults	O
5	(	O
6	8	O
7	weeks	O
8	old	O
9	),	O
10	the	O
11	external	O
12	genitalia	O
13	of	O
14	TA	O
15	-	O
16	exposed	O
17	offspring	O
18	were	O
19	normal	O
20	.	O

1	This	O
2	sequence	O
3	also	O
4	confers	O
5	VDR	B
6	and	O
7	vitamin	O
8	D	O
9	responsiveness	O
10	to	O
11	a	O
12	heterologous	O
13	promoter	O
14	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	identified	O
6	a	O
7	novel	O
8	type	O
9	of	O
10	inhibitory	O
11	domain	O
12	in	O
13	the	O
14	N	O
15	-	O
16	terminal	O
17	60	O
18	amino	O
19	acids	O
20	of	O
21	IRF	B
22	-	I
23	1	I
24	which	O
25	strongly	O
26	inhibits	O
27	its	O
28	transcriptional	O
29	activity	O
30	.	O

1	Second	O
2	,	O
3	nitrate	O
4	induction	O
5	of	O
6	aeg	O
7	-	I
8	46	I
9	.	O
10	5	I
11	operon	I
12	expression	O
13	is	O
14	substantially	O
15	enhanced	O
16	in	O
17	narL	O
18	null	O
19	strains	O
20	(	O
21	M	O
22	.	O
23	H	O
24	.	O

1	Once	O
2	HIT	O
3	II	O
4	is	O
5	suspected	O
6	,	O
7	heparin	O
8	(	O
9	and	O
10	low	O
11	-	O
12	molecular	O
13	-	O
14	weight	O
15	heparins	O
16	)	O
17	should	O
18	be	O
19	stopped	O
20	immediately	O
21	.	O

1	In	O
2	the	O
3	absence	O
4	of	O
5	other	O
6	stabilizers	O
7	,	O
8	increased	O
9	sucrose	O
10	can	O
11	provide	O
12	increased	O
13	thermoresistance	O
14	to	O
15	the	O
16	virus	O
17	in	O
18	2	O
19	.	O
20	5	O
21	%	O
22	albumin	B
23	.	O

1	Analysis	O
2	of	O
3	the	O
4	protein	O
5	sequences	O
6	of	O
7	these	O
8	two	O
9	replicases	O
10	,	O
11	together	O
12	with	O
13	previously	O
14	characterized	O
15	H	O
16	.	O
17	pylori	O
18	plasmid	O
19	replication	O
20	proteins	O
21	,	O
22	supports	O
23	the	O
24	formation	O
25	of	O
26	a	O
27	distinct	O
28	class	O
29	of	O
30	H	O
31	.	O
32	pylori	O
33	plasmid	O
34	proteins	O
35	.	O

1	Viscosity	O
2	experiments	O
3	on	O
4	the	O
5	catalytic	O
6	fragment	I
7	kinase	I
8	reaction	O
9	demonstrated	O
10	that	O
11	the	O
12	chemical	O
13	(	O
14	phosphoryl	O
15	transfer	O
16	)	O
17	step	O
18	had	O
19	a	O
20	reduced	O
21	rate	O
22	.	O

1	Children	O
2	with	O
3	ADD	O
4	showed	O
5	an	O
6	attenuated	O
7	frontal	O
8	CNV	O
9	-	O
10	1	O
11	amplitude	O
12	and	O
13	a	O
14	trend	O
15	towards	O
16	increased	O
17	CNV	O
18	-	O
19	1	O
20	and	O
21	CNV	O
22	-	O
23	2	O
24	occipital	O
25	amplitudes	O
26	.	O

1	Interestingly	O
2	,	O
3	PKA	B
4	activity	O
5	is	O
6	dispensable	O
7	in	O
8	a	O
9	strain	O
10	lacking	O
11	Msn2p	O
12	and	O
13	Msn4p	O
14	activity	O
15	.	O

1	This	O
2	phosphorylation	O
3	can	O
4	be	O
5	catalyzed	O
6	by	O
7	a	O
8	break	O
9	-	O
10	ended	O
11	double	O
12	-	O
13	stranded	O
14	DNA	O
15	-	O
16	activated	O
17	protein	I
18	kinase	I
19	activity	O
20	from	O
21	the	O
22	sea	O
23	urchin	O
24	nucleus	O
25	in	O
26	vitro	O
27	.	O

1	Conversely	O
2	,	O
3	treatment	O
4	of	O
5	human	B
6	protein	I
7	-	I
8	tyrosine	I
9	phosphatase	I
10	alpha	I
11	-	O
12	overexpressing	O
13	cells	O
14	with	O
15	phenylarsine	O
16	oxide	O
17	led	O
18	to	O
19	a	O
20	loss	O
21	of	O
22	the	O
23	constitutive	O
24	NF	B
25	-	I
26	kappa	I
27	B	I
28	activity	O
29	.	O

1	Adjuvant	O
2	therapy	O
3	for	O
4	colon	O
5	cancer	O
6	]	O
7	Surgery	O
8	alone	O
9	may	O
10	fail	O
11	to	O
12	cure	O
13	a	O
14	considerable	O
15	number	O
16	of	O
17	locally	O
18	advanced	O
19	colon	O
20	cancers	O
21	.	O

1	It	O
2	is	O
3	now	O
4	estimated	O
5	that	O
6	inactivation	O
7	mutants	O
8	of	O
9	PTEN	O
10	exist	O
11	in	O
12	60	O
13	%	O
14	of	O
15	all	O
16	forms	O
17	of	O
18	solid	O
19	tumors	O
20	.	O

1	Mutations	O
2	in	O
3	the	O
4	RP2	O
5	locus	O
6	at	O
7	Xp11	O
8	.	O
9	3	O
10	were	O
11	found	O
12	in	O
13	a	O
14	further	O
15	10	O
16	-	O
17	20	O
18	%	O
19	of	O
20	XLRP	O
21	patients	O
22	,	O
23	as	O
24	predicted	O
25	from	O
26	linkage	O
27	studies	O
28	.	O

1	As	O
2	for	O
3	31	O
4	stage	O
5	I	O
6	-	O
7	II	O
8	lung	O
9	cancer	O
10	patients	O
11	,	O
12	CR	O
13	has	O
14	been	O
15	observed	O
16	in	O
17	82	O
18	.	O
19	8	O
20	%	O
21	of	O
22	them	O
23	and	O
24	PR	O
25	in	O
26	13	O
27	.	O
28	8	O
29	%;	O
30	the	O
31	response	O
32	was	O
33	always	O
34	assessed	O
35	with	O
36	chest	O
37	radiography	O
38	,	O
39	CT	O
40	,	O
41	FBS	O
42	,	O
43	cytology	O
44	and	O
45	/	O
46	or	O
47	histology	O
48	.	O

1	To	O
2	search	O
3	for	O
4	genes	O
5	that	O
6	interact	O
7	with	O
8	the	O
9	SLK1	B
10	-	I
11	SLT2	I
12	pathway	O
13	,	O
14	a	O
15	synthetic	O
16	lethal	O
17	suppression	O
18	screen	O
19	was	O
20	carried	O
21	out	O
22	.	O

1	Rigid	O
2	point	O
3	feature	O
4	registration	O
5	using	O
6	mutual	O
7	information	O
8	.	O

1	Eukaryotic	B
2	translation	I
3	initiation	I
4	factor	I
5	4GI	O
6	is	O
7	a	O
8	cellular	O
9	target	O
10	for	O
11	NS1	B
12	protein	O
13	,	O
14	a	O
15	translational	O
16	activator	O
17	of	O
18	influenza	O
19	virus	O
20	.	O

1	Of	O
2	the	O
3	compounds	O
4	tested	O
5	,	O
6	alpha	O
7	-(	O
8	3	O
9	-	O
10	methyl	O
11	-	O
12	2	I
13	-	O
14	quinoxalinyl	I
15	)-	O
16	N	O
17	-	I
18	methylnitrone	I
19	1	I
20	,	O
21	4	O
22	-	O
23	dioxide	O
24	(	O
25	2	O
26	)	O
27	was	O
28	the	O
29	most	O
30	active	O
31	agent	O
32	in	O
33	vivo	O
34	against	O
35	the	O
36	gram	O
37	-	O
38	negative	O
39	and	O
40	the	O
41	gram	O
42	-	O
43	positive	O
44	organisms	O
45	.	O

1	In	O
2	contrast	O
3	to	O
4	T	O
5	cells	O
6	,	O
7	in	O
8	fibroblasts	O
9	PILOT	B
10	gene	I
11	expression	O
12	requires	O
13	only	O
14	one	O
15	signal	O
16	(	O
17	PMA	O
18	)	O
19	and	O
20	is	O
21	not	O
22	affected	O
23	by	O
24	CyA	O
25	.	O

1	Clinical	O
2	differentiation	O
3	of	O
4	patients	O
5	with	O
6	mild	O
7	diplegic	O
8	cerebral	O
9	palsy	O
10	(	O
11	CP	O
12	)	O
13	and	O
14	idiopathic	O
15	toe	O
16	walking	O
17	(	O
18	ITW	O
19	)	O
20	can	O
21	be	O
22	difficult	O
23	.	O

1	Moreover	O
2	,	O
3	promoters	O
4	containing	O
5	a	O
6	TATA	O
7	box	O
8	in	O
9	the	O
10	absence	O
11	of	O
12	Sp1	B
13	sites	I
14	or	O
15	Sp1	B
16	sites	I
17	in	O
18	the	O
19	absence	O
20	of	O
21	a	O
22	TATA	O
23	box	O
24	were	O
25	equally	O
26	inducible	O
27	in	O
28	vitro	O
29	,	O
30	as	O
31	was	O
32	an	O
33	RNA	B
34	polymerase	I
35	III	I
36	promoter	I
37	.	O

1	Naturally	O
2	acquired	O
3	antibodies	O
4	were	O
5	demonstrated	O
6	in	O
7	some	O
8	rabbits	O
9	kept	O
10	on	O
11	commercial	O
12	farms	O
13	.	O

1	METHODS	O
2	:	O
3	Rats	O
4	received	O
5	continuous	O
6	intragastric	O
7	infusion	O
8	of	O
9	elemental	O
10	diet	O
11	or	O
12	with	O
13	supplementation	O
14	of	O
15	oatbase	O
16	,	O
17	Lactobacillus	O
18	reuteri	O
19	R2LC	O
20	,	O
21	and	O
22	Lactobacillus	O
23	plantarum	O
24	DSM	O
25	9843	O
26	,	O
27	with	O
28	and	O
29	without	O
30	fermentation	O
31	,	O
32	from	O
33	the	O
34	beginning	O
35	of	O
36	the	O
37	study	O
38	.	O

1	Co	O
2	-	O
3	transfection	O
4	of	O
5	a	O
6	tat	B
7	expressing	O
8	plasmid	O
9	with	O
10	these	O
11	viruses	O
12	containing	O
13	the	O
14	tat	B
15	ORF	I
16	mutations	O
17	resulted	O
18	in	O
19	higher	O
20	levels	O
21	of	O
22	virus	O
23	production	O
24	demonstrating	O
25	that	O
26	the	O
27	effects	O
28	of	O
29	both	O
30	mutants	O
31	are	O
32	tat	B
33	specific	O
34	.	O

1	Triumph	O
2	of	O
3	Leninist	O
4	national	O
5	policy	O

1	A	O
2	comparison	O
3	among	O
4	the	O
5	5	O
6	'	O
7	flanking	O
8	regions	O
9	encompassing	O
10	the	O
11	presumptive	O
12	HS	B
13	promoter	O
14	of	O
15	the	O
16	soybean	B
17	HS	I
18	-	I
19	protein	I
20	genes	O
21	demonstrated	O
22	this	O
23	region	O
24	to	O
25	be	O
26	extremely	O
27	homologous	O
28	.	O

1	VirD2	O
2	is	O
3	one	O
4	of	O
5	the	O
6	key	O
7	Agrobacterium	O
8	tumefaciens	O
9	proteins	O
10	involved	O
11	in	O
12	T	O
13	-	O
14	DNA	O
15	processing	O
16	and	O
17	transfer	O
18	.	O

1	Using	O
2	himA	O
3	mutants	O
4	,	O
5	we	O
6	confirmed	O
7	that	O
8	IHF	B
9	plays	O
10	a	O
11	role	O
12	in	O
13	the	O
14	molybdate	O
15	-	O
16	dependent	O
17	regulation	O
18	of	O
19	dmsA	B
20	-	I
21	lacZ	B
22	expression	O
23	in	O
24	vivo	O
25	.	O

1	The	O
2	full	O
3	-	O
4	length	O
5	N	O
6	gene	O
7	,	O
8	encoded	O
9	by	O
10	open	O
11	reading	O
12	frame	O
13	7	O
14	,	O
15	was	O
16	cloned	O
17	from	O
18	the	O
19	Canadian	O
20	PRRS	O
21	virus	O
22	,	O
23	PA	B
24	-	O
25	8	O
26	.	O

1	One	O
2	RNA	O
3	construct	O
4	which	O
5	consisted	O
6	of	O
7	112	O
8	nucleotides	O
9	(	O
10	nt	O
11	)	O
12	from	O
13	nt	O
14	639	O
15	to	O
16	nt	O
17	750	O
18	formed	O
19	a	O
20	heterodimeric	O
21	complex	O
22	with	O
23	the	O
24	RNA	O
25	which	O
26	consisted	O
27	of	O
28	200	O
29	nucleotides	O
30	from	O
31	nt	O
32	551	O
33	to	O
34	nt	O
35	750	O
36	.	O

1	After	O
2	90	O
3	d	O
4	a	O
5	subsurface	O
6	,	O
7	radiolucent	O
8	caries	O
9	-	O
10	like	O
11	lesion	O
12	was	O
13	observed	O
14	in	O
15	two	O
16	specimens	O
17	only	O
18	.	O

1	The	O
2	majority	O
3	of	O
4	tumors	O
5	occurred	O
6	in	O
7	the	O
8	nasal	O
9	cavities	O
10	,	O
11	although	O
12	significant	O
13	incidences	O
14	were	O
15	also	O
16	found	O
17	in	O
18	the	O
19	larynx	O
20	,	O
21	trachea	O
22	and	O
23	stem	O
24	bronchi	O
25	.	O

1	Surprisingly	O
2	,	O
3	double	O
4	mutants	O
5	of	O
6	the	O
7	shy2	O
8	-	O
9	1D	O
10	mutant	O
11	with	O
12	the	O
13	phytochrome	B
14	-	I
15	deficient	O
16	mutants	I
17	hy2	I
18	,	O
19	hy3	O
20	(	O
21	phyB	B
22	-	I
23	1	I
24	)	O
25	and	O
26	fre1	O
27	-	O
28	1	I
29	(	O
30	phyA	O
31	-	O
32	201	O
33	)	O
34	showed	O
35	reduced	O
36	photomorphogenic	O
37	response	O
38	in	O
39	darkness	O
40	with	O
41	a	O
42	longer	O
43	hypocotyl	O
44	,	O
45	a	O
46	longer	O
47	inflorescence	O
48	stem	O
49	,	O
50	and	O
51	a	O
52	lower	O
53	level	O
54	expression	O
55	of	O
56	the	O
57	CAB	O
58	gene	O
59	than	O
60	the	O
61	shy2	O
62	-	O
63	1D	O
64	single	O
65	mutant	O
66	.	O

1	We	O
2	have	O
3	been	O
4	able	O
5	to	O
6	map	O
7	specific	O
8	DNA	O
9	fragments	O
10	at	O
11	the	O
12	bases	O
13	of	O
14	chromatin	O
15	loops	O
16	with	O
17	the	O
18	help	O
19	of	O
20	a	O
21	novel	O
22	extraction	O
23	procedure	O
24	by	O
25	using	O
26	lithium	O
27	-	O
28	3	O
29	',	O
30	5	O
31	'-	O
32	diiodosalicylate	O
33	.	O

1	The	O
2	deduced	O
3	amino	O
4	acid	O
5	sequences	O
6	of	O
7	each	O
8	of	O
9	the	O
10	W3A1	O
11	ETF	O
12	subunits	O
13	exhibit	O
14	only	O
15	approximately	O
16	30	O
17	%	O
18	identity	O
19	with	O
20	the	O
21	corresponding	O
22	subunits	O
23	of	O
24	the	O
25	ETF	O
26	from	O
27	human	O
28	,	O
29	rat	O
30	,	O
31	and	O
32	Paracoccus	O
33	denitrificans	O
34	,	O
35	which	O
36	as	O
37	a	O
38	group	O
39	are	O
40	greater	O
41	than	O
42	50	O
43	%	O
44	identical	O
45	.	O

1	The	O
2	promoter	O
3	for	O
4	HMG	B
5	-	I
6	CoA	I
7	synthase	I
8	contains	O
9	two	O
10	binding	O
11	sites	O
12	for	O
13	the	O
14	sterol	B
15	regulatory	I
16	element	I
17	-	I
18	binding	I
19	proteins	I
20	(	O
21	SREBPs	B
22	).	O

1	Human	B
2	acid	I
3	ceramidase	I
4	((	I
5	AC	I
6	)	O
7	N	O
8	-	O
9	acylsphingosine	O
10	amidohydrolase	O
11	,	O
12	EC	B
13	3	I
14	.	O
15	5	O
16	.	O

1	Comprising	O
2	a	O
3	126	O
4	-	O
5	nucleotide	O
6	5	O
7	'	O
8	untranscribed	O
9	genomic	O
10	sequence	O
11	and	O
12	a	O
13	466	O
14	-	O
15	nucleotide	O
16	5	O
17	'	O
18	noncoding	O
19	cDNA	O
20	sequence	O
21	,	O
22	the	O
23	592	O
24	-	O
25	nucleotide	O
26	5	O
27	'	O
28	CpG	O
29	island	O
30	lacked	O
31	TATA	O
32	and	O
33	CAAT	O
34	boxes	O
35	but	O
36	displayed	O
37	a	O
38	high	O
39	G	O
40	+	O
41	C	O
42	content	O
43	,	O
44	was	O
45	enriched	O
46	for	O
47	CpG	O
48	dinucleotides	O
49	,	O
50	and	O
51	contained	O
52	a	O
53	potential	O
54	Sp1	B
55	-	O
56	binding	O
57	site	O
58	,	O
59	i	O
60	.	O
61	e	O
62	.,	O
63	features	O
64	compatible	O
65	with	O
66	a	O
67	housekeeping	O
68	gene	O
69	.	O

1	Mutating	O
2	the	O
3	E	O
4	-	O
5	box	O
6	in	O
7	the	O
8	context	O
9	of	O
10	the	O
11	3	O
12	'-	O
13	flanking	O
14	region	O
15	confirmed	O
16	that	O
17	it	O
18	contributes	O
19	to	O
20	the	O
21	enhancement	O
22	of	O
23	transcriptional	O
24	activity	O
25	of	O
26	the	O
27	alpha1	B
28	(	I
29	I	I
30	)	I
31	collagen	I
32	gene	I
33	promoter	I
34	.	O

1	In	O
2	order	O
3	to	O
4	examine	O
5	the	O
6	potential	O
7	role	O
8	of	O
9	transcriptional	O
10	silencing	O
11	during	O
12	productive	O
13	HSV	O
14	-	O
15	1	O
16	infection	O
17	,	O
18	recombinant	O
19	viruses	O
20	were	O
21	generated	O
22	in	O
23	which	O
24	wild	O
25	-	O
26	type	O
27	or	O
28	mutant	O
29	ICP34	O
30	.	O
31	5	O
32	promoters	O
33	controlling	O
34	the	O
35	expression	O
36	of	O
37	a	O
38	chloramphenicol	B
39	acetyltransferase	I
40	reporter	O
41	gene	O
42	were	O
43	inserted	O
44	into	O
45	the	O
46	thymidine	B
47	kinase	I
48	gene	O
49	of	O
50	the	O
51	viral	O
52	genome	O
53	.	O

1	RNA	B
2	polymerase	I
3	II	I
4	inhibition	O
5	increased	O
6	the	O
7	binding	O
8	of	O
9	ARE	O
10	(	O
11	AUBP	O
12	activity	O
13	)	O
14	and	O
15	poly	O
16	(	O
17	U	O
18	)-	O
19	Sepharose	O
20	by	O
21	cytoplasmic	O
22	hnRNP	I
23	A1	I
24	,	O
25	while	O
26	nuclear	B
27	hnRNP	I
28	A1	I
29	binding	O
30	was	O
31	unaffected	O
32	.	O

1	A	O
2	great	O
3	deal	O
4	of	O
5	information	O
6	is	O
7	available	O
8	on	O
9	the	O
10	morphology	O
11	of	O
12	the	O
13	claustrum	O
14	in	O
15	various	O
16	animal	O
17	species	O
18	,	O
19	as	O
20	well	O
21	as	O
22	on	O
23	its	O
24	neuronal	O
25	distribution	O
26	and	O
27	relationships	O
28	with	O
29	the	O
30	cerebral	O
31	cortex	O
32	and	O
33	other	O
34	nuclei	O
35	.	O

1	CONCLUSION	O
2	:	O
3	These	O
4	results	O
5	suggest	O
6	that	O
7	vibration	O
8	-	O
9	induced	O
10	neural	O
11	involvement	O
12	can	O
13	be	O
14	considered	O
15	neither	O
16	pure	O
17	digital	O
18	neuropathy	O
19	,	O
20	nor	O
21	definite	O
22	CTS	O
23	,	O
24	as	O
25	previously	O
26	described	O
27	.	O

1	Acute	O
2	appearance	O
3	of	O
4	hemiparesis	O
5	or	O
6	hemiplegia	O
7	with	O
8	initial	O
9	marked	O
10	spasticity	O
11	was	O
12	observed	O
13	in	O
14	8	O
15	stroke	O
16	patients	O
17	.	O

1	It	O
2	was	O
3	also	O
4	found	O
5	that	O
6	there	O
7	is	O
8	no	O
9	significant	O
10	difference	O
11	between	O
12	the	O
13	prevalence	O
14	of	O
15	nasal	O
16	carriage	O
17	of	O
18	S	O
19	.	O
20	aureus	O
21	amongst	O
22	the	O
23	hospital	O
24	staff	O
25	and	O
26	the	O
27	patients	O
28	.	O

1	The	O
2	concentration	O
3	of	O
4	alpha	B
5	2	I
6	-	I
7	macroglobulin	I
8	,	O
9	alpha	B
10	1	I
11	-	I
12	antitrypsin	I
13	,	O
14	plasminogen	B
15	,	O
16	C3	B
17	-	I
18	complement	I
19	,	O
20	fibrinogen	B
21	degradation	O
22	products	O
23	(	O
24	FDP	O
25	)	O
26	and	O
27	fibrinolytic	O
28	activity	O
29	,	O
30	were	O
31	studied	O
32	in	O
33	the	O
34	aqueous	O
35	humour	O
36	and	O
37	serum	O
38	from	O
39	nine	O
40	patients	O
41	with	O
42	Fuchs	O
43	'	O
44	endothelial	O
45	dystrophy	O
46	,	O
47	17	O
48	patients	O
49	with	O
50	uncomplicated	O
51	senile	O
52	cataract	O
53	and	O
54	in	O
55	the	O
56	secondary	O
57	aqueous	O
58	from	O
59	six	O
60	cataract	O
61	patients	O
62	.	O

1	Sak	B
2	kinase	I
3	gene	O
4	structure	O
5	and	O
6	transcriptional	O
7	regulation	O
8	.	O

1	The	O
2	ESEG	O
3	'	O
4	s	O
5	are	O
6	a	O
7	direct	O
8	result	O
9	of	O
10	the	O
11	NEXT	O
12	study	O
13	.	O

1	These	O
2	findings	O
3	suggest	O
4	that	O
5	the	O
6	MAP	B
7	kinase	I
8	activator	I
9	/	I
10	MAP	I
11	kinase	I
12	system	O
13	may	O
14	be	O
15	the	O
16	downstream	O
17	components	O
18	of	O
19	ras	B
20	signal	O
21	transduction	O
22	pathways	O
23	.	O

1	Oculus	O
2	-	O
3	500	O
4	is	O
5	a	O
6	group	O
7	of	O
8	high	O
9	resolution	O
10	imaging	O
11	boards	O
12	for	O
13	use	O
14	with	O
15	IBM	O
16	-	O
17	AT	O
18	and	O
19	compatible	O
20	computers	O
21	.	O

1	Ten	O
2	-	O
3	year	O
4	experience	O
5	with	O
6	one	O
7	-	O
8	stage	O
9	proctocolectomy	O
10	and	O
11	anal	O
12	ileostomy	O
13	.	O

1	In	O
2	the	O
3	first	O
4	group	O
5	,	O
6	0	O
7	.	O
8	02	O
9	%	O
10	Prazosin	O
11	(	O
12	0	O
13	.	O
14	5	O
15	mg	O
16	/	O
17	kg	O
18	)	O
19	was	O
20	administered	O
21	intravenously	O
22	for	O
23	1	O
24	.	O
25	5	O
26	hours	O
27	before	O
28	the	O
29	application	O
30	of	O
31	Oxy	O
32	-	O
33	Hb	B
34	or	O
35	PGF2	O
36	alpha	O
37	.	O

1	Enhancer	O
2	and	O
3	promoter	O
4	elements	O
5	directing	O
6	activation	O
7	and	O
8	glucocorticoid	O
9	repression	O
10	of	O
11	the	O
12	alpha	B
13	1	I
14	-	I
15	fetoprotein	I
16	gene	I
17	in	O
18	hepatocytes	O
19	.	O

1	Identification	O
2	and	O
3	nucleotide	O
4	sequence	O
5	of	O
6	Rhizobium	O
7	meliloti	O
8	insertion	O
9	sequence	O
10	ISRm3	O
11	:	O
12	similarity	O
13	between	O
14	the	O
15	putative	O
16	transposase	O
17	encoded	O
18	by	O
19	ISRm3	O
20	and	O
21	those	O
22	encoded	O
23	by	O
24	Staphylococcus	O
25	aureus	O
26	IS256	O
27	and	O
28	Thiobacillus	O
29	ferrooxidans	O
30	IST2	O
31	.	O

1	A	O
2	consensus	O
3	sequence	O
4	indicates	O
5	a	O
6	highly	O
7	conserved	O
8	lysine	O
9	residue	O
10	,	O
11	K120	O
12	of	O
13	endonuclease	B
14	III	I
15	or	O
16	K241	O
17	of	O
18	Ogg1	B
19	,	O
20	respectively	O
21	.	O

1	Thigh	O
2	girth	O
3	correlated	O
4	positively	O
5	with	O
6	HDL	B
7	and	O
8	HDL2	B
9	-	I
10	C	I
11	and	O
12	mass	O
13	,	O
14	and	O
15	with	O
16	LDL	B
17	particle	O
18	size	O
19	among	O
20	women	O
21	.	O

1	Critical	O
2	residues	O
3	required	O
4	for	O
5	repression	O
6	are	O
7	located	O
8	within	O
9	the	O
10	C	O
11	-	O
12	terminal	O
13	27	O
14	amino	O
15	acids	O
16	of	O
17	c	B
18	-	I
19	Fos	I
20	,	O
21	since	O
22	v	B
23	-	I
24	Fos	I
25	and	O
26	C	O
27	-	O
28	terminal	O
29	truncations	O
30	of	O
31	c	B
32	-	I
33	Fos	I
34	did	O
35	not	O
36	down	O
37	regulate	O
38	.	O

1	These	O
2	case	O
3	reports	O
4	provide	O
5	further	O
6	evidence	O
7	that	O
8	LiCO3	O
9	can	O
10	be	O
11	a	O
12	useful	O
13	medication	O
14	in	O
15	the	O
16	treatment	O
17	of	O
18	aggressive	O
19	behavior	O
20	and	O
21	affective	O
22	instability	O
23	after	O
24	brain	O
25	injury	O
26	,	O
27	but	O
28	that	O
29	it	O
30	has	O
31	significant	O
32	potential	O
33	for	O
34	neurotoxicity	O
35	in	O
36	this	O
37	population	O
38	,	O
39	particularly	O
40	when	O
41	used	O
42	in	O
43	conjunction	O
44	with	O
45	neuroleptic	O
46	agents	O
47	.	O

1	The	O
2	brackets	O
3	were	O
4	bonded	O
5	to	O
6	100	O
7	freshly	O
8	extracted	O
9	bovine	O
10	incisors	O
11	,	O
12	and	O
13	,	O
14	after	O
15	storage	O
16	in	O
17	tap	O
18	water	O
19	at	O
20	room	O
21	temperature	O
22	for	O
23	24	O
24	hours	O
25	,	O
26	they	O
27	were	O
28	subsequently	O
29	tested	O
30	in	O
31	a	O
32	shear	O
33	mode	O
34	using	O
35	a	O
36	universal	O
37	testing	O
38	machine	O
39	.	O

1	This	O
2	structure	O
3	of	O
4	cucumisin	O
5	suggests	O
6	that	O
7	it	O
8	is	O
9	probably	O
10	synthesized	O
11	as	O
12	an	O
13	inactive	O
14	precursor	O
15	.	O

1	Furthermore	O
2	,	O
3	loss	O
4	of	O
5	methylation	O
6	also	O
7	greatly	O
8	reduced	O
9	the	O
10	association	O
11	of	O
12	another	O
13	yeast	O
14	B	O
15	-	O
16	type	O
17	subunit	O
18	,	O
19	Rts1p	O
20	.	O

1	The	O
2	histologic	O
3	grade	O
4	for	O
5	the	O
6	same	O
7	anatomic	O
8	site	O
9	varied	O
10	among	O
11	hearts	O
12	and	O
13	among	O
14	different	O
15	anatomic	O
16	sites	O
17	in	O
18	the	O
19	same	O
20	heart	O
21	.	O

1	These	O
2	modifications	O
3	may	O
4	improve	O
5	the	O
6	interlaboratory	O
7	reproducibility	O
8	of	O
9	CD34	B
10	determinations	O
11	due	O
12	to	O
13	the	O
14	reduction	O
15	in	O
16	sample	O
17	handling	O
18	and	O
19	calculation	O
20	of	O
21	results	O
22	.	O

1	The	O
2	highest	O
3	prevalence	O
4	of	O
5	reported	O
6	pet	O
7	allergy	O
8	,	O
9	chronic	O
10	cough	O
11	,	O
12	wheeze	O
13	,	O
14	attacks	O
15	of	O
16	shortness	O
17	of	O
18	breath	O
19	with	O
20	wheezing	O
21	,	O
22	and	O
23	doctor	O
24	-	O
25	diagnosed	O
26	asthma	O
27	was	O
28	found	O
29	in	O
30	children	O
31	who	O
32	had	O
33	pets	O
34	in	O
35	the	O
36	past	O
37	but	O
38	not	O
39	anymore	O
40	.	O

1	Alternatively	O
2	processed	O
3	isoforms	O
4	of	O
5	cellular	O
6	nucleic	O
7	acid	O
8	-	O
9	binding	O
10	protein	O
11	interact	O
12	with	O
13	a	O
14	suppressor	O
15	region	O
16	of	O
17	the	O
18	human	B
19	beta	I
20	-	I
21	myosin	I
22	heavy	I
23	chain	I
24	gene	I
25	.	O

1	Soft	O
2	-	O
3	x	O
4	-	O
5	ray	O
6	lasing	O
7	at	O
8	32	O
9	.	O
10	6	O
11	nm	O
12	in	O
13	Ne	O
14	-	O
15	like	O
16	Ti	O
17	ions	O
18	driven	O
19	by	O
20	40	O
21	J	O
22	of	O
23	energy	O
24	from	O
25	two	O
26	650	O
27	-	O
28	ps	O
29	laser	O
30	pulses	O
31	.	O

1	The	O
2	most	O
3	important	O
4	one	O
5	among	O
6	them	O
7	is	O
8	Cyclosporin	O
9	A	O
10	,	O
11	which	O
12	is	O
13	a	O
14	selective	O
15	immunosuppressive	O
16	drug	O
17	.	O

1	In	O
2	the	O
3	SPP2	O
4	screening	O
5	test	O
6	,	O
7	a	O
8	few	O
9	plates	O
10	were	O
11	not	O
12	seen	O
13	in	O
14	both	O
15	groups	O
16	.	O

1	Dominant	O
2	negative	O
3	Sos	B
4	did	O
5	not	O
6	affect	O
7	carbachol	O
8	stimulation	O
9	of	O
10	HA	B
11	-	I
12	ERK2	B
13	but	O
14	inhibited	O
15	the	O
16	stimulatory	O
17	effect	O
18	of	O
19	EGF	B
20	by	O
21	60	O
22	%.	O

1	Using	O
2	a	O
3	series	O
4	of	O
5	mutant	O
6	T	I
7	antigens	I
8	expressed	O
9	by	O
10	recombinant	O
11	baculoviruses	O
12	in	O
13	Sf9	O
14	cells	O
15	,	O
16	we	O
17	find	O
18	that	O
19	the	O
20	origin	O
21	unwinding	O
22	activities	O
23	of	O
24	both	O
25	TS677	O
26	-->	O
27	A	O
28	and	O
29	TS677	O
30	,	O
31	679	O
32	-->	O
33	A	O
34	are	O
35	inhibited	O
36	by	O
37	the	O
38	T	B
39	-	I
40	antigen	I
41	kinase	I
42	,	O
43	as	O
44	is	O
45	wild	B
46	-	I
47	type	I
48	T	I
49	antigen	I
50	.	O

1	Neither	O
2	CES1	O
3	nor	O
4	CES4	B
5	is	O
6	essential	O
7	for	O
8	cell	O
9	growth	O
10	,	O
11	and	O
12	a	O
13	double	O
14	deletion	O
15	mutant	O
16	is	O
17	viable	O
18	.	O

1	The	O
2	purposes	O
3	of	O
4	this	O
5	study	O
6	were	O
7	1	O
8	)	O
9	to	O
10	examine	O
11	the	O
12	effect	O
13	of	O
14	high	O
15	intensity	O
16	,	O
17	low	O
18	frequency	O
19	transcutaneous	O
20	electrical	O
21	nerve	O
22	stimulation	O
23	at	O
24	auricular	O
25	acupuncture	O
26	points	O
27	on	O
28	experimental	O
29	pain	O
30	threshold	O
31	measured	O
32	at	O
33	the	O
34	wrist	O
35	and	O
36	2	O
37	)	O
38	to	O
39	determine	O
40	the	O
41	changes	O
42	in	O
43	effect	O
44	over	O
45	time	O
46	.	O

1	Three	O
2	pyridoxine	O
3	derivatives	O
4	have	O
5	been	O
6	isolated	O
7	from	O
8	the	O
9	fresh	O
10	stem	O
11	bark	O
12	of	O
13	Albizzia	O
14	julibrissin	O
15	DURAZZ	O
16	..	O

1	The	O
2	genomic	O
3	structure	O
4	of	O
5	four	O
6	members	O
7	of	O
8	the	O
9	SRC	B
10	-	I
11	family	I
12	revealed	O
13	nearly	O
14	identical	O
15	exon	O
16	/	O
17	intron	O
18	boundaries	O
19	within	O
20	the	O
21	catalytic	O
22	domain	O
23	of	O
24	this	O
25	family	O
26	.	O

1	A	O
2	novel	O
3	phosphotyrosine	O
4	-	O
5	binding	O
6	domain	O
7	in	O
8	the	O
9	N	O
10	-	O
11	terminal	O
12	transforming	O
13	region	O
14	of	O
15	Cbl	B
16	interacts	O
17	directly	O
18	and	O
19	selectively	O
20	with	O
21	ZAP	B
22	-	I
23	70	I
24	in	O
25	T	O
26	cells	O
27	.	O

1	We	O
2	conclude	O
3	that	O
4	CPET	O
5	is	O
6	a	O
7	useful	O
8	investigation	O
9	in	O
10	the	O
11	management	O
12	of	O
13	patients	O
14	with	O
15	cardiopulmonary	O
16	disease	O
17	and	O
18	complements	O
19	the	O
20	various	O
21	other	O
22	investigations	O
23	offered	O
24	by	O
25	a	O
26	pulmonary	O
27	function	O
28	laboratory	O
29	.	O

1	The	O
2	aims	O
3	of	O
4	this	O
5	study	O
6	were	O
7	to	O
8	determine	O
9	and	O
10	rank	O
11	the	O
12	frequency	O
13	of	O
14	self	O
15	reported	O
16	visual	O
17	disability	O
18	in	O
19	daily	O
20	tasks	O
21	performed	O
22	by	O
23	glaucoma	O
24	patients	O
25	;	O
26	to	O
27	examine	O
28	the	O
29	interrelation	O
30	between	O
31	disabilities	O
32	using	O
33	factor	O
34	analysis	O
35	;	O
36	to	O
37	study	O
38	the	O
39	relation	O
40	between	O
41	perceived	O
42	visual	O
43	difficulty	O
44	and	O
45	a	O
46	measure	O
47	of	O
48	the	O
49	severity	O
50	of	O
51	visual	O
52	field	O
53	loss	O
54	;	O
55	to	O
56	develop	O
57	a	O
58	glaucoma	O
59	specific	O
60	subgroup	O
61	of	O
62	questions	O
63	;	O
64	and	O
65	examine	O
66	the	O
67	validity	O
68	and	O
69	reliability	O
70	of	O
71	this	O
72	subgroup	O
73	of	O
74	questions	O
75	.	O

1	Despite	O
2	the	O
3	high	O
4	frequency	O
5	of	O
6	natural	O
7	infection	O
8	,	O
9	the	O
10	seropositive	O
11	rates	O
12	of	O
13	JEV	O
14	antibody	O
15	still	O
16	correlated	O
17	well	O
18	with	O
19	the	O
20	dose	O
21	of	O
22	vaccine	O
23	received	O
24	,	O
25	i	O
26	.	O
27	e	O
28	.,	O
29	67	O
30	%	O
31	(	O
32	1122	O
33	/	O
34	1664	O
35	),	O
36	66	O
37	%	O
38	(	O
39	65	O
40	/	O
41	97	O
42	),	O
43	33	O
44	%	O
45	(	O
46	4	O
47	/	O
48	12	O
49	)	O
50	and	O
51	40	O
52	%	O
53	(	O
54	19	O
55	/	O
56	47	O
57	)	O
58	for	O
59	children	O
60	receiving	O
61	3	O
62	,	O
63	2	O
64	,	O
65	1	O
66	,	O
67	and	O
68	0	O
69	dose	O
70	of	O
71	JE	O
72	vaccines	O
73	,	O
74	respectively	O
75	(	O
76	P	O
77	<	O
78	0	O
79	.	O
80	0001	O
81	Chi	O
82	-	O
83	square	O
84	for	O
85	trend	O
86	test	O
87	).	O

1	Glomerular	O
2	mesangial	O
3	cells	O
4	expressed	O
5	an	O
6	abundant	O
7	1	O
8	.	O
9	1	O
10	kb	O
11	mRNA	O
12	transcript	O
13	for	O
14	Id1	O
15	,	O
16	but	O
17	in	O
18	contrast	O
19	to	O
20	other	O
21	cell	O
22	types	O
23	Id1	B
24	mRNA	O
25	was	O
26	expressed	O
27	in	O
28	both	O
29	randomly	O
30	cycling	O
31	cells	O
32	and	O
33	in	O
34	serum	O
35	-	O
36	deprived	O
37	,	O
38	quiescent	O
39	cultures	O
40	.	O

1	Phenazone	O
2	potentiates	O
3	the	O
4	local	O
5	anaesthetic	O
6	effect	O
7	of	O
8	lidocaine	O
9	in	O
10	mice	O
11	.	O

1	These	O
2	data	O
3	confirm	O
4	the	O
5	existence	O
6	of	O
7	hyperlipemic	O
8	abdominal	O
9	crisis	O
10	as	O
11	a	O
12	distinct	O
13	entity	O
14	and	O
15	testify	O
16	to	O
17	the	O
18	importance	O
19	of	O
20	recognizing	O
21	this	O
22	syndrome	O
23	in	O
24	order	O
25	to	O
26	avoid	O
27	the	O
28	occurrence	O
29	of	O
30	acute	O
31	pancreatitis	O
32	and	O
33	the	O
34	performance	O
35	of	O
36	unnecessary	O
37	and	O
38	potentially	O
39	harmful	O
40	surgery	O
41	.	O

1	Conversely	O
2	,	O
3	when	O
4	VDR	B
5	is	O
6	overexpressed	O
7	,	O
8	vitamin	O
9	D3	O
10	attenuates	O
11	9	O
12	-	O
13	cis	O
14	RA	O
15	induction	O
16	from	O
17	an	O
18	RXR	B
19	-	O
20	responsive	O
21	element	O
22	.	O

1	The	O
2	human	B
3	insulin	B
4	-	I
5	like	I
6	growth	I
7	factor	I
8	II	I
9	(	O
10	IGF	B
11	-	I
12	II	I
13	)	O
14	gene	O
15	contains	O
16	four	O
17	promoters	O
18	(	O
19	P1	O
20	,	O
21	P2	O
22	,	O
23	P3	O
24	and	O
25	P4	O
26	).	O

1	Statistics	O
2	for	O
3	nurse	O
4	managers	O
5	--	O
6	3	O
7	.	O

1	Characterization	O
2	of	O
3	the	O
4	promoter	O
5	for	O
6	the	O
7	human	B
8	85	I
9	kDa	I
10	cytosolic	I
11	phospholipase	I
12	A2	I
13	gene	I
14	.	O

1	Elimination	O
2	of	O
3	ETH1	O
4	in	O
5	apn1	O
6	strains	O
7	also	O
8	increased	O
9	spontaneous	O
10	mutation	O
11	rates	O
12	9	O
13	-	O
14	or	O
15	31	O
16	-	O
17	fold	O
18	compared	O
19	to	O
20	the	O
21	wild	O
22	type	O
23	as	O
24	determined	O
25	by	O
26	reversion	O
27	to	O
28	adenine	O
29	or	O
30	lysine	O
31	prototrophy	O
32	,	O
33	respectively	O
34	.	O

1	The	O
2	conditions	O
3	for	O
4	obtaining	O
5	titanium	O
6	dioxide	O
7	from	O
8	the	O
9	substrates	O
10	titanium	O
11	tetrachloride	O
12	and	O
13	oxygen	O
14	and	O
15	applying	O
16	this	O
17	to	O
18	a	O
19	surgical	O
20	stainless	O
21	steel	O
22	of	O
23	the	O
24	type	O
25	316L	O
26	by	O
27	the	O
28	plasma	O
29	assisted	O
30	chemical	O
31	vapour	O
32	deposition	O
33	method	O
34	have	O
35	been	O
36	determined	O
37	.	O

1	Purified	O
2	PLB	O
3	showed	O
4	optimal	O
5	lyase	B
6	activity	O
7	at	O
8	pH	O
9	10	O
10	.	O
11	0	O
12	.	O

1	Resources	O
2	for	O
3	helping	O
4	patients	O
5	to	O
6	quit	O
7	smoking	O
8	.	O

1	There	O
2	were	O
3	differences	O
4	between	O
5	males	O
6	(	O
7	p	O
8	<	O
9	0	O
10	.	O
11	05	O
12	)	O
13	for	O
14	most	O
15	of	O
16	the	O
17	characteristics	O
18	studied	O
19	.	O

1	The	O
2	subjects	O
3	received	O
4	a	O
5	single	O
6	500	O
7	mg	O
8	dose	O
9	of	O
10	acetaminophen	O
11	i	O
12	.	O
13	v	O
14	.	O
15	and	O
16	concentrations	O
17	in	O
18	plasma	O
19	were	O
20	measured	O
21	for	O
22	360	O
23	minutes	O
24	and	O
25	in	O
26	urine	O
27	for	O
28	24	O
29	h	O
30	in	O
31	order	O
32	to	O
33	estimate	O
34	the	O
35	production	O
36	of	O
37	metabolites	O
38	.	O

1	Site	O
2	-	O
3	directed	O
4	mutagenesis	O
5	of	O
6	residues	O
7	in	O
8	this	O
9	domain	O
10	(	O
11	R82A	O
12	,	O
13	K85A	O
14	,	O
15	K88A	O
16	,	O
17	and	O
18	V89A	O
19	)	O
20	resulted	O
21	in	O
22	proteins	O
23	which	O
24	failed	O
25	to	O
26	transactivate	O
27	from	O
28	the	O
29	HTLV	O
30	-	O
31	1	O
32	LTR	O
33	in	O
34	vivo	O
35	.	O

1	Seven	O
2	of	O
3	these	O
4	had	O
5	counterparts	O
6	in	O
7	the	O
8	US	O
9	of	O
10	herpes	O
11	simplex	O
12	type	O
13	1	O
14	(	O
15	HSV	O
16	-	I
17	1	I
18	),	O
19	pseudorabies	O
20	virus	O
21	(	O
22	PRV	O
23	),	O
24	and	O
25	equine	B
26	herpesvirus	I
27	type	I
28	1	I
29	(	O
30	EHV	O
31	-	O
32	1	O
33	).	O

1	CONCLUSIONS	O
2	:	O
3	The	O
4	largest	O
5	value	O
6	of	O
7	the	O
8	joint	O
9	space	O
10	may	O
11	be	O
12	used	O
13	when	O
14	evaluating	O
15	rheumatoid	B
16	AC	I
17	joint	O
18	space	O
19	.	O

1	Its	O
2	potential	O
3	as	O
4	a	O
5	diagnostic	O
6	tool	O
7	for	O
8	epidemiological	O
9	surveillance	O
10	was	O
11	assessed	O
12	in	O
13	comparison	O
14	with	O
15	three	O
16	other	O
17	diagnostic	O
18	tests	O
19	:	O
20	stool	O
21	examination	O
22	,	O
23	ELISA	O
24	with	O
25	soluble	O
26	egg	O
27	antigen	I
28	(	O
29	SEA	O
30	)	O
31	and	O
32	the	O
33	circumoval	O
34	precipitin	O
35	test	O
36	(	O
37	COPT	O
38	).	O

1	IgM	B
2	and	O
3	IgG	B
4	anti	I
5	A	I
6	and	O
7	anti	B
8	B	I
9	antibody	I
10	status	O
11	of	O
12	100	O
13	antenatal	O
14	O	O
15	group	O
16	mothers	O
17	(	O
18	who	O
19	had	O
20	non	O
21	O	O
22	group	O
23	husbands	O
24	)	O
25	were	O
26	studied	O
27	.	O

1	Biliary	O
2	-	O
3	enteric	O
4	fistulas	O

1	Erythrocyte	O
2	protoporphyrin	O
3	concentration	O
4	increased	O
5	significantly	O
6	(	O
7	P	O
8	less	O
9	than	O
10	0	O
11	.	O
12	05	O
13	)	O
14	by	O
15	14	O
16	days	O
17	in	O
18	dogs	O
19	fed	O
20	the	O
21	basal	O
22	diet	O
23	,	O
24	and	O
25	remained	O
26	significantly	O
27	high	O
28	relative	O
29	to	O
30	that	O
31	in	O
32	dogs	O
33	of	O
34	the	O
35	other	O
36	dietary	O
37	groups	O
38	for	O
39	the	O
40	remainder	O
41	of	O
42	the	O
43	study	O
44	.	O

1	Deep	O
2	tans	O
3	were	O
4	induced	O
5	over	O
6	the	O
7	backs	O
8	of	O
9	volunteers	O
10	with	O
11	repeated	O
12	exposure	O
13	to	O
14	longwave	O
15	ultraviolet	O
16	radiation	O
17	(	O
18	UV	O
19	-	O
20	A	O
21	).	O

1	Elevated	O
2	IOP	O
3	developed	O
4	in	O
5	35	O
6	patients	O
7	(	O
8	44	O
9	eyes	O
10	)	O
11	during	O
12	the	O
13	study	O
14	.	O

1	BACKGROUND	O
2	:	O
3	Chronic	O
4	alcohol	O
5	consumption	O
6	has	O
7	been	O
8	demonstrated	O
9	to	O
10	be	O
11	deleterious	O
12	to	O
13	bone	O
14	health	O
15	.	O

1	Phosphatidylinositol	B
2	3	I
3	-	O
4	kinase	I
5	requirement	O
6	in	O
7	activation	O
8	of	O
9	the	O
10	ras	B
11	/	I
12	C	I
13	-	I
14	raf	B
15	-	I
16	1	I
17	/	O
18	MEK	B
19	/	O
20	ERK	B
21	and	O
22	p70	B
23	(	O
24	s6k	O
25	)	O
26	signaling	O
27	cascade	O
28	by	O
29	the	O
30	insulinomimetic	O
31	agent	O
32	vanadyl	O
33	sulfate	O
34	.	O

1	The	O
2	degree	O
3	of	O
4	hypoperfusion	O
5	was	O
6	slightly	O
7	related	O
8	to	O
9	decrease	O
10	in	O
11	FEV1	O
12	.	O
13	0	O
14	%,	O
15	V25	O
16	and	O
17	PaO2	O
18	and	O
19	increase	O
20	in	O
21	circulating	O
22	blood	O
23	volume	O
24	and	O
25	peripheral	O
26	red	O
27	blood	O
28	cell	O
29	counts	O
30	.	O

1	Five	O
2	out	O
3	of	O
4	eight	O
5	consecutive	O
6	cases	O
7	with	O
8	initial	O
9	symptoms	O
10	of	O
11	a	O
12	'	O
13	midline	O
14	granuloma	O
15	'	O
16	were	O
17	identified	O
18	as	O
19	malignant	O
20	histiocytosis	O
21	(	O
22	histiocytic	O
23	sarcoma	O
24	)	O
25	which	O
26	within	O
27	5	O
28	months	O
29	to	O
30	4	O
31	years	O
32	led	O
33	to	O
34	generalization	O
35	and	O
36	death	O
37	.	O

1	A	O
2	developmentally	O
3	modulated	O
4	chromatin	O
5	structure	O
6	at	O
7	the	O
8	mouse	B
9	immunoglobulin	B
10	kappa	I
11	3	I
12	'	I
13	enhancer	I
14	.	O

1	BCR	B
2	-	O
3	ABL	B
4	and	O
5	v	B
6	-	O
7	abl	I
8	oncogenes	O
9	induce	O
10	distinct	O
11	patterns	O
12	of	O
13	thymic	O
14	lymphoma	O
15	involving	O
16	different	O
17	lymphocyte	O
18	subsets	O
19	.	O

1	The	O
2	distribution	O
3	phase	O
4	is	O
5	followed	O
6	by	O
7	an	O
8	elimination	O
9	phase	O
10	with	O
11	a	O
12	much	O
13	longer	O
14	half	O
15	-	O
16	life	O
17	(	O
18	mean	O
19	value	O
20	375	O
21	min	O
22	)	O
23	and	O
24	a	O
25	volume	O
26	of	O
27	distribution	O
28	of	O
29	approximately	O
30	200	O
31	-	O
32	400	O
33	l	O
34	.	O

1	In	O
2	a	O
3	second	O
4	series	O
5	of	O
6	experiments	O
7	,	O
8	the	O
9	efficacy	O
10	of	O
11	PDC	B
12	/	O
13	HDC	B
14	Ac	I
15	was	O
16	evaluated	O
17	in	O
18	both	O
19	single	O
20	and	O
21	multiple	O
22	dose	O
23	regiments	O
24	.	O

1	Similarly	O
2	,	O
3	actuarial	O
4	interpretations	O
5	for	O
6	the	O
7	second	O
8	protocols	O
9	were	O
10	not	O
11	more	O
12	frequently	O
13	selected	O
14	by	O
15	therapists	O
16	as	O
17	more	O
18	valid	O
19	,	O
20	regardless	O
21	of	O
22	treatment	O
23	condition	O
24	and	O
25	elevation	O
26	of	O
27	the	O
28	F	B
29	and	O
30	F	B
31	-	I
32	K	I
33	indices	O
34	on	O
35	the	O
36	first	O
37	MMPI	O
38	profile	O
39	.	O

1	In	O
2	the	O
3	lattice	O
4	,	O
5	23	O
6	%	O
7	of	O
8	the	O
9	sites	O
10	are	O
11	occupied	O
12	,	O
13	95	O
14	%	O
15	of	O
16	the	O
17	atoms	O
18	are	O
19	in	O
20	the	O
21	lowest	O
22	energy	O
23	magnetic	O
24	sublevel	O
25	,	O
26	and	O
27	37	O
28	%	O
29	are	O
30	in	O
31	the	O
32	lowest	O
33	3D	O
34	vibrational	O
35	state	O
36	.	O

1	In	O
2	the	O
3	past	O
4	,	O
5	immunology	O
6	in	O
7	Singapore	O
8	was	O
9	mainly	O
10	confined	O
11	to	O
12	serology	O
13	for	O
14	the	O
15	diagnosis	O
16	of	O
17	certain	O
18	infectious	O
19	diseases	O
20	.	O

1	This	O
2	reveals	O
3	a	O
4	new	O
5	test	O
6	for	O
7	short	O
8	saphenous	O
9	incompetence	O
10	and	O
11	shows	O
12	that	O
13	14	O
14	per	O
15	cent	O
16	of	O
17	varices	O
18	stem	O
19	from	O
20	a	O
21	saphenopopliteal	O
22	reflux	O
23	.	O

1	Thrombolysis	O
2	was	O
3	followed	O
4	by	O
5	a	O
6	similar	O
7	increase	O
8	of	O
9	platelet	O
10	activity	O
11	with	O
12	maximal	O
13	values	O
14	reached	O
15	at	O
16	the	O
17	3rd	O
18	hour	O
19	in	O
20	both	O
21	groups	O
22	(	O
23	196	O
24	+/-	O
25	43	O
26	IU	O
27	/	O
28	ml	O
29	in	O
30	Group	O
31	1	O
32	and	O
33	192	O
34	+/-	O
35	39	O
36	in	O
37	Group	O
38	2	O
39	:	O
40	p	O
41	&	O
42	lt	O
43	;	O
44	001versus	O
45	baseline	O
46	and	O
47	p	O
48	NS	O
49	between	O
50	the	O
51	groups	O
52	).	O

1	In	O
2	addition	O
3	a	O
4	significant	O
5	Treatment	O
6	X	O
7	Strain	O
8	interaction	O
9	was	O
10	due	O
11	to	O
12	the	O
13	larger	O
14	defecation	O
15	numbers	O
16	displayed	O
17	by	O
18	the	O
19	taurine	O
20	-	O
21	injected	O
22	MR	O
23	rats	O
24	relative	O
25	to	O
26	the	O
27	saline	O
28	-	O
29	injected	O
30	MR	O
31	rats	O
32	.	O

1	Mis3	O
2	is	O
3	needed	O
4	for	O
5	the	O
6	formation	O
7	of	O
8	18S	B
9	ribosome	I
10	RNA	I
11	,	O
12	and	O
13	may	O
14	hence	O
15	direct	O
16	the	O
17	level	O
18	of	O
19	proteins	O
20	required	O
21	for	O
22	the	O
23	coupling	O
24	.	O

1	Mucin	O
2	gene	O
3	expression	O
4	has	O
5	been	O
6	shown	O
7	to	O
8	be	O
9	altered	O
10	in	O
11	many	O
12	intestinal	O
13	diseases	O
14	and	O
15	especially	O
16	cancers	O
17	of	O
18	the	O
19	gastrointestinal	O
20	tract	O
21	.	O

1	Methyl	O
2	mercury	O
3	intoxication	O
4	in	O
5	rat	O
6	kidneys	O
7	.	O

1	The	O
2	administration	O
3	of	O
4	the	O
5	GnRH	B
6	agonist	O
7	reduced	O
8	the	O
9	bone	O
10	mineral	O
11	density	O
12	in	O
13	the	O
14	whole	O
15	femur	O
16	to	O
17	91	O
18	.	O
19	0	O
20	%	O
21	of	O
22	that	O
23	in	O
24	the	O
25	control	O
26	group	O
27	.	O

1	In	O
2	8	O
3	healthy	O
4	volunteers	O
5	there	O
6	were	O
7	no	O
8	significant	O
9	differences	O
10	in	O
11	AUC	O
12	,	O
13	peak	O
14	plasma	O
15	concentrations	O
16	or	O
17	time	O
18	to	O
19	peak	O
20	concentration	O
21	when	O
22	OXC	O
23	was	O
24	administered	O
25	either	O
26	with	O
27	or	O
28	without	O
29	ERY	O
30	.	O

1	Relationship	O
2	of	O
3	CDK	B
4	-	I
5	activating	I
6	kinase	I
7	and	I
8	RNA	B
9	polymerase	I
10	II	I
11	CTD	I
12	kinase	I
13	TFIIH	I
14	/	O
15	TFIIK	O
16	.	O

1	Catch	O
2	-	O
3	up	O
4	growth	O
5	was	O
6	observed	O
7	only	O
8	for	O
9	a	O
10	12	O
11	-	O
12	month	O
13	period	O
14	in	O
15	4	O
16	children	O
17	with	O
18	a	O
19	bone	O
20	age	O
21	of	O
22	7	O
23	to	O
24	8	O
25	years	O
26	.	O

1	Inspection	O
2	of	O
3	enhancer	O
4	mutants	O
5	suggests	O
6	that	O
7	trans	O
8	-	O
9	activation	O
10	by	O
11	hLEF	O
12	/	O
13	GAL4	B
14	is	O
15	especially	O
16	dependent	O
17	on	O
18	TCF	B
19	-	I
20	2	I
21	,	O
22	a	O
23	distinct	O
24	T	O
25	-	O
26	cell	O
27	-	O
28	enriched	O
29	protein	O
30	that	O
31	binds	O
32	to	O
33	sequences	O
34	flanking	O
35	the	O
36	hLEF	B
37	-	I
38	binding	I
39	site	I
40	in	O
41	the	O
42	enhancer	O
43	.	O

1	As	O
2	the	O
3	rate	O
4	of	O
5	protein	O
6	synthesis	O
7	decreases	O
8	during	O
9	late	O
10	embryogenesis	O
11	,	O
12	levels	O
13	of	O
14	SEC	B
15	-	I
16	1	I
17	and	O
18	its	O
19	cognate	O
20	mRNA	O
21	decline	O
22	precipitously	O
23	.	O

1	Analysis	O
2	of	O
3	the	O
4	sequence	O
5	identified	O
6	four	O
7	open	O
8	reading	O
9	frames	O
10	(	O
11	ORFs	O
12	)	O
13	which	O
14	are	O
15	designated	O
16	UL1	O
17	,	O
18	UL2	O
19	,	O
20	UL3	O
21	,	O
22	and	O
23	UL3	O
24	.	O
25	5	O
26	based	O
27	on	O
28	their	O
29	homology	O
30	with	O
31	proteins	O
32	of	O
33	herpes	O
34	simplex	I
35	virus	I
36	-	I
37	1	I
38	(	O
39	HSV	B
40	-	I
41	1	I
42	),	O
43	pseudorabies	O
44	virus	O
45	(	O
46	PRV	O
47	),	O
48	equine	B
49	herpesvirus	I
50	-	I
51	1	I
52	,	O
53	and	O
54	varicella	B
55	-	I
56	zoster	I
57	virus	O
58	.	O

1	In	O
2	addition	O
3	,	O
4	our	O
5	results	O
6	show	O
7	that	O
8	ERKs	B
9	and	O
10	PI3Ks	O
11	can	O
12	synergise	O
13	to	O
14	convert	O
15	ectoderm	B
16	into	O
17	mesoderm	O
18	.	O

1	Studied	O
2	groups	O
3	were	O
4	(	O
5	1	O
6	)	O
7	untreated	O
8	control	O
9	,	O
10	n	O
11	=	O
12	12	O
13	;	O
14	(	O
15	2	O
16	)	O
17	FK	O
18	-	O
19	1	O
20	,	O
21	n	O
22	=	O
23	8	O
24	;	O
25	(	O
26	3	O
27	)	O
28	FK	O
29	-	O
30	3	O
31	,	O
32	n	O
33	=	O
34	8	O
35	.	O

1	Plasma	B
2	renin	I
3	activity	O
4	does	O
5	not	O
6	predict	O
7	the	O
8	antihypertensive	O
9	efficacy	O
10	of	O
11	chlorthalidone	O
12	.	O

1	This	O
2	generalization	O
3	of	O
4	MFP	O
5	involves	O
6	defining	O
7	an	O
8	appropriate	O
9	high	O
10	-	O
11	resolution	O
12	cost	O
13	function	O
14	,	O
15	parametrizing	O
16	the	O
17	search	O
18	space	O
19	of	O
20	the	O
21	environment	O
22	and	O
23	source	O
24	,	O
25	constructing	O
26	solutions	O
27	of	O
28	the	O
29	wave	O
30	equation	O
31	,	O
32	and	O
33	utilizing	O
34	a	O
35	nonlinear	O
36	optimization	O
37	method	O
38	to	O
39	search	O
40	the	O
41	parameter	O
42	landscape	O
43	for	O
44	the	O
45	global	O
46	minimum	O
47	of	O
48	the	O
49	cost	O
50	function	O
51	.	O

1	In	O
2	vitro	O
3	transcription	O
4	extracts	O
5	from	O
6	ret1	O
7	-	O
8	1	O
9	cells	O
10	terminate	O
11	less	O
12	efficiently	O
13	at	O
14	weak	O
15	transcription	O
16	termination	O
17	signals	O
18	than	O
19	those	O
20	from	O
21	RET1	O
22	cells	O
23	,	O
24	using	O
25	a	O
26	variety	O
27	of	O
28	tRNA	O
29	templates	O
30	.	O

1	Higher	O
2	CYP3A23	O
3	basal	O
4	activity	O
5	appears	O
6	to	O
7	be	O
8	due	O
9	to	O
10	an	O
11	E	O
12	-	O
13	box	O
14	in	O
15	3A23SiteA	O
16	that	O
17	interacts	O
18	with	O
19	USF1	O
20	,	O
21	a	O
22	ubiquitous	O
23	bHLH	O
24	/	O
25	leucine	O
26	zipper	O
27	transcription	O
28	factor	O
29	.	O

1	Naltrexone	O
2	has	O
3	been	O
4	recently	O
5	approved	O
6	by	O
7	the	O
8	Food	O
9	and	O
10	Drug	O
11	Administration	O
12	for	O
13	the	O
14	treatment	O
15	of	O
16	alcohol	O
17	dependence	O
18	.	O

1	Allelic	O
2	variation	O
3	in	O
4	HLA	B
5	-	I
6	B	I
7	and	O
8	HLA	B
9	-	I
10	C	I
11	sequences	I
12	and	O
13	the	O
14	evolution	O
15	of	O
16	the	O
17	HLA	B
18	-	I
19	B	I
20	alleles	I
21	.	O

1	This	O
2	cluster	O
3	consisted	O
4	of	O
5	four	O
6	apparently	O
7	unrelated	O
8	ESTs	O
9	and	O
10	two	O
11	genes	O
12	,	O
13	pregnancy	O
14	-	O
15	associated	O
16	plasma	B
17	protein	I
18	-	I
19	A	I
20	(	O
21	PAPP	B
22	-	I
23	A	I
24	)	O
25	and	O
26	a	O
27	novel	O
28	gene	O
29	(	O
30	tentatively	O
31	named	O
32	EST	O
33	-	O
34	YD1	O
35	).	O

1	Regression	O
2	analyses	O
3	identified	O
4	7	O
5	risk	O
6	and	O
7	7	O
8	protective	O
9	factors	O
10	with	O
11	minimal	O
12	overlap	O
13	.	O

1	However	O
2	,	O
3	deletions	O
4	of	O
5	the	O
6	C	O
7	terminal	O
8	11	O
9	or	O
10	14	O
11	amino	O
12	acids	O
13	had	O
14	more	O
15	substantial	O
16	effects	O
17	.	O

1	Transient	O
2	transfection	O
3	experiments	O
4	revealed	O
5	that	O
6	Pax	B
7	-	I
8	8	I
9	isoforms	I
10	a	O
11	and	O
12	b	O
13	,	O
14	but	O
15	not	O
16	c	B
17	and	O
18	d	I
19	,	O
20	strongly	O
21	stimulate	O
22	transcription	O
23	from	O
24	a	O
25	promoter	O
26	containing	O
27	six	O
28	copies	O
29	of	O
30	a	O
31	paired	B
32	-	I
33	domain	I
34	recognition	I
35	sequence	I
36	.	O

1	Two	O
2	studies	O
3	on	O
4	the	O
5	relationship	O
6	between	O
7	taking	O
8	a	O
9	commercial	O
10	coaching	O
11	course	O
12	and	O
13	performance	O
14	on	O
15	the	O
16	Medical	O
17	College	O
18	Admission	O
19	Test	O
20	(	O
21	MCAT	O
22	)	O
23	are	O
24	reported	O
25	.	O

1	Similarity	O
2	is	O
3	most	O
4	striking	O
5	in	O
6	the	O
7	zinc	O
8	knuckle	O
9	region	O
10	,	O
11	a	O
12	region	O
13	characteristic	O
14	of	O
15	gag	B
16	genes	O
17	of	O
18	most	O
19	replication	O
20	-	O
21	competent	O
22	retroelements	O
23	.	O

1	INTERVENTIONS	O
2	:	O
3	Patients	O
4	received	O
5	rt	B
6	-	I
7	PA	I
8	,	O
9	heparin	O
10	,	O
11	and	O
12	aspirin	O
13	.	O

1	All	O
2	were	O
3	experienced	O
4	hearing	O
5	aid	O
6	users	O
7	who	O
8	wore	O
9	linear	O
10	Class	O
11	D	O
12	instruments	O
13	with	O
14	input	O
15	compression	O
16	limiting	O
17	at	O
18	the	O
19	time	O
20	of	O
21	their	O
22	enrollment	O
23	in	O
24	this	O
25	study	O
26	.	O

1	The	O
2	ensembles	O
3	are	O
4	considered	O
5	to	O
6	be	O
7	one	O
8	of	O
9	the	O
10	forms	O
11	of	O
12	activity	O
13	of	O
14	the	O
15	structured	O
16	morphofunctional	O
17	cortical	O
18	units	O
19	,	O
20	i	O
21	.	O
22	e	O
23	.	O
24	the	O
25	columns	O
26	.	O

1	TNF	B
2	Treatment	O
3	of	O
4	cell	O
5	activated	O
6	the	O
7	p38	B
8	MAP	I
9	kinase	I
10	pathway	O
11	,	O
12	as	O
13	revealed	O
14	by	O
15	increased	O
16	phosphorylation	O
17	of	O
18	p38	B
19	MAP	I
20	kinase	I
21	itself	O
22	,	O
23	activation	O
24	of	O
25	the	O
26	substrate	B
27	protein	I
28	MAPKAP	B
29	kinase	I
30	-	I
31	2	I
32	,	O
33	and	O
34	culminating	O
35	in	O
36	the	O
37	phosphorylation	O
38	of	O
39	the	O
40	heat	B
41	shock	I
42	protein	I
43	27	I
44	(	O
45	hsp27	O
46	).	O

1	This	O
2	intron	O
3	occupies	O
4	a	O
5	conserved	O
6	position	O
7	corresponding	O
8	to	O
9	that	O
10	of	O
11	intron	O
12	1	O
13	in	O
14	the	O
15	transit	O
16	peptide	O
17	region	O
18	of	O
19	chloroplast	O
20	GAPDH	O
21	genes	O
22	(	O
23	GapA	O
24	and	O
25	GapB	O
26	)	O
27	of	O
28	higher	O
29	plants	O
30	.	O

1	We	O
2	concluded	O
3	that	O
4	activation	O
5	of	O
6	c	B
7	-	I
8	fosER	O
9	mediated	O
10	transcriptional	O
11	inhibition	O
12	of	O
13	p21	B
14	(	O
15	Cip1	B
16	/	O
17	WAF1	B
18	)	O
19	through	O
20	a	O
21	previously	O
22	uncharacterized	O
23	AP	B
24	-	I
25	1	I
26	site	I
27	,	O
28	revealing	O
29	an	O
30	important	O
31	role	O
32	for	O
33	c	B
34	-	I
35	fos	I
36	in	O
37	negative	O
38	control	O
39	of	O
40	cell	O
41	cycle	O
42	regulatory	O
43	genes	O
44	.	O

1	Two	O
2	differentially	O
3	expressed	O
4	LNX	O
5	messages	O
6	encode	O
7	overlapping	O
8	proteins	O
9	with	O
10	predicted	O
11	molecular	O
12	masses	O
13	of	O
14	80	O
15	kDa	O
16	(	O
17	LNX	O
18	)	O
19	and	O
20	70	O
21	kDa	O
22	(	O
23	LNX	O
24	-	O
25	b	O
26	).	O

1	Mutation	O
2	of	O
3	either	O
4	the	O
5	AP	B
6	-	I
7	1	I
8	or	O
9	the	O
10	ets	B
11	component	O
12	of	O
13	this	O
14	site	O
15	also	O
16	prevented	O
17	promoter	O
18	activity	O
19	in	O
20	SMCs	O
21	.	O

1	While	O
2	no	O
3	obvious	O
4	transmembrane	O
5	regions	O
6	were	O
7	identified	O
8	,	O
9	several	O
10	short	O
11	hydrophobic	O
12	amino	O
13	acid	O
14	stretches	O
15	were	O
16	found	O
17	to	O
18	be	O
19	localized	O
20	in	O
21	and	O
22	around	O
23	the	O
24	Pro	O
25	II	O
26	region	O
27	,	O
28	and	O
29	these	O
30	may	O
31	be	O
32	responsible	O
33	for	O
34	attachment	O
35	of	O
36	precursors	O
37	to	O
38	membranes	O
39	.	O

1	A	O
2	study	O
3	in	O
4	vivo	O
5	of	O
6	adrenergic	O
7	receptors	O
8	in	O
9	the	O
10	rectum	O
11	and	O
12	in	O
13	the	O
14	internal	O
15	and	O
16	sphincter	O
17	of	O
18	the	O
19	cat	O
20	.	O

1	Interestingly	O
2	,	O
3	in	O
4	the	O
5	adult	O
6	,	O
7	transgene	O
8	expression	O
9	patterns	O
10	within	O
11	the	O
12	cerebellum	O
13	in	O
14	two	O
15	lines	O
16	appeared	O
17	to	O
18	mark	O
19	distinct	O
20	anterior	O
21	-	O
22	posterior	O
23	compartments	O
24	.	O

1	Total	O
2	cholesterol	O
3	was	O
4	also	O
5	reduced	O
6	at	O
7	week	O
8	12	O
9	by	O
10	17	O
11	.	O
12	0	O
13	%	O
14	(	O
15	20	O
16	mg	O
17	/	O
18	day	O
19	)	O
20	and	O
21	15	O
22	.	O
23	7	O
24	%	O
25	(	O
26	20	O
27	-	O
28	30	O
29	mg	O
30	/	O
31	day	O
32	),	O
33	and	O
34	at	O
35	week	O
36	52	O
37	by	O
38	20	O
39	.	O
40	4	O
41	%	O
42	(<	O
43	or	O
44	=	O
45	20	O
46	mg	O
47	/	O
48	day	O
49	)	O
50	and	O
51	19	O
52	.	O
53	2	O
54	%	O
55	(>	O
56	or	O
57	=	O
58	30	O
59	mg	O
60	/	O
61	day	O
62	).	O

1	This	O
2	Tbx6	O
3	-	O
4	subfamily	O
5	gene	O
6	is	O
7	likely	O
8	to	O
9	participate	O
10	in	O
11	paraxial	O
12	mesoderm	O
13	formation	O
14	and	O
15	somitogenesis	O
16	in	O
17	human	O
18	embryo	O
19	.	O

1	We	O
2	show	O
3	that	O
4	c	B
5	-	I
6	Fos	I
7	(	O
8	the	O
9	c	B
10	-	I
11	fos	I
12	protooncogene	I
13	product	I
14	),	O
15	which	O
16	is	O
17	an	O
18	intrinsically	O
19	unstable	O
20	nuclear	O
21	protein	I
22	,	O
23	is	O
24	metabolically	O
25	highly	O
26	stabilized	O
27	,	O
28	and	O
29	greatly	O
30	enhances	O
31	the	O
32	transforming	O
33	efficiency	O
34	of	O
35	NIH	O
36	3T3	O
37	cells	O
38	,	O
39	by	O
40	Mos	O
41	.	O

1	Homozygous	O
2	individuals	O
3	usually	O
4	develop	O
5	purpura	O
6	fulminans	O
7	as	O
8	newborns	O
9	;	O
10	heterozygous	O
11	protein	O
12	C	O
13	-	O
14	deficient	O
15	individuals	O
16	are	O
17	at	O
18	increased	O
19	risk	O
20	for	O
21	venous	O
22	thrombosis	O
23	and	O
24	pulmonary	O
25	embolism	O
26	.	O

1	The	O
2	interaction	O
3	between	O
4	U	O
5	(	O
6	L	O
7	)	O
8	3	O
9	.	O

1	Partial	O
2	sequencing	O
3	of	O
4	the	O
5	region	O
6	downstream	O
7	of	O
8	ORF	B
9	-	I
10	Pto	I
11	revealed	O
12	homology	O
13	to	O
14	the	O
15	ru	B
16	/	O
17	AB	O
18	genes	O
19	,	O
20	involved	O
21	in	O
22	UV	O
23	resistance	O
24	,	O
25	from	O
26	plasmid	O
27	pPSR1	O
28	.	O

1	Frog	O
2	type	O
3	I	O
4	(	O
5	Ft	O
6	I	O
7	)	O
8	and	O
9	frog	O
10	type	O
11	II	I
12	(	O
13	Ft	B
14	II	I
15	)	O
16	slowly	O
17	adapting	O
18	(	O
19	SA	O
20	)	O
21	units	O
22	produced	O
23	spikes	O
24	only	O
25	at	O
26	the	O
27	indentation	O
28	phase	O
29	,	O
30	and	O
31	the	O
32	threshold	O
33	response	O
34	phase	O
35	(	O
36	TRP	O
37	),	O
38	i	O
39	.	O
40	e	O
41	..	O
42	the	O
43	phase	O
44	of	O
45	the	O
46	first	O
47	spike	O
48	was	O
49	for	O
50	ca	O
51	.	O

1	Space	O
2	limitations	O
3	prevent	O
4	an	O
5	exhaustive	O
6	review	O
7	of	O
8	all	O
9	biologic	O
10	pharmaceuticals	O
11	,	O
12	such	O
13	as	O
14	tissue	B
15	plasminogen	I
16	activating	I
17	substance	I
18	,	O
19	hormones	O
20	(	O
21	e	O
22	.	O
23	g	O
24	.,	O
25	thyroid	O
26	,	O
27	insulin	B
28	,	O
29	growth	B
30	hormone	I
31	,	O
32	erythropoietin	B
33	),	O
34	clotting	O
35	factors	O
36	,	O
37	and	O
38	blood	O
39	products	O
40	.	O

1	Characterization	O
2	of	O
3	these	O
4	R	O
5	subunits	O
6	by	O
7	their	O
8	8	O
9	-	O
10	azido	O
11	-	O
12	cAMP	O
13	photoaffinity	O
14	labeling	O
15	and	O
16	immunoreactivity	O
17	,	O
18	as	O
19	well	O
20	as	O
21	by	O
22	a	O
23	phosphorylation	O
24	-	O
25	dependent	O
26	mobility	O
27	shift	O
28	on	O
29	sodium	O
30	dodecyl	O
31	sulfate	O
32	-	O
33	polyacrylamide	O
34	gel	O
35	electrophoresis	O
36	(	O
37	SDS	O
38	-	O
39	PAGE	O
40	),	O
41	indicated	O
42	subunit	O
43	sizes	O
44	of	O
45	RII	B
46	beta	O
47	(	O
48	53	O
49	kDa	O
50	)	O
51	greater	O
52	than	O
53	RII	B
54	alpha	I
55	dephosphoform	O
56	(	O
57	51	O
58	kDa	O
59	)	O
60	greater	O
61	than	O
62	RI	O
63	alpha	O
64	(	O
65	49	O
66	kDa	O
67	).	O

1	To	O
2	characterize	O
3	the	O
4	gene	O
5	products	O
6	,	O
7	the	O
8	cvaA	B
9	gene	I
10	was	O
11	subcloned	O
12	and	O
13	expressed	O
14	under	O
15	the	O
16	control	O
17	of	O
18	T7	B
19	RNA	I
20	polymerase	I
21	promoter	I
22	.	O

1	Expression	O
2	of	O
3	ME31B	O
4	cDNA	O
5	in	O
6	S	O
7	.	O
8	pombe	O
9	suppresses	O
10	the	O
11	ste13	B
12	mutation	I
13	.	O

1	Significance	O
2	of	O
3	delta	O
4	-	O
5	aminolevulinic	O
6	acid	O
7	analysis	O
8	in	O
9	clinical	O
10	tests	O

1	In	O
2	comparison	O
3	with	O
4	the	O
5	16	O
6	introns	O
7	reported	O
8	in	O
9	AHA3	O
10	,	O
11	AHA2	B
12	is	O
13	missing	O
14	one	O
15	intron	O
16	in	O
17	the	O
18	5	O
19	'-	O
20	untranslated	O
21	region	O
22	and	O
23	a	O
24	second	O
25	intron	O
26	in	O
27	the	O
28	C	O
29	-	O
30	terminal	O
31	coding	O
32	region	O
33	.	O

1	Also	O
2	,	O
3	samples	O
4	of	O
5	serum	O
6	were	O
7	absorbed	O
8	with	O
9	the	O
10	various	O
11	solid	O
12	-	O
13	phase	O
14	allergens	O
15	and	O
16	the	O
17	reactivity	O
18	of	O
19	the	O
20	remaining	O
21	IgE	B
22	antibodies	I
23	was	O
24	determined	O
25	.	O

1	The	O
2	present	O
3	treatment	O
4	strategy	O
5	in	O
6	progressive	O
7	disorders	O
8	is	O
9	mainly	O
10	based	O
11	on	O
12	the	O
13	complementary	O
14	effect	O
15	of	O
16	intensive	O
17	radiochemotherapy	O
18	,	O
19	autologous	O
20	stem	O
21	-	O
22	cell	O
23	transplantation	O
24	and	O
25	the	O
26	rational	O
27	use	O
28	of	O
29	cytokines	O
30	,	O
31	mostly	O
32	colony	O
33	-	O
34	stimulating	O
35	factors	O
36	.	O

1	Pharmacokinetic	O
2	profile	O
3	of	O
4	clonazepam	O
5	in	O
6	rhesus	O
7	monkeys	O
8	.	O

1	Unfolding	O
2	can	O
3	be	O
4	described	O
5	by	O
6	a	O
7	two	O
8	-	O
9	state	O
10	process	O
11	since	O
12	a	O
13	ratio	O
14	of	O
15	delta	O
16	Hcalorimetric	O
17	to	O
18	delta	O
19	Hvan	O
20	'	O
21	t	O
22	Hoff	O
23	equals	O
24	0	O
25	.	O
26	96	O
27	.	O

1	Two	O
2	related	O
3	cDNAs	O
4	were	O
5	isolated	O
6	that	O
7	encode	O
8	proteins	O
9	that	O
10	recognize	O
11	the	O
12	XMyoDa	O
13	TATA	O
14	motif	O
15	.	O

1	XXI	O
2	.	O

1	The	O
2	HPLC	O
3	method	O
4	involves	O
5	an	O
6	octadecylsilane	O
7	column	O
8	at	O
9	55	O
10	degrees	O
11	C	O
12	,	O
13	a	O
14	mixture	O
15	of	O
16	water	O
17	-	O
18	acetonitrile	O
19	-	O
20	orthophosphoric	O
21	acid	O
22	(	O
23	779	O
24	:	O
25	220	O
26	:	O
27	1	O
28	,	O
29	v	O
30	/	O
31	v	O
32	)	O
33	as	O
34	mobile	O
35	phase	O
36	and	O
37	detection	O
38	at	O
39	226	O
40	nm	O
41	.	O

1	Influence	O
2	of	O
3	metoprolol	O
4	treatment	O
5	on	O
6	sympatho	O
7	-	O
8	adrenal	O
9	activation	O
10	of	O
11	fibrinolysis	O
12	.	O

1	After	O
2	one	O
3	accommodation	O
4	night	O
5	,	O
6	sleep	O
7	EEG	O
8	recordings	O
9	were	O
10	performed	O
11	during	O
12	three	O
13	consecutive	O
14	nights	O
15	in	O
16	ten	O
17	drug	O
18	-	O
19	free	O
20	inpatients	O
21	presenting	O
22	generalized	O
23	anxiety	O
24	disorder	O
25	(	O
26	GAD	O
27	)	O
28	with	O
29	significant	O
30	depression	O
31	,	O
32	compared	O
33	with	O
34	a	O
35	age	O
36	-	O
37	and	O
38	sex	O
39	-	O
40	matched	O
41	group	O
42	of	O
43	patients	O
44	with	O
45	GAD	O
46	and	O
47	a	O
48	group	O
49	of	O
50	primary	O
51	major	O
52	depressive	O
53	disorder	O
54	(	O
55	MDD	O
56	)	O
57	patients	O
58	.	O

1	Acquired	O
2	bile	O
3	duct	O
4	blockage	O
5	:	O
6	entry	O
7	of	O
8	hepatobiliary	O
9	agent	O
10	into	O
11	an	O
12	intrahepatic	O
13	abscess	O
14	.	O

1	This	O
2	last	O
3	includes	O
4	tissue	O
5	O2	O
6	transfer	O
7	(	O
8	Ft	O
9	')	O
10	and	O
11	mitochondrial	O
12	O2	O
13	utilization	O
14	(	O
15	Fm	O
16	').	O

1	These	O
2	results	O
3	imply	O
4	that	O
5	the	O
6	GCN3	O
7	product	O
8	can	O
9	promote	O
10	either	O
11	repression	O
12	or	O
13	activation	O
14	of	O
15	GCN4	B
16	expression	O
17	depending	O
18	on	O
19	amino	O
20	acid	O
21	availability	O
22	.	O

1	However	O
2	,	O
3	the	O
4	use	O
5	of	O
6	cyclosporin	O
7	A	O
8	is	O
9	associated	O
10	with	O
11	an	O
12	increased	O
13	prevalence	O
14	of	O
15	hypertension	O
16	in	O
17	kidney	O
18	transplant	O
19	recipients	O
20	.	O

1	The	O
2	nucleotide	O
3	sequence	O
4	of	O
5	the	O
6	region	O
7	upstream	O
8	from	O
9	M	O
10	.	O
11	voltae	O
12	ORFtrpA	O
13	was	O
14	determined	O
15	and	O
16	revealed	O
17	the	O
18	presence	O
19	of	O
20	an	O
21	ORF	O
22	of	O
23	1227	O
24	nucleotides	O
25	(	O
26	ORFtrpB	O
27	)	O
28	encoding	O
29	a	O
30	409	O
31	amino	O
32	acid	O
33	polypeptide	O
34	of	O
35	mol	O
36	.	O
37	wt	O
38	.	O

1	In	O
2	2	O
3	subjects	O
4	the	O
5	phytomitogen	O
6	reactivity	O
7	of	O
8	the	O
9	lymphocytes	O
10	was	O
11	improved	O
12	after	O
13	treatment	O
14	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	beta	B
6	-	I
7	1	I
8	may	O
9	act	O
10	as	O
11	a	O
12	tissue	O
13	-	O
14	specific	O
15	,	O
16	trans	O
17	-	O
18	acting	O
19	regulator	O
20	of	O
21	the	O
22	expression	O
23	of	O
24	the	O
25	beta	B
26	-	I
27	zein	I
28	gene	I
29	in	O
30	developing	O
31	maize	O
32	endosperm	O
33	.	O

1	Genetic	O
2	and	O
3	molecular	O
4	data	O
5	indicate	O
6	that	O
7	wild	O
8	-	O
9	type	O
10	Pan	O
11	and	O
12	CiD	O
13	compete	O
14	for	O
15	binding	O
16	to	O
17	Arm	O
18	,	O
19	leading	O
20	to	O
21	a	O
22	compromised	O
23	transduction	O
24	of	O
25	the	O
26	Wg	O
27	signal	O
28	in	O
29	heterozygous	O
30	ciD	O
31	/+	O
32	animals	O
33	and	O
34	to	O
35	a	O
36	dramatic	O
37	enhancement	O
38	of	O
39	the	O
40	gain	O
41	-	O
42	of	O
43	-	O
44	function	O
45	activity	O
46	of	O
47	CiD	O
48	in	O
49	homozygous	O
50	mutants	O
51	.	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	cynomolgus	O
6	monkeys	O
7	are	O
8	either	O
9	less	O
10	sensitive	O
11	or	O
12	respond	O
13	differently	O
14	than	O
15	rhesus	O
16	monkeys	O
17	to	O
18	some	O
19	of	O
20	the	O
21	pharmacological	O
22	effects	O
23	of	O
24	norcocaine	O
25	.	O

1	The	O
2	active	O
3	derivatives	O
4	of	O
5	the	O
6	present	O
7	series	O
8	were	O
9	also	O
10	tested	O
11	for	O
12	their	O
13	analgesic	O
14	activity	O
15	against	O
16	aconitine	O
17	-	O
18	induced	O
19	writhing	O
20	in	O
21	albino	O
22	mice	O
23	and	O
24	ulcerogenic	O
25	activity	O
26	in	O
27	albino	O
28	rats	O
29	.	O

1	Herein	O
2	,	O
3	we	O
4	show	O
5	that	O
6	Smad3	B
7	physically	O
8	interacts	O
9	with	O
10	the	O
11	HMG	B
12	box	I
13	domain	I
14	of	O
15	LEF1	O
16	and	O
17	that	O
18	TGFbeta	O
19	and	O
20	Wnt	B
21	pathways	O
22	synergize	O
23	to	O
24	activate	O
25	transcription	O
26	of	O
27	the	O
28	Xenopus	B
29	homeobox	I
30	gene	I
31	twin	O
32	(	O
33	Xtwn	O
34	).	O

1	To	O
2	investigate	O
3	the	O
4	molecular	O
5	mechanisms	O
6	of	O
7	this	O
8	Tax	B
9	-	O
10	mediated	O
11	inhibition	O
12	,	O
13	we	O
14	analyzed	O
15	its	O
16	effect	O
17	on	O
18	the	O
19	transcriptional	O
20	activity	O
21	of	O
22	the	O
23	myogenic	O
24	MyoD	B
25	protein	I
26	,	O
27	which	O
28	was	O
29	used	O
30	as	O
31	a	O
32	paradigm	O
33	of	O
34	bHLH	B
35	factors	I
36	.	O

1	Comparative	O
2	mapping	O
3	of	O
4	the	O
5	Brassica	O
6	S	O
7	locus	I
8	region	O
9	and	O
10	its	O
11	homeolog	O
12	in	O
13	Arabidopsis	O
14	.	O

1	We	O
2	conclude	O
3	that	O
4	c	B
5	-	I
6	Abl	I
7	activates	O
8	c	B
9	-	I
10	myc	I
11	transcription	O
12	indirectly	O
13	with	O
14	no	O
15	requirement	O
16	for	O
17	DNA	O
18	binding	O
19	by	O
20	c	B
21	-	I
22	Abl	I
23	.	O

1	For	O
2	228	O
3	of	O
4	425	O
5	deaths	O
6	(	O
7	54	O
8	%)	O
9	occurring	O
10	among	O
11	26	O
12	100	O
13	people	O
14	of	O
15	known	O
16	age	O
17	in	O
18	the	O
19	Malumfashi	O
20	area	O
21	of	O
22	northern	O
23	Nigeria	O
24	,	O
25	data	O
26	were	O
27	collected	O
28	on	O
29	symptoms	O
30	present	O
31	prior	O
32	to	O
33	death	O
34	.	O

1	Solitary	O
2	thyroid	O
3	nodule	O
4	.	O

1	Uroflowmetry	O
2	can	O
3	detect	O
4	dysuria	O
5	,	O
6	which	O
7	may	O
8	be	O
9	poorly	O
10	perceived	O
11	or	O
12	even	O
13	unknown	O
14	to	O
15	the	O
16	subjects	O
17	themselves	O
18	.	O

1	This	O
2	study	O
3	proposes	O
4	an	O
5	estimator	O
6	for	O
7	such	O
8	global	O
9	synchronizing	O
10	effects	O
11	upon	O
12	unit	O
13	-	O
14	pair	O
15	correlations	O
16	based	O
17	on	O
18	local	O
19	field	O
20	potentials	O
21	(	O
22	LFPs	O
23	).	O

1	PULSE	O
2	is	O
3	used	O
4	to	O
5	set	O
6	such	O
7	NMR	O
8	spectroscopic	O
9	parameters	O
10	as	O
11	the	O
12	delay	O
13	and	O
14	duration	O
15	of	O
16	rf	O
17	transmit	O
18	and	O
19	receive	O
20	gates	O
21	,	O
22	rf	O
23	phase	O
24	,	O
25	sampling	O
26	times	O
27	,	O
28	and	O
29	such	O
30	imaging	O
31	parameters	O
32	as	O
33	rf	O
34	pulse	O
35	shape	O
36	and	O
37	gradient	O
38	waveforms	O
39	.	O

1	Concordantly	O
2	,	O
3	it	O
4	was	O
5	shown	O
6	that	O
7	the	O
8	dnHLH	B
9	protein	I
10	Id1	O
11	inhibits	O
12	differentiation	O
13	of	O
14	muscle	O
15	and	O
16	myeloid	O
17	cells	O
18	in	O
19	vitro	O
20	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	also	O
6	constructed	O
7	and	O
8	expressed	O
9	chimeric	O
10	fusion	O
11	protein	O
12	that	O
13	contains	O
14	HIV	O
15	-	O
16	2	I
17	gag	I
18	with	O
19	V3	B
20	domains	O
21	of	O
22	HIV	O
23	-	O
24	1IIIB	O
25	,	O
26	HIV	O
27	-	O
28	1MN	O
29	,	O
30	HIV	O
31	-	O
32	1SF2	O
33	and	O
34	HIV	O
35	-	O
36	1RF	O
37	.	O

1	The	O
2	5	O
3	-	O
4	year	O
5	OS	O
6	for	O
7	stage	O
8	IIIB	O
9	was	O
10	30	O
11	.	O
12	9	O
13	%,	O
14	compared	O
15	to	O
16	7	O
17	.	O
18	8	O
19	%	O
20	for	O
21	stage	O
22	IV	O
23	.	O

1	We	O
2	propose	O
3	that	O
4	noi	O
5	/	O
6	pax2	O
7	.	O
8	1	O
9	participates	O
10	in	O
11	sequential	O
12	signaling	O
13	processes	O
14	as	O
15	a	O
16	key	O
17	integrator	O
18	of	O
19	midbrain	O
20	-	O
21	hindbrain	O
22	boundary	O
23	development	O
24	.	O

1	The	O
2	antibody	O
3	titer	O
4	of	O
5	202	O
6	chickens	O
7	to	O
8	SA	O
9	-	O
10	11	O
11	rotavirus	O
12	was	O
13	determined	O
14	by	O
15	enzyme	O
16	-	O
17	linked	O
18	immunosorbent	O
19	blocking	O
20	assay	O
21	.	O

1	Northern	O
2	blotting	O
3	analysis	O
4	indicates	O
5	that	O
6	expression	O
7	of	O
8	the	O
9	genes	O
10	corresponding	O
11	to	O
12	these	O
13	clones	O
14	is	O
15	confined	O
16	to	O
17	pollen	O
18	tissue	O
19	.	O

1	In	O
2	this	O
3	regard	O
4	,	O
5	we	O
6	have	O
7	recently	O
8	observed	O
9	that	O
10	a	O
11	constitutively	O
12	active	O
13	G	B
14	protein	I
15	-	I
16	coupled	I
17	receptor	I
18	(	O
19	GPCR	B
20	)	O
21	encoded	O
22	by	O
23	the	O
24	Kaposi	O
25	'	O
26	s	O
27	sarcoma	O
28	-	O
29	associated	O
30	herpes	O
31	virus	O
32	(	O
33	KSHV	O
34	)/	O
35	human	O
36	herpes	I
37	virus	I
38	8	I
39	is	O
40	oncogenic	O
41	and	O
42	stimulates	O
43	angiogenesis	O
44	by	O
45	increasing	O
46	the	O
47	secretion	O
48	of	O
49	vascular	B
50	endothelial	I
51	growth	I
52	factor	I
53	(	O
54	VEGF	B
55	),	O
56	which	O
57	is	O
58	a	O
59	key	O
60	angiogenic	O
61	stimulator	O
62	and	O
63	a	O
64	critical	O
65	mitogen	O
66	for	O
67	the	O
68	development	O
69	of	O
70	Kaposi	O
71	'	O
72	s	O
73	sarcoma	O
74	.	O

1	In	O
2	addition	O
3	to	O
4	protein	O
5	binding	O
6	at	O
7	sequences	O
8	known	O
9	to	O
10	be	O
11	involved	O
12	in	O
13	the	O
14	regulation	O
15	of	O
16	transcription	O
17	,	O
18	genomic	O
19	footprinting	O
20	of	O
21	the	O
22	entire	O
23	promoter	O
24	region	O
25	also	O
26	showed	O
27	that	O
28	a	O
29	protein	O
30	factor	O
31	is	O
32	constitutively	O
33	bound	O
34	to	O
35	the	O
36	first	O
37	intron	O
38	of	O
39	the	O
40	rep3	B
41	gene	I
42	.	O

1	No	O
2	relevant	O
3	changes	O
4	in	O
5	heart	O
6	rate	O
7	,	O
8	body	O
9	weight	O
10	,	O
11	and	O
12	plasma	O
13	levels	O
14	of	O
15	renin	B
16	activity	O
17	and	O
18	aldosterone	O
19	concentration	O
20	were	O
21	observed	O
22	.	O

1	Comparison	O
2	with	O
3	the	O
4	bovine	B
5	gene	O
6	showed	O
7	that	O
8	the	O
9	5	O
10	'-	O
11	flanking	O
12	region	O
13	of	O
14	the	O
15	hATP1	B
16	gene	O
17	has	O
18	an	O
19	unconserved	O
20	guanine	O
21	-	O
22	cytosine	O
23	(	O
24	GC	O
25	)	O
26	rich	O
27	region	O
28	,	O
29	including	O
30	several	O
31	binding	O
32	motifs	O
33	of	O
34	transcriptional	O
35	factors	O
36	,	O
37	such	O
38	as	O
39	Sp1	B
40	,	O
41	AP	B
42	-	I
43	2	I
44	,	O
45	and	O
46	GCF	O
47	.	O

1	This	O
2	sequence	O
3	is	O
4	very	O
5	similar	O
6	to	O
7	the	O
8	insulin	B
9	response	O
10	sequence	O
11	found	O
12	in	O
13	the	O
14	regulatory	O
15	region	O
16	of	O
17	other	O
18	genes	O
19	negatively	O
20	regulated	O
21	by	O
22	insulin	B
23	such	O
24	as	O
25	those	O
26	encoding	O
27	phosphoenolpyruvate	B
28	carboxykinase	I
29	,	I
30	tyrosine	B
31	aminotransferase	I
32	,	O
33	and	O
34	insulin	B
35	-	I
36	like	I
37	growth	I
38	factor	I
39	-	I
40	binding	I
41	protein	I
42	1	I
43	.	O

1	Rats	O
2	with	O
3	one	O
4	olfactory	O
5	bulb	O
6	removed	O
7	and	O
8	the	O
9	contralateral	O
10	naris	O
11	closed	O
12	can	O
13	detect	O
14	odors	O
15	.	O

1	The	O
2	repression	O
3	domain	O
4	,	O
5	and	O
6	indeed	O
7	the	O
8	entire	O
9	Cdc68	B
10	protein	O
11	,	O
12	is	O
13	highly	O
14	conserved	O
15	,	O
16	as	O
17	shown	O
18	by	O
19	the	O
20	sequence	O
21	of	O
22	the	O
23	Cdc68	O
24	functional	O
25	homolog	O
26	from	O
27	the	O
28	yeast	O
29	Kluyveromyces	O
30	lactis	O
31	and	O
32	by	O
33	database	O
34	searches	O
35	.	O

1	The	O
2	LMW	O
3	FGF	B
4	-	I
5	2	I
6	up	O
7	-	O
8	regulated	O
9	the	O
10	PKC	B
11	epsilon	I
12	levels	O
13	by	O
14	1	O
15	.	O
16	6	O
17	-	O
18	fold	O
19	;	O
20	by	O
21	contrast	O
22	the	O
23	HMW	O
24	isoform	O
25	down	O
26	-	O
27	regulated	O
28	the	O
29	level	O
30	of	O
31	this	O
32	PKC	B
33	isotype	I
34	by	O
35	about	O
36	3	O
37	-	O
38	fold	O
39	and	O
40	increased	O
41	the	O
42	amount	O
43	of	O
44	PKC	B
45	delta	I
46	by	O
47	1	O
48	.	O
49	7	O
50	-	O
51	fold	O
52	.	O

1	Role	O
2	of	O
3	superoxide	B
4	dismutase	I
5	in	O
6	cellular	O
7	oxidative	O
8	processes	O
9	and	O
10	method	O
11	of	O
12	its	O
13	determination	O
14	in	O
15	biological	O
16	materials	O

1	Practical	O
2	use	O
3	and	O
4	interpretation	O
5	of	O
6	viral	O
7	hepatitis	O
8	B	O
9	markers	O
10	and	O
11	hepatic	O
12	biopsy	O
13	in	O
14	HBs	B
15	Ag	I
16	carriers	O
17	and	O
18	at	O
19	the	O
20	chronic	O
21	hepatitis	O
22	stage	O

1	PBSX	O
2	is	O
3	induced	O
4	by	O
5	agents	O
6	which	O
7	elicit	O
8	the	O
9	SOS	O
10	response	O
11	.	O

1	The	O
2	availability	O
3	of	O
4	sequence	O
5	from	O
6	multiple	O
7	species	O
8	has	O
9	permitted	O
10	us	O
11	to	O
12	determine	O
13	that	O
14	the	O
15	UBE	B
16	site	I
17	has	O
18	close	O
19	similarity	O
20	to	O
21	motifs	O
22	that	O
23	bind	O
24	members	O
25	of	O
26	the	O
27	NF	B
28	-	I
29	1	I
30	family	I
31	of	O
32	transcription	O
33	factors	O
34	.	O

1	Experimental	O
2	adhesion	O
3	prophylaxis	O
4	with	O
5	recombinant	B
6	tissue	B
7	plasminogen	I
8	activator	I
9	.	O

1	In	O
2	the	O
3	commercially	O
4	available	O
5	intravenous	O
6	formulation	O
7	of	O
8	Cyclosporin	O
9	A	O
10	(	O
11	Sandimmun	O
12	),	O
13	polyoxyethylated	O
14	castor	O
15	oil	O
16	(	O
17	Cremophor	O
18	EL	O
19	)	O
20	is	O
21	used	O
22	as	O
23	a	O
24	solubilizing	O
25	agent	O
26	.	O

1	Moreover	O
2	,	O
3	radiolabeled	O
4	EFI	O
5	,	O
6	NF	B
7	-	I
8	Y	I
9	,	O
10	or	O
11	CBF	O
12	DNAs	O
13	give	O
14	rise	O
15	to	O
16	identical	O
17	gel	O
18	retardation	O
19	patterns	O
20	in	O
21	extracts	O
22	from	O
23	a	O
24	variety	O
25	of	O
26	different	O
27	cell	O
28	types	O
29	.	O

1	Pol32Delta	O
2	strains	O
3	are	O
4	weak	O
5	antimutators	O
6	and	O
7	are	O
8	defective	O
9	for	O
10	damage	O
11	-	O
12	induced	O
13	mutagenesis	O
14	.	O

1	Gel	O
2	mobility	O
3	shift	O
4	assays	O
5	using	O
6	a	O
7	synthetic	O
8	E6	O
9	motif	O
10	detected	O
11	a	O
12	B	O
13	-	O
14	cell	O
15	-	O
16	specific	O
17	complex	O
18	in	O
19	addition	O
20	to	O
21	a	O
22	ubiquitous	O
23	band	O
24	found	O
25	also	O
26	in	O
27	T	O
28	cells	O
29	and	O
30	HeLa	O
31	cells	O
32	.	O

1	On	O
2	the	O
3	amount	O
4	and	O
5	significance	O
6	of	O
7	the	O
8	effective	O
9	glucose	O
10	level	O
11	in	O
12	tumors	O
13	.	O

1	Crosstalk	O
2	among	O
3	the	O
4	pathways	O
5	may	O
6	explain	O
7	how	O
8	some	O
9	forms	O
10	of	O
11	stress	O
12	can	O
13	contribute	O
14	to	O
15	the	O
16	development	O
17	of	O
18	a	O
19	malignancy	O
20	.	O

1	Marked	O
2	hemolysis	O
3	significantly	O
4	increased	O
5	plasma	O
6	values	O
7	of	O
8	potassium	O
9	,	O
10	phosphorus	O
11	,	O
12	total	O
13	protein	O
14	,	O
15	and	O
16	aspartate	B
17	aminotransferase	I
18	.	O

1	In	O
2	contrast	O
3	with	O
4	the	O
5	previously	O
6	reported	O
7	HMGR1	B
8	mRNA	I
9	(	O
10	HMGR1S	O
11	mRNA	O
12	),	O
13	which	O
14	is	O
15	detected	O
16	at	O
17	high	O
18	levels	O
19	in	O
20	all	O
21	tissues	O
22	of	O
23	the	O
24	plant	O
25	,	O
26	HMGR1L	O
27	mRNA	O
28	is	O
29	present	O
30	at	O
31	relatively	O
32	low	O
33	levels	O
34	and	O
35	its	O
36	expression	O
37	is	O
38	restricted	O
39	mostly	O
40	to	O
41	seedlings	O
42	,	O
43	roots	O
44	and	O
45	inflorescences	O
46	.	O

1	You	O
2	make	O
3	the	O
4	diagnosis	O
5	.	O

1	Seventy	O
2	-	O
3	two	O
4	of	O
5	73	O
6	negative	O
7	controls	O
8	and	O
9	all	O
10	positive	O
11	blocks	O
12	as	O
13	seen	O
14	on	O
15	soft	O
16	tissue	O
17	radiographs	O
18	(	O
19	STRs	O
20	)	O
21	were	O
22	correctly	O
23	coded	O
24	(	O
25	specificity	O
26	98	O
27	.	O
28	6	O
29	%,	O
30	sensitivity	O
31	100	O
32	%).	O

1	Significant	O
2	correlations	O
3	were	O
4	obtained	O
5	between	O
6	changes	O
7	in	O
8	SSEP	O
9	in	O
10	response	O
11	to	O
12	AS	O
13	and	O
14	the	O
15	presence	O
16	of	O
17	not	O
18	deep	O
19	residual	O
20	-	O
21	organic	O
22	disturbances	O
23	,	O
24	so	O
25	-	O
26	called	O
27	"	O
28	ground	O
29	"	O
30	in	O
31	psychogenic	O
32	disorders	O
33	.	O

1	There	O
2	is	O
3	no	O
4	TATA	O
5	box	O
6	appropriately	O
7	spaced	O
8	upstream	O
9	from	O
10	the	O
11	transcription	O
12	initiation	O
13	site	O
14	.	O

1	Issues	O
2	of	O
3	distribution	O
4	of	O
5	kinetic	O
6	energy	O
7	of	O
8	traumatizing	O
9	object	O
10	in	O
11	direct	O
12	contact	O
13	interaction	O
14	with	O
15	head	O
16	during	O
17	impact	O
18	are	O
19	discussed	O
20	from	O
21	position	O
22	of	O
23	biomechanics	O
24	.	O

1	When	O
2	the	O
3	entire	O
4	diet	O
5	consisted	O
6	of	O
7	SBF	B
8	,	O
9	voluntary	O
10	feed	O
11	intake	O
12	was	O
13	reduced	O
14	,	O
15	indicating	O
16	that	O
17	SBF	B
18	should	O
19	not	O
20	be	O
21	fed	O
22	to	O
23	ponies	O
24	as	O
25	the	O
26	sole	O
27	dietary	O
28	ingredient	O
29	.	O

1	Epididymal	O
2	growth	O
3	was	O
4	retarded	O
5	in	O
6	animals	O
7	maintained	O
8	solely	O
9	on	O
10	chickpea	O
11	haulm	O
12	and	O
13	improved	O
14	with	O
15	supplementation	O
16	.	O

1	A	O
2	new	O
3	vector	O
4	,	O
5	pHBK280	O
6	,	O
7	was	O
8	designed	O
9	to	O
10	facilitate	O
11	this	O
12	analysis	O
13	.	O

1	Based	O
2	on	O
3	these	O
4	results	O
5	,	O
6	a	O
7	new	O
8	model	O
9	for	O
10	the	O
11	regulation	O
12	of	O
13	nif	B
14	/	O
15	fix	I
16	gene	I
17	expression	O
18	in	O
19	A	O
20	.	O
21	caulinodans	O
22	is	O
23	proposed	O
24	.	O

1	The	O
2	human	O
3	immunodeficiency	O
4	virus	O
5	type	I
6	1	I
7	(	O
8	HIV	B
9	-	I
10	1	I
11	)	O
12	Rev	B
13	protein	I
14	is	O
15	a	O
16	positive	O
17	posttranscriptional	O
18	regulator	O
19	of	O
20	viral	O
21	structural	O
22	gene	O
23	expression	O
24	and	O
25	essential	O
26	for	O
27	virus	O
28	replication	O
29	.	O

1	Despite	O
2	an	O
3	overall	O
4	survival	O
5	rate	O
6	of	O
7	43	O
8	%,	O
9	survival	O
10	to	O
11	discharge	O
12	varied	O
13	greatly	O
14	(	O
15	0	O
16	to	O
17	100	O
18	%)	O
19	among	O
20	the	O
21	24	O
22	diagnostic	O
23	groups	O
24	:	O
25	tumor	O
26	lysis	O
27	syndrome	O
28	and	O
29	systemic	O
30	lupus	O
31	erythematosus	O
32	(	O
33	3	O
34	/	O
35	3	O
36	patients	O
37	each	O
38	,	O
39	100	O
40	%),	O
41	hemolytic	O
42	uremic	O
43	syndrome	O
44	(	O
45	8	O
46	/	O
47	9	O
48	patients	O
49	,	O
50	89	O
51	%).	O

1	Nature	O
2	398	O
3	,	O
4	828	O
5	-	O
6	830	O
7	)	O
8	that	O
9	the	O
10	amino	O
11	acid	O
12	sequences	O
13	of	O
14	peptide	O
15	fragments	O
16	obtained	O
17	from	O
18	a	O
19	polypeptide	O
20	found	O
21	in	O
22	a	O
23	complex	O
24	of	O
25	proteins	O
26	that	O
27	alters	O
28	chromatin	O
29	structure	O
30	(	O
31	ARC	B
32	)	O
33	are	O
34	identical	O
35	to	O
36	portions	O
37	of	O
38	the	O
39	deduced	O
40	open	O
41	reading	O
42	frame	O
43	of	O
44	TIG	B
45	-	I
46	1	I
47	mRNA	I
48	.	O

1	Serum	B
2	alkaline	I
3	phosphatase	I
4	activity	O
5	,	O
6	bone	O
7	mass	O
8	measurements	O
9	,	O
10	dual	O
11	energy	O
12	x	O
13	-	O
14	ray	O
15	absortiometric	O
16	analysis	O
17	of	O
18	mineral	O
19	density	O
20	,	O
21	and	O
22	mechanical	O
23	testing	O
24	values	O
25	in	O
26	vertebrae	O
27	and	O
28	femora	O
29	of	O
30	the	O
31	-	O
32	D	O
33	Sal	O
34	animals	O
35	did	O
36	not	O
37	significantly	O
38	differ	O
39	from	O
40	those	O
41	in	O
42	+	O
43	D	O
44	Sal	O
45	animals	O
46	.	O

1	CONCLUSION	O
2	:	O
3	In	O
4	our	O
5	animal	O
6	model	O
7	,	O
8	blood	O
9	-	O
10	brain	O
11	barrier	O
12	disruption	O
13	was	O
14	a	O
15	reproducible	O
16	,	O
17	integral	O
18	finding	O
19	of	O
20	single	O
21	-	O
22	fraction	O
23	,	O
24	high	O
25	-	O
26	dose	O
27	irradiation	O
28	injury	O
29	.	O

1	Sodium	O
2	restriction	O
3	in	O
4	cardiac	O
5	failure	O
6	.	O

1	Neither	O
2	model	O
3	,	O
4	as	O
5	applied	O
6	,	O
7	provided	O
8	a	O
9	satisfactory	O
10	account	O
11	of	O
12	the	O
13	effects	O
14	of	O
15	the	O
16	main	O
17	variables	O
18	of	O
19	number	O
20	of	O
21	tones	O
22	and	O
23	amount	O
24	of	O
25	perturbation	O
26	.(	O
27	ABSTRACT	O
28	TRUNCATED	O
29	AT	O
30	400	O
31	WORDS	O
32	)	O

1	Substantial	O
2	amounts	O
3	of	O
4	liposomal	O
5	ampicillin	O
6	were	O
7	recovered	O
8	from	O
9	isolated	O
10	Kupffer	O
11	cells	O
12	,	O
13	the	O
14	target	O
15	cells	O
16	of	O
17	L	O
18	.	O
19	monocytogenes	O
20	after	O
21	intravenous	O
22	inoculation	O
23	.	O

1	Renal	O
2	response	O
3	to	O
4	captopril	O
5	in	O
6	severe	O
7	heart	O
8	failure	O
9	:	O
10	role	O
11	of	O
12	furosemide	O
13	in	O
14	natriuresis	O
15	and	O
16	reversal	O
17	of	O
18	hyponatremia	O
19	.	O

1	In	O
2	addition	O
3	to	O
4	its	O
5	effect	O
6	in	O
7	augmenting	O
8	the	O
9	neutrophil	O
10	response	O
11	to	O
12	eccentric	O
13	exercise	O
14	,	O
15	vitamin	O
16	E	O
17	causes	O
18	a	O
19	greater	O
20	increase	O
21	in	O
22	circulating	O
23	creatine	B
24	kinase	I
25	activity	O
26	,	O
27	perhaps	O
28	indicating	O
29	increased	O
30	skeletal	O
31	muscle	O
32	repair	O
33	.	O

1	Analysis	O
2	of	O
3	SRE	O
4	oligonucleotide	O
5	gel	O
6	mobility	O
7	shift	O
8	assays	O
9	with	O
10	nuclear	O
11	extracts	O
12	from	O
13	Sertoli	O
14	cells	O
15	demonstrated	O
16	the	O
17	presence	O
18	of	O
19	both	O
20	the	O
21	SRF	B
22	and	O
23	the	O
24	ubiquitously	O
25	expressed	O
26	bHLH	B
27	protein	I
28	E12	B
29	/	O
30	E47	O
31	.	O

1	The	O
2	concentrations	O
3	of	O
4	C4	O
5	and	O
6	C1	B
7	-	O
8	INH	O
9	increased	O
10	with	O
11	advancing	O
12	stage	O
13	of	O
14	disease	O
15	and	O
16	were	O
17	above	O
18	normal	O
19	mean	O
20	values	O
21	in	O
22	all	O
23	stages	O
24	.	O

1	Our	O
2	findings	O
3	support	O
4	the	O
5	view	O
6	of	O
7	a	O
8	multifactorial	O
9	genesis	O
10	of	O
11	the	O
12	cardiac	O
13	involvement	O
14	in	O
15	uremic	O
16	patients	O
17	.	O

1	Conservative	O
2	treatment	O
3	of	O
4	bladder	O
5	carcinoma	O
6	by	O
7	partial	O
8	cystectomy	O
9	and	O
10	interstitial	O
11	iridium	O
12	192	O
13	.	O

1	Retreatment	O
2	of	O
3	these	O
4	2	O
5	dogs	O
6	resulted	O
7	in	O
8	a	O
9	similar	O
10	,	O
11	but	O
12	blunted	O
13	,	O
14	response	O
15	to	O
16	human	B
17	immunoglobulin	I
18	.	O

1	It	O
2	encodes	O
3	a	O
4	protein	O
5	with	O
6	three	O
7	zinc	O
8	fingers	O
9	similar	O
10	to	O
11	those	O
12	of	O
13	the	O
14	transcription	O
15	factor	I
16	Sp1	B
17	.	O

1	Whole	O
2	blood	O
3	serotonin	O
4	levels	O
5	were	O
6	investigated	O
7	in	O
8	a	O
9	control	O
10	group	O
11	(	O
12	n	O
13	=	O
14	35	O
15	)	O
16	and	O
17	in	O
18	a	O
19	group	O
20	of	O
21	chronic	O
22	renal	O
23	failure	O
24	patients	O
25	(	O
26	n	O
27	=	O
28	127	O
29	)	O
30	on	O
31	various	O
32	treatment	O
33	regimen	O
34	i	O
35	.	O
36	e	O
37	.	O
38	conservative	O
39	treatment	O
40	(	O
41	n	O
42	=	O
43	39	O
44	),	O
45	maintenance	O
46	haemodialysis	O
47	(	O
48	n	O
49	=	O
50	35	O
51	)	O
52	and	O
53	after	O
54	renal	O
55	transplantation	O
56	(	O
57	n	O
58	=	O
59	53	O
60	).	O

1	Reward	O
2	value	O
3	of	O
4	prosodic	O
5	features	O
6	of	O
7	language	O
8	for	O
9	autistic	O
10	,	O
11	mentally	O
12	retarded	O
13	,	O
14	and	O
15	normal	O
16	children	O
17	.	O

1	Furthermore	O
2	,	O
3	the	O
4	validity	O
5	of	O
6	this	O
7	new	O
8	subset	O
9	of	O
10	questions	O
11	was	O
12	shown	O
13	to	O
14	be	O
15	significant	O
16	(	O
17	r	O
18	=	O
19	0	O
20	.	O
21	037	O
22	,	O
23	p	O
24	<	O
25	0	O
26	.	O
27	05	O
28	)	O
29	for	O
30	the	O
31	correlation	O
32	between	O
33	a	O
34	measure	O
35	of	O
36	the	O
37	severity	O
38	of	O
39	binocular	O
40	visual	O
41	field	O
42	loss	O
43	and	O
44	the	O
45	mean	O
46	score	O
47	of	O
48	the	O
49	variables	O
50	used	O
51	in	O
52	the	O
53	glaucoma	O
54	specific	O
55	subgroup	O
56	of	O
57	questions	O
58	.	O

1	Prolonged	O
2	suspension	O
3	induced	O
4	a	O
5	significant	O
6	change	O
7	in	O
8	the	O
9	geometric	O
10	configuration	O
11	of	O
12	the	O
13	femur	O
14	middiaphysis	O
15	by	O
16	increasing	O
17	the	O
18	minimum	O
19	diameter	O
20	(	O
21	12	O
22	%)	O
23	without	O
24	any	O
25	significant	O
26	alterations	O
27	in	O
28	cortical	O
29	area	O
30	,	O
31	density	O
32	,	O
33	mineral	O
34	,	O
35	and	O
36	collagen	B
37	concentrations	O
38	.	O

1	This	O
2	is	O
3	based	O
4	on	O
5	partitioning	O
6	an	O
7	underlying	O
8	multivariate	O
9	normal	O
10	distribution	O
11	.	O

1	Using	O
2	a	O
3	MOS	O
4	-	O
5	Hypersil	O
6	reversed	O
7	-	O
8	phase	O
9	column	O
10	with	O
11	a	O
12	phosphate	O
13	buffer	O
14	--	O
15	acetonitrile	O
16	mobile	O
17	phase	O
18	,	O
19	baseline	O
20	separation	O
21	of	O
22	antipyrine	O
23	,	O
24	its	O
25	metabolites	O
26	3	O
27	-	O
28	hydroxymethylantipyrine	O
29	,	O
30	norantipyrine	O
31	and	O
32	4	O
33	-	O
34	hydroxyantipyrine	O
35	,	O
36	and	O
37	the	O
38	internal	O
39	standard	O
40	,	O
41	phenacetin	O
42	,	O
43	was	O
44	achieved	O
45	within	O
46	6	O
47	min	O
48	.	O

1	Both	O
2	HERV	O
3	-	O
4	K	O
5	type	O
6	1	I
7	and	O
8	2	O
9	clones	O
10	were	O
11	isolated	O
12	.	O

1	We	O
2	used	O
3	oligonucleotide	O
4	-	O
5	directed	O
6	mutagenesis	O
7	to	O
8	alter	O
9	a	O
10	site	O
11	in	O
12	MucA	O
13	homologous	O
14	to	O
15	the	O
16	Ala	O
17	-	O
18	Gly	O
19	cleavage	O
20	site	O
21	of	O
22	LexA	B
23	.	O

1	The	O
2	in	O
3	vitro	O
4	relaxivity	O
5	of	O
6	the	O
7	complex	O
8	is	O
9	16	O
10	.	O
11	24	O
12	s	O
13	(-	O
14	1	O
15	)	O
16	mM	O
17	(-	O
18	1	O
19	).	O

1	The	O
2	susceptibility	O
3	of	O
4	the	O
5	PPNG	O
6	strains	O
7	to	O
8	clinically	O
9	relevant	O
10	antibiotics	O
11	varied	O
12	with	O
13	the	O
14	plasmid	O
15	pattern	O
16	;	O
17	this	O
18	stresses	O
19	the	O
20	necessity	O
21	of	O
22	permanent	O
23	surveillance	O
24	of	O
25	gonococcal	O
26	infections	O
27	and	O
28	of	O
29	regular	O
30	evaluation	O
31	of	O
32	the	O
33	recommendations	O
34	for	O
35	antimicrobial	O
36	treatment	O
37	.	O

1	The	O
2	cDNAs	O
3	cross	O
4	-	O
5	hybridize	O
6	with	O
7	genomic	O
8	sequences	O
9	in	O
10	rat	O
11	,	O
12	human	O
13	,	O
14	and	O
15	chicken	O
16	DNA	O
17	,	O
18	but	O
19	not	O
20	with	O
21	DNA	O
22	from	O
23	frog	O
24	,	O
25	Drosophila	O
26	,	O
27	or	O
28	sea	O
29	urchin	O
30	.	O

1	However	O
2	,	O
3	the	O
4	rtFc	B
5	gamma	I
6	R	I
7	alpha	I
8	cDNA	I
9	clone	O
10	is	O
11	complementary	O
12	to	O
13	at	O
14	least	O
15	two	O
16	different	O
17	-	O
18	sized	O
19	mRNAs	O
20	expressed	O
21	by	O
22	CRNK	O
23	-	O
24	16	O
25	cells	O
26	,	O
27	contrasting	O
28	the	O
29	single	O
30	Fc	B
31	gamma	I
32	R	I
33	-	I
34	related	I
35	mRNA	O
36	species	O
37	expressed	O
38	by	O
39	human	O
40	and	O
41	mouse	O
42	natural	O
43	killer	O
44	cells	O
45	.	O

1	Salzburg	O
2	,	O
3	9	O
4	-	O
5	12	O
6	September	O
7	1987	O
8	.	O

1	Latanoprost	O
2	produces	O
3	an	O
4	additional	O
5	reduction	O
6	of	O
7	intraocular	O
8	pressure	O
9	(	O
10	IOP	O
11	)	O
12	when	O
13	used	O
14	in	O
15	combination	O
16	with	O
17	timolol	O
18	,	O
19	pilocarpine	O
20	,	O
21	acetazolamide	O
22	and	O
23	dipivefrin	O
24	.	O

1	A511	O
2	is	O
3	a	O
4	broad	O
5	-	O
6	host	O
7	-	O
8	range	O
9	,	O
10	virulent	O
11	myovirus	O
12	for	O
13	Listeria	O
14	monocytogenes	O
15	.	O

1	S	O
2	.,	O
3	and	O
4	Walter	O
5	,	O
6	P	O
7	.	O

1	RESULTS	O
2	:	O
3	Fournier	O
4	'	O
5	s	O
6	gangrene	O
7	occurs	O
8	worldwide	O
9	.	O

1	Absorption	O
2	varied	O
3	between	O
4	65	O
5	and	O
6	95	O
7	per	O
8	cent	O
9	,	O
10	with	O
11	a	O
12	mean	O
13	absorption	O
14	of	O
15	80	O
16	per	O
17	cent	O
18	,	O
19	in	O
20	both	O
21	pregnant	O
22	and	O
23	non	O
24	-	O
25	pregnant	O
26	subjects	O
27	.	O

1	The	O
2	possible	O
3	mechanisms	O
4	underlying	O
5	differences	O
6	in	O
7	post	O
8	-	O
9	tetanic	O
10	effects	O
11	from	O
12	muscle	O
13	and	O
14	cutaneous	O
15	afferents	O
16	in	O
17	adults	O
18	and	O
19	neonates	O
20	are	O
21	discussed	O
22	.	O

1	Sequence	O
2	analysis	O
3	of	O
4	these	O
5	regions	O
6	showed	O
7	a	O
8	CAAT	O
9	box	O
10	upstream	O
11	of	O
12	exon	O
13	1a	O
14	and	O
15	high	O
16	G	O
17	-	I
18	C	I
19	content	O
20	regions	O
21	within	O
22	both	O
23	P1	O
24	and	O
25	P2	O
26	.	O

1	Translation	O
2	of	O
3	specific	O
4	cellular	O
5	genes	O
6	from	O
7	the	O
8	chimeric	O
9	viral	O
10	-	O
11	cellular	O
12	transcripts	O
13	seems	O
14	to	O
15	be	O
16	unlikely	O
17	.	O

1	CPAP	O
2	reduced	O
3	isotime	O
4	(	O
5	defined	O
6	as	O
7	the	O
8	last	O
9	common	O
10	minute	O
11	of	O
12	exercise	O
13	)	O
14	VO2	O
15	and	O
16	dyspnea	O
17	in	O
18	those	O
19	patients	O
20	with	O
21	more	O
22	severe	O
23	lung	O
24	disease	O
25	,	O
26	but	O
27	these	O
28	values	O
29	tended	O
30	to	O
31	increase	O
32	slightly	O
33	in	O
34	the	O
35	patients	O
36	with	O
37	only	O
38	mild	O
39	lung	O
40	disease	O
41	.	O

1	In	O
2	support	O
3	of	O
4	a	O
5	role	O
6	at	O
7	the	O
8	spindle	O
9	,	O
10	two	O
11	-	O
12	hybrid	O
13	library	O
14	screening	O
15	with	O
16	HEF1	B
17	identifies	O
18	the	O
19	human	O
20	homolog	O
21	of	O
22	the	O
23	G2	O
24	/	O
25	M	O
26	spindle	O
27	-	I
28	regulatory	I
29	protein	I
30	Dim1p	I
31	as	O
32	a	O
33	specific	O
34	interactor	O
35	with	O
36	a	O
37	region	O
38	of	O
39	HEF1	B
40	encompassed	I
41	in	O
42	p55	B
43	(	O
44	HEF1	B
45	).	O

1	At	O
2	the	O
3	time	O
4	of	O
5	the	O
6	seizure	O
7	,	O
8	the	O
9	patient	O
10	was	O
11	asked	O
12	to	O
13	read	O
14	a	O
15	test	O
16	phrase	O
17	aloud	O
18	until	O
19	it	O
20	was	O
21	read	O
22	correctly	O
23	and	O
24	clearly	O
25	.	O

1	When	O
2	introduced	O
3	into	O
4	recJ	O
5	+	O
6	strains	O
7	,	O
8	srjA	O
9	mutations	O
10	conferred	O
11	hyperrecombinational	O
12	and	O
13	hyper	O
14	-	O
15	UVr	O
16	phenotypes	O
17	.	O

1	After	O
2	phosphorylation	O
3	,	O
4	STAT	B
5	proteins	I
6	are	O
7	transported	O
8	into	O
9	the	O
10	nucleus	O
11	and	O
12	exhibit	O
13	transcriptional	O
14	activity	O
15	.	O

1	Pseudomembranous	O
2	conjunctivitis	O
3	following	O
4	bone	O
5	marrow	O
6	transplantation	O
7	:	O
8	immunopathological	O
9	and	O
10	ultrastructural	O
11	study	O
12	of	O
13	one	O
14	case	O
15	.	O

1	Radiolabeled	O
2	recombinant	O
3	TARC	O
4	specifically	O
5	bound	O
6	to	O
7	T	O
8	cell	O
9	lines	O
10	and	O
11	peripheral	O
12	T	O
13	cells	O
14	but	O
15	not	O
16	to	O
17	monocytes	O
18	or	O
19	granulocytes	O
20	.	O

1	The	O
2	tissue	O
3	-	O
4	specific	O
5	expression	O
6	of	O
7	DP	B
8	family	I
9	members	O
10	suggests	O
11	that	O
12	the	O
13	combination	O
14	of	O
15	DP	B
16	/	O
17	E2F	B
18	heterodimers	O
19	that	O
20	constitute	O
21	DRTF1	O
22	/	O
23	E2F	B
24	is	O
25	influenced	O
26	by	O
27	the	O
28	phenotype	O
29	of	O
30	the	O
31	cell	O
32	.	O

1	Different	O
2	doses	O
3	of	O
4	15	O
5	-	O
6	methyl	O
7	-	O
8	PGF2	O
9	alpha	O
10	(	O
11	0	O
12	.	O
13	125	O
14	-	O
15	10	O
16	mg	O
17	)	O
18	were	O
19	used	O
20	to	O
21	induce	O
22	luteolysis	O
23	and	O
24	oestrus	O
25	in	O
26	7	O
27	heifers	O
28	with	O
29	28	O
30	treatments	O
31	on	O
32	day	O
33	8	O
34	-	O
35	12	O
36	of	O
37	the	O
38	oestrous	O
39	cycle	O
40	.	O

1	Calibration	O
2	and	O
3	a	O
4	correction	O
5	of	O
6	blood	O
7	O2	O
8	content	O
9	measured	O
10	by	O
11	Po2	O
12	and	O
13	CO	O
14	saturation	O
15	.	O

1	O2	O
2	and	O
3	CO2	O
4	in	O
5	the	O
6	tracheostomy	O
7	tube	O
8	were	O
9	continuously	O
10	monitored	O
11	by	O
12	mass	O
13	spectrometry	O
14	using	O
15	a	O
16	special	O
17	sample	O
18	-	O
19	hold	O
20	phase	O
21	-	O
22	locked	O
23	sampling	O
24	technique	O
25	.	O

1	The	O
2	effects	O
3	of	O
4	mean	O
5	luminance	O
6	were	O
7	also	O
8	measured	O
9	and	O
10	a	O
11	general	O
12	expression	O
13	that	O
14	would	O
15	take	O
16	them	O
17	into	O
18	account	O
19	was	O
20	derived	O
21	.	O

1	The	O
2	duration	O
3	of	O
4	diabetes	O
5	mellitus	O
6	in	O
7	these	O
8	patients	O
9	was	O
10	from	O
11	5	O
12	months	O
13	to	O
14	6	O
15	years	O
16	,	O
17	and	O
18	in	O
19	all	O
20	patients	O
21	this	O
22	was	O
23	the	O
24	first	O
25	myocardial	O
26	infarction	O
27	.	O

1	Eleven	O
2	healthy	O
3	,	O
4	normotensive	O
5	males	O
6	undergoing	O
7	routine	O
8	restorative	O
9	dental	O
10	care	O
11	were	O
12	evaluated	O
13	during	O
14	treatment	O
15	for	O
16	possible	O
17	hemodynamic	O
18	alterations	O
19	in	O
20	response	O
21	to	O
22	potential	O
23	sympathetic	O
24	nervous	O
25	system	O
26	stimulation	O
27	.	O

1	Both	O
2	parents	O
3	are	O
4	clinically	O
5	normal	O
6	and	O
7	unrelated	O
8	.	O

1	On	O
2	the	O
3	comparison	O
4	of	O
5	correlated	O
6	proportions	O
7	for	O
8	clustered	O
9	data	O
10	.	O

1	The	O
2	interaction	O
3	does	O
4	not	O
5	depend	O
6	on	O
7	the	O
8	presence	O
9	of	O
10	the	O
11	correct	O
12	amino	O
13	-	O
14	terminal	O
15	DNA	O
16	binding	O
17	domain	O
18	or	O
19	the	O
20	amino	O
21	acid	O
22	sequences	O
23	between	O
24	the	O
25	DNA	O
26	binding	O
27	domain	O
28	and	O
29	the	O
30	last	O
31	ten	O
32	amino	O
33	acids	O
34	.	O

1	In	O
2	Malmo	O
3	,	O
4	Sweden	O
5	,	O
6	17	O
7	,	O
8	181	O
9	school	O
10	children	O
11	born	O
12	in	O
13	the	O
14	years	O
15	1961	O
16	-	O
17	1965	O
18	were	O
19	screened	O
20	for	O
21	scoliosis	O
22	once	O
23	a	O
24	year	O
25	between	O
26	the	O
27	ages	O
28	of	O
29	7	O
30	and	O
31	16	O
32	years	O
33	,	O
34	during	O
35	1971	O
36	-	O
37	1980	O
38	.	O

1	These	O
2	genes	O
3	are	O
4	expressed	O
5	within	O
6	a	O
7	few	O
8	hours	O
9	of	O
10	the	O
11	initiation	O
12	of	O
13	development	O
14	;	O
15	their	O
16	mRNAs	O
17	accumulate	O
18	to	O
19	a	O
20	peak	O
21	at	O
22	12	O
23	hr	O
24	and	O
25	persist	O
26	until	O
27	culmination	O
28	.	O

1	The	O
2	E1	B
3	replication	O
4	protein	O
5	of	O
6	bovine	B
7	papillomavirus	O
8	type	O
9	1	O
10	contains	O
11	an	O
12	extended	O
13	nuclear	O
14	localization	O
15	signal	O
16	that	O
17	includes	O
18	a	O
19	p34cdc2	B
20	phosphorylation	O
21	site	O
22	.	O

1	Glutathione	B
2	S	I
3	-	I
4	transferase	I
5	(	O
6	GST	B
7	)-	O
8	E2F	B
9	and	O
10	GST	B
11	-	O
12	DP	O
13	fusion	O
14	proteins	O
15	were	O
16	found	O
17	to	O
18	cooperate	O
19	in	O
20	binding	O
21	to	O
22	the	O
23	three	O
24	E2F	B
25	sites	I
26	in	O
27	the	O
28	DNA	B
29	polymerase	I
30	alpha	I
31	gene	I
32	promoter	I
33	in	O
34	vitro	O
35	.	O

1	Previous	O
2	work	O
3	showed	O
4	that	O
5	repA	B
6	(	I
7	initiator	I
8	protein	I
9	)	O
10	expression	O
11	requires	O
12	tap	O
13	(	O
14	leader	O
15	peptide	O
16	)	O
17	translation	O
18	.	O

1	In	O
2	a	O
3	second	O
4	experiment	O
5	involving	O
6	an	O
7	18	O
8	-	O
9	h	O
10	lung	O
11	clearance	O
12	assay	O
13	,	O
14	we	O
15	used	O
16	the	O
17	mAb	B
18	3	O
19	.	O
20	2	O
21	.	O
22	3	O
23	to	O
24	deplete	O
25	rats	O
26	of	O
27	LGL	O
28	/	O
29	NK	O
30	cells	O
31	with	O
32	the	O
33	following	O
34	rationale	O
35	:	O
36	if	O
37	LGL	O
38	/	O
39	NK	O
40	cells	O
41	are	O
42	necessary	O
43	to	O
44	mediate	O
45	an	O
46	event	O
47	,	O
48	then	O
49	in	O
50	their	O
51	absence	O
52	,	O
53	that	O
54	event	O
55	should	O
56	not	O
57	occur	O
58	.	O

1	Although	O
2	it	O
3	is	O
4	well	O
5	known	O
6	that	O
7	calcium	O
8	channel	O
9	blockers	O
10	can	O
11	influence	O
12	contraction	O
13	of	O
14	vascular	O
15	smooth	O
16	muscle	O
17	,	O
18	there	O
19	is	O
20	less	O
21	knowledge	O
22	on	O
23	its	O
24	effect	O
25	on	O
26	excitation	O
27	contraction	O
28	coupling	O
29	in	O
30	the	O
31	endocrine	O
32	glands	O
33	and	O
34	more	O
35	specifically	O
36	on	O
37	insulin	B
38	and	O
39	glucagon	B
40	release	O
41	.	O

1	The	O
2	proteins	O
3	differ	O
4	in	O
5	the	O
6	presence	O
7	or	O
8	absence	O
9	of	O
10	a	O
11	21	O
12	-	O
13	amino	O
14	-	O
15	acid	O
16	sequence	O
17	located	O
18	24	O
19	amino	O
20	acids	O
21	C	O
22	terminal	O
23	of	O
24	the	O
25	translational	O
26	initiation	O
27	codon	O
28	.	O

1	Shift	O
2	-	O
3	down	O
4	experiments	O
5	indicated	O
6	that	O
7	the	O
8	10	O
9	(	O
10	4	O
11	)-	O
12	to	O
13	10	O
14	(	O
15	5	O
16	)-	O
17	fold	O
18	reduction	O
19	in	O
20	virus	O
21	yield	O
22	at	O
23	the	O
24	nonpermissive	O
25	temperature	O
26	was	O
27	due	O
28	to	O
29	the	O
30	disfunction	O
31	of	O
32	alpha	B
33	TIF	I
34	late	O
35	in	O
36	infection	O
37	,	O
38	presumably	O
39	in	O
40	virion	O
41	maturation	O
42	.	O

1	FISH	O
2	using	O
3	a	O
4	whole	O
5	chromosome	O
6	4	O
7	paint	O
8	demonstrated	O
9	multiple	O
10	rearrangements	O
11	involving	O
12	chromosome	O
13	4	O
14	in	O
15	MCF	O
16	-	O
17	7	O
18	AdVp3000	O
19	and	O
20	MCF	O
21	-	O
22	7	O
23	MX	O
24	,	O
25	while	O
26	S1	O
27	-	O
28	M1	O
29	-	O
30	80	O
31	contained	O
32	only	O
33	a	O
34	simple	O
35	reciprocal	O
36	translocation	O
37	.	O

1	To	O
2	study	O
3	the	O
4	regulation	O
5	of	O
6	its	O
7	expression	O
8	,	O
9	the	O
10	human	B
11	aldehyde	I
12	reductase	I
13	gene	I
14	and	O
15	promoter	O
16	were	O
17	cloned	O
18	and	O
19	characterized	O
20	.	O

1	The	O
2	pigment	O
3	intensity	O
4	of	O
5	both	O
6	melanized	O
7	colonies	O
8	and	O
9	appressoria	O
10	of	O
11	CAL	O
12	transformants	O
13	was	O
14	weaker	O
15	than	O
16	that	O
17	of	O
18	the	O
19	wild	O
20	type	O
21	.	O

1	The	O
2	rate	O
3	-	O
4	decreasing	O
5	effects	O
6	of	O
7	morphine	O
8	and	O
9	U50488	O
10	were	O
11	reversed	O
12	completely	O
13	by	O
14	a	O
15	0	O
16	.	O
17	01	O
18	and	O
19	1	O
20	.	O
21	0	O
22	mg	O
23	/	O
24	kg	O
25	dose	O
26	of	O
27	naloxone	O
28	,	O
29	respectively	O
30	.	O

1	Our	O
2	study	O
3	reveals	O
4	that	O
5	the	O
6	modular	O
7	structure	O
8	of	O
9	the	O
10	FSH	B
11	receptor	I
12	gene	I
13	generates	O
14	motifs	O
15	that	O
16	allows	O
17	coupling	O
18	to	O
19	different	O
20	effectors	O
21	.	O

1	Specific	O
2	binding	O
3	was	O
4	not	O
5	observed	O
6	with	O
7	either	O
8	the	O
9	orthologous	O
10	rat	O
11	or	O
12	mouse	O
13	fragments	O
14	using	O
15	human	O
16	or	O
17	rodent	O
18	extracts	O
19	.	O

1	Its	O
2	vasodilatory	O
3	,	O
4	anti	O
5	-	O
6	vasopressor	O
7	,	O
8	and	O
9	platelet	O
10	stabilizing	O
11	effects	O
12	could	O
13	be	O
14	expected	O
15	to	O
16	counteract	O
17	the	O
18	placental	O
19	ischemia	O
20	,	O
21	hypertension	O
22	and	O
23	excessive	O
24	coagulation	O
25	that	O
26	are	O
27	seen	O
28	in	O
29	pre	O
30	-	O
31	eclampsia	O
32	.	O

1	Comparisons	O
2	with	O
3	other	O
4	known	O
5	germins	O
6	and	O
7	germin	O
8	-	O
9	like	O
10	proteins	O
11	indicate	O
12	that	O
13	these	O
14	Arabidopsis	B
15	GLP	B
16	subfamilies	I
17	are	O
18	unique	O
19	from	O
20	wheat	B
21	germin	O
22	.	O

1	It	O
2	was	O
3	concluded	O
4	,	O
5	that	O
6	on	O
7	a	O
8	given	O
9	section	O
10	,	O
11	75	O
12	,	O
13	7	O
14	per	O
15	cent	O
16	of	O
17	the	O
18	trabeculae	O
19	were	O
20	in	O
21	contact	O
22	with	O
23	vascular	O
24	cavities	O
25	.	O

1	For	O
2	replication	O
3	reporter	O
4	constructs	O
5	where	O
6	E1	B
7	and	O
8	E2	B
9	are	O
10	supplied	O
11	in	O
12	trans	O
13	by	O
14	the	O
15	respective	O
16	expression	O
17	vectors	O
18	,	O
19	distance	O
20	between	O
21	the	O
22	half	O
23	sites	O
24	seems	O
25	to	O
26	play	O
27	a	O
28	major	O
29	role	O
30	,	O
31	yet	O
32	the	O
33	phasing	O
34	relationships	O
35	are	O
36	measurable	O
37	.	O

1	Mnt	B
2	:	O
3	Max	B
4	complexes	O
5	also	O
6	efficiently	O
7	suppress	O
8	Myc	B
9	-	I
10	dependent	O
11	activation	O
12	from	O
13	the	O
14	same	O
15	promoter	O
16	.	O

1	Elimination	O
2	of	O
3	bagassosis	O
4	in	O
5	Louisiana	O
6	paper	O
7	manufacturing	O
8	plant	O
9	workers	O
10	.	O

1	The	O
2	regional	O
3	blockade	O
4	of	O
5	H1R	O
6	was	O
7	observed	O
8	mainly	O
9	in	O
10	the	O
11	frontal	O
12	,	O
13	temporal	O
14	and	O
15	anterior	O
16	cingulate	O
17	cortices	O
18	,	O
19	and	O
20	the	O
21	intravenous	O
22	administration	O
23	of	O
24	d	O
25	-	O
26	chlorpheniramine	O
27	as	O
28	a	O
29	therapeutic	O
30	dose	O
31	(	O
32	2	O
33	mg	O
34	)	O
35	blocked	O
36	over	O
37	60	O
38	%	O
39	of	O
40	H1R	O
41	in	O
42	the	O
43	frontal	O
44	cortices	O
45	.	O

1	Antihistamines	O
2	in	O
3	asthma	O
4	.	O

1	Electroglottography	O
2	is	O
3	a	O
4	useful	O
5	,	O
6	non	O
7	-	O
8	invasive	O
9	technique	O
10	that	O
11	can	O
12	assist	O
13	in	O
14	the	O
15	assessment	O
16	of	O
17	vocal	O
18	fold	O
19	dysfunction	O
20	.	O

1	Transcriptional	O
2	control	O
3	of	O
4	a	O
5	nuclear	O
6	gene	O
7	encoding	O
8	a	O
9	mitochondrial	O
10	fatty	I
11	acid	I
12	oxidation	O
13	enzyme	O
14	in	O
15	transgenic	O
16	mice	O
17	:	O
18	role	O
19	for	O
20	nuclear	O
21	receptors	O
22	in	O
23	cardiac	O
24	and	O
25	brown	O
26	adipose	O
27	expression	O
28	.	O

1	In	O
2	addition	O
3	,	O
4	negatively	O
5	regulatory	O
6	region	O
7	may	O
8	exist	O
9	from	O
10	-	O
11	1782	O
12	to	O
13	-	O
14	1295	O
15	bp	O
16	.	O

1	Sixty	O
2	-	O
3	five	O
4	patients	O
5	(	O
6	aged	O
7	between	O
8	3	O
9	years	O
10	5	O
11	months	O
12	and	O
13	60	O
14	years	O
15	)	O
16	suffering	O
17	from	O
18	medically	O
19	resistant	O
20	temporal	O
21	lobe	O
22	epilepsy	O
23	(	O
24	TLE	O
25	)	O
26	were	O
27	operated	O
28	on	O
29	over	O
30	a	O
31	period	O
32	of	O
33	33	O
34	months	O
35	in	O
36	Bethel	O
37	Epilepsy	O
38	Center	O
39	.	O

1	This	O
2	hypothesis	O
3	is	O
4	consistent	O
5	with	O
6	the	O
7	occurrence	O
8	of	O
9	PEA3	B
10	binding	I
11	sites	I
12	in	O
13	the	O
14	PEA3	B
15	promoter	I
16	and	O
17	with	O
18	the	O
19	ability	O
20	of	O
21	PEA3	B
22	to	O
23	transactivate	O
24	this	O
25	promoter	O
26	.	O

1	The	O
2	two	O
3	IL6	B
4	mRNA	I
5	species	O
6	are	O
7	generated	O
8	by	O
9	alternative	O
10	polyadenylation	O
11	at	O
12	sites	O
13	separated	O
14	by	O
15	a	O
16	distance	O
17	of	O
18	1	O
19	.	O
20	2	O
21	kilobases	O
22	.	O

1	The	O
2	active	O
3	open	O
4	reading	O
5	frame	O
6	in	O
7	the	O
8	clone	O
9	maps	O
10	at	O
11	27	O
12	min	O
13	on	O
14	the	O
15	E	O
16	.	O
17	coli	O
18	chromosome	O
19	and	O
20	is	O
21	identical	O
22	in	O
23	sequence	O
24	to	O
25	a	O
26	wild	O
27	type	O
28	counterpart	O
29	.	O

1	Both	O
2	antidepressants	O
3	elevated	O
4	the	O
5	pain	O
6	threshold	O
7	acutely	O
8	,	O
9	while	O
10	pretreatment	O
11	with	O
12	pCPA	O
13	largely	O
14	blocked	O
15	the	O
16	analgesia	O
17	.	O

1	RESULTS	O
2	:	O
3	In	O
4	the	O
5	AGA	O
6	group	O
7	,	O
8	both	O
9	fetal	O
10	and	O
11	maternal	B
12	serum	I
13	prolactin	I
14	concentration	O
15	increased	O
16	significantly	O
17	with	O
18	gestation	O
19	(	O
20	P	O
21	<	O
22	0	O
23	.	O
24	001	O
25	and	O
26	P	O
27	<	O
28	0	O
29	.	O
30	01	O
31	,	O
32	respectively	O
33	).	O

1	A	O
2	third	O
3	series	O
4	of	O
5	mice	O
6	were	O
7	given	O
8	a	O
9	single	O
10	injection	O
11	of	O
12	5	O
13	-	O
14	OH	O
15	-	O
16	DA	O
17	,	O
18	sacrificed	O
19	,	O
20	and	O
21	prepared	O
22	for	O
23	ultrastructural	O
24	study	O
25	.	O

1	The	O
2	five	O
3	-	O
4	drug	O
5	combination	O
6	of	O
7	fluorouracil	O
8	imidazole	O
9	carboxamide	O
10	dimethyl	O
11	triazeno	O
12	,	O
13	vincristine	O
14	,	O
15	bis	O
16	-	O
17	chloroethyl	O
18	nitrosourea	O
19	,	O
20	and	O
21	prednisone	O
22	(	O
23	FIVB	O
24	+	O
25	P	O
26	)	O
27	was	O
28	given	O
29	to	O
30	120	O
31	women	O
32	with	O
33	metastatic	O
34	breast	O
35	cancer	O
36	.	O

1	HRES	O
2	has	O
3	been	O
4	found	O
5	to	O
6	be	O
7	clinically	O
8	useful	O
9	in	O
10	assessing	O
11	histologic	O
12	damage	O
13	following	O
14	pneumatic	O
15	dilatation	O
16	and	O
17	in	O
18	localizing	O
19	the	O
20	LES	O
21	during	O
22	the	O
23	administration	O
24	of	O
25	intrasphincter	O
26	botulinum	B
27	toxin	I
28	injection	O
29	in	O
30	the	O
31	treatment	O
32	of	O
33	achalasia	O
34	.	O

1	The	O
2	1	O
3	,	O
4	2	O
5	,	O
6	3	O
7	and	O
8	4	O
9	year	O
10	survival	O
11	rates	O
12	were	O
13	94	O
14	%,	O
15	84	O
16	%,	O
17	76	O
18	%	O
19	and	O
20	63	O
21	%,	O
22	respectively	O
23	.	O

1	A	O
2	significant	O
3	degree	O
4	of	O
5	homology	O
6	was	O
7	also	O
8	found	O
9	among	O
10	these	O
11	genes	O
12	and	O
13	the	O
14	Mtase	O
15	gene	O
16	of	O
17	related	O
18	phage	O
19	SPR	O
20	,	O
21	which	O
22	codes	O
23	for	O
24	an	O
25	enzyme	O
26	with	O
27	different	O
28	modification	O
29	specificity	O
30	.	O

1	High	O
2	-	O
3	affinity	O
4	binding	O
5	sites	O
6	for	O
7	both	O
8	GR	B
9	and	O
10	AP	B
11	-	I
12	1	I
13	nucleoproteins	I
14	were	O
15	identified	O
16	at	O
17	adjacent	O
18	elements	O
19	within	O
20	the	O
21	nGRE	O
22	.	O

1	Studies	O
2	of	O
3	MPO	B
4	gene	I
5	regulation	O
6	can	O
7	help	O
8	to	O
9	elucidate	O
10	the	O
11	mechanism	O
12	of	O
13	normal	O
14	and	O
15	abnormal	O
16	myeloid	O
17	differentiation	O
18	.	O

1	Identification	O
2	of	O
3	a	O
4	new	O
5	gene	O
6	in	O
7	the	O
8	streptococcal	O
9	plasmid	O
10	pLS1	O
11	:	O
12	the	O
13	rnaI	O
14	gene	O
15	.	O

1	Switching	O
2	FDC	O
3	-	O
4	P1	O
5	/	O
6	MAC	O
7	cells	O
8	from	O
9	growth	O
10	in	O
11	M	B
12	-	O
13	CSF	I
14	to	O
15	GM	B
16	-	I
17	CSF	I
18	caused	O
19	the	O
20	selective	O
21	degradation	O
22	of	O
23	c	B
24	-	I
25	fms	I
26	mRNA	I
27	within	O
28	6	O
29	h	O
30	after	O
31	factor	O
32	switching	O
33	.	O

1	For	O
2	this	O
3	purpose	O
4	,	O
5	a	O
6	segment	O
7	of	O
8	dxr	O
9	was	O
10	amplified	O
11	from	O
12	Synechococcus	O
13	leopoliensis	O
14	SAUG	O
15	1402	O
16	-	O
17	1	O
18	DNA	O
19	via	O
20	PCR	O
21	using	O
22	oligonucleotides	O
23	for	O
24	conserved	O
25	regions	O
26	.	O

1	The	O
2	use	O
3	of	O
4	specific	O
5	antibodies	O
6	allowed	O
7	the	O
8	identification	O
9	of	O
10	at	O
11	least	O
12	RAR	B
13	beta	I
14	in	O
15	some	O
16	of	O
17	the	O
18	DNA	O
19	-	O
20	protein	O
21	complexes	O
22	,	O
23	although	O
24	the	O
25	four	O
26	sequences	O
27	bind	O
28	single	O
29	RARs	O
30	transfected	O
31	in	O
32	COS	O
33	cells	O
34	much	O
35	less	O
36	efficiently	O
37	,	O
38	or	O
39	not	O
40	at	O
41	all	O
42	,	O
43	when	O
44	compared	O
45	to	O
46	a	O
47	canonical	O
48	RAR	B
49	responsive	O
50	element	O
51	.	O

1	Cardiovascular	O
2	risk	O
3	factors	O
4	were	O
5	measured	O
6	by	O
7	standardized	O
8	techniques	O
9	.	O

1	Using	O
2	the	O
3	rap1t	B
4	alleles	I
5	to	O
6	generate	O
7	wild	O
8	-	O
9	type	O
10	cells	O
11	differing	O
12	only	O
13	in	O
14	telomere	O
15	tract	O
16	lengths	O
17	,	O
18	we	O
19	also	O
20	show	O
21	that	O
22	telomere	O
23	position	O
24	effects	O
25	are	O
26	highly	O
27	sensitive	O
28	to	O
29	changes	O
30	in	O
31	the	O
32	size	O
33	(	O
34	or	O
35	structure	O
36	)	O
37	of	O
38	the	O
39	telomeric	O
40	tract	O
41	.	O

1	In	O
2	the	O
3	icosahaedral	O
4	MVMi	O
5	capsid	O
6	,	O
7	this	O
8	sequence	O
9	forms	O
10	the	O
11	carboxy	O
12	end	O
13	of	O
14	the	O
15	amphipathic	O
16	beta	I
17	-	I
18	strand	O
19	I	O
20	(	O
21	betaI	O
22	),	O
23	and	O
24	all	O
25	its	O
26	basic	O
27	residues	O
28	are	O
29	contiguously	O
30	positioned	O
31	at	O
32	the	O
33	face	O
34	that	O
35	in	O
36	the	O
37	unassembled	O
38	subunit	O
39	would	O
40	be	O
41	exposed	O
42	to	O
43	solvent	O
44	.	O

1	The	O
2	availability	O
3	of	O
4	cryoprecipitate	O
5	and	O
6	DDAVP	O
7	offers	O
8	an	O
9	alternative	O
10	and	O
11	effective	O
12	treatment	O
13	for	O
14	the	O
15	temporary	O
16	reversal	O
17	of	O
18	uremic	O
19	bleeding	O
20	in	O
21	patients	O
22	who	O
23	require	O
24	urgent	O
25	invasive	O
26	procedures	O
27	.	O

1	IdB	O
2	1031	O
3	was	O
4	first	O
5	extracted	O
6	by	O
7	liquid	O
8	-	O
9	solid	O
10	partition	O
11	and	O
12	the	O
13	extracts	O
14	were	O
15	evaporated	O
16	and	O
17	analysed	O
18	on	O
19	a	O
20	reversed	O
21	-	O
22	phase	O
23	column	O
24	under	O
25	isocratic	O
26	conditions	O
27	,	O
28	using	O
29	either	O
30	an	O
31	electrochemical	O
32	or	O
33	a	O
34	UV	O
35	detector	O
36	.	O

1	Polyhomeotic	O
2	and	O
3	Posterior	O
4	Sex	O
5	Combs	O
6	may	O
7	participate	O
8	in	O
9	a	O
10	more	O
11	general	O
12	transcriptional	O
13	mechanism	O
14	that	O
15	causes	O
16	modulated	O
17	gene	O
18	repression	O
19	,	O
20	whereas	O
21	the	O
22	inclusion	O
23	of	O
24	Polycomb	B
25	protein	O
26	in	O
27	the	O
28	complex	O
29	at	O
30	PREs	O
31	leads	O
32	to	O
33	stable	O
34	silencing	O
35	.	O

1	Diagnosis	O
2	:	O
3	progressive	O
4	multifocal	O
5	leukoencephalopathy	O
6	.	O

1	The	O
2	assay	O
3	exhibits	O
4	a	O
5	dynamic	O
6	range	O
7	of	O
8	0	O
9	.	O
10	1	O
11	-	O
12	100	O
13	micrograms	O
14	l	O
15	-	O
16	1	O
17	using	O
18	a	O
19	monoclonal	O
20	antibody	O
21	or	O
22	alternatively	O
23	10	O
24	micrograms	O
25	l	O
26	-	O
27	1	O
28	to	O
29	10	O
30	mg	O
31	l	O
32	-	O
33	1	O
34	using	O
35	commercially	O
36	available	O
37	antiserum	O
38	.	O

1	During	O
2	a	O
3	disease	O
4	remission	O
5	there	O
6	was	O
7	an	O
8	increase	O
9	in	O
10	GAG	O
11	secretion	O
12	with	O
13	urine	O
14	,	O
15	linked	O
16	with	O
17	hyperheparinuria	O
18	(	O
19	13	O
20	.	O
21	1	O
22	-	O
23	fold	O
24	,	O
25	P	O
26	less	O
27	than	O
28	0	O
29	.	O
30	001	O
31	).	O

1	The	O
2	E	O
3	-	O
4	box	O
5	sequence	O
6	in	O
7	the	O
8	SE2	O
9	fragment	O
10	of	O
11	the	O
12	transferrin	B
13	promoter	I
14	was	O
15	CATCTG	O
16	and	O
17	was	O
18	similar	O
19	in	O
20	gel	O
21	shifts	O
22	to	O
23	the	O
24	consensus	O
25	E	O
26	-	O
27	box	O
28	elements	O
29	(	O
30	CANNTG	O
31	)	O
32	previously	O
33	characterized	O
34	.	O

1	At	O
2	least	O
3	some	O
4	of	O
5	the	O
6	difference	O
7	in	O
8	stability	O
9	of	O
10	the	O
11	two	O
12	kinds	O
13	of	O
14	complexes	O
15	was	O
16	due	O
17	to	O
18	the	O
19	fact	O
20	that	O
21	the	O
22	dissociation	O
23	rate	O
24	of	O
25	the	O
26	A	O
27	stem	O
28	substrate	O
29	from	O
30	the	O
31	protein	O
32	-	O
33	DNA	O
34	complexes	O
35	was	O
36	approximately	O
37	fourfold	O
38	faster	O
39	than	O
40	that	O
41	of	O
42	the	O
43	complete	O
44	TR	B
45	.	O

1	We	O
2	conclude	O
3	that	O
4	common	O
5	upstream	O
6	signals	O
7	cause	O
8	activation	O
9	of	O
10	Ras	B
11	and	O
12	TC21	B
13	,	O
14	but	O
15	activated	O
16	TC21	B
17	controls	O
18	cell	O
19	growth	O
20	via	O
21	distinct	O
22	Raf	B
23	-	O
24	independent	O
25	downstream	O
26	signaling	O
27	pathways	O
28	.	O

1	Oncological	O
2	,	O
3	clinical	O
4	and	O
5	psychological	O
6	aspects	O
7	are	O
8	evaluated	O
9	according	O
10	to	O
11	experience	O
12	accumulated	O
13	in	O
14	recent	O
15	years	O
16	,	O
17	with	O
18	immediate	O
19	and	O
20	delayed	O
21	reconstruction	O
22	,	O
23	carried	O
24	out	O
25	in	O
26	the	O
27	most	O
28	diverse	O
29	specialized	O
30	centers	O
31	.	O

1	Clinical	O
2	and	O
3	angiographic	O
4	examinations	O
5	in	O
6	occlusion	O
7	disease	O
8	of	O
9	the	O
10	great	O
11	intestinal	O
12	arteries	O

1	The	O
2	transposon	O
3	-	O
4	inactivated	O
5	gene	O
6	,	O
7	designated	O
8	pilP	O
9	,	O
10	is	O
11	525	O
12	bp	O
13	long	O
14	,	O
15	potentially	O
16	encoding	O
17	a	O
18	19	O
19	.	O
20	1	O
21	-	O
22	kDa	O
23	protein	O
24	precursor	O
25	that	O
26	contains	O
27	a	O
28	typical	O
29	membrane	O
30	lipoprotein	O
31	leader	O
32	sequence	O
33	.	O

1	Insulin	B
2	-	I
3	like	I
4	growth	I
5	factor	I
6	1	I
7	(	O
8	IGF	B
9	-	I
10	1	I
11	)	O
12	in	O
13	burn	O
14	patients	O
15	.	O

1	Pharmacokinetics	O
2	of	O
3	Carbamazepine	O
4	in	O
5	man	O
6	:	O
7	a	O
8	review	O
9	.	O

1	The	O
2	high	O
3	degree	O
4	of	O
5	conservation	O
6	between	O
7	NQO2	O
8	and	O
9	NQO1	O
10	gene	O
11	organization	O
12	and	O
13	sequence	O
14	confirmed	O
15	that	O
16	NQO2	O
17	gene	O
18	encodes	O
19	for	O
20	a	O
21	second	O
22	member	O
23	of	O
24	the	O
25	NQO	B
26	gene	I
27	family	I
28	in	O
29	human	O
30	.	O

1	Consistent	O
2	with	O
3	this	O
4	interpretation	O
5	,	O
6	a	O
7	mutant	O
8	form	O
9	of	O
10	XRN1	O
11	,	O
12	which	O
13	encodes	O
14	a	O
15	5	O
16	'-	O
17	3	O
18	'	O
19	exonuclease	O
20	,	O
21	was	O
22	identified	O
23	as	O
24	an	O
25	extragenic	O
26	suppressor	O
27	that	O
28	increases	O
29	the	O
30	half	O
31	-	O
32	life	O
33	of	O
34	rhis4	O
35	mRNA	O
36	,	O
37	leading	O
38	to	O
39	a	O
40	10	O
41	-	O
42	fold	O
43	increase	O
44	in	O
45	steady	O
46	-	O
47	state	O
48	mRNA	O
49	levels	O
50	compared	O
51	to	O
52	the	O
53	wild	B
54	-	I
55	type	I
56	HIS4	I
57	mRNA	I
58	level	O
59	.	O

1	NOT4	O
2	interacts	O
3	with	O
4	NOT1	O
5	and	O
6	NOT3	O
7	in	O
8	the	O
9	two	O
10	-	O
11	hybrid	O
12	assay	O
13	,	O
14	and	O
15	overexpression	O
16	of	O
17	NOT3	O
18	or	O
19	NOT4	O
20	suppresses	O
21	not1	O
22	and	O
23	not2	O
24	mutations	O
25	.	O

1	Lac	O
2	operators	O
3	were	O
4	introduced	O
5	into	O
6	several	O
7	positions	O
8	within	O
9	the	O
10	CAB	O
11	promoter	O
12	and	O
13	operator	O
14	-	O
15	free	O
16	plasmid	O
17	was	O
18	used	O
19	as	O
20	control	O
21	.	O

1	The	O
2	bactericidal	O
3	activity	O
4	of	O
5	six	O
6	new	O
7	rifamycin	O
8	derivatives	O
9	--	O
10	rifabutin	O
11	(	O
12	RBU	O
13	),	O
14	FCE	O
15	22250	O
16	(	O
17	F22	O
18	),	O
19	rifapentine	O
20	(	O
21	RPE	O
22	),	O
23	CGP	O
24	29861	O
25	(	O
26	C29	O
27	),	O
28	CGP	O
29	7040	O
30	(	O
31	C70	O
32	)	O
33	and	O
34	CGP	O
35	27557	O
36	(	O
37	C27	O
38	)	O
39	and	O
40	rifampicin	O
41	(	O
42	RMP	O
43	)--	O
44	have	O
45	been	O
46	measured	O
47	against	O
48	log	O
49	phase	O
50	and	O
51	,	O
52	as	O
53	a	O
54	better	O
55	test	O
56	of	O
57	sterilising	O
58	activity	O
59	,	O
60	against	O
61	stationary	O
62	phase	O
63	cultures	O
64	of	O
65	Mycobacterium	O
66	tuberculosis	O
67	,	O
68	H37Rv	O
69	.	O

1	Cat	B
2	proteins	I
3	are	O
4	tyrosine	O
5	-	O
6	phosphorylated	O
7	when	O
8	co	O
9	-	O
10	expressed	O
11	in	O
12	cells	O
13	with	O
14	the	O
15	focal	B
16	adhesion	I
17	kinase	I
18	Fak	I
19	and	O
20	Src	B
21	.	O

1	The	O
2	cDNA	O
3	clone	O
4	was	O
5	used	O
6	as	O
7	a	O
8	homologous	O
9	probe	O
10	to	O
11	isolate	O
12	a	O
13	truncated	O
14	genomic	O
15	clone	O
16	encoding	O
17	H2A1	B
18	.	O

1	There	O
2	were	O
3	18	O
4	patients	O
5	with	O
6	Group	O
7	II	O
8	(	O
9	a	O
10	)	O
11	tumors	O
12	;	O
13	although	O
14	tumor	O
15	biopsy	O
16	was	O
17	attempted	O
18	on	O
19	eight	O
20	of	O
21	these	O
22	,	O
23	pathological	O
24	diagnosis	O
25	at	O
26	the	O
27	time	O
28	of	O
29	surgery	O
30	was	O
31	made	O
32	in	O
33	only	O
34	one	O
35	case	O
36	.	O

1	An	O
2	examination	O
3	was	O
4	performed	O
5	in	O
6	15	O
7	patients	O
8	who	O
9	had	O
10	developed	O
11	pronounced	O
12	osteomalacia	O
13	following	O
14	gastric	O
15	resection	O
16	.	O

1	We	O
2	also	O
3	show	O
4	by	O
5	immunogold	O
6	electron	O
7	microscopy	O
8	immunocytochemistry	O
9	that	O
10	amphiphysin	O
11	I	O
12	is	O
13	localized	O
14	in	O
15	the	O
16	nerve	O
17	terminal	O
18	cytomatrix	O
19	and	O
20	is	O
21	partially	O
22	associated	O
23	with	O
24	endocytic	O
25	intermediates	O
26	.	O

1	Endogenous	O
2	RMP	O
3	was	O
4	immunologically	O
5	detected	O
6	interacting	O
7	with	O
8	assembled	O
9	RPB5	B
10	in	O
11	RNA	B
12	polymerase	I
13	in	O
14	mammalian	O
15	cells	O
16	.	O

1	Who	O
2	says	O
3	'	O
4	National	O
5	Health	O
6	Dis	O
7	-	O
8	service	O
9	'.	O

1	These	O
2	transcripts	O
3	contain	O
4	the	O
5	5	O
6	'	O
7	ends	O
8	of	O
9	mature	O
10	UbCRBP	O
11	mRNAs	O
12	;	O
13	extend	O
14	through	O
15	UbCRBP	O
16	,	O
17	across	O
18	the	O
19	intergenic	O
20	region	O
21	,	O
22	and	O
23	a	O
24	significant	O
25	distance	O
26	3	O
27	'	O
28	into	O
29	the	O
30	enolase	O
31	gene	O
32	.	O

1	Somatostatin	B
2	-	O
3	producing	O
4	endocrine	O
5	pancreatic	O
6	tumor	O
7	in	O
8	Recklinghausen	O
9	'	O
10	s	O
11	neurofibromatosis	O
12	.	O

1	The	O
2	effect	O
3	of	O
4	six	O
5	arginine	O
6	mutations	O
7	of	O
8	oxidative	O
9	phosphorylation	O
10	and	O
11	AAC	O
12	expression	O
13	.	O

1	The	O
2	segmental	O
3	and	O
4	regional	O
5	projections	O
6	of	O
7	the	O
8	sciatic	O
9	,	O
10	tibial	O
11	and	O
12	common	O
13	peroneal	O
14	nerves	O
15	to	O
16	the	O
17	substantia	O
18	gelatinosa	O
19	of	O
20	the	O
21	spinal	O
22	cord	O
23	in	O
24	rats	O
25	--	O
26	an	O
27	experimental	O
28	study	O
29	by	O
30	means	O
31	of	O
32	an	O
33	acid	O
34	phosphatase	O
35	(	O
36	ACP	O
37	)	O
38	method	O
39	.	O

1	In	O
2	addition	O
3	,	O
4	the	O
5	-	O
6	119	O
7	to	O
8	-	O
9	81	O
10	fragment	O
11	of	O
12	the	O
13	CCK	B
14	promoter	I
15	contains	O
16	a	O
17	transcriptional	O
18	enhancer	O
19	that	O
20	potentiates	O
21	the	O
22	transcription	O
23	from	O
24	the	O
25	herpes	B
26	simplex	I
27	virus	I
28	thymidine	I
29	kinase	I
30	promoter	I
31	in	O
32	a	O
33	position	O
34	-	O
35	and	O
36	orientation	O
37	-	O
38	independent	O
39	manner	O
40	.	O

1	A	I
2	4	I
3	.	O
4	8	O
5	-	O
6	kilobase	O
7	BamHI	B
8	-	I
9	HindIII	I
10	fragment	I
11	encoding	O
12	the	O
13	entire	O
14	Neurospora	B
15	crassa	I
16	CuZn	I
17	superoxide	I
18	dismutase	I
19	gene	I
20	(	O
21	herein	O
22	designated	O
23	sod	B
24	-	I
25	1	I
26	)	O
27	was	O
28	isolated	O
29	from	O
30	a	O
31	genomic	O
32	library	O
33	using	O
34	two	O
35	60	O
36	-	O
37	base	O
38	deoxyoligonucleotide	O
39	probes	O
40	corresponding	O
41	to	O
42	the	O
43	published	O
44	N	O
45	.	O
46	crassa	O
47	amino	O
48	acid	O
49	sequence	O
50	.	O

1	This	O
2	loss	O
3	was	O
4	independent	O
5	of	O
6	drug	O
7	concentration	O
8	and	O
9	a	O
10	correction	O
11	factor	O
12	was	O
13	employed	O
14	to	O
15	calculate	O
16	the	O
17	true	O
18	free	O
19	diazepam	O
20	concentration	O
21	.	O

1	Transplantation	O
2	of	O
3	kidneys	O
4	of	O
5	juvenile	O
6	donors	O
7	in	O
8	adult	O
9	recipients	O
10	.	O

1	The	O
2	other	O
3	transmembrane	O
4	regions	O
5	as	O
6	well	O
7	as	O
8	the	O
9	nucleoplasmic	O
10	domain	O
11	are	O
12	not	O
13	required	O
14	for	O
15	sorting	O
16	.	O

1	Analysis	O
2	of	O
3	an	O
4	autopsy	O
5	population	O
6	.	O

1	3600	O
2	-	O
3	fold	O
4	to	O
5	apparent	O
6	homogeneity	O
7	with	O
8	a	O
9	41	O
10	%	O
11	yield	O
12	by	O
13	affinity	O
14	chromatography	O
15	utilizing	O
16	DNA	O
17	-	O
18	cellulose	O
19	;	O
20	the	O
21	purity	O
22	of	O
23	the	O
24	final	O
25	preparation	O
26	was	O
27	assessed	O
28	by	O
29	SDS	O
30	/	O
31	PAGE	O
32	,	O
33	lack	O
34	of	O
35	contamination	O
36	by	O
37	other	O
38	nucleases	O
39	and	O
40	production	O
41	of	O
42	a	O
43	monospecific	O
44	antibody	O
45	against	O
46	the	O
47	enzyme	O
48	.	O

1	Five	O
2	of	O
3	10	O
4	scars	O
5	studied	O
6	decreased	O
7	at	O
8	least	O
9	50	O
10	%	O
11	in	O
12	linear	O
13	dimensions	O
14	.	O

1	The	O
2	predicted	O
3	molecular	O
4	weight	O
5	of	O
6	the	O
7	polyprotein	O
8	encoded	O
9	by	O
10	ORF1	O
11	is	O
12	33	O
13	kilodaltons	O
14	(	O
15	kDa	O
16	).	O

1	Mutation	O
2	of	O
3	the	O
4	C	B
5	/	I
6	EBP	I
7	binding	I
8	sites	I
9	in	O
10	the	O
11	Rous	O
12	sarcoma	O
13	virus	O
14	long	I
15	terminal	I
16	repeat	I
17	and	O
18	gag	B
19	enhancers	I
20	.	O

1	The	O
2	method	O
3	is	O
4	applied	O
5	to	O
6	determine	O
7	aberration	O
8	constants	O
9	of	O
10	a	O
11	CM300	O
12	FEG	O
13	/	O
14	UT	O
15	microscope	O
16	with	O
17	correction	O
18	of	O
19	the	O
20	three	O
21	-	O
22	fold	O
23	astigmatism	O
24	.	O

1	Members	O
2	of	O
3	the	O
4	titin	B
5	/	O
6	myosin	B
7	light	I
8	chain	I
9	kinase	I
10	family	I
11	play	O
12	an	O
13	essential	O
14	role	O
15	in	O
16	the	O
17	organization	O
18	of	O
19	the	O
20	actin	B
21	/	I
22	myosin	I
23	cytoskeleton	I
24	,	O
25	especially	O
26	in	O
27	sarcomere	O
28	assembly	O
29	and	O
30	function	O
31	.	O

1	Its	O
2	transcription	O
3	has	O
4	been	O
5	shown	O
6	to	O
7	be	O
8	induced	O
9	40	O
10	-	O
11	50	O
12	-	O
13	fold	O
14	in	O
15	response	O
16	to	O
17	oxygen	O
18	or	O
19	heme	O
20	deficiency	O
21	,	O
22	in	O
23	part	O
24	through	O
25	relief	O
26	of	O
27	repression	O
28	exerted	O
29	by	O
30	Rox1p	O
31	and	O
32	in	O
33	part	O
34	by	O
35	activation	O
36	mediated	O
37	by	O
38	an	O
39	upstream	O
40	activation	O
41	sequence	O
42	(	O
43	UAS	O
44	).	O

1	The	O
2	GEF	B
3	and	O
4	GAP	B
5	activities	O
6	for	O
7	Ypt1p	O
8	localize	O
9	to	O
10	particulate	O
11	cellular	O
12	fractions	O
13	.	O

1	Detection	O
2	of	O
3	anti	B
4	-	O
5	lymphocyte	O
6	antibodies	I
7	using	O
8	the	O
9	immunoperoxidase	B
10	antiglobulin	I
11	technic	O
12	.	O

1	Wherever	O
2	the	O
3	site	O
4	of	O
5	the	O
6	conditioning	O
7	stimulation	O
8	,	O
9	these	O
10	modifications	O
11	disappeared	O
12	after	O
13	ischaemia	O
14	of	O
15	the	O
16	leg	O
17	.	O

1	We	O
2	have	O
3	developed	O
4	a	O
5	rAAV	O
6	-	O
7	mediated	O
8	gene	O
9	transfer	O
10	system	O
11	for	O
12	the	O
13	rat	B
14	preproinsulin	I
15	II	I
16	gene	I
17	.	O

1	In	O
2	several	O
3	studies	O
4	the	O
5	RDFS	O
6	has	O
7	shown	O
8	evidence	O
9	of	O
10	reliability	O
11	and	O
12	validity	O
13	.	O

1	Two	O
2	polyadenylation	O
3	sites	O
4	were	O
5	used	O
6	,	O
7	one	O
8	at	O
9	the	O
10	end	O
11	of	O
12	the	O
13	early	O
14	(	O
15	E	O
16	)	O
17	region	O
18	of	O
19	the	O
20	viral	O
21	DNA	O
22	,	O
23	the	O
24	other	O
25	at	O
26	the	O
27	end	O
28	of	O
29	the	O
30	late	O
31	(	O
32	L	O
33	)	O
34	region	O
35	.	O

1	Using	O
2	mutated	O
3	IL2R	B
4	alpha	B
5	promoter	I
6	constructs	O
7	in	O
8	transient	O
9	transfection	O
10	and	O
11	DNA	O
12	binding	O
13	assays	O
14	,	O
15	we	O
16	now	O
17	demonstrate	O
18	that	O
19	sequences	O
20	located	O
21	immediately	O
22	upstream	O
23	and	O
24	downstream	O
25	of	O
26	the	O
27	kappa	B
28	B	I
29	enhancer	I
30	also	O
31	contribute	O
32	to	O
33	the	O
34	regulation	O
35	of	O
36	IL2R	B
37	alpha	I
38	gene	I
39	expression	O
40	.	O

1	Enzyme	O
2	histochemical	O
3	findings	O
4	in	O
5	the	O
6	ultimobranchial	O
7	body	O
8	of	O
9	the	O
10	horse	B

1	Furthermore	O
2	the	O
3	median	O
4	increase	O
5	in	O
6	cyclosporine	O
7	DR	O
8	/	O
9	C	O
10	(	O
11	SS	O
12	trough	O
13	)	O
14	was	O
15	18	O
16	l	O
17	h	O
18	-	O
19	1	O
20	(-	O
21	3	O
22	.	O
23	1	O
24	to	O
25	42	O
26	.	O
27	1	O
28	l	O
29	h	O
30	-	O
31	1	O
32	,	O
33	interquartile	O
34	range	O
35	).	O

1	In	O
2	line	O
3	with	O
4	the	O
5	small	O
6	values	O
7	for	O
8	QS	O
9	/	O
10	QC	O
11	,	O
12	our	O
13	results	O
14	further	O
15	indicate	O
16	that	O
17	even	O
18	large	O
19	,	O
20	well	O
21	-	O
22	perfused	O
23	,	O
24	occluded	O
25	air	O
26	spaces	O
27	in	O
28	the	O
29	lung	O
30	will	O
31	hardly	O
32	affect	O
33	the	O
34	recovered	O
35	ventilation	O
36	/	O
37	perfusion	O
38	distribution	O
39	obtained	O
40	from	O
41	inert	O
42	gas	O
43	data	O
44	when	O
45	CDCSF6	O
46	exceeds	O
47	0	O
48	.	O
49	1	O
50	ml	O
51	.	O
52	min	O
53	-	O
54	1	O
55	.	O
56	mmHg	O
57	-	O
58	1	O
59	.	O

1	Increasing	O
2	the	O
3	cut	B
4	-	O
5	off	O
6	point	O
7	to	O
8	3	O
9	positive	O
10	responses	O
11	decreased	O
12	the	O
13	sensitivity	O
14	to	O
15	81	O
16	%	O
17	and	O
18	increased	O
19	the	O
20	specificity	O
21	to	O
22	94	O
23	%.	O

1	The	O
2	p55	B
3	mRNA	I
4	is	O
5	undetectable	O
6	in	O
7	non	O
8	-	O
9	EBV	O
10	-	O
11	infected	O
12	B	O
13	-	O
14	and	O
15	T	O
16	-	O
17	cell	O
18	lines	O
19	or	O
20	in	O
21	a	O
22	myelomonocytic	O
23	cell	O
24	line	O
25	(	O
26	U937	O
27	).	O

1	Diet	O
2	therapy	O
3	with	O
4	soy	O
5	proteins	O
6	for	O
7	chronic	O
8	stomach	O
9	ulcers	O

1	In	O
2	support	O
3	of	O
4	this	O
5	interpretation	O
6	we	O
7	demonstrate	O
8	that	O
9	MQ9b	O
10	binds	O
11	strongly	O
12	5	O
13	of	O
14	17	O
15	motif	O
16	-	O
17	positive	O
18	,	O
19	pathogen	O
20	-	O
21	derived	O
22	synthetic	O
23	peptides	O
24	.	O

1	A	O
2	single	O
3	1	O
4	.	O
5	8	O
6	-	O
7	kb	O
8	transcript	O
9	mRNA	O
10	was	O
11	detected	O
12	by	O
13	Northern	O
14	(	O
15	RNA	O
16	)	O
17	blot	O
18	analysis	O
19	,	O
20	and	O
21	its	O
22	5	O
23	'	O
24	end	O
25	maps	O
26	to	O
27	a	O
28	position	O
29	51	O
30	bp	O
31	upstream	O
32	from	O
33	the	O
34	site	O
35	of	O
36	initiation	O
37	of	O
38	protein	O
39	synthesis	O
40	.	O

1	Mutation	O
2	of	O
3	Enh4	O
4	,	O
5	an	O
6	essential	O
7	GT	O
8	-	O
9	IIC	O
10	-	O
11	like	O
12	enhanson	O
13	in	O
14	the	O
15	context	O
16	of	O
17	the	O
18	intact	O
19	enhancer	O
20	,	O
21	abolishes	O
22	silencer	O
23	activity	O
24	,	O
25	and	O
26	multimerized	O
27	GT	O
28	-	O
29	IIC	O
30	enhansons	O
31	mimic	O
32	the	O
33	intact	O
34	CSEn	B
35	enhancer	O
36	/	O
37	silencer	O
38	activities	O
39	in	O
40	BeWo	O
41	and	O
42	GC	O
43	cells	O
44	,	O
45	respectively	O
46	.	O

1	The	O
2	first	O
3	gene	O
4	codes	O
5	for	O
6	a	O
7	protein	O
8	containing	O
9	11	O
10	cystein	O
11	residues	O
12	in	O
13	an	O
14	arrangement	O
15	typical	O
16	for	O
17	Fe	O
18	/	O
19	S	O
20	proteins	O
21	.	O

1	We	O
2	conclude	O
3	that	O
4	c	B
5	-	I
6	Myb	I
7	regulates	O
8	the	O
9	RAG	B
10	-	I
11	2	I
12	promoter	I
13	in	O
14	T	O
15	cells	O
16	by	O
17	binding	O
18	to	O
19	this	O
20	consensus	O
21	c	B
22	-	I
23	Myb	I
24	binding	I
25	site	I
26	.	O

1	Our	O
2	results	O
3	establish	O
4	GKLF	O
5	as	O
6	a	O
7	sequence	O
8	-	O
9	specific	O
10	transcription	O
11	factor	O
12	likely	O
13	involved	O
14	in	O
15	regulation	O
16	of	O
17	expression	O
18	of	O
19	endogenous	O
20	genes	O
21	.	O

1	Two	O
2	of	O
3	these	O
4	six	O
5	cases	O
6	showed	O
7	mucosal	O
8	spread	O
9	without	O
10	stromal	O
11	invasion	O
12	(	O
13	type	O
14	A	O
15	);	O
16	the	O
17	remaining	O
18	four	O
19	cases	O
20	presented	O
21	a	O
22	direct	O
23	extension	O
24	(	O
25	type	O
26	B	O
27	)	O
28	from	O
29	muscle	O
30	-	O
31	invasive	O
32	carcinomas	O
33	of	O
34	the	O
35	bladder	O
36	.	O

1	LDL	B
2	cholesterol	I
3	decreased	O
4	from	O
5	4	O
6	.	O
7	74	O
8	+/-	O
9	0	O
10	.	O
11	87	O
12	to	O
13	3	O
14	.	O
15	78	O
16	+/-	O
17	0	O
18	.	O
19	78	O
20	mmol	O
21	/	O
22	l	O
23	after	O
24	8	O
25	weeks	O
26	on	O
27	simvastatin	O
28	(	O
29	P	O
30	<	O
31	0	O
32	.	O
33	001	O
34	),	O
35	and	O
36	apo	O
37	B	O
38	fell	O
39	from	O
40	142	O
41	+/-	O
42	31	O
43	to	O
44	112	O
45	+/-	O
46	22	O
47	mg	O
48	/	O
49	dl	O
50	(	O
51	P	O
52	<	O
53	0	O
54	.	O
55	001	O
56	).	O

1	In	O
2	a	O
3	second	O
4	patient	O
5	the	O
6	VT	O
7	became	O
8	nonsustained	O
9	.	O

1	This	O
2	study	O
3	was	O
4	performed	O
5	to	O
6	assess	O
7	the	O
8	role	O
9	of	O
10	additional	O
11	diagnostic	O
12	laparoscopy	O
13	in	O
14	the	O
15	preoperative	O
16	staging	O
17	of	O
18	patients	O
19	with	O
20	adenocarcinoma	O
21	of	O
22	the	O
23	esophagus	O
24	,	O
25	gastric	O
26	cancer	O
27	and	O
28	pancreatic	O
29	cancer	O
30	prior	O
31	to	O
32	intended	O
33	curative	O
34	surgery	O
35	.	O

1	Differential	O
2	signaling	O
3	and	O
4	immediate	B
5	-	I
6	early	I
7	gene	I
8	activation	O
9	by	O
10	four	O
11	splice	O
12	variants	O
13	of	O
14	the	O
15	human	B
16	pituitary	I
17	adenylate	I
18	cyclase	I
19	-	I
20	activating	I
21	polypeptide	I
22	receptor	I
23	(	O
24	hPACAP	B
25	-	I
26	R	I
27	).	O

1	M	O
2	.	O
3	leprae	O
4	OxyR	B
5	was	O
6	overproduced	O
7	and	O
8	purified	O
9	,	O
10	and	O
11	its	O
12	binding	O
13	to	O
14	the	O
15	oxyR	B
16	-	I
17	ahpC	O
18	intergenic	O
19	region	O
20	of	O
21	M	O
22	.	O
23	leprae	O
24	was	O
25	demonstrated	O
26	.	O

1	The	O
2	assembly	O
3	of	O
4	sequence	O
5	ready	O
6	,	O
7	high	O
8	-	O
9	resolution	O
10	physical	O
11	maps	O
12	and	O
13	construction	O
14	of	O
15	minimally	O
16	overlapping	O
17	contigs	O
18	for	O
19	the	O
20	human	O
21	as	O
22	well	O
23	as	O
24	model	O
25	genomes	O
26	requires	O
27	accurate	O
28	determination	O
29	of	O
30	the	O
31	extent	O
32	of	O
33	overlap	O
34	between	O
35	adjacent	O
36	clones	O
37	as	O
38	well	O
39	as	O
40	their	O
41	relative	O
42	orientation	O
43	.	O

1	In	O
2	E	O
3	.	O
4	coli	O
5	,	O
6	CheW	O
7	mediates	O
8	the	O
9	physical	O
10	coupling	O
11	of	O
12	the	O
13	receptors	O
14	to	O
15	the	O
16	kinase	O
17	CheA	O
18	.	O

1	According	O
2	to	O
3	out	O
4	field	O
5	research	O
6	,	O
7	the	O
8	tick	O
9	fauna	O
10	was	O
11	very	O
12	rich	O
13	throughout	O
14	that	O
15	area	O
16	,	O
17	and	O
18	it	O
19	was	O
20	permissible	O
21	enough	O
22	to	O
23	determine	O
24	ticks	O
25	as	O
26	the	O
27	vectors	O
28	,	O
29	based	O
30	on	O
31	arising	O
32	of	O
33	anti	B
34	-	I
35	SF	I
36	group	I
37	rickettsiae	I
38	(	O
39	SFGR	B
40	)	O
41	antibody	O
42	in	O
43	mice	O
44	inoculated	O
45	with	O
46	some	O
47	tick	O
48	emulsions	O
49	,	O
50	findings	O
51	of	O
52	rickettsiae	O
53	reactive	O
54	to	O
55	patient	O
56	sera	O
57	or	O
58	a	O
59	species	O
60	-	O
61	specific	O
62	monoclonal	O
63	antibody	O
64	to	O
65	JSFR	O
66	in	O
67	the	O
68	hemolymph	O
69	cells	O
70	of	O
71	some	O
72	ticks	O
73	,	O
74	and	O
75	electron	O
76	microscopical	O
77	observations	O
78	of	O
79	SFGR	O
80	in	O
81	various	O
82	internal	O
83	organs	O
84	including	O
85	the	O
86	salivary	O
87	gland	O
88	of	O
89	ticks	O
90	.	O

1	The	O
2	percentages	O
3	of	O
4	formed	O
5	cysts	O
6	and	O
7	growth	O
8	rates	O
9	were	O
10	monthly	O
11	estimated	O
12	and	O
13	analyzed	O
14	rhythmometrically	O
15	by	O
16	cosinor	O
17	for	O
18	5	O
19	clonal	O
20	cultures	O
21	of	O
22	Scripsiella	O
23	trochoidea	O
24	Stein	O
25	grown	O
26	for	O
27	2	O
28	years	O
29	under	O
30	laboratory	O
31	conditions	O
32	,	O
33	rended	O
34	as	O
35	constant	O
36	as	O
37	possible	O
38	from	O
39	the	O
40	view	O
41	point	O
42	of	O
43	environmental	O
44	temperature	O
45	(	O
46	24	O
47	+/-	O
48	1	O
49	degree	O
50	C	O
51	),	O
52	lighting	O
53	(	O
54	25	O
55	microEin	O
56	m	B
57	-	I
58	2	I
59	s	I
60	-	I
61	1	I
62	),	O
63	and	O
64	artificial	O
65	seawater	O
66	.	O

1	Furthermore	O
2	it	O
3	was	O
4	suggested	O
5	that	O
6	FK506	O
7	plasma	O
8	levels	O
9	were	O
10	concerned	O
11	with	O
12	the	O
13	appearance	O
14	of	O
15	side	O
16	effect	O
17	.	O

1	Skn	B
2	-	O
3	1a	O
4	lacking	O
5	the	O
6	C	O
7	-	O
8	terminal	O
9	region	O
10	completely	O
11	lost	O
12	transactivation	O
13	ability	O
14	,	O
15	irrespective	O
16	of	O
17	the	O
18	promoter	O
19	tested	O
20	,	O
21	and	O
22	was	O
23	able	O
24	to	O
25	block	O
26	transactivation	O
27	by	O
28	normal	O
29	Skn	B
30	-	I
31	1a	I
32	in	O
33	competition	O
34	assays	O
35	.	O

1	Clone	O
2	pSRc200	O
3	hybrid	O
4	selected	O
5	an	O
6	mRNA	O
7	that	O
8	on	O
9	cell	O
10	-	O
11	free	O
12	translation	O
13	produced	O
14	a	O
15	38	O
16	-	O
17	kDa	O
18	polypeptide	O
19	.	O

1	The	O
2	mouse	B
3	beta	I
4	2	I
5	-	I
6	syntrophin	I
7	gene	I
8	(	O
9	>	O
10	33	O
11	kilobases	O
12	)	O
13	contains	O
14	seven	O
15	exons	O
16	,	O
17	all	O
18	of	O
19	which	O
20	have	O
21	homologues	O
22	at	O
23	the	O
24	corresponding	O
25	position	O
26	in	O
27	the	O
28	alpha	B
29	1	I
30	-	I
31	syntrophin	I
32	gene	O
33	.	O

1	Coactivation	O
2	of	O
3	endogenous	O
4	or	O
5	exogenous	O
6	G	O
7	(	O
8	q	I
9	)-	I
10	coupled	I
11	receptors	I
12	with	O
13	the	O
14	delta	B
15	-	I
16	opioid	I
17	receptor	I
18	produced	O
19	strong	O
20	stimulations	O
21	of	O
22	PLCbeta	O
23	and	O
24	such	O
25	responses	O
26	could	O
27	be	O
28	partially	O
29	blocked	O
30	by	O
31	pertussis	B
32	toxin	I
33	.	O

1	Experiences	O
2	with	O
3	the	O
4	clinical	O
5	and	O
6	experimental	O
7	use	O
8	of	O
9	Urat	O
10	-	O
11	I	O
12	lithotriptor	O
13	.	O

1	Supplementation	O
2	was	O
3	stopped	O
4	when	O
5	pl	O
6	-	O
7	ALB	O
8	reached	O
9	2	O
10	.	O
11	0	O
12	g	O
13	/	O
14	dL	O
15	.	O

1	265	O
2	,	O
3	1102	O
4	-	O
5	1110	O
6	).	O

1	Mechanism	O
2	of	O
3	immunogenesis	O
4	in	O
5	vaccination	O
6	with	O
7	streptomycin	O
8	-	O
9	dependent	O
10	mutants	O
11	of	O
12	salmonellae	O
13	and	O
14	shigellae	O
15	.	O

1	The	O
2	Saccharomyces	O
3	cerevisiae	O
4	GAL1	O
5	and	O
6	GAL10	B
7	genes	I
8	are	O
9	controlled	O
10	in	O
11	response	O
12	to	O
13	the	O
14	availability	O
15	of	O
16	galactose	O
17	and	O
18	glucose	O
19	by	O
20	multiple	O
21	activating	O
22	and	O
23	repressing	O
24	proteins	O
25	bound	O
26	at	O
27	adjacent	O
28	or	O
29	overlapping	O
30	sites	O
31	in	O
32	UASG	O
33	.	O

1	Human	O
2	T	I
3	-	I
4	cell	I
5	leukemia	I
6	virus	I
7	type	I
8	I	I
9	Tax	I
10	activation	O
11	of	O
12	NF	B
13	-	I
14	kappa	I
15	B	I
16	/	O
17	Rel	B
18	involves	O
19	phosphorylation	O
20	and	O
21	degradation	O
22	of	O
23	I	B
24	kappa	I
25	B	I
26	alpha	I
27	and	O
28	RelA	B
29	(	O
30	p65	B
31	)-	O
32	mediated	O
33	induction	O
34	of	O
35	the	O
36	c	B
37	-	I
38	rel	I
39	gene	I
40	.	O

1	Three	O
2	classes	O
3	of	O
4	test	O
5	objects	O
6	were	O
7	considered	O
8	:	O
9	(	O
10	1	O
11	)	O
12	a	O
13	multicompartment	O
14	test	O
15	object	O
16	for	O
17	31P	O
18	MRS	O
19	measurements	O
20	performed	O
21	with	O
22	slice	O
23	-	O
24	selective	O
25	sequences	O
26	;	O
27	(	O
28	2	O
29	)	O
30	a	O
31	two	O
32	-	O
33	compartment	O
34	test	O
35	object	O
36	for	O
37	volume	O
38	-	O
39	selection	O
40	1H	O
41	MRS	O
42	;	O
43	and	O
44	(	O
45	3	O
46	)	O
47	two	O
48	-	O
49	compartment	O
50	test	O
51	objects	O
52	for	O
53	assessing	O
54	the	O
55	performance	O
56	of	O
57	experimental	O
58	systems	O
59	using	O
60	ISIS	O
61	as	O
62	volume	O
63	localization	O
64	sequence	O
65	in	O
66	31P	O
67	MRS	O
68	.	O

1	A	O
2	chimeric	O
3	VP16	B
4	-	I
5	Tat	I
6	construct	O
7	containing	O
8	the	O
9	leucine	O
10	mutations	O
11	showed	O
12	no	O
13	increased	O
14	AP	B
15	-	I
16	1	I
17	responsiveness	O
18	in	O
19	comparison	O
20	with	O
21	that	O
22	of	O
23	the	O
24	VP16	B
25	activation	O
26	domain	O
27	alone	O
28	.	O

1	Shoulder	O
2	forearm	O
3	support	O
4	for	O
5	the	O
6	subluxed	O
7	shoulder	O
8	.	O

1	Wild	O
2	-	O
3	type	O
4	protein	O
5	bound	O
6	azido	O
7	-	O
8	ATP	O
9	well	O
10	,	O
11	but	O
12	mutants	O
13	with	O
14	substitutions	O
15	in	O
16	the	O
17	consensus	O
18	amino	O
19	acids	O
20	were	O
21	unable	O
22	to	O
23	bind	O
24	azido	O
25	-	O
26	ATP	O
27	.	O

1	FZD4	O
2	is	O
3	homologous	O
4	to	O
5	FZD9	O
6	and	O
7	FZD10	O
8	,	O
9	and	O
10	overall	O
11	amino	O
12	acid	O
13	identity	O
14	is	O
15	as	O
16	follows	O
17	:	O
18	FZD4	O
19	vs	O
20	FZD9	O
21	,	O
22	51	O
23	.	O
24	6	O
25	%;	O
26	FZD4	O
27	vs	O
28	FZD10	O
29	,	O
30	51	O
31	.	O
32	2	O
33	%;	O
34	FZD9	O
35	vs	O
36	FZD10	O
37	,	O
38	65	O
39	.	O
40	7	O
41	%.	O

1	Lengthy	O
2	and	O
3	repeated	O
4	hemodialyses	O
5	were	O
6	required	O
7	to	O
8	lower	O
9	lithemia	O
10	to	O
11	nontoxic	O
12	ranges	O
13	.	O

1	Electromagnetic	O
2	blood	O
3	flow	O
4	(	O
5	BF	O
6	)	O
7	probe	O
8	was	O
9	applied	O
10	on	O
11	the	O
12	left	O
13	anterior	O
14	descending	O
15	artery	O
16	(	O
17	LAD	O
18	).	O

1	Glutamic	O
2	acid	O
3	in	O
4	a	O
5	dose	O
6	of	O
7	1	O
8	/	O
9	100	O
10	of	O
11	the	O
12	LD50	O
13	was	O
14	injected	O
15	in	O
16	the	O
17	form	O
18	of	O
19	sodium	O
20	salt	O
21	into	O
22	male	O
23	and	O
24	female	O
25	Wistar	O
26	rats	O
27	for	O
28	7	O
29	days	O
30	after	O
31	8	O
32	-	O
33	and	O
34	12	O
35	-	O
36	day	O
37	injections	O
38	of	O
39	dexazone	O
40	.	O

1	Drosophila	O
2	230	O
3	-	O
4	kD	O
5	TFIID	B
6	subunit	O
7	,	O
8	a	O
9	functional	O
10	homolog	O
11	of	O
12	the	O
13	human	B
14	cell	I
15	cycle	I
16	gene	I
17	product	I
18	,	O
19	negatively	O
20	regulates	O
21	DNA	O
22	binding	O
23	of	O
24	the	O
25	TATA	O
26	box	O
27	-	O
28	binding	O
29	subunit	O
30	of	O
31	TFIID	B
32	.	O

1	We	O
2	tried	O
3	amphotericin	O
4	B	O
5	(	O
6	AmB	O
7	),	O
8	and	O
9	remission	O
10	of	O
11	the	O
12	tumor	O
13	was	O
14	obtained	O
15	.	O

1	Two	O
2	splice	O
3	variants	O
4	of	O
5	ALF1	O
6	cDNA	O
7	have	O
8	been	O
9	found	O
10	,	O
11	differing	O
12	by	O
13	a	O
14	72	O
15	-	O
16	bp	O
17	insertion	O
18	,	O
19	coding	O
20	for	O
21	putative	O
22	proteins	O
23	of	O
24	682	O
25	and	O
26	706	O
27	amino	O
28	acids	O
29	.	O

1	A	O
2	cDNA	O
3	for	O
4	a	O
5	newly	O
6	discovered	O
7	pseudogene	O
8	,	O
9	closely	O
10	related	O
11	to	O
12	the	O
13	mouse	O
14	mast	O
15	cell	O
16	chymases	O
17	was	O
18	isolated	O
19	by	O
20	polymerase	O
21	chain	O
22	reaction	O
23	amplification	O
24	from	O
25	a	O
26	mouse	O
27	connective	O
28	tissue	O
29	-	O
30	like	O
31	mast	O
32	cell	O
33	line	O
34	.	O

1	Estradiol	O
2	is	O
3	known	O
4	to	O
5	induce	O
6	expression	O
7	of	O
8	certain	O
9	proto	O
10	-	O
11	oncogenes	O
12	,	O
13	and	O
14	this	O
15	led	O
16	us	O
17	to	O
18	examine	O
19	potential	O
20	regulatory	O
21	regions	O
22	of	O
23	the	O
24	cellular	O
25	c	B
26	-	I
27	fos	I
28	oncogene	I
29	.	O

1	the	O
2	sensitivity	O
3	and	O
4	specificity	O
5	of	O
6	diagnostic	O
7	techniques	O
8	and	O
9	of	O
10	the	O
11	safety	O
12	and	O
13	efficacy	O
14	of	O
15	therapeutic	O
16	modalities	O
17	to	O
18	make	O
19	true	O
20	family	O
21	health	O
22	care	O
23	possible	O
24	?	O
25	(	O
26	2	O
27	)	O
28	If	O
29	this	O
30	type	O
31	of	O
32	care	O
33	is	O
34	possible	O
35	,	O
36	how	O
37	are	O
38	the	O
39	needs	O
40	of	O
41	the	O
42	family	O
43	and	O
44	its	O
45	individual	O
46	members	O
47	met	O
48	,	O
49	or	O
50	value	O
51	judgements	O
52	made	O
53	about	O
54	their	O
55	relative	O
56	importance	O
57	?	O
58	and	O
59	(	O
60	3	O
61	)	O
62	What	O
63	are	O
64	the	O
65	consequences	O
66	for	O
67	the	O
68	health	O
69	care	O
70	delivery	O
71	system	O
72	of	O
73	this	O
74	type	O
75	of	O
76	care	O
77	?	O
78	An	O
79	extensive	O
80	literature	O
81	review	O
82	is	O
83	used	O
84	in	O
85	an	O
86	attempt	O
87	to	O
88	answer	O
89	these	O
90	queries	O
91	,	O
92	from	O
93	which	O
94	questions	O
95	for	O
96	further	O
97	study	O
98	are	O
99	posed	O
100	.	O
1	These	O
2	findings	O
3	demonstrate	O
4	that	O
5	haemodialysis	O
6	patients	O
7	with	O
8	chronic	O
9	hepatitis	O
10	C	O
11	respond	O
12	well	O
13	to	O
14	interferon	B
15	treatment	O
16	and	O
17	that	O
18	a	O
19	long	O
20	-	O
21	term	O
22	response	O
23	is	O
24	achieved	O
25	in	O
26	a	O
27	high	O
28	proportion	O
29	of	O
30	patients	O
31	.	O

1	Adverse	O
2	foetal	B
3	outcome	O
4	in	O
5	specific	O
6	IgM	B
7	positive	O
8	Chlamydia	O
9	trachomatis	O
10	infection	O
11	in	O
12	pregnancy	O
13	.	O

1	Equine	O
2	amnion	O
3	and	O
4	live	O
5	yeast	O
6	cell	O
7	derivative	O
8	were	O
9	evaluated	O
10	as	O
11	a	O
12	biological	O
13	dressing	O
14	and	O
15	as	O
16	a	O
17	topical	O
18	wound	O
19	medicament	O
20	respectively	O
21	,	O
22	in	O
23	the	O
24	treatment	O
25	of	O
26	granulating	O
27	wounds	O
28	of	O
29	the	O
30	distal	O
31	portion	O
32	of	O
33	the	O
34	limbs	O
35	of	O
36	horses	O
37	.	O

1	Symptoms	O
2	due	O
3	to	O
4	the	O
5	action	O
6	of	O
7	mastocyte	O
8	mediators	O
9	were	O
10	observed	O
11	.	O

1	Further	O
2	,	O
3	the	O
4	reduction	O
5	in	O
6	5	O
7	-	O
8	hydroxytryptophan	O
9	(	O
10	5	O
11	-	O
12	HTP	O
13	)	O
14	accumulation	O
15	by	O
16	LSD	O
17	showed	O
18	regional	O
19	differences	O
20	in	O
21	inhibition	O
22	by	O
23	methiothepin	O
24	(	O
25	hypothalamus	O
26	greater	O
27	than	O
28	cortex	O
29	greater	O
30	than	O
31	striatum	O
32	)	O
33	which	O
34	paralleled	O
35	the	O
36	autoreceptor	O
37	antagonist	O
38	activity	O
39	of	O
40	methiothepin	O
41	in	O
42	vitro	O
43	.(	O
44	ABSTRACT	O
45	TRUNCATED	O
46	AT	O
47	250	O
48	WORDS	O
49	)	O

1	These	O
2	studies	O
3	support	O
4	the	O
5	view	O
6	that	O
7	HMG	B
8	I	I
9	(	O
10	Y	I
11	)	O
12	is	O
13	an	O
14	important	O
15	cofactor	O
16	for	O
17	HLA	B
18	-	I
19	DRA	I
20	gene	I
21	activation	O
22	by	O
23	Oct	B
24	-	I
25	2A	I
26	and	O
27	provide	O
28	insights	O
29	into	O
30	its	O
31	mechanism	O
32	of	O
33	action	O
34	.	O

1	Composites	O
2	as	O
3	restoration	O
4	materials	O

1	The	O
2	survival	O
3	rate	O
4	at	O
5	forty	O
6	months	O
7	in	O
8	15	O
9	patients	O
10	with	O
11	N2	O
12	disease	O
13	who	O
14	underwent	O
15	R2b	O
16	operation	O
17	was	O
18	51	O
19	%.	O

1	Furthermore	O
2	,	O
3	in	O
4	the	O
5	ischemia	O
6	/	O
7	angiotension	O
8	II	O
9	-	O
10	induced	O
11	AHF	O
12	model	O
13	,	O
14	NIC	O
15	decreased	O
16	left	O
17	ventricular	O
18	end	O
19	-	O
20	diastolic	O
21	pressure	O
22	(	O
23	LVEDP	O
24	).	O

1	Transcription	O
2	from	O
3	adenovirus	O
4	E2	B
5	-	I
6	early	I
7	promoter	I
8	is	O
9	controlled	O
10	by	O
11	a	O
12	unique	O
13	array	O
14	of	O
15	four	O
16	cis	O
17	-	O
18	acting	O
19	elements	O
20	which	O
21	include	O
22	an	O
23	atypical	O
24	TBP	B
25	site	O
26	,	O
27	two	O
28	E2F	B
29	sites	O
30	present	O
31	in	O
32	an	O
33	inverted	O
34	orientation	O
35	relative	O
36	to	O
37	each	O
38	other	O
39	,	O
40	and	O
41	an	O
42	ATF	B
43	site	O
44	.	O

1	A	O
2	novel	O
3	Drosophila	B
4	A	I
5	kinase	I
6	anchor	I
7	protein	I
8	,	O
9	Drosophila	B
10	A	I
11	kinase	I
12	anchor	I
13	protein	O
14	200	O
15	(	O
16	DAKAP200	O
17	),	O
18	is	O
19	predicted	O
20	to	O
21	be	O
22	involved	O
23	in	O
24	routing	O
25	,	O
26	mediating	O
27	,	O
28	and	O
29	integrating	O
30	signals	O
31	carried	O
32	by	O
33	cAMP	O
34	,	O
35	Ca	O
36	(	O
37	2	O
38	+),	O
39	and	O
40	diacylglycerol	O
41	(	O
42	Li	O
43	,	O
44	Z	O
45	.,	O
46	Rossi	O
47	,	O
48	E	O
49	.	O

1	Responsiveness	O
2	to	O
3	beta	B
4	-	O
5	2	I
6	agonist	O
7	therapy	O
8	was	O
9	retained	O
10	with	O
11	both	O
12	agents	O
13	(	O
14	p	O
15	less	O
16	than	O
17	0	O
18	.	O
19	05	O
20	).	O

1	It	O
2	has	O
3	a	O
4	grave	O
5	prognosis	O
6	with	O
7	>	O
8	70	O
9	%	O
10	mortality	O
11	in	O
12	3	O
13	months	O
14	,	O
15	despite	O
16	mechanical	O
17	ventilation	O
18	.	O

1	The	O
2	protector	O
3	doubled	O
4	the	O
5	estimated	O
6	fall	O
7	distance	O
8	for	O
9	fracture	O
10	of	O
11	the	O
12	trochanter	O
13	.	O

1	Two	O
2	new	O
3	glucosidase	O
4	inhibitors	O
5	(	O
6	BAY	O
7	m	O
8	1099	O
9	and	O
10	BAY	O
11	o	I
12	1248	O
13	)	O
14	were	O
15	studied	O
16	in	O
17	volunteers	O
18	and	O
19	type	O
20	II	O
21	diabetics	O
22	under	O
23	various	O
24	conditions	O
25	.	O

1	The	O
2	glial	O
3	cyst	O
4	wall	O
5	was	O
6	lined	O
7	in	O
8	part	O
9	by	O
10	flattened	O
11	or	O
12	cuboidal	O
13	epithelium	O
14	.	O

1	IL	B
2	-	I
3	2	I
4	is	O
5	accepted	O
6	as	O
7	a	O
8	standard	O
9	treatment	O
10	used	O
11	alone	O
12	,	O
13	or	O
14	in	O
15	combination	O
16	with	O
17	chemotherapy	O
18	or	O
19	biotherapy	O
20	in	O
21	the	O
22	management	O
23	of	O
24	metastatic	O
25	melanoma	O
26	and	O
27	metastatic	O
28	renal	O
29	cell	O
30	carcinoma	O
31	.	O

1	A	O
2	control	O
3	group	O
4	of	O
5	nine	O
6	women	O
7	(	O
8	age	O
9	23	O
10	-	O
11	40	O
12	years	O
13	)	O
14	on	O
15	oral	O
16	contraceptives	O
17	(	O
18	Nordette	O
19	-	O
20	28	O
21	)	O
22	was	O
23	also	O
24	studied	O
25	four	O
26	times	O
27	during	O
28	a	O
29	pill	O
30	cycle	O
31	.	O

1	Accordingly	O
2	,	O
3	no	O
4	Ha	B
5	-	I
6	ras	I
7	codon	O
8	12	O
9	mutations	O
10	are	O
11	found	O
12	in	O
13	the	O
14	EtNU	O
15	-	O
16	induced	O
17	mammary	O
18	tumors	O
19	.	O

1	Tctex	O
2	-	O
3	1	O
4	binding	O
5	required	O
6	the	O
7	first	O
8	19	O
9	amino	O
10	acids	O
11	of	O
12	Fyn	B
13	and	O
14	integrity	O
15	of	O
16	two	O
17	lysine	O
18	residues	O
19	within	O
20	this	O
21	sequence	O
22	that	O
23	were	O
24	previously	O
25	shown	O
26	to	O
27	be	O
28	important	O
29	for	O
30	Fyn	B
31	interactions	O
32	with	O
33	the	O
34	immunoreceptor	O
35	tyrosine	O
36	-	O
37	based	O
38	activation	O
39	motifs	O
40	(	O
41	ITAMs	O
42	)	O
43	of	O
44	lymphocyte	B
45	Ag	I
46	receptors	I
47	.	O

1	Therefore	O
2	,	O
3	the	O
4	rbcL	B
5	-	I
6	rbcS	I
7	locus	I
8	seems	O
9	to	O
10	be	O
11	barely	O
12	expressed	O
13	under	O
14	a	O
15	standard	O
16	condition	O
17	for	O
18	photoautotrophic	O
19	growth	O
20	.	O

1	Hu	B
2	-	I
3	Met	I
4	-	I
5	1	I
6	mRNA	I
7	expression	O
8	in	O
9	a	O
10	small	O
11	number	O
12	of	O
13	human	O
14	T	O
15	cell	O
16	tumor	O
17	lines	O
18	did	O
19	not	O
20	correlate	O
21	with	O
22	any	O
23	particular	O
24	phenotype	O
25	or	O
26	stage	O
27	of	O
28	development	O
29	.	O

1	Three	O
2	mog	B
3	-	O
4	1	I
5	alleles	O
6	possess	O
7	premature	O
8	stop	O
9	codons	O
10	and	O
11	are	O
12	likely	O
13	to	O
14	be	O
15	null	O
16	alleles	O
17	,	O
18	and	O
19	one	O
20	is	O
21	a	O
22	missense	O
23	mutation	O
24	and	O
25	is	O
26	likely	O
27	to	O
28	retain	O
29	residual	O
30	activity	O
31	.	O
32	mog	B
33	-	I
34	1	I
35	mRNA	I
36	is	O
37	expressed	O
38	in	O
39	both	O
40	germ	O
41	line	O
42	and	O
43	somatic	O
44	tissues	O
45	and	O
46	appears	O
47	to	O
48	be	O
49	ubiquitous	O
50	.	O

1	Localization	O
2	of	O
3	67	O
4	exons	O
5	on	O
6	a	O
7	YAC	O
8	contig	O
9	spanning	O
10	1	O
11	.	O
12	5	O
13	Mb	O
14	around	O
15	the	O
16	multidrug	O
17	resistance	O
18	gene	O
19	region	O
20	of	O
21	human	O
22	chromosome	O
23	7q21	O
24	.	O
25	1	O
26	.	O

1	Compared	O
2	to	O
3	its	O
4	counterpart	O
5	in	O
6	the	O
7	GPB	O
8	gene	O
9	,	O
10	exon	O
11	3	O
12	of	O
13	the	O
14	GPE	O
15	gene	O
16	contains	O
17	several	O
18	point	O
19	mutations	O
20	,	O
21	an	O
22	insertion	O
23	of	O
24	24	O
25	bp	O
26	,	O
27	and	O
28	a	O
29	stop	O
30	codon	O
31	which	O
32	shortens	O
33	the	O
34	reading	O
35	frame	O
36	.	O

1	How	O
2	do	O
3	graduates	O
4	of	O
5	different	O
6	types	O
7	of	O
8	programs	O
9	perform	O
10	on	O
11	state	O
12	boards	O
13	?	O

1	This	O
2	study	O
3	was	O
4	undertaken	O
5	to	O
6	define	O
7	the	O
8	mechanism	O
9	for	O
10	the	O
11	respiratory	O
12	inhibition	O
13	observed	O
14	during	O
15	high	O
16	-	O
17	frequency	O
18	oscillatory	O
19	ventilation	O
20	(	O
21	HFOV	O
22	).	O

1	In	O
2	fact	O
3	,	O
4	SPT	O
5	activity	O
6	in	O
7	the	O
8	fly	O
9	expressing	O
10	epitope	O
11	-	O
12	tagged	O
13	Lace	O
14	was	O
15	absorbed	O
16	by	O
17	epitope	O
18	-	O
19	specific	O
20	antibody	O
21	.	O

1	Effects	O
2	of	O
3	rhG	B
4	-	I
5	CSF	I
6	on	O
7	neutrophil	O
8	functions	O
9	and	O
10	survival	O
11	in	O
12	sepsis	O
13	induced	O
14	diabetic	O
15	rats	O
16	.	O

1	The	O
2	pre	O
3	-	O
4	mRNA	O
5	splicing	O
6	factor	O
7	U2AF	O
8	(	O
9	U2	B
10	small	I
11	nuclear	I
12	ribonucleoprotein	I
13	particle	I
14	[	O
15	snRNP	O
16	]	O
17	auxiliary	O
18	factor	O
19	)	O
20	plays	O
21	a	O
22	critical	O
23	role	O
24	in	O
25	3	O
26	'	O
27	splice	O
28	site	O
29	selection	O
30	.	O

1	In	O
2	ferrets	O
3	naturally	O
4	infected	O
5	with	O
6	H	O
7	.	O
8	mustelae	O
9	,	O
10	a	O
11	single	O
12	dose	O
13	(	O
14	50	O
15	mg	O
16	/	O
17	kg	O
18	,	O
19	per	O
20	os	O
21	)	O
22	of	O
23	fluorofamide	O
24	completely	O
25	inhibited	O
26	bacterial	O
27	urease	I
28	.	O

1	The	O
2	cell	O
3	cycle	O
4	-	O
5	regulated	O
6	transcription	I
7	factor	I
8	E2F	I
9	is	O
10	also	O
11	known	O
12	to	O
13	bend	O
14	DNA	O
15	upon	O
16	binding	O
17	.	O

1	The	O
2	results	O
3	showed	O
4	that	O
5	the	O
6	sensitivity	O
7	of	O
8	the	O
9	3	O
10	given	O
11	guinea	O
12	pig	O
13	strains	O
14	was	O
15	comparable	O
16	.	O

1	Serum	B
2	gastrin	B
3	and	O
4	AFP	B
5	levels	O
6	had	O
7	the	O
8	same	O
9	evolution	O
10	and	O
11	appear	O
12	to	O
13	have	O
14	the	O
15	same	O
16	interest	O
17	to	O
18	follow	O
19	the	O
20	course	O
21	of	O
22	the	O
23	disease	O
24	.	O

1	GATA	B
2	-	I
3	1	I
4	mRNA	I
5	was	O
6	present	O
7	in	O
8	equivalent	O
9	levels	O
10	in	O
11	both	O
12	erythroid	O
13	cell	O
14	lines	O
15	,	O
16	but	O
17	at	O
18	a	O
19	low	O
20	level	O
21	in	O
22	FDC	O
23	-	O
24	P1	O
25	cells	O
26	.	O

1	The	O
2	ipiO	O
3	genes	O
4	code	O
5	for	O
6	two	O
7	almost	O
8	identical	O
9	152	O
10	-	O
11	aa	O
12	proteins	O
13	which	O
14	do	O
15	not	O
16	have	O
17	any	O
18	homology	O
19	with	O
20	sequences	O
21	present	O
22	in	O
23	data	O
24	libraries	O
25	.	O

1	The	O
2	RS447	O
3	human	O
4	megasatellite	O
5	tandem	O
6	repetitive	O
7	sequence	O
8	encodes	O
9	a	O
10	novel	O
11	deubiquitinating	O
12	enzyme	O
13	with	O
14	a	O
15	functional	O
16	promoter	O
17	.	O

1	MSSP	B
2	proteins	I
3	have	O
4	been	O
5	identified	O
6	by	O
7	their	O
8	binding	O
9	to	O
10	an	O
11	upstream	O
12	element	O
13	of	O
14	c	B
15	-	I
16	myc	I
17	.	O

1	The	O
2	transcription	O
3	and	O
4	alternative	O
5	splicing	O
6	of	O
7	human	O
8	ORL1	I
9	and	O
10	GAIP	O
11	are	O
12	cell	O
13	-	O
14	type	O
15	specific	O
16	.	O

1	Some	O
2	of	O
3	the	O
4	peptide	O
5	:	O
6	MBP	B
7	fusions	O
8	were	O
9	also	O
10	analyzed	O
11	using	O
12	surface	O
13	plasmon	O
14	resonance	O
15	.	O

1	This	O
2	phenomenon	O
3	may	O
4	be	O
5	regarded	O
6	as	O
7	a	O
8	variant	O
9	of	O
10	selective	O
11	individual	O
12	cell	O
13	death	O
14	,	O
15	currently	O
16	referred	O
17	to	O
18	as	O
19	apoptosis	O
20	,	O
21	which	O
22	has	O
23	not	O
24	been	O
25	previously	O
26	reported	O
27	in	O
28	a	O
29	case	O
30	of	O
31	embryonal	O
32	rhabdomyosarcoma	O
33	.	O

1	In	O
2	the	O
3	studies	O
4	described	O
5	in	O
6	this	O
7	report	O
8	,	O
9	we	O
10	have	O
11	investigated	O
12	the	O
13	signaling	O
14	pathway	O
15	(	O
16	s	O
17	)	O
18	that	O
19	are	O
20	responsible	O
21	for	O
22	CREB	B
23	activation	O
24	in	O
25	normal	O
26	T	O
27	cells	O
28	.	O

1	Deletion	O
2	and	O
3	site	O
4	-	O
5	directed	O
6	mutagenesis	O
7	localized	O
8	a	O
9	novel	O
10	SF	B
11	-	I
12	1	I
13	regulatory	I
14	element	I
15	(	O
16	TCA	O
17	GGGCCA	O
18	;	O
19	-	O
20	137	O
21	to	O
22	-	O
23	129	O
24	)	O
25	adjacent	O
26	to	O
27	a	O
28	variant	O
29	cAMP	O
30	-	O
31	response	O
32	element	O
33	(	O
34	CRE	O
35	;	O
36	-	O
37	120	O
38	to	O
39	-	O
40	114	O
41	).	O

1	Metastasis	O
2	of	O
3	colon	O
4	carcinoma	O
5	to	O
6	the	O
7	lip	O
8	.	O

1	Many	O
2	canonical	O
3	TATA	O
4	sequences	O
5	are	O
6	present	O
7	upstream	O
8	from	O
9	these	O
10	VZV	O
11	transcriptional	O
12	start	O
13	sites	O
14	but	O
15	,	O
16	apparently	O
17	,	O
18	are	O
19	not	O
20	used	O
21	.	O

1	The	O
2	SH3	B
3	domains	O
4	of	O
5	Grb2	B
6	bound	O
7	in	O
8	vitro	O
9	to	O
10	specific	O
11	proline	O
12	-	O
13	rich	O
14	motifs	O
15	in	O
16	the	O
17	HPK1	B
18	tail	O
19	and	O
20	functioned	O
21	synergistically	O
22	to	O
23	direct	O
24	the	O
25	stable	O
26	binding	O
27	of	O
28	Grb2	B
29	to	O
30	HPK1	B
31	in	O
32	transfected	O
33	Cos1	O
34	cells	O
35	.	O

1	Evidence	O
2	for	O
3	a	O
4	novel	O
5	MAPKKK	O
6	-	O
7	independent	O
8	pathway	O
9	controlling	O
10	the	O
11	stress	B
12	activated	O
13	Sty1	B
14	/	O
15	Spc1	B
16	MAP	I
17	kinase	I
18	in	O
19	fission	O
20	yeast	O
21	.	O

1	These	O
2	two	O
3	mAbs	O
4	used	O
5	the	O
6	same	O
7	V	O
8	(	O
9	H	O
10	)	O
11	and	O
12	J	O
13	(	O
14	H	B
15	)	O
16	gene	O
17	segments	O
18	,	O
19	but	O
20	different	O
21	D	O
22	,	O
23	Vkappa	O
24	,	O
25	and	O
26	Jkappa	B
27	genes	I
28	.	O

1	Adriamycin	O
2	:	O
3	comparison	O
4	of	O
5	a	O
6	5	O
7	-	O
8	week	O
9	schedule	O
10	with	O
11	a	O
12	3	O
13	-	O
14	week	O
15	schedule	O
16	in	O
17	the	O
18	treatment	O
19	of	O
20	breast	O
21	cancer	O
22	.	O

1	UPMC	O
2	is	O
3	not	O
4	the	O
5	only	O
6	organization	O
7	pursuing	O
8	controlled	O
9	NHBC	O
10	organ	O
11	procurement	O
12	,	O
13	however	O
14	.	O

1	Three	O
2	new	O
3	aromatase	B
4	inhibitors	O
5	have	O
6	recently	O
7	completed	O
8	phase	O
9	III	O
10	evaluation	O
11	as	O
12	treatment	O
13	of	O
14	metastatic	O
15	breast	O
16	cancer	O
17	in	O
18	post	O
19	-	O
20	menopausal	O
21	women	O
22	whose	O
23	disease	O
24	has	O
25	progressed	O
26	despite	O
27	tamoxifen	O
28	therapy	O
29	:	O
30	anastrozole	O
31	(	O
32	ARIMIDEX	O
33	,	O
34	Zeneca	O
35	),	O
36	letrozole	O
37	(	O
38	FEMARA	O
39	,	O
40	Novartis	O
41	)	O
42	and	O
43	vorozole	O
44	(	O
45	RIVIZOR	O
46	,	O
47	Janssen	O
48	).	O

1	We	O
2	screened	O
3	a	O
4	K562	O
5	cDNA	O
6	library	O
7	and	O
8	identified	O
9	novel	O
10	transcripts	O
11	,	O
12	MZF1B	O
13	and	O
14	MZF1C	O
15	.	O

1	Molecular	O
2	cloning	O
3	of	O
4	a	O
5	novel	O
6	human	O
7	I	I
8	-	I
9	mfa	I
10	domain	I
11	-	O
12	containing	O
13	protein	O
14	that	O
15	differently	O
16	regulates	O
17	human	O
18	T	O
19	-	O
20	cell	O
21	leukemia	O
22	virus	O
23	type	O
24	I	O
25	and	O
26	HIV	O
27	-	O
28	1	O
29	expression	O
30	.	O

1	No	O
2	difference	O
3	in	O
4	telomere	O
5	length	O
6	was	O
7	seen	O
8	in	O
9	mutants	O
10	affected	O
11	in	O
12	the	O
13	regulation	O
14	of	O
15	Cdc2	B
16	,	O
17	whereas	O
18	some	O
19	of	O
20	the	O
21	DNA	O
22	repair	O
23	mutants	O
24	examined	O
25	had	O
26	slightly	O
27	longer	O
28	telomeres	O
29	than	O
30	did	O
31	the	O
32	wild	O
33	type	O
34	.	O

1	Analysis	O
2	of	O
3	the	O
4	5	O
5	'	O
6	flanking	O
7	region	O
8	of	O
9	the	O
10	gene	O
11	also	O
12	revealed	O
13	the	O
14	presence	O
15	of	O
16	multiple	O
17	TATA	O
18	and	O
19	CAAT	O
20	sequences	O
21	.	O

1	Furthermore	O
2	,	O
3	the	O
4	initial	O
5	plasma	O
6	retinol	O
7	level	O
8	in	O
9	conjunction	O
10	with	O
11	RBP	B
12	was	O
13	found	O
14	to	O
15	be	O
16	even	O
17	lower	O
18	in	O
19	12	O
20	patients	O
21	(	O
22	35	O
23	.	O
24	1	O
25	micrograms	O
26	dl	O
27	-	O
28	1	O
29	,	O
30	3	O
31	.	O
32	7	O
33	mg	O
34	dl	O
35	-	O
36	1	O
37	)	O
38	who	O
39	subsequently	O
40	had	O
41	cancer	O
42	recurrence	O
43	than	O
44	in	O
45	those	O
46	who	O
47	remained	O
48	free	O
49	of	O
50	apparent	O
51	cancer	O
52	(	O
53	44	O
54	.	O
55	5	O
56	micrograms	O
57	dl	O
58	-	O
59	1	O
60	,	O
61	4	O
62	.	O
63	6	O
64	mg	O
65	dl	O
66	-	O
67	1	O
68	).	O

1	Stable	O
2	transfection	O
3	of	O
4	the	O
5	BL	O
6	cell	O
7	line	O
8	Raji	O
9	with	O
10	constructs	O
11	containing	O
12	core	O
13	promoter	O
14	mutations	O
15	confirmed	O
16	that	O
17	the	O
18	proximal	O
19	Sp1	B
20	site	I
21	and	O
22	the	O
23	TATA	O
24	box	O
25	are	O
26	essential	O
27	for	O
28	the	O
29	activation	O
30	of	O
31	promoter	O
32	P1	O
33	by	O
34	the	O
35	Ig	B
36	kappa	I
37	enhancers	I
38	.	O

1	The	O
2	prognosis	O
3	of	O
4	seven	O
5	patients	O
6	who	O
7	received	O
8	ABSCT	O
9	was	O
10	significantly	O
11	better	O
12	than	O
13	that	O
14	of	O
15	13	O
16	patients	O
17	who	O
18	received	O
19	conventional	O
20	therapy	O
21	alone	O
22	.	O

1	Truncated	B
2	forms	O
3	of	O
4	a	O
5	novel	O
6	yeast	O
7	protein	O
8	suppress	O
9	the	O
10	lethality	O
11	of	O
12	a	O
13	G	B
14	protein	I
15	alpha	I
16	subunit	I
17	deficiency	O
18	by	O
19	interacting	O
20	with	O
21	the	O
22	beta	O
23	subunit	O
24	.	O

1	Human	B
2	isoforms	O
3	,	O
4	designated	O
5	1	O
6	to	O
7	4	I
8	,	O
9	differ	O
10	from	O
11	each	O
12	other	O
13	by	O
14	the	O
15	start	O
16	codon	O
17	used	O
18	.	O

1	An	O
2	important	O
3	mechanism	O
4	by	O
5	which	O
6	the	O
7	tumor	B
8	suppressor	I
9	p53	I
10	maintains	O
11	genomic	O
12	stability	O
13	is	O
14	to	O
15	induce	O
16	cell	O
17	cycle	O
18	arrest	O
19	through	O
20	activation	O
21	of	O
22	the	O
23	cyclin	B
24	-	I
25	dependent	I
26	kinase	I
27	inhibitor	O
28	p21	B
29	(	O
30	WAF1	B
31	/	O
32	Cip1	B
33	)	O
34	gene	O
35	.	O

1	Cell	O
2	survival	O
3	by	O
4	Epo	B
5	did	O
6	not	O
7	require	O
8	activation	O
9	of	O
10	other	O
11	known	O
12	signaling	O
13	pathways	O
14	including	O
15	PI	B
16	-	I
17	3	I
18	kinase	I
19	,	O
20	PLC	B
21	-	I
22	gamma	I
23	,	O
24	Ras	B
25	or	O
26	Stats	B
27	.	O

1	In	O
2	PB	O
3	mice	O
4	,	O
5	there	O
6	was	O
7	only	O
8	a	O
9	small	O
10	deficit	O
11	in	O
12	the	O
13	number	O
14	of	O
15	the	O
16	hippocampal	O
17	pyramidal	O
18	neurons	O
19	compared	O
20	to	O
21	controls	O
22	(	O
23	15	O
24	%,	O
25	p	O
26	less	O
27	than	O
28	0	O
29	.	O
30	01	O
31	),	O
32	and	O
33	no	O
34	deficit	O
35	in	O
36	the	O
37	granule	O
38	cells	O
39	.	O

1	These	O
2	data	O
3	suggest	O
4	that	O
5	:	O
6	(	O
7	a	O
8	)	O
9	proSRIF	O
10	cleavage	O
11	is	O
12	initiated	O
13	in	O
14	the	O
15	TGN	O
16	,	O
17	and	O
18	(	O
19	b	O
20	)	O
21	this	O
22	reaction	O
23	requires	O
24	an	O
25	acidic	O
26	pH	O
27	which	O
28	is	O
29	facilitated	O
30	by	O
31	a	O
32	Golgi	O
33	-	O
34	associated	O
35	vacuolar	O
36	-	O
37	type	O
38	ATPase	I
39	.	O

1	Nucleotide	O
2	sequence	O
3	analysis	O
4	of	O
5	the	O
6	Pseudomonas	B
7	putida	O
8	PpG7	B
9	salicylate	B
10	hydroxylase	I
11	gene	I
12	(	O
13	nahG	O
14	)	O
15	and	O
16	its	O
17	3	O
18	'-	O
19	flanking	O
20	region	O
21	.	O

1	S6	I
2	kinase	I
3	activation	O
4	requires	O
5	displacement	O
6	of	O
7	this	O
8	inhibitory	O
9	segment	O
10	,	O
11	which	O
12	is	O
13	proposed	O
14	to	O
15	occur	O
16	consequent	O
17	to	O
18	its	O
19	multiple	O
20	phosphorylation	O
21	.	O

1	Transformed	O
2	bacterial	O
3	colonies	O
4	were	O
5	screened	O
6	for	O
7	recombinant	O
8	plasmids	O
9	containing	O
10	cDNA	O
11	coding	O
12	for	O
13	BiP	B
14	by	O
15	hybrid	O
16	-	O
17	selected	O
18	mRNA	O
19	translation	O
20	.	O

1	During	O
2	the	O
3	last	O
4	6	O
5	months	O
6	of	O
7	the	O
8	study	O
9	a	O
10	striking	O
11	change	O
12	in	O
13	epidemiology	O
14	concerning	O
15	hepatitis	O
16	A	O
17	was	O
18	seen	O
19	,	O
20	apparently	O
21	caused	O
22	by	O
23	a	O
24	steep	O
25	increase	O
26	in	O
27	the	O
28	incidence	O
29	of	O
30	this	O
31	type	O
32	of	O
33	hepatitis	O
34	among	O
35	drug	O
36	addicts	O
37	.	O

1	However	O
2	,	O
3	only	O
4	complete	O
5	DnaJ	O
6	can	O
7	cooperate	O
8	with	O
9	DnaK	O
10	and	O
11	a	O
12	third	O
13	protein	O
14	,	O
15	GrpE	O
16	,	O
17	in	O
18	refolding	B
19	denatured	O
20	firefly	B
21	luciferase	I
22	.	O

1	Diltiazem	O
2	resulted	O
3	in	O
4	a	O
5	significant	O
6	increase	O
7	in	O
8	epicardial	O
9	diameter	O
10	(+	O
11	10	O
12	%;	O
13	p	O
14	=	O
15	0	O
16	.	O
17	001	O
18	)	O
19	and	O
20	in	O
21	coronary	O
22	blood	O
23	flow	O
24	(	O
25	CBF	O
26	)	O
27	(+	O
28	30	O
29	%;	O
30	p	O
31	=	O
32	0	O
33	.	O
34	0001	O
35	).	O

1	Collaborative	O
2	study	O
3	of	O
4	Japanese	O
5	Pharmacopoeia	O
6	Heparin	O
7	Sodium	O
8	Reference	O
9	Standard	O

1	First	O
2	,	O
3	a	O
4	pet54	O
5	::	O
6	LEU2	B
7	cytoductant	O
8	bearing	O
9	the	O
10	'	O
11	short	O
12	'	O
13	mitochondrial	O
14	genome	O
15	that	O
16	lacks	O
17	both	O
18	COX1	O
19	introns	O
20	aI5	O
21	alpha	O
22	and	O
23	aI5	O
24	beta	O
25	is	O
26	defective	O
27	only	O
28	in	O
29	COX3	O
30	gene	O
31	expression	O
32	and	O
33	not	O
34	in	O
35	COX1	O
36	mRNA	O
37	splicing	O
38	or	O
39	mRNA	O
40	translation	O
41	.	O

1	Derivatives	O
2	of	O
3	fluorene	O
4	.	O

1	P	O
2	.,	O
3	Peyron	O
4	,	O
5	J	O
6	.	O

1	Site	O
2	S	I
3	-	I
4	II	I
5	also	O
6	spans	O
7	a	O
8	23	O
9	bp	O
10	sequence	O
11	containing	O
12	two	O
13	tandem	O
14	consensus	O
15	binding	O
16	sites	O
17	with	O
18	three	O
19	base	O
20	pair	O
21	mismatches	O
22	in	O
23	each	O
24	and	O
25	a	O
26	one	O
27	base	O
28	pair	O
29	deletion	O
30	.	O

1	IRF	B
2	-	I
3	1	I
4	acts	O
5	as	O
6	a	O
7	transcriptional	O
8	activator	O
9	,	O
10	while	O
11	IRF	B
12	-	I
13	2	I
14	acts	O
15	as	O
16	a	O
17	repressor	O
18	.	O

1	The	O
2	positive	O
3	-	O
4	acting	O
5	global	O
6	sulfur	O
7	regulatory	O
8	protein	O
9	,	O
10	CYS3	O
11	,	O
12	of	O
13	Neurospora	B
14	crassa	I
15	turns	O
16	on	O
17	the	O
18	expression	O
19	of	O
20	a	O
21	family	O
22	of	O
23	unlinked	O
24	structural	O
25	genes	O
26	that	O
27	encode	O
28	enzymes	O
29	of	O
30	sulfur	O
31	catabolism	O
32	.	O

1	The	O
2	imino	O
3	proton	O
4	of	O
5	T3	O
6	in	O
7	the	O
8	O6meG	O
9	.	O
10	T	O
11	12	O
12	-	O
13	mer	O
14	and	O
15	G3	O
16	in	O
17	the	O
18	O6meG	O
19	.	O
20	N	O
21	12	O
22	-	O
23	mer	O
24	helix	O
25	,	O
26	which	O
27	are	O
28	associated	O
29	with	O
30	the	O
31	modification	O
32	site	O
33	,	O
34	resonate	O
35	at	O
36	unusually	O
37	high	O
38	field	O
39	(	O
40	8	O
41	.	O
42	5	O
43	to	O
44	9	O
45	.	O
46	0	O
47	ppm	O
48	)	O
49	compared	O
50	to	O
51	imino	O
52	protons	O
53	in	O
54	Watson	O
55	-	O
56	Crick	O
57	base	O
58	pairs	O
59	(	O
60	12	O
61	.	O
62	5	O
63	to	O
64	14	O
65	.	O
66	5	O
67	ppm	O
68	).	O

1	In	O
2	the	O
3	present	O
4	experiments	O
5	,	O
6	we	O
7	investigate	O
8	the	O
9	role	O
10	played	O
11	by	O
12	the	O
13	temporal	O
14	pattern	O
15	of	O
16	neural	O
17	activity	O
18	during	O
19	the	O
20	ontogeny	O
21	of	O
22	frequency	O
23	tuning	O
24	in	O
25	the	O
26	mouse	O
27	central	O
28	auditory	O
29	system	O
30	.	O

1	In	O
2	the	O
3	IA	O
4	task	O
5	,	O
6	post	O
7	-	O
8	training	O
9	intraperitoneal	O
10	injections	O
11	of	O
12	picrotoxin	O
13	and	O
14	bicuculline	O
15	induced	O
16	a	O
17	dose	O
18	-	O
19	dependent	O
20	enhancement	O
21	of	O
22	retention	O
23	measured	O
24	24	O
25	h	O
26	after	O
27	the	O
28	training	O
29	,	O
30	while	O
31	retention	O
32	was	O
33	not	O
34	affected	O
35	by	O
36	bicuculline	O
37	methiodide	O
38	(	O
39	a	O
40	GABA	O
41	receptor	O
42	antagonist	O
43	that	O
44	does	O
45	not	O
46	readily	O
47	cross	O
48	the	O
49	blood	O
50	-	O
51	brain	O
52	barrier	O
53	).	O

1	False	O
2	positive	O
3	amniotic	O
4	fluid	O
5	alpha	O
6	fetoprotein	I
7	levels	O
8	resulting	O
9	from	O
10	contamination	O
11	with	O
12	fetal	O
13	blood	O
14	:	O
15	results	O
16	of	O
17	an	O
18	experiment	O
19	.	O

1	To	O
2	identify	O
3	cis	O
4	-	O
5	acting	O
6	elements	O
7	that	O
8	target	O
9	c	B
10	-	I
11	myc	I
12	mRNA	I
13	for	O
14	downregulation	O
15	during	O
16	myogenesis	O
17	,	O
18	we	O
19	stably	O
20	transfected	O
21	C2C12	O
22	cells	O
23	with	O
24	mutant	B
25	myc	I
26	genes	I
27	or	O
28	chimeric	O
29	genes	O
30	in	O
31	which	O
32	various	O
33	myc	B
34	sequences	I
35	were	O
36	fused	O
37	to	O
38	the	O
39	human	B
40	beta	I
41	-	I
42	globin	I
43	gene	I
44	or	O
45	to	O
46	the	O
47	bacterial	B
48	chloramphenicol	I
49	acetyltransferase	I
50	(	O
51	CAT	B
52	)	O
53	gene	O
54	.	O

1	Successful	O
2	treatment	O
3	with	O
4	nasal	O
5	continuous	O
6	positive	O
7	airway	O
8	pressure	O
9	(	O
10	8	O
11	.	O
12	3	O
13	+/-	O
14	1	O
15	.	O
16	5	O
17	cmH2O	O
18	)	O
19	for	O
20	3	O
21	days	O
22	caused	O
23	a	O
24	significant	O
25	decrease	O
26	in	O
27	mean	O
28	blood	O
29	pressure	O
30	in	O
31	OSAS	O
32	.	O

1	Upon	O
2	analysis	O
3	of	O
4	various	O
5	deletion	O
6	and	O
7	point	O
8	-	O
9	mutated	O
10	variants	O
11	of	O
12	the	O
13	human	B
14	IL	I
15	-	I
16	6	I
17	gene	I
18	promoter	I
19	coupled	I
20	to	O
21	a	O
22	reporter	O
23	gene	O
24	,	O
25	we	O
26	screened	O
27	for	O
28	possible	O
29	cooperating	O
30	transcription	O
31	factors	I
32	.	O

1	The	O
2	effect	O
3	of	O
4	nitric	B
5	oxide	I
6	synthase	I
7	inhibitor	O
8	on	O
9	reperfusion	O
10	injury	O
11	of	O
12	the	O
13	brain	O
14	under	O
15	hypothermic	O
16	circulatory	O
17	arrest	O
18	.	O

1	Analysis	O
2	of	O
3	hematopoietic	B
4	growth	I
5	factor	I
6	prescriptions	O
7	in	O
8	19	O
9	french	O
10	cancer	O
11	centers	O

1	Our	O
2	study	O
3	differs	O
4	from	O
5	previous	O
6	studies	O
7	in	O
8	that	O
9	it	O
10	is	O
11	limited	O
12	to	O
13	one	O
14	diagnostic	O
15	entity	O
16	,	O
17	yet	O
18	at	O
19	the	O
20	same	O
21	time	O
22	evaluates	O
23	a	O
24	broad	O
25	range	O
26	of	O
27	social	O
28	and	O
29	work	O
30	-	O
31	related	O
32	factors	O
33	in	O
34	disability	O
35	.	O

1	Two	O
2	patients	O
3	withdrew	O
4	from	O
5	therapy	O
6	,	O
7	one	O
8	for	O
9	personal	O
10	reasons	O
11	and	O
12	one	O
13	because	O
14	a	O
15	paraspinal	O
16	mass	O
17	developed	O
18	.	O

1	Despite	O
2	the	O
3	absence	O
4	of	O
5	exercise	O
6	-	O
7	induced	O
8	asthma	O
9	(	O
10	EIA	O
11	)	O
12	while	O
13	breathing	O
14	WH	O
15	air	O
16	,	O
17	asthmatic	O
18	patients	O
19	still	O
20	had	O
21	significantly	O
22	higher	O
23	mean	O
24	GH	B
25	increments	O
26	than	O
27	normal	O
28	subjects	O
29	(	O
30	9	O
31	.	O
32	2	O
33	vs	O
34	2	O
35	.	O
36	3	O
37	ng	O
38	/	O
39	ml	O
40	,	O
41	P	O
42	less	O
43	than	O
44	0	O
45	.	O
46	05	O
47	).	O

1	Unlike	O
2	the	O
3	introns	O
4	of	O
5	other	O
6	duplicated	O
7	ribosomal	B
8	protein	O
9	genes	O
10	which	O
11	are	O
12	highly	O
13	diverged	O
14	,	O
15	the	O
16	duplicated	O
17	S13	B
18	genes	O
19	have	O
20	two	O
21	nearly	O
22	identical	O
23	DNA	O
24	sequences	O
25	of	O
26	25	O
27	and	O
28	31	O
29	bp	O
30	in	O
31	length	O
32	within	O
33	their	O
34	introns	O
35	.	O

1	We	O
2	show	O
3	that	O
4	these	O
5	three	O
6	gain	O
7	-	O
8	of	O
9	-	O
10	function	O
11	mutants	O
12	differ	O
13	considerably	O
14	in	O
15	their	O
16	ability	O
17	to	O
18	bypass	O
19	the	O
20	sex	O
21	determination	O
22	signal	O
23	,	O
24	with	O
25	SxlM4	O
26	being	O
27	the	O
28	strongest	O
29	and	O
30	SxlM1	O
31	the	O
32	weakest	O
33	.	O

1	Since	O
2	proteins	O
3	containing	O
4	TPR	O
5	elements	O
6	are	O
7	typically	O
8	involved	O
9	in	O
10	multiple	O
11	protein	O
12	-	O
13	protein	O
14	interactions	O
15	,	O
16	we	O
17	suggest	O
18	that	O
19	the	O
20	102kD	B
21	protein	O
22	interacts	O
23	within	O
24	the	O
25	tri	O
26	-	O
27	snRNP	O
28	with	O
29	both	O
30	the	O
31	U5	B
32	and	O
33	U4	B
34	/	O
35	U6	B
36	snRNPs	I
37	,	O
38	thus	O
39	bridging	O
40	the	O
41	two	O
42	particles	O
43	.	O

1	Localization	O
2	of	O
3	the	O
4	brachial	O
5	plexus	O
6	with	O
7	the	O
8	nerve	O
9	stimulator	O
10	is	O
11	equally	O
12	effective	O
13	at	O
14	the	O
15	interscalene	O
16	,	O
17	supraclavicular	O
18	,	O
19	and	O
20	axillary	O
21	sites	O
22	.	O

1	The	O
2	distribution	O
3	of	O
4	the	O
5	various	O
6	repeats	O
7	suggests	O
8	its	O
9	organization	O
10	is	O
11	similar	O
12	to	O
13	the	O
14	beta	O
15	-	O
16	heterochromatic	O
17	regions	O
18	near	O
19	the	O
20	base	O
21	of	O
22	the	O
23	major	O
24	chromosome	O
25	arms	O
26	.	O

1	Because	O
2	there	O
3	is	O
4	great	O
5	need	O
6	for	O
7	iron	O
8	in	O
9	the	O
10	EPO	B
11	-	O
12	stimulated	O
13	erythroid	O
14	progenitors	O
15	,	O
16	it	O
17	is	O
18	essential	O
19	that	O
20	serum	O
21	ferritin	B
22	and	O
23	transferrin	B
24	saturation	O
25	levels	O
26	should	O
27	be	O
28	maintained	O
29	over	O
30	300	O
31	microg	O
32	/	O
33	liter	O
34	and	O
35	30	O
36	%,	O
37	respectively	O
38	.	O

1	Obesity	O
2	was	O
3	strongly	O
4	associated	O
5	with	O
6	the	O
7	proportions	O
8	of	O
9	nonprotein	O
10	-	O
11	bound	O
12	and	O
13	albumin	B
14	-	O
15	bound	O
16	estradiol	O
17	,	O
18	and	O
19	inversely	O
20	associated	O
21	with	O
22	sex	B
23	hormone	I
24	binding	O
25	globulin	I
26	(	O
27	SHBG	B
28	)	O
29	levels	O
30	and	O
31	the	O
32	proportion	O
33	of	O
34	SHBG	B
35	-	O
36	bound	O
37	estradiol	O
38	.	O

1	Furthermore	O
2	,	O
3	both	O
4	rhHR23	O
5	proteins	O
6	function	O
7	in	O
8	a	O
9	defined	O
10	NER	O
11	system	O
12	reconstituted	O
13	with	O
14	purified	O
15	proteins	O
16	,	O
17	indicating	O
18	direct	O
19	involvement	O
20	of	O
21	hHR23	O
22	proteins	O
23	in	O
24	the	O
25	DNA	O
26	repair	O
27	reaction	O
28	via	O
29	interaction	O
30	with	O
31	XPC	O
32	.	O

1	The	O
2	association	O
3	of	O
4	clopamide	O
5	and	O
6	hydergine	O
7	(	O
8	Brinedine	O
9	)	O
10	in	O
11	the	O
12	treatment	O
13	of	O
14	the	O
15	vasculo	O
16	-	O
17	renal	O
18	syndromes	O
19	of	O
20	pregnancy	O

1	Egd1p	O
2	is	O
3	homologous	O
4	to	O
5	human	O
6	BTF3b	O
7	,	O
8	recently	O
9	identified	O
10	as	O
11	the	O
12	beta	O
13	subunit	O
14	of	O
15	the	O
16	heterodimeric	O
17	nascent	O
18	-	O
19	polypeptide	O
20	-	O
21	associated	O
22	complex	O
23	(	O
24	NAC	B
25	)	O
26	involved	O
27	in	O
28	ensuring	O
29	signal	O
30	-	O
31	sequence	O
32	-	O
33	specific	O
34	protein	O
35	sorting	O
36	and	O
37	translocation	O
38	[	O
39	Wiedmann	O
40	et	O
41	al	O
42	.,	O
43	Nature	O
44	370	O
45	(	O
46	1994	O
47	)	O
48	434	O
49	-	O
50	440	O
51	].	O

1	A	O
2	potential	O
3	TATA	O
4	box	O
5	is	O
6	located	O
7	29	O
8	base	O
9	pairs	O
10	upstream	O
11	of	O
12	the	O
13	first	O
14	transcription	O
15	initiation	O
16	site	O
17	.	O

1	We	O
2	report	O
3	a	O
4	case	O
5	of	O
6	pheochromocytoma	O
7	manifesting	O
8	during	O
9	the	O
10	third	O
11	trimester	O
12	of	O
13	pregnancy	O
14	.	O

1	Each	O
2	repeat	O
3	consists	O
4	of	O
5	12	O
6	nt	O
7	,	O
8	coding	O
9	for	O
10	the	O
11	reiterated	O
12	sequence	O
13	,	O
14	K	O
15	/	O
16	NPAG	O
17	.	O

1	Oncogenic	O
2	activation	O
3	of	O
4	the	O
5	tyrosine	B
6	kinase	I
7	domain	O
8	of	O
9	the	O
10	human	B
11	trk	B
12	proto	I
13	-	I
14	oncogene	I
15	by	O
16	fusion	O
17	to	O
18	a	O
19	cell	O
20	adhesion	O
21	molecule	O
22	.	O

1	Its	O
2	organization	O
3	and	O
4	regulation	O
5	indicate	O
6	that	O
7	the	O
8	S	O
9	.	O
10	pombe	O
11	URA1	O
12	gene	O
13	product	O
14	appears	O
15	very	O
16	similar	O
17	to	O
18	the	O
19	S	O
20	.	O
21	cerevisiae	O
22	URA2	B
23	gene	I
24	product	I
25	.	O

1	Comparison	O
2	of	O
3	data	O
4	obtained	O
5	with	O
6	the	O
7	results	O
8	of	O
9	chronic	O
10	treatment	O
11	with	O
12	the	O
13	opioid	O
14	antagonist	O
15	permits	O
16	to	O
17	conclude	O
18	that	O
19	the	O
20	chronic	O
21	blockade	O
22	increases	O
23	the	O
24	fatiguability	O
25	to	O
26	a	O
27	great	O
28	extent	O
29	than	O
30	chronic	O
31	activation	O
32	of	O
33	opioid	O
34	system	O
35	.	O

1	Since	O
2	RCC1p	O
3	acts	O
4	as	O
5	GNRP	O
6	for	O
7	Ran	B
8	,	O
9	a	O
10	small	B
11	nuclear	I
12	GTPase	I
13	of	O
14	the	O
15	ras	B
16	superfamily	I
17	,	O
18	we	O
19	have	O
20	identified	O
21	two	O
22	homologs	O
23	of	O
24	Ran	B
25	in	O
26	S	I
27	.	O
28	cerevisiae	O
29	(	O
30	CNR1	O
31	and	O
32	CNR2	O
33	).	O

1	Molecular	O
2	and	O
3	genetic	O
4	analysis	O
5	of	O
6	the	O
7	yeast	O
8	early	O
9	meiotic	O
10	recombination	O
11	genes	O
12	REC102	O
13	and	O
14	REC107	O
15	/	O
16	MER2	O
17	.	O

1	The	O
2	above	O
3	results	O
4	mean	O
5	that	O
6	the	O
7	increase	O
8	in	O
9	alpha	B
10	-	I
11	adrenergic	I
12	receptors	I
13	makes	O
14	the	O
15	prostate	O
16	,	O
17	which	O
18	has	O
19	been	O
20	already	O
21	hypertrophied	O
22	,	O
23	less	O
24	elastic	O
25	,	O
26	inhibiting	O
27	external	O
28	urinary	O
29	sphincter	O
30	function	O
31	.	O

1	In	O
2	contrast	O
3	to	O
4	full	O
5	-	O
6	length	I
7	E2F	B
8	-	I
9	3	I
10	,	O
11	which	O
12	is	O
13	expressed	O
14	only	O
15	at	O
16	the	O
17	G1	O
18	/	O
19	S	O
20	boundary	O
21	,	O
22	E2F	B
23	-	I
24	3B	I
25	is	O
26	detected	O
27	throughout	O
28	the	O
29	cell	O
30	cycle	O
31	with	O
32	peak	O
33	levels	O
34	in	O
35	GO	O
36	where	O
37	it	O
38	is	O
39	associated	O
40	with	O
41	Rb	B
42	.	O

1	A	O
2	long	O
3	follow	O
4	-	O
5	up	O
6	study	O
7	revealed	O
8	that	O
9	convalescent	O
10	stage	O
11	children	O
12	still	O
13	have	O
14	the	O
15	potency	O
16	to	O
17	have	O
18	an	O
19	immediate	O
20	type	O
21	hypersensitivity	O
22	reaction	O
23	on	O
24	exposure	O
25	to	O
26	mite	O
27	antigen	O
28	,	O
29	with	O
30	a	O
31	high	O
32	titer	O
33	of	O
34	mite	O
35	specific	O
36	IgE	B
37	in	O
38	their	O
39	sera	O
40	,	O
41	but	O
42	they	O
43	are	O
44	free	O
45	from	O
46	asthmatic	O
47	attacks	O
48	because	O
49	of	O
50	the	O
51	reduction	O
52	in	O
53	the	O
54	amount	O
55	of	O
56	mite	O
57	antigen	O
58	in	O
59	the	O
60	body	O
61	,	O
62	as	O
63	shown	O
64	by	O
65	the	O
66	reduction	O
67	in	O
68	the	O
69	amount	O
70	of	O
71	mite	O
72	specific	O
73	IgG	B
74	.	O

1	HYPOTHESIS	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	this	O
7	study	O
8	was	O
9	to	O
10	investigate	O
11	the	O
12	oxidative	O
13	susceptibility	O
14	of	O
15	apolipoprotein	B
16	B	I
17	-	I
18	containing	O
19	lipoproteins	O
20	and	O
21	antioxidant	O
22	status	O
23	in	O
24	patients	O
25	with	O
26	acute	O
27	coronary	O
28	syndromes	O
29	and	O
30	chronic	O
31	stable	O
32	angina	O
33	pectoris	O
34	.	O

1	In	O
2	EEG	O
3	only	O
4	single	O
5	slow	O
6	waves	O
7	above	O
8	left	O
9	temporal	O
10	region	O
11	were	O
12	revealed	O
13	.	O

1	GAL4	B
2	-	O
3	VP16	I
4	-	O
5	mediated	O
6	antirepression	O
7	required	O
8	an	O
9	auxiliary	O
10	factor	O
11	,	O
12	denoted	O
13	as	O
14	a	O
15	co	O
16	-	O
17	antirepressor	O
18	,	O
19	which	O
20	was	O
21	partially	O
22	purified	O
23	from	O
24	Drosophila	O
25	embryos	O
26	.	O

1	A	O
2	single	O
3	-	O
4	case	O
5	experimental	O
6	ABAB	O
7	multiple	O
8	baseline	O
9	design	O
10	was	O
11	employed	O
12	to	O
13	test	O
14	for	O
15	treatment	O
16	effectiveness	O
17	.	O

1	Cotransfection	O
2	of	O
3	either	O
4	construct	O
5	with	O
6	plasmids	O
7	encoding	O
8	PKI	O
9	(	O
10	1	O
11	-	O
12	31	O
13	)	O
14	inhibits	O
15	cAMP	O
16	-	O
17	stimulated	O
18	but	O
19	not	O
20	basal	O
21	-	O
22	or	O
23	phorbol	O
24	ester	O
25	-	O
26	stimulated	O
27	expression	O
28	.	O

1	In	O
2	a	O
3	country	O
4	where	O
5	general	O
6	HIV	O
7	prevalence	O
8	is	O
9	low	O
10	,	O
11	the	O
12	strategy	O
13	is	O
14	cost	O
15	-	O
16	effective	O
17	for	O
18	location	O
19	and	O
20	counselling	O
21	of	O
22	unknowingly	O
23	seropositive	O
24	individuals	O
25	.	O

1	The	O
2	present	O
3	research	O
4	evaluated	O
5	the	O
6	possibility	O
7	that	O
8	polyethylene	O
9	glycol	O
10	400	O
11	(	O
12	PEG	O
13	400	O
14	)	O
15	might	O
16	be	O
17	efficacious	O
18	,	O
19	toxic	O
20	,	O
21	or	O
22	both	O
23	.	O

1	We	O
2	discuss	O
3	these	O
4	results	O
5	with	O
6	respect	O
7	to	O
8	the	O
9	transcriptional	O
10	induction	O
11	of	O
12	the	O
13	HNF	B
14	-	I
15	3	I
16	alpha	I
17	gene	I
18	in	O
19	respiratory	O
20	epithelium	O
21	during	O
22	embryogenesis	O
23	.	O

1	Using	O
2	in	O
3	organello	O
4	footprint	O
5	analysis	O
6	,	O
7	we	O
8	demonstrate	O
9	that	O
10	within	O
11	human	O
12	placental	O
13	mitochondria	O
14	there	O
15	is	O
16	a	O
17	high	O
18	level	O
19	of	O
20	protein	O
21	-	O
22	DNA	O
23	binding	O
24	at	O
25	regularly	O
26	phased	O
27	intervals	O
28	throughout	O
29	a	O
30	500	O
31	-	O
32	bp	O
33	region	O
34	encompassing	O
35	the	O
36	D	O
37	-	O
38	loop	O
39	DNA	O
40	origins	O
41	and	O
42	two	O
43	promoter	O
44	regions	O
45	.	O

1	A	O
2	series	O
3	of	O
4	amino	O
5	terminal	O
6	deletion	O
7	mutants	O
8	(	O
9	d10	O
10	,	O
11	d20	O
12	,	O
13	d27	O
14	,	O
15	d31	O
16	,	O
17	d40	O
18	,	O
19	d44	O
20	,	O
21	and	O
22	d73	O
23	)	O
24	were	O
25	compared	O
26	for	O
27	processing	O
28	,	O
29	cell	O
30	surface	O
31	expression	O
32	,	O
33	and	O
34	maintenance	O
35	of	O
36	their	O
37	biological	O
38	attributes	O
39	by	O
40	recombinant	O
41	expression	O
42	of	O
43	mutant	O
44	genes	O
45	using	O
46	a	O
47	plasmid	O
48	vector	O
49	(	O
50	pcDL	O
51	-	O
52	SR	B
53	alpha	I
54	-	I
55	296	O
56	)	O
57	in	O
58	CV	O
59	-	O
60	1	O
61	and	O
62	HeLa	O
63	cells	O
64	.	O

1	Leukemia	B
2	in	O
3	twins	O
4	:	O
5	world	O
6	-	O
7	wide	O
8	review	O
9	of	O
10	clinical	O
11	cases	O
12	.	O

1	METHODS	O
2	--	O
3	16	O
4	volunteered	O
5	for	O
6	spirometry	O
7	with	O
8	methacholine	O
9	provocation	O
10	test	O
11	including	O
12	a	O
13	test	O
14	for	O
15	small	O
16	airways	O
17	function	O
18	by	O
19	volume	O
20	of	O
21	trapped	O
22	gas	O
23	(	O
24	VTG	O
25	).	O

1	A	O
2	diagnosis	O
3	of	O
4	IgA	B
5	lambda	O
6	multiple	O
7	myeloma	O
8	with	O
9	peritoneal	O
10	involvement	O
11	was	O
12	made	O
13	.	O

1	Effect	O
2	of	O
3	nitrous	O
4	oxide	O
5	(	O
6	N2O	O
7	)	O
8	on	O
9	the	O
10	somatosympathetic	O
11	A	O
12	-	O
13	and	O
14	C	O
15	-	O
16	reflexes	O
17	was	O
18	investigated	O
19	using	O
20	artificially	O
21	ventilated	O
22	rats	O
23	anesthetized	O
24	with	O
25	alpha	O
26	-	O
27	chloralose	O
28	and	O
29	urethane	O
30	.	O

1	The	O
2	studied	O
3	protein	O
4	fragments	O
5	consist	O
6	of	O
7	residues	O
8	Arg183	O
9	-	O
10	His267	O
11	of	O
12	the	O
13	human	O
14	ER	I
15	and	O
16	residues	O
17	Lys438	O
18	-	O
19	Gln520	O
20	of	O
21	the	O
22	rat	B
23	GR	I
24	.	O

1	A	O
2	quantitative	O
3	analysis	O
4	of	O
5	the	O
6	diffraction	O
7	intensity	O
8	as	O
9	function	O
10	of	O
11	the	O
12	accumulated	O
13	electron	O
14	dose	O
15	suggests	O
16	the	O
17	possibility	O
18	of	O
19	recording	O
20	up	O
21	to	O
22	250	O
23	diffraction	O
24	patterns	O
25	with	O
26	3	O
27	.	O
28	5	O
29	A	O
30	resolution	O
31	from	O
32	a	O
33	single	O
34	crotoxin	O
35	complex	O
36	crystal	O
37	128	O
38	A	O
39	thick	O
40	.	O

1	Targeted	O
2	disruption	O
3	of	O
4	the	O
5	OGG1	O
6	gene	O
7	in	O
8	yeast	O
9	revealed	O
10	a	O
11	second	O
12	OG	B
13	glycosylase	I
14	/	I
15	lyase	I
16	protein	I
17	,	O
18	tentatively	O
19	named	O
20	Ogg2	O
21	,	O
22	which	O
23	differs	O
24	from	O
25	Ogg1	B
26	in	O
27	that	O
28	it	O
29	preferentially	O
30	acts	O
31	on	O
32	OG	O
33	:	O
34	G	O
35	.	O

1	Bacterial	O
2	recovery	O
3	of	O
4	SA	O
5	from	O
6	the	O
7	liver	O
8	/	O
9	spleen	O
10	and	O
11	the	O
12	cecal	O
13	tonsil	O
14	in	O
15	contact	O
16	poults	O
17	and	O
18	SG	O
19	from	O
20	contact	O
21	chicks	O
22	treated	O
23	with	O
24	ILK	B
25	was	O
26	dramatically	O
27	reduced	O
28	when	O
29	compared	O
30	to	O
31	non	O
32	-	O
33	treated	O
34	contact	O
35	poults	O
36	and	O
37	chicks	O
38	.	O

1	Effects	O
2	of	O
3	cisapride	O
4	on	O
5	upper	O
6	-	O
7	gastrointestinal	O
8	motility	O
9	and	O
10	digestive	O
11	hormones	O

1	Thirty	O
2	cadaver	O
3	brains	O
4	were	O
5	examined	O
6	under	O
7	X	O
8	6	O
9	to	O
10	16	O
11	magnification	O
12	in	O
13	order	O
14	to	O
15	define	O
16	the	O
17	microsurgical	O
18	anatomy	O
19	of	O
20	the	O
21	pineal	O
22	region	O
23	,	O
24	particularly	O
25	the	O
26	relationship	O
27	of	O
28	the	O
29	pineal	O
30	body	O
31	,	O
32	posterior	O
33	cerebral	O
34	artery	O
35	,	O
36	superior	O
37	cerebellar	O
38	artery	O
39	,	O
40	vein	O
41	of	O
42	Galen	O
43	,	O
44	basal	O
45	vein	O
46	of	O
47	Rosenthal	O
48	,	O
49	internal	O
50	cerebral	O
51	vein	O
52	,	O
53	straight	O
54	sinus	O
55	,	O
56	bridging	O
57	vein	O
58	,	O
59	the	O
60	size	O
61	of	O
62	the	O
63	tentorial	O
64	notch	O
65	,	O
66	and	O
67	the	O
68	third	O
69	and	O
70	the	O
71	fourth	O
72	cranial	O
73	nerves	O
74	.	O

1	A	O
2	Chinese	O
3	(	O
4	HK	O
5	)	O
6	SF	O
7	-	O
8	36	O
9	survey	O
10	form	O
11	was	O
12	developed	O
13	by	O
14	an	O
15	iterative	O
16	translation	O
17	process	O
18	.	O

1	Praziquantel	O
2	and	O
3	Albendazole	O
4	were	O
5	found	O
6	effective	O
7	in	O
8	the	O
9	treatment	O
10	of	O
11	neurocysticercosis	O
12	,	O
13	but	O
14	because	O
15	of	O
16	serious	O
17	side	O
18	effects	O
19	encountered	O
20	in	O
21	some	O
22	cases	O
23	,	O
24	the	O
25	drugs	O
26	should	O
27	be	O
28	used	O
29	cautiously	O
30	in	O
31	selected	O
32	cases	O
33	only	O
34	.	O

1	CONCLUSIONS	O
2	:	O
3	These	O
4	routinely	O
5	collected	O
6	data	O
7	provided	O
8	quantitative	O
9	estimates	O
10	of	O
11	changes	O
12	in	O
13	CBZ	O
14	Cl	O
15	/	O
16	F	O
17	due	O
18	to	O
19	comedication	O
20	and	O
21	an	O
22	age	O
23	-	O
24	related	O
25	decrease	O
26	in	O
27	Cl	O
28	/	O
29	F	O
30	The	O
31	derived	O
32	regression	O
33	equations	O
34	reasonably	O
35	predicted	O
36	concentrations	O
37	in	O
38	a	O
39	separate	O
40	validation	O
41	set	O
42	.	O

1	Strontium	O
2	-	O
3	90	O
4	was	O
5	inject	O
6	i	O
7	.	O
8	v	O
9	.	O
10	into	O
11	pregnant	O
12	rats	O
13	on	O
14	day	O
15	18	O
16	post	O
17	conception	O
18	(	O
19	p	O
20	.	O
21	c	O
22	.).	O

1	OBJECTIVE	O
2	:	O
3	To	O
4	evaluate	O
5	the	O
6	relationship	O
7	between	O
8	blood	O
9	flow	O
10	in	O
11	the	O
12	tumor	O
13	assessed	O
14	by	O
15	color	O
16	Doppler	O
17	ultrasound	O
18	,	O
19	microvessel	O
20	density	O
21	,	O
22	and	O
23	vascular	O
24	endothelial	O
25	growth	O
26	factor	O
27	levels	O
28	in	O
29	endometrial	O
30	carcinoma	O
31	.	O

1	The	O
2	low	O
3	number	O
4	of	O
5	false	O
6	positives	O
7	indicates	O
8	that	O
9	our	O
10	scheme	O
11	would	O
12	not	O
13	confuse	O
14	the	O
15	radiologist	O
16	by	O
17	suggesting	O
18	normal	O
19	regions	O
20	as	O
21	suspicious	O
22	.	O

1	With	O
2	Sair	O
3	and	O
4	So2	O
5	,	O
6	mean	O
7	vital	O
8	capacity	O
9	was	O
10	reduced	O
11	by	O
12	44	O
13	%	O
14	from	O
15	control	O
16	.	O

1	Most	O
2	eukaryotic	O
3	mRNAs	O
4	are	O
5	translated	O
6	by	O
7	a	O
8	"	O
9	scanning	O
10	ribosome	O
11	"	O
12	mechanism	O
13	.	O

1	The	O
2	RMRI	O
3	was	O
4	tested	O
5	for	O
6	interrater	O
7	reliability	O
8	using	O
9	three	O
10	simulated	O
11	and	O
12	10	O
13	actual	O
14	patients	O
15	.	O

1	of	O
2	tat	B
3	cDNA	O
4	in	O
5	sense	O
6	orientation	O
7	(	O
8	tat	B
9	/	O
10	S	O
11	),	O
12	together	O
13	with	O
14	a	O
15	plasmid	O
16	containing	O
17	the	O
18	c	B
19	-	I
20	fos	I
21	promoter	I
22	(	O
23	FC3	O
24	,	O
25	from	O
26	-	O
27	711	O
28	to	O
29	+	O
30	42	O
31	)	O
32	in	O
33	front	O
34	of	O
35	the	O
36	bacterial	B
37	chloramphenicol	I
38	acetyltransferase	I
39	(	O
40	CAT	B
41	)	O
42	gene	O
43	significantly	O
44	enhanced	O
45	CAT	B
46	activity	O
47	in	O
48	Jurkat	O
49	cells	O
50	activated	O
51	by	O
52	the	O
53	addition	O
54	of	O
55	15	O
56	%	O
57	fetal	O
58	calf	O
59	serum	O
60	(	O
61	FCS	O
62	)	O
63	or	O
64	5	O
65	micrograms	O
66	/	O
67	mL	O
68	phytohemagglutinin	B
69	plus	O
70	10	O
71	(-	O
72	7	O
73	)	O
74	mol	O
75	/	O
76	L	O
77	phorbol	O
78	myristate	O
79	acetate	O
80	(	O
81	PMA	O
82	)	O
83	and	O
84	U937	O
85	cells	O
86	activated	O
87	by	O
88	15	O
89	%	O
90	FCS	O
91	or	O
92	10	O
93	(-	O
94	7	O
95	)	O
96	mol	O
97	/	O
98	L	O
99	PMA	O
100	.	O
1	To	O
2	test	O
3	whether	O
4	or	O
5	not	O
6	SOCS	O
7	-	O
8	3	O
9	also	O
10	binds	O
11	to	O
12	the	O
13	IGFIR	B
14	,	O
15	we	O
16	cloned	O
17	human	O
18	SOCS	I
19	-	I
20	3	I
21	by	O
22	reverse	O
23	transcription	O
24	-	O
25	polymerase	O
26	chain	O
27	reaction	O
28	from	O
29	human	O
30	skeletal	I
31	muscle	O
32	mRNA	O
33	.	O

1	In	O
2	the	O
3	present	O
4	study	O
5	we	O
6	have	O
7	investigated	O
8	the	O
9	regulatory	O
10	mechanism	O
11	for	O
12	CD95L	O
13	expression	O
14	.	O

1	A	O
2	five	O
3	-	O
4	phase	O
5	experiment	O
6	was	O
7	designed	O
8	to	O
9	investigate	O
10	(	O
11	a	O
12	)	O
13	whether	O
14	contingent	O
15	music	O
16	-	O
17	listening	O
18	would	O
19	act	O
20	as	O
21	a	O
22	reinforcer	O
23	to	O
24	increase	O
25	arithmetic	O
26	performance	O
27	of	O
28	EMR	O
29	children	O
30	and	O
31	(	O
32	b	O
33	)	O
34	whether	O
35	this	O
36	contingent	O
37	reinforcement	O
38	would	O
39	affect	O
40	preference	O
41	for	O
42	that	O
43	reinforcer	O
44	.	O

1	Analysis	O
2	of	O
3	promoter	O
4	and	O
5	androgen	O
6	regulatory	O
7	sequences	O
8	required	O
9	for	O
10	optimal	O
11	transcription	O
12	of	O
13	the	O
14	rat	O
15	androgen	O
16	-	O
17	binding	I
18	protein	I
19	gene	I
20	.	O

1	Comparison	O
2	of	O
3	the	O
4	plant	O
5	nuclear	O
6	tRNA	I
7	3	I
8	'	O
9	processing	O
10	enzyme	O
11	with	O
12	the	O
13	plant	O
14	mitochondrial	O
15	one	O
16	suggests	O
17	that	O
18	both	O
19	activities	O
20	are	O
21	different	O
22	enzymes	O
23	.	O

1	Directives	O
2	concerning	O
3	medical	O
4	care	O

1	Therefore	O
2	,	O
3	Mxi1	O
4	and	O
5	Mad	B
6	might	O
7	antagonize	O
8	Myc	B
9	function	O
10	and	O
11	are	O
12	candidate	O
13	tumor	O
14	suppressor	O
15	genes	O
16	.	O

1	However	O
2	,	O
3	the	O
4	truncated	O
5	deer	O
6	receptor	I
7	lacks	O
8	the	O
9	most	O
10	C	O
11	-	O
12	terminal	O
13	tyrosine	O
14	residue	O
15	in	O
16	the	O
17	intracellular	O
18	domain	O
19	which	O
20	is	O
21	believed	O
22	to	O
23	be	O
24	essential	O
25	for	O
26	activation	O
27	of	O
28	the	O
29	beta	B
30	-	I
31	casein	I
32	promoter	I
33	.	O

1	Thus	O
2	,	O
3	the	O
4	class	O
5	C	O
6	-	I
7	Vps	O
8	complex	O
9	directs	O
10	multiple	O
11	reactions	O
12	during	O
13	the	O
14	docking	O
15	and	O
16	fusion	O
17	of	O
18	vesicles	O
19	with	O
20	the	O
21	vacuole	O
22	,	O
23	each	O
24	of	O
25	which	O
26	contributes	O
27	to	O
28	the	O
29	overall	O
30	specificity	O
31	and	O
32	efficiency	O
33	of	O
34	this	O
35	transport	O
36	process	O
37	.	O

1	When	O
2	cells	O
3	were	O
4	microinjected	O
5	with	O
6	TFOs	O
7	designed	O
8	to	O
9	bind	O
10	to	O
11	a	O
12	30	O
13	-	O
14	bp	O
15	polypurine	O
16	site	O
17	situated	O
18	between	O
19	the	O
20	two	O
21	TK	B
22	genes	I
23	,	O
24	recombination	O
25	was	O
26	observed	O
27	at	O
28	frequencies	O
29	in	O
30	the	O
31	range	O
32	of	O
33	1	O
34	%,	O
35	2	O
36	,	O
37	500	O
38	-	O
39	fold	O
40	above	O
41	the	O
42	background	O
43	.	O

1	Disturbances	O
2	of	O
3	placental	O
4	maturation	O
5	,	O
6	2	O
7	.	O

1	Rabbit	B
2	eyes	O
3	were	O
4	removed	O
5	and	O
6	held	O
7	in	O
8	temperature	O
9	-	O
10	regulated	O
11	chambers	O
12	and	O
13	irrigated	O
14	with	O
15	saline	O
16	.	O

1	The	O
2	shift	O
3	to	O
4	the	O
5	nonpermissive	O
6	temperature	O
7	is	O
8	accompanied	O
9	by	O
10	the	O
11	loss	O
12	of	O
13	guanyl	O
14	nucleotide	O
15	-	O
16	dependent	O
17	activity	O
18	of	O
19	adenylylcyclase	O
20	in	O
21	vitro	O
22	.	O

1	Homodimers	O
2	of	O
3	the	O
4	three	O
5	proteins	O
6	specifically	O
7	recognize	O
8	the	O
9	G	O
10	-	O
11	box	I
12	motif	I
13	,	O
14	with	O
15	GBF1	O
16	and	O
17	GBF3	O
18	binding	O
19	symmetrically	O
20	to	O
21	this	O
22	palindromic	O
23	sequence	O
24	.	O

1	Haemodynamic	O
2	responses	O
3	to	O
4	antagonism	O
5	of	O
6	bocurarine	O
7	block	O
8	with	O
9	atropine	O
10	-	O
11	neostigmine	O
12	mixture	O
13	in	O
14	children	O
15	.	O

1	The	O
2	proposed	O
3	algorithm	O
4	consists	O
5	of	O
6	several	O
7	steps	O
8	.	O

1	A	O
2	newly	O
3	developed	O
4	broad	O
5	-	O
6	spectrum	O
7	fluoroquinolone	O
8	,	O
9	levofloxacin	O
10	(	O
11	LVFX	O
12	,	O
13	DR	O
14	-	O
15	3355	O
16	),	O
17	was	O
18	evaluated	O
19	in	O
20	vitro	O
21	and	O
22	in	O
23	vivo	O
24	in	O
25	comparison	O
26	with	O
27	ciprofloxacin	O
28	(	O
29	CPFX	O
30	),	O
31	ofloxacin	O
32	(	O
33	OFLX	O
34	)	O
35	and	O
36	norfloxacin	O
37	(	O
38	NFLX	O
39	).	O

1	This	O
2	protein	O
3	with	O
4	a	O
5	hydrophobic	O
6	amino	O
7	terminus	O
8	appears	O
9	to	O
10	be	O
11	a	O
12	secreted	O
13	protein	O
14	.	O

1	Interferon	B
2	-	I
3	alpha	I
4	may	O
5	exacerbate	O
6	cryoblobulinemia	O
7	-	O
8	related	O
9	ischemic	O
10	manifestations	O
11	:	O
12	an	O
13	adverse	O
14	effect	O
15	potentially	O
16	related	O
17	to	O
18	its	O
19	anti	O
20	-	O
21	angiogenic	O
22	activity	O
23	.	O

1	The	O
2	dnaK	B
3	operon	I
4	of	O
5	Bacillus	O
6	subtilis	O
7	is	O
8	heptacistronic	O
9	.	O

1	Platelet	O
2	number	O
3	and	O
4	life	O
5	span	O
6	were	O
7	determined	O
8	in	O
9	the	O
10	last	O
11	trimester	O
12	of	O
13	pregnancy	O
14	in	O
15	22	O
16	women	O
17	who	O
18	were	O
19	delivered	O
20	of	O
21	small	O
22	-	O
23	for	O
24	-	O
25	gestational	O
26	age	O
27	(	O
28	SGA	O
29	)	O
30	infants	O
31	and	O
32	in	O
33	21	O
34	women	O
35	with	O
36	infants	O
37	having	O
38	normal	O
39	birth	O
40	weights	O
41	.	O

1	We	O
2	have	O
3	isolated	O
4	and	O
5	sequenced	O
6	two	O
7	overlapping	O
8	cDNA	O
9	fragments	O
10	which	O
11	could	O
12	encode	O
13	the	O
14	complete	O
15	amino	O
16	acid	O
17	sequence	O
18	of	O
19	rat	O
20	testis	I
21	fructose	I
22	-	I
23	6	I
24	-	I
25	phosphate	I
26	,	O
27	2	I
28	-	I
29	kinase	I
30	:	O
31	fructose	O
32	-	O
33	2	I
34	,	O
35	6	O
36	-	O
37	bisphosphatase	O
38	.	O

1	Cell	O
2	lines	O
3	derived	O
4	from	O
5	the	O
6	tumors	O
7	were	O
8	examined	O
9	by	O
10	fluorescent	O
11	in	O
12	situ	O
13	hybridization	O
14	for	O
15	the	O
16	status	O
17	of	O
18	the	O
19	transferred	O
20	human	O
21	chromosome	O
22	and	O
23	by	O
24	PCR	O
25	for	O
26	marker	O
27	loss	O
28	.	O

1	Imaging	O
2	features	O
3	of	O
4	splenic	O
5	epidermoid	O
6	cyst	O
7	with	O
8	pathologic	O
9	correlation	O
10	.	O

1	Delayed	O
2	mortality	O
3	of	O
4	mice	O
5	following	O
6	inhalation	O
7	of	O
8	acute	O
9	doses	O
10	of	O
11	CH2O	O
12	,	O
13	SO2Cl2	O
14	,	O
15	and	O
16	Br2	O
17	.	O

1	The	O
2	complete	O
3	cDNA	O
4	sequence	O
5	of	O
6	human	B
7	betaV	I
8	spectrin	I
9	is	O
10	available	O
11	from	O
12	GenBank	O
13	(	O
14	TM	B
15	)	O
16	as	O
17	accession	O
18	number	O
19	.	O

1	In	O
2	addition	O
3	,	O
4	a	O
5	noncanonical	O
6	C	B
7	/	O
8	EBP	I
9	-	I
10	binding	I
11	site	O
12	within	O
13	the	O
14	Gadd45gamma	B
15	promoter	I
16	where	O
17	C	B
18	/	I
19	EBPbeta	I
20	and	O
21	C	B
22	/	O
23	EBPdelta	I
24	could	O
25	bind	O
26	,	O
27	was	O
28	identified	O
29	by	O
30	electrophoretic	O
31	mobility	O
32	shift	O
33	assay	O
34	(	O
35	EMSA	O
36	)	O
37	and	O
38	reporter	O
39	gene	O
40	analysis	O
41	.	O

1	Circularized	B
2	Ac	B
3	/	O
4	Ds	B
5	transposons	O
6	:	O
7	formation	O
8	,	O
9	structure	O
10	and	O
11	fate	O
12	.	O

1	Using	O
2	Ki	B
3	-	I
4	ras	I
5	-	O
6	transformed	O
7	3T3	O
8	cells	O
9	as	O
10	a	O
11	model	O
12	system	O
13	,	O
14	we	O
15	show	O
16	that	O
17	both	O
18	RA	O
19	and	O
20	the	O
21	'	O
22	dissociating	O
23	'	O
24	retinoids	O
25	inhibit	O
26	anchorage	O
27	-	O
28	independent	O
29	cell	O
30	proliferation	O
31	,	O
32	suggesting	O
33	that	O
34	retinoid	O
35	-	O
36	induced	O
37	growth	O
38	inhibition	O
39	may	O
40	be	O
41	related	O
42	to	O
43	AP1	B
44	transrepression	I
45	.	O

1	Finally	O
2	,	O
3	we	O
4	show	O
5	that	O
6	complexes	O
7	similar	O
8	to	O
9	the	O
10	C25	O
11	,	O
12	C30	O
13	and	O
14	C35	O
15	complexes	O
16	are	O
17	formed	O
18	by	O
19	rat	O
20	cortex	O
21	nuclear	O
22	extracts	O
23	and	O
24	the	O
25	SAA	O
26	element	O
27	in	O
28	EMSA	O
29	experiments	O
30	,	O
31	suggesting	O
32	the	O
33	relevance	O
34	of	O
35	our	O
36	in	O
37	vitro	O
38	observations	O
39	to	O
40	the	O
41	in	O
42	vivo	O
43	functioning	O
44	of	O
45	the	O
46	rat	O
47	APP	B
48	promoter	I
49	.	O

1	Anti	B
2	-	I
3	hepatitis	I
4	A	I
5	virus	O
6	(	O
7	HAV	B
8	)	O
9	titer	O
10	after	O
11	vaccination	O
12	was	O
13	measured	O
14	in	O
15	83	O
16	HIV	O
17	-	O
18	positive	O
19	and	O
20	39	O
21	HIV	O
22	-	O
23	negative	O
24	men	O
25	.	O

1	Human	B
2	ULK1	I
3	,	O
4	a	O
5	novel	O
6	serine	B
7	/	I
8	threonine	I
9	kinase	I
10	related	I
11	to	O
12	UNC	B
13	-	I
14	51	I
15	kinase	I
16	of	O
17	Caenorhabditis	O
18	elegans	O
19	:	O
20	cDNA	O
21	cloning	O
22	,	O
23	expression	O
24	,	O
25	and	O
26	chromosomal	O
27	assignment	O
28	.	O

1	This	O
2	was	O
3	obtained	O
4	with	O
5	the	O
6	thermal	O
7	neutron	O
8	fluency	O
9	2	O
10	.	O
11	0	O
12	x	O
13	10	O
14	(	O
15	10	O
16	)	O
17	n	O
18	/	O
19	cm2	O
20	.	O

1	To	O
2	do	O
3	this	O
4	,	O
5	segments	O
6	of	O
7	DNA	O
8	from	O
9	the	O
10	5	O
11	'	O
12	flank	O
13	of	O
14	the	O
15	initiation	O
16	sites	O
17	for	O
18	germline	O
19	epsilon	O
20	RNA	O
21	were	O
22	ligated	O
23	to	O
24	a	O
25	luciferase	B
26	reporter	I
27	gene	I
28	and	O
29	transfected	O
30	into	O
31	two	O
32	mouse	O
33	B	O
34	cell	O
35	lines	O
36	,	O
37	one	O
38	of	O
39	which	O
40	can	O
41	be	O
42	induced	O
43	to	O
44	switch	O
45	to	O
46	IgE	B
47	.	O

1	Basal	O
2	FSH	B
3	and	O
4	LH	B
5	levels	O
6	were	O
7	significantly	O
8	lower	O
9	in	O
10	addicts	O
11	;	O
12	after	O
13	GnRH	B
14	stimulation	O
15	the	O
16	addicts	B
17	'	I
18	FSH	B
19	and	O
20	LH	B
21	values	O
22	increased	O
23	but	O
24	not	O
25	significantly	O
26	compared	O
27	to	O
28	controls	O
29	.	O

1	The	O
2	absolute	O
3	concentrations	O
4	of	O
5	alpha	B
6	2	I
7	-	I
8	plasmin	I
9	inhibitor	O
10	,	O
11	alpha	B
12	2	I
13	-	I
14	macroglobulin	I
15	,	O
16	and	O
17	antithrombin	B
18	III	I
19	increased	O
20	with	O
21	exercise	O
22	(	O
23	all	O
24	P	O
25	less	O
26	than	O
27	0	O
28	.	O
29	005	O
30	),	O
31	but	O
32	when	O
33	concentrations	O
34	were	O
35	corrected	O
36	for	O
37	acute	O
38	shifts	O
39	of	O
40	plasma	O
41	water	O
42	during	O
43	exercise	O
44	,	O
45	the	O
46	quantity	O
47	of	O
48	these	O
49	inhibitors	O
50	actually	O
51	decreased	O
52	(	O
53	all	O
54	P	O
55	less	O
56	than	O
57	0	O
58	.	O
59	005	O
60	).	O

1	Functional	O
2	magnetic	O
3	resonance	O
4	imaging	O
5	(	O
6	fMRI	O
7	)	O
8	has	O
9	been	O
10	increasingly	O
11	used	O
12	in	O
13	studying	O
14	human	O
15	brain	O
16	function	O
17	given	O
18	its	O
19	non	O
20	-	O
21	invasive	O
22	feature	O
23	and	O
24	good	O
25	spatial	O
26	resolution	O
27	.	O

1	The	O
2	gene	O
3	(	O
4	ApxII	O
5	)	O
6	encoding	O
7	both	O
8	chloroplastic	B
9	ascorbate	I
10	peroxidase	I
11	isoenzymes	I
12	was	O
13	isolated	O
14	and	O
15	the	O
16	organization	O
17	of	O
18	the	O
19	gene	O
20	was	O
21	determined	O
22	.	O

1	The	O
2	original	O
3	technique	O
4	was	O
5	developed	O
6	in	O
7	the	O
8	1960	O
9	'	O
10	s	O
11	to	O
12	analyze	O
13	the	O
14	inner	O
15	ear	O
16	fluid	O
17	as	O
18	a	O
19	diagnostic	O
20	procedure	O
21	(	O
22	i	O
23	.	O
24	e	O
25	.,	O
26	diagnostic	O
27	labyrinthotomy	O
28	)	O
29	in	O
30	acoustic	O
31	neuroma	O
32	suspects	O
33	.	O

1	In	O
2	vitro	O
3	DNase	B
4	I	I
5	footprinting	O
6	showed	O
7	that	O
8	OxyR	B
9	-	O
10	C199S	O
11	protected	O
12	Pmom	O
13	from	O
14	-	O
15	104	O
16	to	O
17	-	O
18	46	O
19	on	O
20	the	O
21	top	O
22	strand	O
23	and	O
24	produced	O
25	a	O
26	protection	O
27	pattern	O
28	characteristic	O
29	of	O
30	reduced	O
31	wild	O
32	-	O
33	type	I
34	OxyR	B
35	.	O

1	To	O
2	investigate	O
3	the	O
4	requirements	O
5	for	O
6	CBF2	B
7	binding	O
8	,	O
9	we	O
10	synthesized	O
11	a	O
12	series	O
13	of	O
14	oligonucleotides	O
15	carrying	O
16	double	O
17	transversion	O
18	mutations	O
19	spanning	O
20	both	O
21	the	O
22	conserved	O
23	core	O
24	sequence	O
25	and	O
26	outside	O
27	flanking	O
28	sequences	O
29	.	O

1	Transfection	O
2	of	O
3	HepG2	O
4	and	O
5	SK	O
6	-	O
7	N	O
8	-	O
9	MC	O
10	cells	O
11	with	O
12	constructs	O
13	deleted	O
14	of	O
15	additional	O
16	5	O
17	'-	O
18	flanking	O
19	fragments	O
20	permitted	O
21	the	O
22	definition	O
23	of	O
24	a	O
25	minimal	O
26	200	O
27	bp	O
28	promoter	O
29	fragment	O
30	containing	O
31	the	O
32	pseudo	O
33	-	O
34	TATA	O
35	box	O
36	and	O
37	two	O
38	putative	O
39	SP1	B
40	-	I
41	binding	I
42	sites	I
43	.	O

1	After	O
2	a	O
3	survey	O
4	of	O
5	the	O
6	anatomical	O
7	and	O
8	physiological	O
9	basis	O
10	of	O
11	operative	O
12	treatment	O
13	of	O
14	behaviour	O
15	disorders	O
16	by	O
17	stereotactic	O
18	lesions	O
19	in	O
20	the	O
21	amygdala	O
22	and	O
23	the	O
24	posterior	O
25	medial	O
26	hypothalamus	O
27	the	O
28	author	O
29	describes	O
30	his	O
31	own	O
32	experiences	O
33	with	O
34	603	O
35	operations	O
36	for	O
37	control	O
38	of	O
39	conservatively	O
40	untreatable	O
41	aggressiveness	O
42	.	O

1	Also	O
2	,	O
3	the	O
4	human	B
5	glycoprotein	I
6	alpha	I
7	-	I
8	subunit	I
9	promoter	I
10	was	O
11	induced	O
12	10	O
13	-	O
14	fold	O
15	by	O
16	FSK	O
17	in	O
18	GH4	O
19	rat	O
20	pituitary	O
21	cells	O
22	.(	O
23	ABSTRACT	O
24	TRUNCATED	O
25	AT	O
26	400	O
27	WORDS	O
28	)	O

1	Comparison	O
2	of	O
3	human	O
4	and	O
5	murine	O
6	blk	O
7	sequences	O
8	indicated	O
9	that	O
10	they	O
11	share	O
12	86	O
13	%	O
14	amino	O
15	acid	O
16	identity	O
17	,	O
18	the	O
19	most	O
20	conserved	O
21	region	O
22	being	O
23	the	O
24	catalytic	O
25	domain	O
26	(	O
27	93	O
28	%	O
29	identity	O
30	).	O

1	These	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	sulfhydryl	O
7	group	O
8	of	O
9	certain	O
10	angiotensin	B
11	converting	I
12	enzyme	I
13	inhibitors	O
14	can	O
15	potentiate	O
16	their	O
17	effect	O
18	on	O
19	the	O
20	endogenous	O
21	nitrovasodilator	O
22	EDRF	O
23	.	O

1	In	O
2	Saccharomyces	O
3	cerevisiae	O
4	,	O
5	PHO85	O
6	encodes	O
7	a	O
8	cyclin	B
9	-	I
10	dependent	I
11	protein	I
12	kinase	I
13	(	O
14	Cdk	B
15	)	O
16	catalytic	O
17	subunit	O
18	with	O
19	multiple	O
20	regulatory	O
21	roles	O
22	thought	O
23	to	O
24	be	O
25	specified	O
26	by	O
27	association	O
28	with	O
29	different	O
30	cyclin	B
31	partners	I
32	(	O
33	Pcls	O
34	).	O

1	A	O
2	DNA	O
3	fragment	O
4	encoding	O
5	the	O
6	DNA	O
7	-	O
8	binding	O
9	domain	O
10	(	O
11	amino	O
12	acids	O
13	1	O
14	-	O
15	60	O
16	)	O
17	of	O
18	the	O
19	Escherichia	O
20	coli	I
21	fru	I
22	transcriptional	O
23	regulator	O
24	was	O
25	cloned	O
26	into	O
27	the	O
28	pGEX	O
29	-	O
30	KT	O
31	vector	O
32	and	O
33	expressed	O
34	in	O
35	frame	O
36	with	O
37	the	O
38	fused	O
39	gene	O
40	encoding	O
41	glutathione	B
42	S	I
43	-	I
44	transferase	I
45	.	O

1	In	O
2	addition	O
3	,	O
4	expected	O
5	decreases	O
6	in	O
7	ATIC	O
8	enzymatic	O
9	function	O
10	in	O
11	ATIC	O
12	-	O
13	ALK	B
14	-	O
15	containing	O
16	lymphomas	O
17	may	O
18	render	O
19	these	O
20	tumors	O
21	more	O
22	sensitive	O
23	to	O
24	antifolate	O
25	drugs	O
26	such	O
27	as	O
28	methotrexate	O
29	.	O

1	To	O
2	assess	O
3	the	O
4	functional	O
5	importance	O
6	of	O
7	these	O
8	NBS	O
9	in	O
10	the	O
11	overall	O
12	drug	O
13	resistance	O
14	phenotype	O
15	conferred	O
16	by	O
17	mdr1	O
18	,	O
19	we	O
20	introduced	O
21	amino	O
22	acid	O
23	substitutions	O
24	in	O
25	the	O
26	core	O
27	consensus	O
28	sequence	O
29	for	O
30	nucleotide	O
31	binding	O
32	,	O
33	GXGKST	O
34	.	O

1	74	O
2	,	O
3	193	O
4	-	O
5	197	O
6	).	O

1	The	O
2	complete	O
3	gene	O
4	organization	O
5	was	O
6	obtained	O
7	by	O
8	combining	O
9	the	O
10	results	O
11	of	O
12	the	O
13	sequence	O
14	of	O
15	these	O
16	clones	O
17	and	O
18	those	O
19	of	O
20	the	O
21	characterization	O
22	of	O
23	polymerase	O
24	chain	O
25	reaction	O
26	-	O
27	amplified	O
28	genomic	O
29	segments	O
30	.	O

1	An	O
2	unusual	O
3	complication	O
4	in	O
5	an	O
6	unsuitable	O
7	patient	O
8	.	O

1	The	O
2	latency	O
3	time	O
4	for	O
5	the	O
6	lactate	O
7	concentration	O
8	to	O
9	reach	O
10	the	O
11	top	O
12	values	O
13	was	O
14	reduced	O
15	by	O
16	aerobic	O
17	training	O
18	(	O
19	T2	O
20	).	O

1	Use	O
2	of	O
3	prostaglandin	O
4	F2	O
5	alpha	O
6	(	O
7	PGF2	O
8	alpha	O
9	)	O
10	in	O
11	cattle	O
12	breeding	O
13	.	O

1	Alternative	O
2	processing	O
3	of	O
4	the	O
5	tryptophanyl	B
6	-	I
7	tRNA	I
8	synthetase	I
9	mRNA	I
10	from	O
11	interferon	B
12	-	O
13	treated	O
14	human	O
15	cells	O
16	.	O

1	The	O
2	rat	O
3	branched	B
4	-	I
5	chain	I
6	-	I
7	2	I
8	-	I
9	oxo	I
10	-	I
11	acid	I
12	dehydrogenase	I
13	(	O
14	BCOD	B
15	)	O
16	kinase	I
17	mRNA	O
18	is	O
19	transcribed	O
20	from	O
21	a	O
22	TATA	O
23	-	O
24	less	O
25	promoter	O
26	that	O
27	has	O
28	GC	O
29	-	O
30	rich	O
31	sequences	O
32	and	O
33	two	O
34	putative	O
35	Sp1	B
36	binding	O
37	sites	O
38	near	O
39	the	O
40	transcription	O
41	start	O
42	site	O
43	.	O

1	The	O
2	epitope	O
3	-	O
4	protected	O
5	lysine	O
6	(	O
7	K	O
8	)	O
9	was	O
10	present	O
11	in	O
12	a	O
13	30	O
14	-	O
15	aa	O
16	TPO	B
17	fragment	O
18	that	O
19	,	O
20	by	O
21	N	O
22	-	O
23	terminal	O
24	sequencing	O
25	,	O
26	was	O
27	found	O
28	to	O
29	be	O
30	K713	O
31	.	O

1	Thus	O
2	,	O
3	elongin	O
4	C	O
5	is	O
6	found	O
7	to	O
8	oligomerize	O
9	in	O
10	solution	O
11	and	O
12	to	O
13	undergo	O
14	significant	O
15	structural	O
16	rearrangements	O
17	upon	O
18	binding	O
19	of	O
20	two	O
21	different	O
22	partner	O
23	proteins	O
24	.	O

1	A	O
2	neonatal	O
3	alloimmune	O
4	thrombocytopenia	O
5	with	O
6	an	O
7	HPA	O
8	-	O
9	3a	O
10	(	O
11	Baka	O
12	)	O
13	incompatibility	O
14	was	O
15	confirmed	O
16	.	O

1	Polyglactin	O
2	910	O
3	suture	O
4	absorption	O
5	and	O
6	the	O
7	role	O
8	of	O
9	cellular	O
10	enzymes	O
11	.	O

1	The	O
2	p97	B
3	-	O
4	depleted	O
5	nuclei	O
6	remained	O
7	largely	O
8	competent	O
9	for	O
10	nuclear	O
11	protein	O
12	import	O
13	.	O

1	3	O
2	-(	O
3	N	O
4	-	O
5	Alkyl	O
6	-	O
7	N	O
8	-	O
9	2	O
10	-	O
11	chloroethylaminomethyl	O
12	)-	O
13	5	O
14	-	O
15	or	O
16	7	O
17	-	O
18	halogenobenzo	O
19	[	O
20	b	O
21	]	O
22	thiophen	O
23	hydrochlorides	O
24	.	O

1	Promoter	O
2	activity	O
3	was	O
4	high	O
5	in	O
6	cell	O
7	lines	O
8	that	O
9	expressed	O
10	high	O
11	levels	O
12	of	O
13	endogenous	O
14	D3	O
15	mRNA	O
16	,	O
17	as	O
18	indicated	O
19	by	O
20	Northern	O
21	blot	O
22	analyses	O
23	,	O
24	and	O
25	was	O
26	significantly	O
27	reduced	O
28	when	O
29	the	O
30	promoter	O
31	was	O
32	truncated	O
33	to	O
34	-	O
35	122	O
36	bp	O
37	.	O

1	Rams	O
2	were	O
3	weighed	O
4	and	O
5	testis	O
6	size	O
7	was	O
8	estimated	O
9	by	O
10	orchimetry	O
11	at	O
12	each	O
13	time	O
14	period	O
15	.	O

1	Drugs	O
2	suppressed	O
3	>	O
4	or	O
5	=	O
6	75	O
7	%	O
8	of	O
9	the	O
10	total	O
11	premature	O
12	ventricular	O
13	contractions	O
14	in	O
15	all	O
16	patients	O
17	who	O
18	had	O
19	both	O
20	use	O
21	-	O
22	dependent	O
23	QRS	O
24	prolongation	O
25	and	O
26	reverse	O
27	use	O
28	-	O
29	dependent	O
30	QT	O
31	prolongation	O
32	,	O
33	in	O
34	79	O
35	%	O
36	of	O
37	patients	O
38	with	O
39	use	O
40	-	O
41	dependent	O
42	QRS	O
43	prolongation	O
44	alone	O
45	,	O
46	in	O
47	70	O
48	%	O
49	with	O
50	reverse	O
51	use	O
52	-	O
53	dependent	O
54	QT	O
55	prolongation	O
56	alone	O
57	,	O
58	and	O
59	in	O
60	11	O
61	%	O
62	with	O
63	neither	O
64	use	O
65	-	O
66	dependent	O
67	QRS	O
68	prolongation	O
69	nor	O
70	reverse	O
71	use	O
72	-	O
73	dependent	O
74	QT	O
75	prolongation	O
76	.	O

1	7	O
2	.	O

1	However	O
2	,	O
3	the	O
4	requirement	O
5	of	O
6	rev3	O
7	for	O
8	the	O
9	production	O
10	of	O
11	G	O
12	.	O
13	C	I
14	-->	O
15	T	O
16	.	O
17	A	O
18	transversions	O
19	by	O
20	the	O
21	rad18	O
22	mutator	O
23	,	O
24	which	O
25	induces	O
26	only	O
27	these	O
28	substitutions	O
29	,	O
30	was	O
31	similar	O
32	to	O
33	that	O
34	for	O
35	rad6	B
36	-	O
37	mediated	O
38	G	O
39	.	O
40	C	I
41	-->	O
42	T	O
43	.	O
44	A	O
45	transversion	O
46	.	O

1	Recombinant	O
2	BRI1	O
3	-	O
4	KD	O
5	autophosphorylated	O
6	on	O
7	serine	O
8	(	O
9	Ser	O
10	)	O
11	and	O
12	threonine	O
13	(	O
14	Thr	O
15	)	O
16	residues	O
17	with	O
18	p	O
19	-	O
20	Ser	O
21	predominating	O
22	.	O

1	No	O
2	hypotension	O
3	was	O
4	noted	O
5	in	O
6	patients	O
7	with	O
8	toxemia	O
9	and	O
10	only	O
11	2	O
12	ran	O
13	a	O
14	fever	O
15	above	O
16	37	O
17	.	O
18	5	O
19	degrees	O
20	C	O
21	.	O

1	As	O
2	the	O
3	length	O
4	of	O
5	the	O
6	fatty	O
7	acid	O
8	decreased	O
9	,	O
10	the	O
11	binding	O
12	affinity	O
13	was	O
14	reduced	O
15	;	O
16	myristic	O
17	acid	O
18	(	O
19	14	O
20	:	O
21	0	O
22	)	O
23	bound	O
24	with	O
25	a	O
26	K	O
27	(	O
28	d	O
29	)	O
30	of	O
31	1409	O
32	+/-	O
33	423	O
34	nM	O
35	,	O
36	but	O
37	medium	O
38	-	O
39	chain	O
40	(	O
41	decanoic	O
42	acid	O
43	,	O
44	10	O
45	:	O
46	0	O
47	)	O
48	and	O
49	short	O
50	-	O
51	chain	O
52	(	O
53	octanoic	O
54	acid	O
55	,	O
56	8	O
57	:	O
58	0	O
59	)	O
60	lipids	O
61	were	O
62	not	O
63	bound	O
64	at	O
65	all	O
66	.	O

1	Vascular	O
2	endothelial	O
3	cells	O
4	undergo	O
5	profound	O
6	changes	O
7	upon	O
8	cellular	O
9	activation	O
10	including	O
11	expression	O
12	of	O
13	a	O
14	spectrum	O
15	of	O
16	cell	O
17	activation	O
18	-	O
19	associated	O
20	genes	O
21	.	O

1	A	O
2	case	O
3	of	O
4	manifest	O
5	latent	O
6	nystagmus	O
7	of	O
8	late	O
9	onset	O
10	in	O
11	a	O
12	13	O
13	-	O
14	year	O
15	-	O
16	old	O
17	girl	O
18	is	O
19	reported	O
20	.	O

1	Limb	O
2	allografts	O
3	in	O
4	rats	O
5	immunosuppressed	O
6	with	O
7	cyclosporin	O
8	A	O
9	.	O

1	A	O
2	new	O
3	DNA	O
4	repair	O
5	gene	O
6	from	O
7	Schizosaccharomyces	O
8	pombe	O
9	with	O
10	homology	O
11	to	O
12	RecA	O
13	was	O
14	identified	O
15	and	O
16	characterized	O
17	.	O

1	This	O
2	result	O
3	suggests	O
4	that	O
5	phosphorylation	O
6	of	O
7	Thr	O
8	14	O
9	and	O
10	/	O
11	or	O
12	Tyr	O
13	15	O
14	inhibits	O
15	p34cdc2	B
16	kinase	I
17	activity	O
18	,	O
19	in	O
20	line	O
21	with	O
22	the	O
23	location	O
24	of	O
25	these	O
26	residues	O
27	within	O
28	the	O
29	putative	O
30	ATP	O
31	binding	O
32	site	O
33	of	O
34	the	O
35	kinase	O
36	.	O

1	Fine	O
2	analysis	O
3	at	O
4	the	O
5	nucleotide	O
6	level	O
7	of	O
8	the	O
9	early	O
10	events	O
11	in	O
12	the	O
13	digestion	O
14	with	O
15	nuclease	B
16	S1	I
17	shows	O
18	that	O
19	the	O
20	enzyme	O
21	attacks	O
22	preferentially	O
23	the	O
24	sequence	O
25	(	O
26	G	B
27	-	I
28	A	I
29	)	O
30	12	O
31	on	O
32	the	O
33	message	O
34	complementary	O
35	strand	O
36	.	O

1	Both	O
2	receptors	I
3	utilize	O
4	protein	I
5	tyrosine	I
6	kinases	I
7	(	O
8	PTKs	B
9	)	O
10	for	O
11	the	O
12	phosphorylation	O
13	of	O
14	various	O
15	signaling	O
16	molecules	O
17	,	O
18	a	O
19	process	O
20	that	O
21	is	O
22	critical	O
23	for	O
24	the	O
25	function	O
26	of	O
27	both	O
28	receptors	O
29	.	O

1	A	O
2	genetic	O
3	complementation	O
4	system	O
5	was	O
6	developed	O
7	in	O
8	which	O
9	tobacco	O
10	etch	O
11	virus	O
12	(	O
13	TEV	B
14	)	O
15	polymerase	O
16	(	O
17	NIb	O
18	)-	O
19	expressing	O
20	transgenic	O
21	plants	O
22	or	O
23	protoplasts	O
24	were	O
25	inoculated	O
26	with	O
27	NIb	O
28	-	O
29	defective	O
30	TEV	O
31	mutants	I
32	.	O

1	Human	O
2	T	O
3	-	I
4	cell	O
5	leukemia	O
6	virus	O
7	type	O
8	I	O
9	(	O
10	HTLV	O
11	-	O
12	I	O
13	)	O
14	encodes	O
15	a	O
16	40	O
17	-	O
18	kDa	O
19	nuclear	O
20	protein	O
21	,	O
22	Tax	B
23	,	O
24	which	O
25	stimulates	O
26	transcription	O
27	from	O
28	three	O
29	21	O
30	-	O
31	base	O
32	pair	O
33	(	O
34	bp	O
35	)	O
36	repeats	O
37	in	O
38	its	O
39	U3	O
40	region	O
41	.	O

1	This	O
2	study	O
3	confirms	O
4	,	O
5	although	O
6	individual	O
7	reaction	O
8	is	O
9	remarkably	O
10	different	O
11	,	O
12	transportation	O
13	as	O
14	a	O
15	potent	O
16	stressor	O
17	for	O
18	Beagle	O
19	dogs	O
20	.	O

1	Three	O
2	patients	O
3	with	O
4	four	O
5	renoureteral	O
6	units	O
7	have	O
8	undergone	O
9	single	O
10	-	O
11	stage	O
12	reconstruction	O
13	involving	O
14	ureteroureterostomy	O
15	and	O
16	ipsilateral	O
17	ureteroneocystostomy	O
18	following	O
19	temporary	O
20	loop	O
21	cutaneous	O
22	ureterostomy	O
23	.	O

1	We	O
2	have	O
3	isolated	O
4	and	O
5	characterized	O
6	the	O
7	GCD6	O
8	and	O
9	GCD7	O
10	genes	O
11	and	O
12	shown	O
13	that	O
14	their	O
15	products	O
16	are	O
17	required	O
18	to	O
19	repress	O
20	GCN4	B
21	translation	O
22	under	O
23	nonstarvation	O
24	conditions	O
25	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	mitochondrial	O
6	presequences	O
7	interact	O
8	with	O
9	the	O
10	mt	B
11	-	I
12	hsp70	I
13	during	O
14	or	O
15	after	O
16	mitochondrial	O
17	protein	O
18	import	O
19	.	O

1	If	O
2	this	O
3	is	O
4	present	O
5	,	O
6	such	O
7	patients	O
8	should	O
9	be	O
10	closely	O
11	monitored	O
12	,	O
13	and	O
14	any	O
15	atypical	O
16	lesions	O
17	biopsied	O
18	.	O

1	Moreover	O
2	,	O
3	increasing	O
4	the	O
5	dosage	O
6	of	O
7	wild	O
8	-	O
9	type	O
10	Fus3	O
11	intensifies	O
12	the	O
13	inhibition	O
14	of	O
15	both	O
16	Ty1	B
17	transposition	O
18	and	O
19	invasive	O
20	growth	O
21	.	O

1	From	O
2	February	O
3	1991	O
4	to	O
5	August	O
6	1997	O
7	,	O
8	124	O
9	patients	O
10	with	O
11	endometrial	O
12	carcinoma	O
13	were	O
14	treated	O
15	postoperatively	O
16	with	O
17	high	O
18	-	O
19	dose	O
20	-	O
21	rate	O
22	vaginal	O
23	vault	O
24	brachytherapy	O
25	as	O
26	the	O
27	only	O
28	adjuvant	O
29	treatment	O
30	.	O

1	Because	O
2	of	O
3	the	O
4	increased	O
5	CPK	B
6	activity	O
7	found	O
8	in	O
9	normal	O
10	newborns	O
11	,	O
12	screening	O
13	for	O
14	Duchenne	O
15	-	O
16	type	O
17	muscular	O
18	dystrophy	O
19	should	O
20	be	O
21	postponed	O
22	for	O
23	a	O
24	few	O
25	weeks	O
26	after	O
27	delivery	O
28	.	O

1	Progression	O
2	after	O
3	first	O
4	-	O
5	line	O
6	chemotherapy	O
7	was	O
8	associated	O
9	with	O
10	significantly	O
11	worse	O
12	survival	O
13	for	O
14	patients	O
15	with	O
16	metastasis	O
17	.	O

1	AP	B
2	was	O
3	induced	O
4	by	O
5	intraductal	O
6	infusion	O
7	of	O
8	two	O
9	different	O
10	concentrations	O
11	of	O
12	glycodeoxycholic	O
13	acid	O
14	(	O
15	GDOC	O
16	17	O
17	mmol	O
18	and	O
19	34	O
20	mmol	O
21	).	O

1	Assessment	O
2	of	O
3	nutrient	O
4	media	O
5	in	O
6	the	O
7	diagnosis	O
8	of	O
9	diptheria	O

1	Jembrana	O
2	disease	O
3	virus	O
4	(	O
5	JDV	O
6	)	O
7	is	O
8	a	O
9	newly	O
10	identified	O
11	bovine	O
12	lentivirus	O
13	that	O
14	is	O
15	closely	O
16	related	O
17	to	O
18	the	O
19	bovine	O
20	immunodeficiency	O
21	virus	O
22	(	O
23	BIV	O
24	).	O

1	In	O
2	this	O
3	report	O
4	,	O
5	we	O
6	focus	O
7	on	O
8	the	O
9	genetics	O
10	of	O
11	the	O
12	region	O
13	of	O
14	the	O
15	17	O
16	hep	B
17	syn	B
18	gB	I
19	gene	I
20	that	O
21	conferred	O
22	both	O
23	the	O
24	syncytial	O
25	and	O
26	pathogenic	O
27	phenotypes	O
28	to	O
29	17	O
30	syn	O
31	+.	O

1	Also	O
2	,	O
3	transient	O
4	overexpression	O
5	of	O
6	this	O
7	protein	O
8	in	O
9	C2C12	O
10	cells	O
11	reduced	O
12	the	O
13	transcription	O
14	of	O
15	a	O
16	CAT	B
17	-	O
18	reporter	O
19	regulated	O
20	by	O
21	an	O
22	E12	B
23	/	O
24	MyoD	B
25	driven	O
26	enhancer	O
27	.	O

1	Transcriptional	O
2	activation	O
3	of	O
4	the	O
5	chicken	B
6	lysozyme	I
7	gene	I
8	by	O
9	NF	B
10	-	I
11	kappa	I
12	Bp65	I
13	(	O
14	RelA	B
15	)	O
16	and	O
17	c	B
18	-	I
19	Rel	I
20	,	O
21	but	O
22	not	O
23	by	O
24	NF	B
25	-	I
26	kappa	I
27	Bp50	I
28	.	O

1	METHODS	O
2	:	O
3	Twenty	O
4	-	O
5	two	O
6	patients	O
7	were	O
8	grouped	O
9	according	O
10	to	O
11	their	O
12	etiology	O
13	based	O
14	on	O
15	the	O
16	study	O
17	of	O
18	antiadrenal	O
19	antibodies	O
20	at	O
21	diagnosis	O
22	of	O
23	the	O
24	disease	O
25	:	O
26	7	O
27	were	O
28	positive	O
29	(	O
30	autoimmune	O
31	etiology	O
32	or	O
33	EAA	O
34	),	O
35	11	O
36	were	O
37	negative	O
38	(	O
39	tuberculous	O
40	etiology	O
41	or	O
42	EAT	O
43	)	O
44	and	O
45	in	O
46	four	O
47	serologic	O
48	study	O
49	was	O
50	not	O
51	available	O
52	(	O
53	undetermined	O
54	etiology	O
55	or	O
56	EAI	O
57	).	O

1	These	O
2	exons	O
3	were	O
4	identified	O
5	by	O
6	cloning	O
7	and	O
8	sequencing	O
9	cDNAs	O
10	obtained	O
11	by	O
12	polymerase	O
13	chain	O
14	reaction	O
15	amplification	O
16	of	O
17	a	O
18	fibroblast	O
19	cDNA	O
20	library	O
21	.	O

1	The	O
2	yeast	O
3	silent	O
4	information	O
5	regulator	O
6	Sir4p	O
7	anchors	O
8	and	O
9	partitions	O
10	plasmids	O
11	.	O

1	A	O
2	positive	O
3	correlation	O
4	between	O
5	serum	B
6	myoglobin	I
7	and	O
8	CA	B
9	III	I
10	concentrations	O
11	(	O
12	rs	O
13	=	O
14	0	O
15	.	O
16	933	O
17	,	O
18	P	O
19	<	O
20	0	O
21	.	O
22	001	O
23	)	O
24	was	O
25	observed	O
26	in	O
27	hemodialyzed	O
28	patients	O
29	with	O
30	chronic	O
31	renal	O
32	failure	O
33	.	O

1	Thus	O
2	,	O
3	the	O
4	B	B
5	-	I
6	S	I
7	mutant	I
8	does	O
9	not	O
10	mimic	O
11	efficiently	O
12	the	O
13	chloroplastic	O
14	GAPDHs	O
15	,	O
16	and	O
17	long	O
18	-	O
19	range	O
20	and	O
21	/	O
22	or	O
23	second	O
24	-	O
25	layer	O
26	effects	O
27	,	O
28	not	O
29	easily	O
30	predictable	O
31	from	O
32	visual	O
33	inspection	O
34	of	O
35	three	O
36	-	O
37	dimensional	O
38	structures	O
39	,	O
40	need	O
41	to	O
42	be	O
43	taken	O
44	into	O
45	account	O
46	for	O
47	designing	O
48	a	O
49	true	O
50	"	O
51	chloroplastic	O
52	-	O
53	like	O
54	"	O
55	mutant	O
56	of	O
57	cytosolic	O
58	GAPDH	O
59	.	O

1	Of	O
2	the	O
3	43	O
4	infants	O
5	with	O
6	a	O
7	(	O
8	probable	O
9	)	O
10	loss	O
11	18	O
12	were	O
13	examined	O
14	again	O
15	at	O
16	3	O
17	months	O
18	corrected	O
19	age	O
20	.	O

1	The	O
2	5	O
3	'-	O
4	nontranslated	O
5	sequences	O
6	and	O
7	parts	O
8	of	O
9	the	O
10	coding	O
11	sequences	O
12	of	O
13	various	O
14	yeast	O
15	genes	O
16	have	O
17	been	O
18	cloned	O
19	into	O
20	representative	O
21	lacZ	B
22	fusion	O
23	vectors	O
24	.	O

1	The	O
2	hypertension	O
3	with	O
4	elevated	O
5	PRA	O
6	,	O
7	however	O
8	,	O
9	was	O
10	resistant	O
11	to	O
12	the	O
13	angiotensin	B
14	II	I
15	(	O
16	AII	O
17	)	O
18	analog	O
19	[	O
20	Sar1	O
21	,	O
22	Ile8	O
23	]	O
24	ALL	O
25	.	O

1	Variables	O
2	evaluated	O
3	were	O
4	number	O
5	of	O
6	weekly	O
7	anginal	O
8	events	O
9	,	O
10	data	O
11	from	O
12	ergometric	O
13	exercise	O
14	testing	O
15	with	O
16	simultaneous	O
17	electrocardiographic	O
18	registration	O
19	,	O
20	semiquantitative	O
21	evaluation	O
22	of	O
23	Tc	O
24	-	O
25	99m	O
26	2	O
27	-	O
28	methoxy	O
29	isobutyl	O
30	isonitrile	O
31	(	O
32	MIBI	O
33	)	O
34	scans	O
35	and	O
36	rheologic	O
37	variables	O
38	.	O

1	Basal	O
2	FVR	O
3	was	O
4	reduced	O
5	by	O
6	approximately	O
7	18	O
8	%	O
9	by	O
10	ERT	O
11	and	O
12	HRT	O
13	,	O
14	but	O
15	FVR	O
16	responses	O
17	to	O
18	noradrenaline	O
19	,	O
20	angiotensin	B
21	II	I
22	,	O
23	acetylcholine	O
24	and	O
25	nitroprusside	O
26	were	O
27	unaffected	O
28	.	O

1	The	O
2	minimal	O
3	region	O
4	of	O
5	overlap	O
6	of	O
7	Langer	O
8	-	O
9	Giedion	O
10	syndrome	O
11	deletions	O
12	,	O
13	previously	O
14	identified	O
15	by	O
16	analysis	O
17	of	O
18	15	O
19	patients	O
20	,	O
21	was	O
22	placed	O
23	on	O
24	the	O
25	map	O
26	by	O
27	analysis	O
28	of	O
29	2	O
30	patients	O
31	whose	O
32	deletions	O
33	define	O
34	the	O
35	endpoints	O
36	.	O

1	Improving	O
2	fissure	O
3	sealant	O
4	quality	O
5	:	O
6	mechanical	O
7	preparation	O
8	and	O
9	filling	O
10	level	O
11	.	O

1	Workers	O
2	with	O
3	"	O
4	sensitivity	O
5	"	O
6	to	O
7	toluene	O
8	diisocyanate	O
9	(	O
10	TDI	O
11	)	O
12	studied	O
13	in	O
14	depth	O
15	in	O
16	an	O
17	attempt	O
18	to	O
19	determine	O
20	mechanisms	O
21	of	O
22	bronchial	O
23	hyperreactivity	O
24	.	O

1	Although	O
2	some	O
3	residues	O
4	are	O
5	found	O
6	reactive	O
7	toward	O
8	dimethylsulphate	O
9	and	O
10	kethoxal	O
11	in	O
12	regions	O
13	predicted	O
14	to	O
15	be	O
16	unpaired	O
17	by	O
18	the	O
19	phylogenetic	O
20	secondary	O
21	structure	O
22	model	O
23	of	O
24	4	O
25	.	O
26	5S	B
27	RNA	I
28	,	O
29	generally	O
30	the	O
31	reactivity	O
32	is	O
33	low	O
34	,	O
35	and	O
36	some	O
37	residues	O
38	in	O
39	internal	O
40	loops	O
41	are	O
42	not	O
43	reactive	O
44	at	O
45	all	O
46	.	O

1	A	O
2	gene	O
3	homologous	O
4	to	O
5	the	O
6	Escherichia	B
7	coli	I
8	dnaA	I
9	gene	I
10	was	O
11	isolated	O
12	from	O
13	Pseudomonas	O
14	putida	O
15	and	O
16	its	O
17	transcription	O
18	was	O
19	investigated	O
20	in	O
21	E	O
22	.	O
23	coli	O
24	as	O
25	well	O
26	as	O
27	in	O
28	P	O
29	.	O
30	putida	O
31	.	O

1	Natl	O
2	.	O

1	In	O
2	addition	O
3	,	O
4	we	O
5	observe	O
6	that	O
7	the	O
8	hUBF	B
9	-	I
10	promoter	I
11	interaction	O
12	is	O
13	highly	O
14	sensitive	O
15	to	O
16	the	O
17	antagonistic	O
18	effects	O
19	of	O
20	cisplatin	O
21	-	O
22	DNA	O
23	adducts	O
24	.	O

1	Clinical	O
2	findings	O
3	were	O
4	:	O
5	height	O
6	183	O
7	cm	O
8	,	O
9	weight	O
10	62	O
11	kg	O
12	,	O
13	increased	O
14	length	O
15	of	O
16	lower	O
17	limbs	O
18	,	O
19	P2	O
20	-	O
21	A2	O
22	pilosity	O
23	and	O
24	micropenis	O
25	.	O

1	Covalent	O
2	modification	O
3	of	O
4	the	O
5	transactivator	B
6	protein	I
7	IE2	B
8	-	I
9	p86	I
10	of	O
11	human	O
12	cytomegalovirus	O
13	by	O
14	conjugation	O
15	to	O
16	the	O
17	ubiquitin	B
18	-	I
19	homologous	I
20	proteins	I
21	SUMO	I
22	-	I
23	1	I
24	and	O
25	hSMT3b	O
26	.	O

1	The	O
2	results	O
3	indicate	O
4	that	O
5	the	O
6	pooling	O
7	requirements	O
8	are	O
9	task	O
10	dependent	O
11	.	O

1	II	O
2	.	O

1	A	O
2	soluble	O
3	62	O
4	-	O
5	kDa	O
6	protein	O
7	was	O
8	produced	O
9	without	O
10	the	O
11	proteolytic	O
12	processing	O
13	by	O
14	inserting	O
15	the	O
16	coding	O
17	sequence	O
18	of	O
19	amino	O
20	acids	O
21	112	O
22	to	O
23	660	O
24	of	O
25	ORF	O
26	-	O
27	2	I
28	in	O
29	a	O
30	baculovirus	O
31	expression	O
32	vector	O
33	and	O
34	using	O
35	the	O
36	corresponding	O
37	virus	O
38	to	O
39	infect	O
40	Sf9	O
41	cells	O
42	.	O

1	The	O
2	apparent	O
3	Kd	O
4	of	O
5	the	O
6	MetRS	O
7	/	O
8	CAU	O
9	operator	O
10	complex	O
11	is	O
12	one	O
13	order	O
14	magnitude	O
15	higher	O
16	than	O
17	that	O
18	of	O
19	the	O
20	ThrRS	O
21	/	O
22	CGU	O
23	operator	O
24	complex	O
25	.	O

1	It	O
2	is	O
3	concluded	O
4	that	O
5	haloperidol	O
6	selectively	O
7	reduced	O
8	the	O
9	animal	O
10	'	O
11	s	O
12	capacity	O
13	to	O
14	'	O
15	programme	O
16	non	O
17	-	O
18	stimulus	O
19	directed	O
20	motor	O
21	behaviour	O
22	'.	O

1	Mutagenesis	O
2	of	O
3	each	O
4	NRF	B
5	-	I
6	1	I
7	motif	O
8	in	O
9	the	O
10	ALAS	O
11	promoter	O
12	gave	O
13	substantially	O
14	lowered	O
15	levels	O
16	of	O
17	chloramphenicol	B
18	acetyltransferase	I
19	expression	O
20	,	O
21	whereas	O
22	mutagenesis	O
23	of	O
24	both	O
25	NRF	B
26	-	I
27	1	I
28	motifs	O
29	resulted	O
30	in	O
31	the	O
32	almost	O
33	complete	O
34	loss	O
35	of	O
36	expression	O
37	.	O

1	These	O
2	results	O
3	suggest	O
4	that	O
5	5	O
6	KE	O
7	X	I
8	3	I
9	/	O
10	W	O
11	may	O
12	be	O
13	the	O
14	optimal	O
15	regimen	O
16	to	O
17	augment	O
18	the	O
19	antitumor	O
20	immunity	O
21	of	O
22	RNL	O
23	.	O

1	The	O
2	efficacy	O
3	and	O
4	safety	O
5	of	O
6	a	O
7	novel	O
8	percutaneous	O
9	anaesthetic	O
10	preparation	O
11	based	O
12	on	O
13	amethocaine	O
14	has	O
15	been	O
16	investigated	O
17	in	O
18	the	O
19	paediatric	O
20	clinical	O
21	environment	O
22	.	O

1	Overexpression	O
2	of	O
3	Trdpm1	O
4	in	O
5	a	O
6	dpm1	O
7	(+)::	O
8	his7	O
9	/	O
10	dpm1	O
11	(+)	O
12	S	O
13	.	O
14	pombe	O
15	diploid	O
16	resulted	O
17	in	O
18	a	O
19	4	O
20	-	O
21	fold	O
22	increase	O
23	in	O
24	specific	O
25	DPM	O
26	synthase	I
27	activity	O
28	.	O

1	To	O
2	test	O
3	the	O
4	feasibility	O
5	of	O
6	using	O
7	liposomes	O
8	to	O
9	deliver	O
10	therapeutic	O
11	agents	O
12	to	O
13	the	O
14	lungs	O
15	,	O
16	the	O
17	effect	O
18	of	O
19	liposome	B
20	-	O
21	encapsulated	O
22	superoxide	B
23	dismutase	I
24	(	O
25	SOD	B
26	)	O
27	or	O
28	catalase	B
29	on	O
30	pulmonary	O
31	oxygen	O
32	toxicity	O
33	was	O
34	studied	O
35	in	O
36	rats	O
37	.	O

1	Effects	O
2	of	O
3	spatial	O
4	and	O
5	temporal	O
6	smoothing	O
7	on	O
8	stimulated	O
9	brillouin	O
10	scattering	O
11	in	O
12	the	O
13	independent	O
14	-	O
15	hot	O
16	-	O
17	spot	O
18	model	O
19	limit	O
20	The	O
21	influence	O
22	of	O
23	laser	O
24	beam	O
25	smoothing	O
26	on	O
27	stimulated	O
28	Brillouin	O
29	backscattering	O
30	(	O
31	SBBS	O
32	)	O
33	is	O
34	studied	O
35	analytically	O
36	in	O
37	the	O
38	limit	O
39	of	O
40	the	O
41	independent	O
42	hot	O
43	spot	O
44	model	O
45	.	O

1	METHODS	O
2	:	O
3	109	O
4	suspected	O
5	cases	O
6	with	O
7	SS	O
8	underwent	O
9	the	O
10	biopsies	O
11	.	O

1	Administration	O
2	of	O
3	the	O
4	dopamine	O
5	agonist	O
6	bromocriptine	O
7	(	O
8	2	O
9	.	O
10	5	O
11	mg	O
12	three	O
13	times	O
14	a	O
15	day	O
16	for	O
17	4	O
18	days	O
19	)	O
20	suppressed	O
21	(	O
22	P	O
23	less	O
24	than	O
25	0	O
26	.	O
27	01	O
28	)	O
29	mean	O
30	24	O
31	-	O
32	h	O
33	plasma	O
34	18	O
35	-	O
36	OHB	O
37	levels	O
38	from	O
39	21	O
40	.	O
41	9	O
42	+/-	O
43	2	O
44	.	O
45	0	O
46	to	O
47	14	O
48	.	O
49	8	O
50	+/-	O
51	1	O
52	.	O
53	4	O
54	ng	O
55	/	O
56	dl	O
57	.	O

1	Chem	O
2	.,	O
3	270	O
4	:	O
5	7117	O
6	-	O
7	7124	O
8	,	O
9	1995	O
10	;	O
11	and	O
12	MT	B
13	Hartsough	O
14	et	O
15	al	O
16	.,	O
17	J	O
18	.	O

1	Refugees	O
2	living	O
3	in	O
4	Lund	O
5	and	O
6	repatriated	O
7	to	O
8	Chile	O
9	considered	O
10	their	O
11	health	O
12	as	O
13	bad	O
14	in	O
15	a	O
16	higher	O
17	proportion	O
18	than	O
19	their	O
20	Swedish	O
21	counterparts	O
22	,	O
23	with	O
24	an	O
25	odds	O
26	ratio	O
27	of	O
28	3	O
29	.	O
30	48	O
31	(	O
32	2	O
33	.	O
34	03	O
35	-	O
36	5	O
37	.	O
38	66	O
39	)	O
40	and	O
41	4	O
42	.	O
43	78	O
44	(	O
45	2	O
46	.	O
47	1	O
48	-	O
49	10	O
50	.	O
51	25	O
52	)	O
53	respectively	O
54	.	O

1	Chrispeels	O
2	[	O
3	1993	O
4	]	O
5	EMBO	O
6	J	O
7	12	O
8	:	O
9	2241	O
10	-	O
11	2247	O
12	).	O

1	Electrocardiographic	O
2	QRS	O
3	complexes	O
4	and	O
5	vectorcardiographic	O
6	QRS	O
7	loop	O

1	To	O
2	investigate	O
3	the	O
4	functions	O
5	of	O
6	GE	O
7	,	O
8	IG	O
9	,	O
10	and	O
11	GS	B
12	sequences	I
13	in	O
14	transcription	O
15	,	O
16	we	O
17	constructed	O
18	plasmids	O
19	containing	O
20	cDNAs	O
21	of	O
22	the	O
23	full	O
24	-	O
25	length	O
26	SV5	O
27	genome	O
28	in	O
29	which	O
30	the	O
31	gene	O
32	junction	O
33	sequences	O
34	(	O
35	GE	O
36	,	O
37	IG	O
38	,	O
39	and	O
40	GS	B
41	sequences	I
42	)	O
43	located	O
44	between	O
45	the	O
46	hemagglutinin	B
47	-	I
48	neuraminidase	I
49	(	O
50	HN	B
51	)	O
52	and	O
53	the	O
54	polymerase	O
55	(	O
56	L	I
57	)	O
58	genes	O
59	were	O
60	replaced	O
61	with	O
62	the	O
63	counterpart	O
64	sequences	O
65	from	O
66	other	O
67	gene	O
68	junctions	O
69	.	O

1	Assessment	O
2	of	O
3	the	O
4	carcinogenicity	O
5	of	O
6	non	O
7	-	O
8	nutritive	O
9	sweetners	O
10	II	O
11	:	O
12	Cyclamates	O
13	and	O
14	cyclohexylamine	O
15	.	O

1	Optical	O
2	-	O
3	absorption	O
4	spectra	O
5	,	O
6	crystal	O
7	-	O
8	field	O
9	energy	O
10	levels	O
11	,	O
12	and	O
13	transition	O
14	line	O
15	strengths	O
16	of	O
17	holmium	O
18	in	O
19	trigonal	O
20	Na3	O

1	Opposite	O
2	effects	O
3	of	O
4	CYP1	O
5	are	O
6	observed	O
7	in	O
8	aerobic	O
9	,	O
10	heme	O
11	-	O
12	sufficient	O
13	cells	O
14	.	O

1	Interaction	O
2	of	O
3	HRI	O
4	with	O
5	Hsc70	O
6	was	O
7	required	O
8	for	O
9	the	O
10	transformation	O
11	of	O
12	HRI	O
13	,	O
14	as	O
15	the	O
16	Hsc70	O
17	antagonist	O
18	clofibric	O
19	acid	O
20	inhibited	O
21	the	O
22	folding	O
23	of	O
24	HRI	O
25	into	O
26	a	O
27	mature	O
28	-	O
29	competent	O
30	conformation	O
31	.	O

1	To	O
2	explore	O
3	the	O
4	function	O
5	of	O
6	human	O
7	SINA	O
8	-	O
9	homologous	O
10	(	O
11	Siah	O
12	)	O
13	proteins	O
14	,	O
15	expression	O
16	plasmids	O
17	encoding	O
18	Siah	O
19	-	O
20	1A	O
21	were	O
22	transiently	O
23	transfected	O
24	into	O
25	293	O
26	epithelial	O
27	cells	O
28	and	O
29	GM701	O
30	fibroblast	O
31	cells	O
32	,	O
33	resulting	O
34	in	O
35	growth	O
36	arrest	O
37	without	O
38	induction	O
39	of	O
40	apoptosis	O
41	.	O

1	Adenylosuccinate	B
2	synthetase	I
3	(	O
4	IMP	O
5	:	O
6	L	B
7	-	O
8	aspartate	I
9	ligase	I
10	(	O
11	GDP	O
12	),	O
13	EC	B
14	6	I
15	.	I
16	3	I
17	.	O
18	4	I
19	.	O
20	4	O
21	)	O
22	plays	O
23	an	O
24	important	O
25	role	O
26	in	O
27	purine	O
28	biosynthesis	O
29	catalyzing	O
30	the	O
31	GTP	O
32	-	O
33	dependent	O
34	conversion	O
35	of	O
36	IMP	O
37	to	O
38	AMP	O
39	.	O

1	A	O
2	consensus	O
3	binding	O
4	site	O
5	for	O
6	the	O
7	transcription	O
8	factor	I
9	SP1	I
10	was	O
11	identified	O
12	in	O
13	intron	O
14	As	O
15	downstream	O
16	of	O
17	the	O
18	proenkephalin	O
19	germ	O
20	cell	O
21	cap	O
22	site	O
23	region	O
24	.	O

1	The	O
2	gene	O
3	product	O
4	of	O
5	cotS	O
6	was	O
7	confirmed	O
8	to	O
9	be	O
10	identical	O
11	to	O
12	Cot40	O
13	-	O
14	2	I
15	by	O
16	SDS	O
17	-	O
18	PAGE	O
19	and	O
20	immunoblotting	O
21	from	O
22	Escherichia	O
23	coli	O
24	transformed	O
25	with	O
26	a	O
27	plasmid	O
28	containing	O
29	the	O
30	cotS	O
31	region	O
32	.	O

1	Gastrointestinal	O
2	manifestations	O
3	of	O
4	systemic	O
5	sclerosis	O

1	PURPOSE	O
2	:	O
3	The	O
4	aim	O
5	of	O
6	this	O
7	study	O
8	was	O
9	to	O
10	evaluate	O
11	the	O
12	bony	O
13	anchorage	O
14	of	O
15	a	O
16	new	O
17	implant	O
18	(	O
19	orderly	O
20	wired	O
21	surface	O
22	effect	O
23	with	O
24	alloy	O
25	Ti	O
26	Al	O
27	Va	O
28	and	O
29	ordered	O
30	pores	O
31	of	O
32	488	O
33	mu	O
34	).	O

1	LON	O
2	-	O
3	72	O
4	(	O
5	34	O
6	isolates	O
7	),	O
8	LON	O
9	-	O
10	73	O
11	(	O
12	1	O
13	),	O
14	LON	O
15	-	O
16	71	O
17	(	O
18	2	O
19	)	O
20	and	O
21	LON	O
22	-	O
23	10	O
24	(	O
25	2	O
26	)	O
27	were	O
28	found	O
29	at	O
30	altitudes	O
31	around	O
32	2000	O
33	m	O
34	,	O
35	3	O
36	of	O
37	them	O
38	in	O
39	a	O
40	single	O
41	village	O
42	.	O

1	Truncation	O
2	variants	O
3	of	O
4	peptides	O
5	isolated	O
6	from	O
7	MHC	B
8	class	I
9	II	I
10	molecules	I
11	suggest	O
12	sequence	O
13	motifs	O
14	.	O

1	Interleukin	B
2	-	O
3	12	O
4	(	O
5	IL	B
6	-	I
7	12	I
8	)	O
9	is	O
10	a	O
11	cytokine	O
12	produced	O
13	by	O
14	peripheral	O
15	blood	O
16	mononuclear	O
17	cells	O
18	(	O
19	PBMC	O
20	)	O
21	that	O
22	causes	O
23	interferon	B
24	-	I
25	gamma	I
26	(	O
27	IFN	B
28	-	I
29	gamma	I
30	)	O
31	production	O
32	and	O
33	enhancement	O
34	of	O
35	cell	O
36	-	O
37	mediated	O
38	cytotoxicity	O
39	.	O

1	Thus	O
2	,	O
3	hGRbeta	O
4	potentially	O
5	functions	O
6	as	O
7	a	O
8	dominant	O
9	negative	O
10	inhibitor	O
11	of	O
12	hGRalpha	O
13	activity	O
14	.	O

1	Takayasu	O
2	'	O
3	s	O
4	disease	O
5	:	O
6	association	O
7	with	O
8	HLA	B
9	-	I
10	B5	O
11	.	O

1	Expression	O
2	of	O
3	constitutively	O
4	active	O
5	MEK1	O
6	,	O
7	the	O
8	kinase	O
9	that	O
10	activates	O
11	ERKs	B
12	,	O
13	or	O
14	overexpression	O
15	of	O
16	ERK2	B
17	,	O
18	but	O
19	not	O
20	JNK1	B
21	,	O
22	inhibited	O
23	Stat3	B
24	activation	O
25	.	O

1	An	O
2	end	O
3	-	O
4	to	O
5	-	O
6	end	O
7	pancreaticojejunostomy	O
8	using	O
9	a	O
10	mechanical	O
11	purse	O
12	-	O
13	string	O
14	device	O
15	.	O

1	Two	O
2	new	O
3	artifacts	O
4	in	O
5	automated	O
6	coagulation	O
7	testing	O
8	.	O

1	Results	O
2	support	O
3	the	O
4	hypothesis	O
5	that	O
6	endogenous	B
7	corticotropin	I
8	-	I
9	releasing	I
10	factor	I
11	,	O
12	perhaps	O
13	acting	O
14	at	O
15	a	O
16	peripheral	O
17	binding	O
18	site	O
19	,	O
20	suppresses	O
21	the	O
22	active	O
23	behavioral	O
24	response	O
25	characteristic	O
26	of	O
27	pups	O
28	during	O
29	the	O
30	early	O
31	phase	O
32	of	O
33	isolation	O
34	in	O
35	novel	O
36	surroundings	O
37	.	O

1	Furthermore	O
2	,	O
3	strains	O
4	with	O
5	mutant	O
6	RPM1	B
7	genes	I
8	also	O
9	accumulate	O
10	precursor	O
11	Rpm1r	B
12	,	O
13	suggesting	O
14	that	O
15	mutations	O
16	in	O
17	either	O
18	gene	O
19	can	O
20	lead	O
21	to	O
22	similar	O
23	biogenesis	O
24	defects	O
25	.	O

1	In	O
2	the	O
3	region	O
4	Walgau	O
5	with	O
6	mixed	O
7	industrial	O
8	-	O
9	rural	O
10	population	O
11	an	O
12	iodine	O
13	deficiency	O
14	I	O
15	was	O
16	found	O
17	in	O
18	81	O
19	%	O
20	and	O
21	an	O
22	iodine	O
23	deficiency	O
24	II	O
25	in	O
26	45	O
27	%.	O

1	Herpes	O
2	virus	O
3	infection	O
4	was	O
5	characterized	O
6	by	O
7	inversion	O
8	of	O
9	the	O
10	T4	O
11	/	O
12	T8	O
13	ratio	O
14	below	O
15	1	O
16	.	O
17	0	O
18	(	O
19	sensitivity	O
20	90	O
21	%,	O
22	specificity	O
23	88	O
24	%),	O
25	caused	O
26	by	O
27	proliferation	O
28	of	O
29	the	O
30	T8	O
31	subpopulation	O
32	,	O
33	which	O
34	--	O
35	compared	O
36	with	O
37	the	O
38	findings	O
39	in	O
40	patients	O
41	with	O
42	rejection	O
43	crises	O
44	--	O
45	was	O
46	significantly	O
47	raised	O
48	(	O
49	P	O
50	less	O
51	than	O
52	0	O
53	.	O
54	001	O
55	).	O

1	The	O
2	ratio	O
3	of	O
4	P	O
5	-	O
6	31	O
7	NMR	O
8	-	O
9	S	O
10	derived	O
11	inorganic	O
12	phosphates	O
13	[	O
14	Pi	O
15	]	O
16	to	O
17	phosphocreatine	O
18	[	O
19	PCr	O
20	]	O
21	was	O
22	significantly	O
23	greater	O
24	at	O
25	rest	O
26	in	O
27	LVH	O
28	baboons	O
29	[	O
30	0	O
31	.	O
32	53	O
33	+/-	O
34	0	O
35	.	O
36	06	O
37	versus	O
38	controls	O
39	=	O
40	0	O
41	.	O
42	41	O
43	+/-	O
44	0	O
45	.	O
46	17	O
47	;	O
48	P	O
49	less	O
50	than	O
51	0	O
52	.	O
53	05	O
54	].	O

1	RT	O
2	-	O
3	PCR	O
4	analysis	O
5	showed	O
6	that	O
7	PLP	B
8	-	O
9	H	I
10	as	O
11	well	O
12	as	O
13	PLP	B
14	-	I
15	C	I
16	and	O
17	PLP	B
18	-	I
19	D	I
20	are	O
21	expressed	O
22	in	O
23	all	O
24	rat	O
25	strains	O
26	examined	O
27	,	O
28	confirming	O
29	that	O
30	PLP	B
31	diversity	O
32	is	O
33	not	O
34	due	O
35	to	O
36	strain	O
37	differences	O
38	.	O

1	A	O
2	variety	O
3	of	O
4	nuclear	O
5	ribonucleoproteins	O
6	are	O
7	believed	O
8	to	O
9	associate	O
10	directly	O
11	with	O
12	nascent	O
13	RNA	B
14	polymerase	I
15	II	I
16	transcripts	I
17	and	O
18	remain	O
19	associated	O
20	during	O
21	subsequent	O
22	nuclear	O
23	RNA	O
24	processing	O
25	reactions	O
26	,	O
27	including	O
28	pre	O
29	-	O
30	mRNA	O
31	polyadenylation	O
32	and	O
33	splicing	O
34	as	O
35	well	O
36	as	O
37	nucleocytoplasmic	O
38	mRNA	O
39	transport	O
40	.	O

1	This	O
2	0	O
3	.	O
4	74	O
5	kb	O
6	cDNA	O
7	contains	O
8	an	O
9	open	O
10	reading	O
11	frame	O
12	(	O
13	ORF	O
14	)	O
15	of	O
16	477	O
17	bp	O
18	encoding	O
19	a	O
20	polypeptide	O
21	of	O
22	159	O
23	amino	O
24	acids	O
25	(	O
26	aa	O
27	)	O
28	which	O
29	differs	O
30	at	O
31	only	O
32	one	O
33	position	O
34	(	O
35	position	O
36	65	O
37	)	O
38	from	O
39	the	O
40	human	B
41	U1	I
42	-	I
43	C	I
44	protein	I
45	.	O

1	Tumor	B
2	cells	O
3	were	O
4	focally	O
5	immunoreactive	O
6	for	O
7	neuron	O
8	-	O
9	specific	O
10	enolase	O
11	,	O
12	insulin	B
13	,	O
14	glucagon	B
15	and	O
16	VIP	B
17	.	O

1	Transcriptional	O
2	regulation	O
3	of	O
4	the	O
5	yeast	B
6	PHO8	I
7	promoter	I
8	in	O
9	comparison	O
10	to	O
11	the	O
12	coregulated	O
13	PHO5	I
14	promoter	I
15	.	O

